https://biospectrumindia.com/rssfeed/bio-med/medical%20diagnostic medical diagnostic https://biospectrumindia.com/news/92/28622/thyrocare-expands-presence-in-madurai-with-launch-of-new-diagnostic-laboratory.html https://biospectrumindia.com/news/92/28622/thyrocare-expands-presence-in-madurai-with-launch-of-new-diagnostic-laboratory.html Thu, 08 Oct 2026 20:53:12 +0530 Thyrocare Technologies has announced the launch of its new diagnostic laboratory in Madurai, Tamil Nadu. The facility was inaugurated by Rahul Guha, Managing Director & CEO, Thyrocare and API Holdings. The launch marks another step in Thyrocare’s efforts to strengthen its diagnostic network and improve access to reliable and affordable diagnostic services across emerging markets. The new laboratory is equipped to cater to routine as well as specialised diagnostic testing requirements and is supported by trained professionals and Thyrocare’s technology-enabled diagnostic processes. The facility is expected to support the growing healthcare needs of patients, laboratories and healthcare partners across Madurai and the surrounding regions. The expansion strengthens Thyrocare’s local presence in Tamil Nadu and enables greater access to its diagnostic services, supported by standardised processes, timely sample processing and reliable reporting. The launch is also aligned with the company’s continued focus on expanding its network beyond key metropolitan markets and bringing quality diagnostic services closer to patients. Sharing his thoughts on the launch, Rahul Guha, Managing Director & CEO, Thyrocare and  API Holdings, said, “At Thyrocare, our focus has always been on making quality and trustworthy diagnostic services more accessible to people across India. The launch of our new laboratory in Madurai is another step towards strengthening our presence in emerging markets and bringing our technology-led diagnostic capabilities closer to patients." With the launch of its new laboratory in Madurai, Thyrocare continues to strengthen its diagnostic footprint across India, with a focus on expanding access to standardised and affordable testing beyond the metro markets. ]]> https://biospectrumindia.com/news/92/28608/neuberg-diagnostics-and-nm-medical-to-build-integrated-diagnostics-network-in-maharashtra.html https://biospectrumindia.com/news/92/28608/neuberg-diagnostics-and-nm-medical-to-build-integrated-diagnostics-network-in-maharashtra.html Tue, 06 Oct 2026 21:30:50 +0530 Neuberg Diagnostics has announced the consolidation of its Maharashtra operations with NM Medical, bringing together some of the state's most respected diagnostic brands and clinical leaders under one unified network. The partnership combines NM Medical's four decades of expertise in advanced radiology, cardiology and preventive wellness with Neuberg's specialised capabilities in Genomics, Metabolomics, Proteomics, Digital Pathology, Immunohistochemistry, Molecular Diagnostics, Nephropathology and Neuropathology.   Patients across Mumbai and Maharashtra will benefit from convenient access to routine and highly specialised testing, advanced imaging and comprehensive preventive wellness through an expanding network of integrated diagnostic centres, advanced pathology laboratories, wellness centres and collection centres. For clinicians, bringing imaging, pathology, molecular diagnostics and genomics together will provide a more comprehensive view of each patient, supporting earlier detection, precise diagnosis, personalised treatment decisions and better disease monitoring. The Maharashtra platform will be led by Dr Nilesh Shah as Chairman, Dr Ajay Shah as Chief Mentor - Pathology, Dr Asish Atre as Chief of Radiology, and Dr Kunal Sehgal and Dr Jay Mehta as Heads of Pathology. Rahil Shah will serve as CEO - Maharashtra, Preventive Wellness & Africa Operations, Neuberg Group, driving the integration and expansion of the network. Under this leadership, Neuberg will expand across Maharashtra through integrated diagnostic centres, advanced pathology laboratories, comprehensive wellness centres and collection centres, bringing advanced diagnostic services closer to patients and clinicians. ]]> https://biospectrumindia.com/news/92/28598/metaqon-introduces-genetic-screening-panel-in-india-to-detect-53-age-related-health-risks.html https://biospectrumindia.com/news/92/28598/metaqon-introduces-genetic-screening-panel-in-india-to-detect-53-age-related-health-risks.html Mon, 05 Oct 2026 20:46:35 +0530 USA-based MetaQon Precision Health has announced the India availability of its Elderly Care genetic panel, designed to help identify predisposition to 53 age-related conditions spanning nine categories: cardiovascular disease, neurodegenerative disorders including Alzheimer's and Parkinson's, osteoporosis, arthritis, type 2 diabetes, respiratory disease, vision and hearing loss, mental health conditions including depression and anxiety, and how a person may respond to common medicines such as aspirin, statins and clopidogrel. The panel is designed to be read and acted on by a treating clinician, giving families and physicians additional information to support earlier, more informed conversations about an older adult's health. India already has an estimated 153 million people aged 60 or older, a number projected to more than double to 347 million by 2050. A nationally representative study of Indian adults in that age group, the Longitudinal Ageing Study in India, found that nearly a quarter already live with two or more chronic conditions at the same time, with hypertension affecting close to a third, bone and joint disease close to one in five, and diabetes around one in seven, well before most families start paying close attention. MetaQon's Elderly Care panel analyses a person's genetic predisposition across all nine categories and combines that with their existing diagnostics and lifestyle information, giving a treating clinician additional information to consider, not a substitute for their own evaluation. The pharmacogenetics component is particularly relevant for older adults, many of whom are already on daily aspirin, statins, or blood thinners such as clopidogrel. Genetic variation can affect how a person metabolises these medicines, and flagging that alongside a person's other results is intended to give a treating physician additional context to weigh alongside standard clinical practice, not to replace it. MetaQon's Elderly Care panel is available now through MetaQon's network of clinic partners in India. Clinics and hospitals interested in offering it to their patients can reach MetaQon through the contact details below. ]]> https://biospectrumindia.com/news/92/28578/asms-and-huwel-lifesciences-join-hands-to-expand-access-to-compact-rt-pcr-testing-across-india.html https://biospectrumindia.com/news/92/28578/asms-and-huwel-lifesciences-join-hands-to-expand-access-to-compact-rt-pcr-testing-across-india.html Wed, 30 Sep 2026 16:37:58 +0530 Hyderabad-based Avio Smart Market Stack Limited (ASMS), formerly Bartronics India Limited, and Huwel Lifesciences are strengthening their collaboration to build a nationwide commercialisation platform for Cubo, Huwel’s ultra-compact RT-PCR system. The initiative aims to expand access to molecular diagnostics across India’s private healthcare sector, including hospitals, diagnostic centres, research institutions and smaller healthcare facilities. As part of the collaboration, the two companies plan to establish a dedicated sales and distribution infrastructure, including the recruitment of senior sales leadership, formation of specialised sales teams and development of strategic channel partnerships. The initiative will initially focus on Cubo while creating opportunities to commercialise Huwel’s broader molecular diagnostics portfolio. Cubo is designed to enable RT-PCR testing beyond conventional centralised laboratory environments. Its ultra-compact design allows molecular diagnostic capabilities to be considered for smaller and more decentralised healthcare settings, potentially reducing dependence on large centralised facilities. This is particularly relevant to India’s healthcare landscape, which spans metropolitan centres as well as a large and geographically distributed network of Tier-II and Tier-III cities, hospitals and diagnostic facilities. The commercialisation strategy will focus on private hospitals, diagnostic chains, independent laboratories, medical colleges, research institutions and other healthcare establishments. The proposed sales organisation will work across direct sales and channel partnerships, supported by product demonstrations, installation support and ongoing customer engagement. Beyond instrument deployment, ASMS and Huwel intend to develop an ecosystem around the platform, comprising compatible molecular assays and consumables that can support recurring testing requirements. Huwel’s capabilities across molecular diagnostic applications could enable Cubo installations to serve multiple testing needs rather than being limited to a single application.   ]]> https://biospectrumindia.com/news/92/28579/4basecare-partners-with-cancer-institute-wia-to-expand-access-to-precision-oncology-in-chennai.html https://biospectrumindia.com/news/92/28579/4basecare-partners-with-cancer-institute-wia-to-expand-access-to-precision-oncology-in-chennai.html Wed, 30 Sep 2026 17:13:49 +0530 4baseCare, a leading precision oncology company in Bengaluru, has partnered with Cancer Institute (WIA), Adyar, Chennai, to expand access to advanced genomic testing for cancer patients. The collaboration brings together the Institute’s patient-centric cancer care ecosystem with 4baseCare’s expertise in comprehensive genomic profiling and precision oncology. It is focused on enabling patients to access advanced molecular testing closer to where they receive care, with accessibility and affordability at the centre of the initiative. This marks 4baseCare’s first laboratory collaboration with a cancer centre in Chennai, further strengthening its growing network of collaborative laboratories and healthcare institutions across India. Genomic profiling provides deeper insight into the molecular characteristics of a patient’s tumour, helping oncologists identify relevant genomic alterations that may inform treatment strategies, including targeted therapies and clinical trial opportunities where appropriate. “Precision oncology can have its greatest impact when advanced genomic testing is accessible to the patients who need it. Our collaboration with Cancer Institute (WIA) is an important step towards making comprehensive genomic testing more accessible and affordable, particularly for patients in Chennai and the wider region,” said Hitesh Goswami, Co-Founder and CEO, 4baseCare.   ]]> https://biospectrumindia.com/news/92/28541/neuberg-diagnostics-prolife-diagnostics-announce-strategic-jv-to-expand-advanced-diagnostics-in-odisha.html https://biospectrumindia.com/news/92/28541/neuberg-diagnostics-prolife-diagnostics-announce-strategic-jv-to-expand-advanced-diagnostics-in-odisha.html Fri, 25 Sep 2026 17:20:42 +0530 Neuberg Diagnostics has entered into a strategic joint venture (JV) with Bhubaneswar-based ProLife Diagnostics to expand access to high-quality, affordable and advanced diagnostic services across Odisha. The new venture, Neuberg ProLife, will combine Neuberg’s pan-India scale, advanced diagnostic capabilities, high-end technology, AI-enabled IT platforms and quality systems with ProLife’s established reputation, local presence and deep understanding of Odisha’s healthcare ecosystem. Neuberg ProLife will offer a comprehensive portfolio spanning routine and specialised pathology, radiology, preventive wellness and advanced diagnostics, including genomics, metabolomics, proteomics, digital pathology and AI-enabled advanced radiology. Dr GSK Velu, Chairman and Managing Director, Neuberg Diagnostics said “Odisha is an important market in Neuberg’s pan-India expansion journey, with significant potential to improve access to quality and advanced diagnostics beyond the major urban centres. Through Neuberg ProLife, we are bringing together Neuberg’s technology, advanced diagnostic expertise and national scale with ProLife’s strong local presence and understanding of Odisha. Our vision is to build a future-ready diagnostic network focused on accessibility, affordability, early detection and preventive healthcare.” As part of its expansion strategy, Neuberg ProLife plans to establish 10 Integrated Diagnostics and Wellness Centres across Bhubaneswar, Cuttack, Rourkela, Berhampur, Sambalpur, Puri, Balasore, Bhadrak, Baripada and Jharsuguda. These centres will be supported by more than 100 satellite laboratories and sample collection centres across Odisha within the next two years. The hub-and-spoke network will enable patients across Tier 2, Tier 3 and emerging markets to access routine and specialised diagnostic services closer to home, reducing the need to travel to larger cities for advanced investigations. ]]> https://biospectrumindia.com/news/92/28532/shaping-the-future-of-indian-diagnostics-key-takeaways-from-the-admi-2026-agm.html https://biospectrumindia.com/news/92/28532/shaping-the-future-of-indian-diagnostics-key-takeaways-from-the-admi-2026-agm.html Wed, 23 Sep 2026 21:04:07 +0530 The Association of Diagnostic Manufacturers of India (ADMI) successfully concluded its highly anticipated Annual General Meeting (AGM) on August 20, 2026, at the REGAL Conference Hall, Hotel The Royal Plaza, New Delhi. The event served as a critical platform for knowledge exchange and a strategic review of the Indian In Vitro Diagnostics (IVD) sector, bringing together key stakeholders from government, regulatory bodies, academia, and the manufacturing industry. During the opening address, Jatin Mahajan, President, ADMI emphasised the critical nature of the industry, noting that 70% of clinical decisions depend on diagnostic tests, making quality and reliability paramount. He officially welcomed the newly elected Secretary, Nital Patel, and Joint Secretary, Prakash Rana, and stressed the necessity of collaboration to reduce import dependence and drive innovation. The AGM featured several pivotal sessions addressing the current challenges and future trajectories of the Indian diagnostics market: Government & Regulatory Alignment: Aman Sharma, Joint Secretary DoP, highlighted government concerns regarding the 70-80% import dependence on IVD products and suggested focusing on individual-use devices to gain a market edge. He also stressed the need to change the current L1 (lowest bidder) public procurement system, advocating for a sustainable pricing model that rewards innovators. Additionally, Pramod Meshram, Deputy Drugs Controller at CDSCO, urged IVD manufacturers to seek MD 40 status for testing laboratories and raised concerns over the low rate of adverse event reporting for Class C and D medical devices. ICMR Initiatives and Technology Transfer: Dr Suchita Markan detailed ICMR’s shift toward translating research into commercial products. She announced a non-exclusive, zero-upfront-fee technology transfer model with a 2% royalty on profits, noting that over 78 technologies have already been transferred. Furthermore, she highlighted a Rs 50-crore QMS-compliant manufacturing facility at IIT Delhi designed to help startups produce pre clinical validation test batches. Academia-Industry Collaboration & Automation: Dr Ravikrishnan Elangovan, IIT, Delhi discussed the paradigm shift in academia toward knowledge application and the development of lab-on-a-chip and microfluidic technologies. These innovations enable rapid, point-of-care diagnostics using very small sample volumes (microliters to nanoliters) for multiplexed assays. To combat the commoditisation of rapid test kits, he advocated for the localisation of raw materials and replacing slow, manual processes with automated “reel-to-reel” machines for dispensing, lamination, and assembly.  Private Equity and Sustainable Financial Growth: Thomas John shared his extensive experience with private equity, warning family-owned businesses to be prepared for equity dilution. He outlined five pillars of sustainable growth: profitable growth, corporate governance, scalable business models, mandatory digital systems like ERP/CRM, and a strong culture of R&D. He strongly advised against structured finance due to high interest rates and emphasized choosing investors based on strategic fit. Advocacy and Community Expansion: The ADMI Secretary Report reviewed recent advocacy efforts, including nine representations regarding GST rationalisation and modifications to the PLI scheme. The association is also working to align testing with WHO PQ standards to resolve bottlenecks with NIB reports for global markets. Looking ahead, ADMI proposed organizing an exclusive pavilion with standard cubicles at upcoming exhibitions like Medica and CACLP to significantly reduce participation costs for its members. ]]> https://biospectrumindia.com/news/92/28534/thyrocare-expands-presence-in-jamshedpur-opening-new-diagnostic-lab-in-collaboration-with-secondmedic.html https://biospectrumindia.com/news/92/28534/thyrocare-expands-presence-in-jamshedpur-opening-new-diagnostic-lab-in-collaboration-with-secondmedic.html Wed, 23 Sep 2026 21:38:06 +0530 Thyrocare Technologies has announced the launch of its new diagnostic laboratory in Jamshedpur, Jharkhand, in collaboration with SecondMedic. The facility was inaugurated by Piyush Singh, Vice President, Thyrocare Technologies.   The launch marks another step in the efforts of Thyrocare towards strengthening its diagnostic network and improving the accessibility of affordable and reliable diagnostic services across the growing markets.   The laboratory is equipped for catering to routine as well as specialised diagnostic testing requirements and is supported by trained professionals, helping to address the evolving healthcare needs of the healthcare partners and patients in the region.   The collaboration with SecondMedic further strengthens the local presence of Thyrocare in Jamshedpur, expanding the reach of its advanced and affordable diagnostic services in Jharkhand and helping people in Jamshedpur to access its quality diagnostic services, supported by timely sample processing and delivery of diagnostic reports. ]]> https://biospectrumindia.com/news/92/28513/deeptek-unveils-global-access-pricing-for-ai-powered-tb-screening.html https://biospectrumindia.com/news/92/28513/deeptek-unveils-global-access-pricing-for-ai-powered-tb-screening.html Mon, 21 Sep 2026 13:27:04 +0530 Pune-based DeepTek, a global leader in AI-powered radiology, has launched Global Access Pricing, a new pricing model enabled through its access agreement with Unitaid and the Clinton Health Access Initiative (CHAI). The initiative makes DeepTek’s WHO-recommended Chest X-ray AI solution significantly more affordable for eligible public-sector and not-for-profit healthcare providers across 138 low- and middle-income countries (LMICs), helping TB programmes expand screening within existing budgets. Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, claiming an estimated 1.23 million lives in 2024. While chest X-rays are critical for TB screening, shortages of radiologists continue to limit timely diagnosis in many high-burden countries. Under Global Access Pricing, eligible programmes can access DeepTek’s AI solution at approximately one-third of its previous pricing, potentially enabling health systems to screen up to three times more people within the same budget. The annual subscription includes unlimited AI analyses per connected X-ray unit, installation, training, product updates, maintenance and technical support, with no hidden add-on costs. The solution supports online, offline and hybrid deployment, including mobile and remote healthcare settings. Beyond TB, DeepTek’s AI detects 20+ clinically relevant chest abnormalities, with transparent pricing also available for additional indications such as cardiomegaly, silicosis and lung cancer.   ]]> https://biospectrumindia.com/news/92/28509/nm-medical-unveils-mumbais-first-open-standing-mri-machine.html https://biospectrumindia.com/news/92/28509/nm-medical-unveils-mumbais-first-open-standing-mri-machine.html Fri, 18 Sep 2026 17:41:57 +0530 NM Medical has announced the launch of Mumbai's first Open Standing MRI machine. The new facility is now operational at NM Medical's center at Marine Lines, Mumbai. Conventional closed MRI machines require patients to lie still inside a narrow tunnel. This Open Standing MRI allows imaging in sitting, standing, and lying positions instead. This helps radiologists assess the spine, joints, and musculoskeletal system under natural, weight bearing conditions, in the same postures where many patients usually feel pain. It is especially suited for patients with claustrophobia or anxiety, elderly patients, patients with mobility challenges, and those who find conventional scanners restrictive. Capturing images while the body bears its own weight can reveal spinal and joint problems that may not show up on a scan taken lying down. This helps doctors decide between conservative treatment and surgery and supports more accurate surgical planning. The machine uses advanced G Scan (Gravity Scan) technology, with Q Spine software for detailed analysis of the spine under load, and True Motion technology to capture movement of joints and the cervical spine. The open design removes the confined tunnel found in traditional MRI machines. Scans do not involve ionising radiation, and most examinations are completed within 20 to 45 minutes. ]]> https://biospectrumindia.com/news/92/28439/sanofi-signs-loi-with-tricog-health-to-support-ai-enabled-cardiac-diagnostics-solutions.html https://biospectrumindia.com/news/92/28439/sanofi-signs-loi-with-tricog-health-to-support-ai-enabled-cardiac-diagnostics-solutions.html Mon, 07 Sep 2026 18:36:07 +0530 Sanofi Healthcare India has signed a Letter of Intent (LoI) with Bengaluru-based Tricog Health, a Bharat Innovates startup, taking a concrete step towards enabling India's startup and entrepreneurship ecosystem.   Sanofi came in touch with Tricog Health at the Bharat Innovates 2026 summit where the Ministry of Education, Government of India showcased 120 of India’s best deep tech startups at a global stage in France.   Under this partnership, Sanofi will provide mentorship, market access support, and potential financial investment to Tricog, a health-tech startup that supplies virtual cardiac diagnostic tools and services that are built by combining artificial intelligence and medical expertise.   The three-year collaboration reflects a shared commitment to nurturing homegrown innovation and building a robust entrepreneurial ecosystem that can drive meaningful impact in healthcare and beyond. This partnership comes against the backdrop of the India-France Year of Innovation 2026 — a landmark bilateral initiative placing innovation at the core of the India-France relationship.   Sanofi also plans to engage with other healthcare innovators among the deep-tech ventures identified under the Bharat Innovates initiative, including those emerging from IITs and other higher education institutions, incubators, and innovation hubs across the country. Sanofi will be extending its support to more startups such as Ahammune Biosciences and the Translational Health Science and Technology Institute, which are addressing some of healthcare's most pressing challenges through cutting-edge research and technology.      Image caption- Prateek Golecha, Chief Growth Officer, Tricog Health (L) with Deepak Arora, Managing Director, Sanofi India (R) ]]> https://biospectrumindia.com/news/92/28430/health-minister-inaugurates-centre-for-advanced-bladder-diagnostics-at-safdarjung-hospital.html https://biospectrumindia.com/news/92/28430/health-minister-inaugurates-centre-for-advanced-bladder-diagnostics-at-safdarjung-hospital.html Fri, 04 Sep 2026 18:13:14 +0530 Union Minister for Health and Family Welfare Jagat Prakash Nadda inaugurated the Centre for Advanced Bladder Diagnostics in the Department of Urology and PET-CT and SPECT-CT facilities in the Department of Nuclear Medicine at Vardhman Mahavir Medical College (VMMC) and Safdarjung Hospital, New Delhi. J P Nadda also visited the Heart Command Centre and Sports Injury Centre located at Safdarjung Hospital and reviewed the services and activities being offered at these centres. The Advanced Bladder Diagnostic Centre has been established with the integration of video urodynamics and near infrared spectroscopy. The facility will provide assistance in conducting detailed assessment of bladder function and diagnosing urinary bladder disorders, including complex cases involving neurological conditions. A significant feature of this centre is the integration of Video Urodynamic Study (VUDS) with brain mapping via Near-Infrared Spectroscopy (NIRS), a first in India. This enables assessment of changes in cerebral blood oxygen levels during bladder filling and emptying and can help clinicians determine whether a bladder disorder is bladder-related, neurological, or a combination of both. The centre is expected to serve approximately 5,000 patients annually, strengthening the availability of specialised urology diagnostic services at the hospital. ]]> https://biospectrumindia.com/news/92/28426/medgenome-launches-oncotrack-mrd-to-transform-personalised-cancer-care-in-india.html https://biospectrumindia.com/news/92/28426/medgenome-launches-oncotrack-mrd-to-transform-personalised-cancer-care-in-india.html Thu, 03 Sep 2026 22:18:31 +0530 Advancing a new frontier in precision cancer care, MedGenome, India’s leading genomics‑driven diagnostics and research services company, has announced the launch of OncoTrack MRD, a personalised and Ultrasensitive NGS-based tumour‑informed Molecular Residual Disease (MRD) test. The test was unveiled at an event in Bengaluru, by leading oncologists Dr Niti Raizada, Dr Vinayak Maka, and Dr Rajeev Vijayakumar, along with Ramprasad Vedam, PhD, CEO, MedGenome Labs. The experts came together to discuss advancements in personalised cancer care in India, the importance of earlier detection of cancer relapse and the role of molecular monitoring in cancer care. MedGenome’s OncoTrackMRD is a comprehensive, personalised, tumour-informed, molecular residual disease test for patients previously diagnosed with cancer. Tailored to each patient using their own tumour tissue, the test analyses circulating tumour DNA to detect and measure residual cancer, identify potential recurrence earlier than conventional methods, and support treatment decisions. Developed in-house, its ultra-sensitive approach is designed to track tumour-specific signals, instead of relying on a generic set of mutations. OncoTrack MRD enables clinicians to monitor relapse throughout the course of cancer care through a simple, repeatable blood test that can be performed multiple times a year, as clinically appropriate. By tracking changes in tumour DNA over time, it provides insights into residual disease and treatment response and can help identify the risk of recurrence earlier. With convenient home sample collection and nationwide availability, OncoTrack MRD enables accessible, longitudinal monitoring for patients across India.    ]]> https://biospectrumindia.com/news/92/28428/iit-m-and-cmc-vellore-build-ai-tools-for-early-kidney-disease-detection.html https://biospectrumindia.com/news/92/28428/iit-m-and-cmc-vellore-build-ai-tools-for-early-kidney-disease-detection.html Thu, 03 Sep 2026 23:09:24 +0530 Researchers from Indian Institute of Technology Madras (IIT-M) and Christian Medical College (CMC), Vellore, have developed a set of Artificial Intelligence (AI)-based tools designed to assist in the early detection and assessment of kidney diseases, which affect millions of people worldwide. The team has developed three technologies that complement each other- A machine learning model that uses clinical and laboratory information to predict the risk of chronic kidney disease (CKD). A deep learning system that automatically analyzes CT scans and classifies them into four categories: normal kidney, kidney cyst, kidney stone, and kidney tumour. A 3D imaging platformthat recreates kidneys from CT scans to precisely assess tumour volume and the percentage of kidney involvement. These tools can enable earlier diagnosis, which could help slow the disease process and reduce the need for expensive interventions like dialysis. The CT image classifier has been trained with over 12,000 images and can distinguish healthy kidneys from cysts, stones and tumors. The 3D imaging framework developed using open-source software provides an inexpensive and repeatable method for measuring tumor burden, which can provide valuable information to help guide treatment decisions. The CKD prediction model was implemented in a user-friendly prototype interface to facilitate future clinical translation. The team also worked on making it more accurate and more easily understood by the doctors who are using it to make their predictions. The team intends to test the models with more patient information sets to validate them and establish stronger partnerships with health care institutions for deployment in the real world. The researchers are also exploring the long-term integration of these AI technologies with minimally invasive wearable sensing systems and Digital Twin platforms to enable personalised kidney health monitoring ]]> https://biospectrumindia.com/news/92/28406/philips-collaborates-with-cent-to-advance-preventive-diagnostics-and-early-risk-detection-in-india.html https://biospectrumindia.com/news/92/28406/philips-collaborates-with-cent-to-advance-preventive-diagnostics-and-early-risk-detection-in-india.html Wed, 02 Sep 2026 13:16:45 +0530 Philips, a global leader in health technology, has announced a strategic collaboration with Cent to advance preventive diagnostics and early risk detection in India. Bringing together Philips' advanced imaging innovations and Cent's preventive health screening model, the collaboration aims to explore new approaches to identifying health risks earlier and supporting a more proactive approach to healthcare. Globally, healthcare systems are evolving from reactive disease management towards predictive and preventive care, and the need for advanced technologies that enable earlier risk identification has become increasingly important. As part of the collaboration, Philips will deploy its helium-free, wide-bore 70 cm 1.5T MRI systems equipped with AI-enabled SmartSpeed image acceleration at Cent preventive health screening centres. The collaboration is intended to support enhanced screening experience for individuals, high-quality imaging and more efficient MRI workflows, while enabling the evaluation of neurological, spine and oncology-related indications and risk assessment pathways. It will also evaluate MRI protocols, clinical workflows and operational requirements necessary to support preventive screening and risk assessment in asymptomatic individuals. ]]> https://biospectrumindia.com/news/92/28411/neuberg-diagnostics-strengthens-north-india-footprint-in-partnership-with-mahajan-imaging-labs.html https://biospectrumindia.com/news/92/28411/neuberg-diagnostics-strengthens-north-india-footprint-in-partnership-with-mahajan-imaging-labs.html Wed, 02 Sep 2026 16:50:11 +0530 Chennai-based Neuberg Diagnostics has entered into a strategic joint venture partnership with Mahajan Imaging & Labs to strengthen and expand pathology and wellness services across North India. The collaboration brings together Neuberg's proven pathology and genomics capabilities, clinical and operational expertise, multi-market experience and IT & digital infrastructure with Mahajan Imaging & Labs' decades of experience in radiology, Nuclear Medicine, PET CT and advanced diagnostics, established presence across Delhi NCR & Jaipur, and deep clinical expertise. As the exclusive partner for seven states of North India, Neuberg is now positioned to leverage Mahajan Imaging & Labs' strong regional presence and existing pathology capabilities to expand its network. Through this partnership, Neuberg will collaborate with Mahajan Imaging & Labs to strengthen and integrate its presence in the existing labs in Noida, Lucknow and Jammu, reinforcing Neuberg's footprint in the region. The two organisations will work towards greater integration across pathology, imaging, nuclear medicine and genomics. This partnership enables Neuberg to enhance its wider network across North India with Mahajan Imaging & Labs' established expertise in complex diagnostic evaluation. For Mahajan Imaging & Labs, the partnership brings operating scale and infrastructure to support its next phase of growth. Kabir Mahajan will serve as Chief Executive Officer for the Joint Venture operations, leading the organisation's operations and growth agenda.   ]]> https://biospectrumindia.com/news/92/28360/mahajan-imaging-labs-opens-integrated-centre-of-excellence-in-diagnostics-in-noida.html https://biospectrumindia.com/news/92/28360/mahajan-imaging-labs-opens-integrated-centre-of-excellence-in-diagnostics-in-noida.html Sat, 22 Aug 2026 18:47:41 +0530 Mahajan Imaging & Labs has expanded its diagnostic services to Uttar Pradesh with the launch of an Integrated Centre of Excellence in Diagnostics in Noida, as early detection and timely diagnosis become increasingly important to healthcare delivery. The facility brings together advanced imaging, pathology, genomics, molecular diagnostics and personalised health assessments at one location, serving patients from Noida, western Uttar Pradesh and the Delhi NCR. The centre was inaugurated by Defence Minister of India, Rajnath Singh, who lit the ceremonial lamp along with Member of Parliament from Gautam Buddh Nagar, Dr Mahesh Sharma; former Cabinet Secretary Rajiv Gauba; Member of NITI Aayog, television anchor and journalist Rajat Sharma; MP Bansuri Swaraj; actor Sharmila Tagore and other dignitaries present at the occasion. The government has expanded the national non-communicable disease (NCD) network to 770 District NCD Clinics, 6,410 NCD clinics at Community Health Centres and 233 Cardiac Care Units, reflecting the wider shift towards earlier detection and management of disease. This shift is also increasing the importance of timely and accurate diagnostics in supporting early detection, clinical decision-making and treatment planning. The newly launched centre includes Uttar Pradesh’s first Ultra-Fast AI-powered 3T MRI scanner, the Excel 3T, along with a 160-slice CT scanner. Other imaging services include 3D-4D ultrasound, Colour Doppler, shear-wave elastography, full-field digital mammography, DEXA bone densitometry, CBCT/OPG and digital X-ray, while neurophysiology services include EEG and EMG. The centre also offers comprehensive pathology services across hematology, clinical biochemistry, microbiology, serology, immunology, histopathology and cytology, along with next-generation sequencing (NGS), molecular diagnostics, genomics and personalised health assessments.   ]]> https://biospectrumindia.com/news/92/28348/orange-health-labs-expands-into-radiology-with-advanced-scanning-centres.html https://biospectrumindia.com/news/92/28348/orange-health-labs-expands-into-radiology-with-advanced-scanning-centres.html Thu, 20 Aug 2026 16:58:14 +0530 Orange Health Labs is expanding beyond pathology into radiology and advanced diagnostic imaging, as the company seeks to build an integrated platform covering multiple aspects of health measurement. The Bengaluru-based company plans to establish state-of-the-art scanning centres as part of its expansion strategy, supported by its recently raised $30 million investment. The funding is being deployed towards advanced laboratory equipment, collection centres and the company’s entry into radiology. “Radiology is not something we are entering just for margins. It is about share of wallet and giving the consumer a comprehensive value proposition for measuring their health,” said Tarun Bhambra, Co-founder, Orange Health Labs. According to the company, around 30 per cent of prescriptions from doctors in key specialties include scans. Orange Health Labs also sees customer drop-off when existing users move to another diagnostic provider for imaging services. By bringing radiology into its platform, the company aims to retain customers within its ecosystem while connecting pathology and imaging data. The strategy could enable doctors and consumers to access a more complete longitudinal view of an individual’s diagnostic history. Orange Health Labs currently operates around 70 stores, including 45 in Bengaluru and 25 across other cities. The company plans to add around 100 stores during the current year, taking its network towards 180–200 centres across its expansion markets. The radiology expansion is part of the company’s wider ambition to move from being an on-demand pathology provider towards a comprehensive health-measurement platform. Alongside physical infrastructure, Orange Health Labs is developing a doctor-facing application that enables physicians to monitor patients’ diagnostic trends. Its consumer platform is also being enhanced with AI-powered insights that can combine historical and current diagnostic data. The company said the broader objective is to give consumers access to pathology, radiology and longitudinal health information through a single ecosystem.   Narayan Kulkarni narayan.kulkarni@mmactiv.com ]]> https://biospectrumindia.com/news/92/28325/4basecare-launches-targt-indiegene-v2-for-comprehensive-cancer-profiling.html https://biospectrumindia.com/news/92/28325/4basecare-launches-targt-indiegene-v2-for-comprehensive-cancer-profiling.html Mon, 17 Aug 2026 16:48:24 +0530 Bengaluru-based startup 4baseCare, a precision oncology company building genomic and clinical intelligence for diverse populations, has announced the launch of TARGT Indiegene® V2, the next generation of its comprehensive genomic profiling (CGP) test for cancer biomarker testing. The journey began on 15 August 2021, when 4baseCare launched the first Indiegene developed from insights generated through Indian tumour genomics and with the ambition of making comprehensive cancer profiling more accessible. Five years of continuous innovation, clinical experience and genomic insights have now led to Indiegene V2. With 2,206 genes, V2 significantly expands the genomic breadth of the original panel. More importantly, it introduces a different way of looking at cancer. Cancer is more than a mutation. Tumours are driven by interconnected biological processes that influence growth, survival, DNA repair, immune evasion and progression. TARGT Indiegene® V2 brings this perspective into CGP through genomic coverage mapped across the Hallmarks of Cancer. “Developed through 4baseCare’s experience in population-relevant oncology and now being taken to global markets, TARGT Indiegene® V2 represents the next chapter in our vision to build globally relevant precision-oncology solutions for diverse and historically underrepresented populations”, said Kshitij Rishi, Co-Founder and COO, 4baseCare. ]]> https://biospectrumindia.com/news/92/28326/tata-capital-healthcare-fund-iii-leads-30-m-investment-in-tenet-diagnostics.html https://biospectrumindia.com/news/92/28326/tata-capital-healthcare-fund-iii-leads-30-m-investment-in-tenet-diagnostics.html Mon, 17 Aug 2026 16:53:50 +0530 Tata Capital Healthcare Fund III (TCHF III), the healthcare-focused private equity fund of Tata Capital Ltd, and Blue Earth Capital AG, a Switzerland-based specialist global impact investor, has announced investment of approximately $30 million in Tenet Medcorp (Tenet Diagnostics) for an undisclosed equity stake. The investment in Tenet marks one of the first investments from Tata Capital Healthcare Fund III, which achieved its first close earlier this year. Founded in 2018 by Sricharan Devineni, Tenet Diagnostics has emerged as a leading integrated diagnostics platform focused on building a network of high-quality radiology and pathology centres across India. The company currently operates more than 35 diagnostic centres across 14 states, supported by a pan India B2B Laboratory network with a super- speciality test menu of over 3,000 tests. This investment will support Tenet’s next phase of growth as the company seeks to deepen its presence in existing markets, strengthen its B2B network and pursue strategic inorganic opportunities. Visalakshi Chandramouli, Managing Partner, Tata Capital Healthcare Fund said, “Diagnostics is increasingly becoming a consumer-driven category where patients value speed, transparency, and accuracy. Under Sricharan’s leadership, Tenet has built one of the fastest-growing integrated diagnostics platforms in India, a model still rare at this scale. The growth is disciplined, with strong accreditation, a balanced B2B-B2C mix, and a proven playbook across three states. Through TCHF III, we’re backing that discipline as a ‘capital-plus’ partner, bringing our expertise and network to fuel Tenet’s next phase of growth.” ]]> https://biospectrumindia.com/news/92/28305/elephas-biosciences-announces-exclusive-commercial-partnership-in-india-with-neuberg-diagnostics.html https://biospectrumindia.com/news/92/28305/elephas-biosciences-announces-exclusive-commercial-partnership-in-india-with-neuberg-diagnostics.html Fri, 14 Aug 2026 13:52:46 +0530 Elephas Biosciences Corporation, a US-based company that has developed an innovative live tissue platform for immunotherapy response prediction, has announced an exclusive partnership with Chennai-based Neuberg Diagnostics, one of India's leading pathology and molecular diagnostics groups. Under the agreement, Neuberg will become Elephas' commercial partner in India, marking a significant step in Elephas' global commercialisation strategy. Elephas continues to pursue strategic partnerships with international organisations that share its mission of improving outcomes for patients undergoing immunotherapy. Together with Elephas, Neuberg will bring the elive™ platform into its own laboratory infrastructure, with the goal of launching its own clinical test in India by the end of 2026.  The partnership combines Neuberg's established oncology diagnostics expertise with Elephas' functional research platform. Pairing these complementary technologies provides oncologists with a more comprehensive view of cancer by integrating molecular profiling with live tumor functional testing. Alongside the commercial agreement, Neuberg will serve as Elephas' research partner in India, processing tumour biopsy samples on the elive platform at its flagship laboratory in Ahmedabad. This research is expected to generate local evidence supporting the platform's performance as it moves toward broader adoption.   ]]> https://biospectrumindia.com/news/92/28314/redcliffe-labs-and-skyroot-aerospace-launch-indias-first-diagnostics-space-sciences-collaboration.html https://biospectrumindia.com/news/92/28314/redcliffe-labs-and-skyroot-aerospace-launch-indias-first-diagnostics-space-sciences-collaboration.html Fri, 14 Aug 2026 21:58:21 +0530 In a landmark initiative coming together of India’s healthcare and private space ecosystems, Redcliffe Labs, one of India’s fastest-growing omnichannel diagnostic service providers, and Skyroot Aerospace, India’s first private company to reach orbit, have joined hands to explore the future of diagnostics in space. The collaboration brings together two distinctly Indian capabilities diagnostic science and space technology to study how diagnostic reagents perform under the extreme conditions of Low Earth Orbit, while exploring how the learnings could advance diagnostics on Earth. The first step is DRIFT-1, which will place Redcliffe Labs' dry diagnostic reagents in Low Earth Orbit for 90 days, alongside an identical ground control. Comparing the two will help establish how the space environment affects reagent stability and performance and generate a flight-heritage dataset for the technology. The initiative extends beyond the first mission, with potential applications spanning space-enabled diagnostics, astronaut health, life sciences and microgravity research, including future point-of-care diagnostic solutions for human spaceflight such as Gaganyaan and the Bharatiya Antariksh Station. For Redcliffe Labs, the opportunity lies in turning this data into knowledge that can inform more resilient diagnostic technologies for challenging environments on Earth, including settings where conventional infrastructure or cold-chain availability is limited.   ]]> https://biospectrumindia.com/news/92/28281/lifecell-international-partners-with-shraddha-diagnostics-for-expansion.html https://biospectrumindia.com/news/92/28281/lifecell-international-partners-with-shraddha-diagnostics-for-expansion.html Mon, 10 Aug 2026 16:26:14 +0530 LifeCell International, one of India’s integrated diagnostics and preventive healthcare companies, has entered into a strategic partnership with Shraddha Diagnostics to expand access to advanced and specialised diagnostic services across Gujarat. The partnership combines Shraddha Diagnostics established regional presence, clinician relationships and expertise in routine diagnostics with LifeCell’s scientific capabilities, specialised diagnostic portfolio and technology-enabled laboratory infrastructure. Together, the organisations will operate the Gujarat business under the Shraddha LifeCell entity. With Shraddha Diagnostics’ existing network of six laboratories and four centres across Ahmedabad and Surat, the partnership will provide access to a combined portfolio of approximately 4,500 diagnostic tests, covering routine pathology as well as specialised areas including genomics, oncology, transplant and IVF diagnostics. Together, LifeCell and Shraddha Diagnostics aim to extend their diagnostic services across the entire state of Gujarat, enabling clinicians and patients to access a broader range of diagnostic capabilities through an integrated regional platform. The partnership will focus on strengthening diagnostic quality and accessibility, expanding the specialised test portfolio, enhancing technology and digital capabilities, and improving the overall experience for patients, clinicians and healthcare partners.   ]]> https://biospectrumindia.com/news/92/28282/shankara-cancer-hospital-and-4basecare-partner-to-make-comprehensive-genomic-testing-more-affordable.html https://biospectrumindia.com/news/92/28282/shankara-cancer-hospital-and-4basecare-partner-to-make-comprehensive-genomic-testing-more-affordable.html Mon, 10 Aug 2026 16:37:25 +0530 4baseCare, a precision oncology company focused on making personalised cancer care accessible and affordable, has partnered with Shankara Cancer Hospital and Research Centre to strengthen its precision oncology capabilities by integrating advanced Next-Generation Sequencing (NGS)-based genomic testing into routine clinical practice. As part of the collaboration, Shankara Cancer Hospital has upgraded its molecular diagnostics laboratory with a high throughput and advanced Next Generation Sequencing platform and adopted TarGT™ Indiegene, 4baseCare's comprehensive genomic profiling assay. The test analyses over 1,200 cancer-associated genes using integrated DNA and RNA sequencing, enabling the detection of clinically actionable biomarkers that help oncologists make more informed, personalised treatment decisions. A key objective of the partnership is to make comprehensive genomic profiling more affordable and accessible. Through this initiative, TarGT™ Indiegene will be offered at a subsidised cost, allowing many more cancer patients to benefit from precision oncology who previously may not have had access due to the high cost of testing. ]]> https://biospectrumindia.com/news/92/28285/govt-supports-commercialisation-of-indigenous-ai-powered-cervical-cancer-screening-technology.html https://biospectrumindia.com/news/92/28285/govt-supports-commercialisation-of-indigenous-ai-powered-cervical-cancer-screening-technology.html Mon, 10 Aug 2026 19:32:24 +0530 The Technology Development Board (TDB) of the Department of Science and Technology (DST), Government of India, has entered into an agreement with Griva Healthcare in Visakhapatnam. The agreement will support the manufacture and commercialisation of an indigenously developed, Artificial Intelligence (AI)-enabled portable digital colposcope 'GrivaVision'. 'Cervivision' helps in early detection of lesions before they become cancerous in the cervix. In collaboration with TDB, the company will set up manufacturing capacity in Kollam, Kerala, enabling extensive production and use of the technology on a commercial scale. This initiative aims to make cervical cancer screening more accessible and affordable, especially in primary and community healthcare centers. Simultaneously, it will help strengthen domestic capabilities in advanced medical devices and reduce dependence on imported diagnostic equipment. GrivaVision is a portable diagnostic platform that integrates a high-definition camera, in-built display, user-friendly interface, advanced optics, and indigenous AI-enabled software. Designed for visualization of the vaginal passage and the examination of cervical lesions, the system assists gynecologists in identifying pre-cancerous abnormalities during routine diagnostic check-ups. The technology is designed according to the Automated Visual Assessment (AVE) standards approved by the World Health Organization (WHO) and its software is ABDM compliant, enabling its integration with India's evolving digital health ecosystem. The product is a category B non-invasive medical device and is licensed to manufacture CDSCO category B. It is being developed to ISO 13485 quality standards. The hardware architecture is the company's own specialty and is patented by Griva Healthcare in India. The company is currently engaged in R&D work at AIC-AMTZ Medivalley, Visakhapatnam, and will help it move towards commercial production at the upcoming facility to be set up in Kerala under the TDB supported project. The technology has been developed and manufactured in India, and more than 50% of its product components are currently indigenously sourced. Large-scale commercialisation is expected to further strengthen the home medical device value chain and create a cost-effective Indian option in cervical cancer diagnosis.   ]]> https://biospectrumindia.com/news/92/28287/redcliffe-labs-acquires-megavision-diagnostics-for-rs-40-cr.html https://biospectrumindia.com/news/92/28287/redcliffe-labs-acquires-megavision-diagnostics-for-rs-40-cr.html Mon, 10 Aug 2026 20:10:39 +0530 Redcliffe Labs has announced the acquisition of Pune-based Megavision Diagnostics Center. The acquisition marks another strategic milestone in Redcliffe's journey towards building an integrated diagnostics platform, strengthening its integrated diagnostics capabilities by bringing advanced imaging and pathology together under one trusted ecosystem. Megavision Diagnostics adds two MRI-equipped centers in Pune's Pimpri-Chinchwad, complementing Redcliffe's established pathology network and enabling patients to access a more comprehensive range of diagnostic services. Having served the region for over two decades, Megavision has earned the trust of patients and clinicians alike through its commitment to clinical excellence and quality imaging services. This acquisition brings together Megavision's strong local legacy with Redcliffe's technology-led diagnostics network, creating a stronger foundation for expanding integrated diagnostic services across Western India. Redcliffe will retain Megavision's entire workforce, ensuring continuity of patient care while further enhancing access to seamless, end-to-end diagnostic solutions. Building on its established pathology presence, Redcliffe Labs is now expanding its integrated diagnostics capabilities to deliver more comprehensive diagnostic services. The acquisition of Megavision Diagnostics lays the foundation for a connected diagnostics ecosystem that brings advanced imaging and pathology together, while marking the beginning of the company's long-term strategy to strengthen its presence through strategic partnerships and acquisitions across Western India. Over the past year, the company expanded its regional presence through the acquisitions of Prime Sonography & Diagnostic Center (Kota) and Sarvodaya Diagnostics (Ajmer), now operating under Redcliffe Medicentre Imaging & Labs. Following the acquisition, Dr Kedar Prabhakar Bhate will continue to lead Megavision Redcliffe Labs, working closely with the Redcliffe Clinical Board to strengthen radiology services and drive the expansion of integrated diagnostics across Pune and the surrounding region.   ]]> https://biospectrumindia.com/views/92/28208/from-precision-to-prediction-decentralising-digitising-and-democratising-diagnostics.html https://biospectrumindia.com/views/92/28208/from-precision-to-prediction-decentralising-digitising-and-democratising-diagnostics.html Sat, 01 Aug 2026 11:11:15 +0530 Diagnostics is moving beyond a single test result in the patient journey to becoming an ongoing intelligence layer across the care continuum. The goal is no longer only to diagnose disease more precisely after it appears, but to detect risk earlier, recognise disease before symptoms emerge, monitor progression in real time, and enable intervention before conditions become more severe, costly, or difficult to treat. This shift makes decentralisation and democratisation essential. If diagnosis is the gateway to care, then access to disease diagnostics determines who gets through that gateway and who does not.   This is exactly why the future of diagnostics cannot be only about precision. It must be timely and accessible. Democratisation makes diagnostic tools easier to access and more affordable across care settings. Decentralisation is the operating model that makes this possible. Point-of-care testing, home-based diagnostics, remote monitoring, digital biomarkers, portable molecular platforms, and connected devices are moving testing closer to the patients.  Precision may improve the quality of diagnosis, but democratisation and decentralisation determine whether that diagnosis reaches the populations that need it most. Innovations enabling predictive and preventive diagnostics With richer health data and technologies such as IoT, advanced analytics, machine learning (ML), and artificial intelligence (AI), healthcare is moving from detecting disease after symptoms appear to identifying risk much earlier. AI analyses large datasets to identify microscopic patterns and early structural anomalies before traditional symptoms emerge. AI imaging detects micro-abnormalities years ahead of tumour formation. For example, Qure.ai (Mumbai, India; NY, US) has developed lung cancer algorithms built from Large Language Models (LLMs) and Agentic AI, which not only improve clinical workflows but also enable early detection. Through its partnership with AstraZeneca and the EDISON Alliance, Qure.ai has reached a five-million-scan milestone across 20 countries, applying AI to routine chest X-rays to create opportunities for earlier detection. AI and ML algorithms can process ultra-high-dimensional, heterogeneous multi-omics datasets to detect latent molecular patterns and predictive biomarkers. MedGenome (Bengaluru) uses next-generation sequencing (NGS) with proprietary bioinformatics and AI (such as their VarMiner tool) to diagnose rare diseases and cancers. It also provides Polygenic Risk Score (PRS) tests that quantify an individual's genetic predisposition to common, complex conditions. AI and ML can be used to create a digital twin, which is a dynamic, virtual replica of an individual patient, organ, or biological system. It integrates real-time data from devices, data from labs and clinical records, and advanced analytics to simulate disease progression, personalise treatment, and predict future risk. Twin Health (Chennai, India; California, US) has developed a Digital Twin technology to track and predict metabolic health through data from smart devices, meal logs, and lab work. It also offers real-time guidance on nutrition, activity, sleep, and stress. Innovations enabling decentralisation and democratisation of diagnosis Point-of-care and portable testing are strong enablers of decentralised diagnostics. Molbio Diagnostics (Goa) offers a point-of-care real-time PCR platform with lab-grade accuracy for multiple infectious diseases. Huwel Lifesciences (Hyderabad) has developed Quantiplus, a rapid and affordable open RT-PCR assay for the detection of adult pulmonary tuberculosis (TB). Genes2Me (Gurugram) provides portable RT-PCR systems and kits for infectious diseases such as human papillomavirus (HPV), TB, dengue, malaria, COVID-19, and others.  Home diagnostics are another powerful route to democratisation. They give people the ability to test more conveniently, privately, and repeatedly. HealthCubed India (Bengaluru) has developed a patented, medical-grade, portable, multiparametric diagnostic system that provides instant results for more than 55 parameters, including blood glucose, haemoglobin, blood pressure, infectious disease markers, and an electrocardiogram (ECG). For quick home diagnostics, smartphones are also becoming a powerful diagnostic interface. They can read paper-based tests, analyse medical images, guide self-testing, and connect patients to clinicians. For example, Spark Diagnostics (Gujarat, India; Texas, US) uses smartphone-based tools to interpret lateral flow assays. Remidio (Bengaluru) has developed the Remidio Medios DR AI smartphone app, which is connected to Remidio’s handheld retinal camera for diabetic retinopathy screening. AI-enabled apps are also expanding access to symptom assessment and guided screening. For example, Pinky Promise (Mumbai) uses an AI-enabled, doctor-in-the-loop model to provide reproductive healthcare support to more than 400,000 Indian women. These innovations bring care closer to the patients.  Finally, connected remote monitoring devices are shifting care from overburdened hospitals and clinics into patients’ homes. This is especially important for chronic disease management, where patients need continuous insight rather than occasional testing. Sensio’s (Bengaluru) Orbyt smart ring enables ECG and impedance cardiography monitoring. Zydus Lifesciences (Ahmedabad) has developed AI-powered continuous glucose monitoring systems, Diasens and GlucoLive, for patients with diabetes, CKD, and post-transplant needs. Challenges and the Way Ahead One of the biggest concerns regarding the point-of-care and home-based diagnostic tests is the potentially lower precision and the accuracy of the test compared with the analytical quality of centralised laboratory testing. When tests are performed by patients, community workers, or non-laboratory personnel, errors can occur in sample collection, device handling, alignment, storage, or result interpretation.  The way forward is not to slow decentralisation, but to make it safe and accurate. Point-of-care and home-based tests need rigorous validation, continuous quality monitoring, and clear performance standards before they scale. Central laboratory oversight will remain important, even in decentralised models. For high-risk conditions such as cancer, TB, HIV, hepatitis, and genetic disorders, decentralised tests should not operate as standalone products. They must be embedded into managed care pathways with confirmatory testing, referral protocols, physician review, and patient counseling. AI-based diagnostics bring another layer of complexity. These models depend heavily on the quality and diversity of the datasets they are trained on. In decentralised settings, real-world data can be noisy, incomplete, irregular, and highly variable across populations. This makes bias testing, demographic validation, and ongoing performance monitoring essential. Human oversight should be built into AI-enabled diagnostics, especially for clinical decision-making, to reduce the risk of biased recommendations, unsafe outputs, or over-reliance on automated interpretation.  AI tools must also be designed for the realities of decentralised care. A model that performs well in controlled environments may not work as effectively in noisy community settings. For example, Wadhwani AI’s (Mumbai) Cough Against TB uses cough sounds and self-reported symptoms to screen for presumptive pulmonary TB. The advanced ML for acoustic biomarker screening can filter out background interference and evaluate respiratory health.  The implementation challenge is equally important. Community screening programmes require standardised training and certification models for frontline workers and decentralised test operators. Digital tools can help by embedding guided workflows, video instructions, automated quality checks, error alerts, result interpretation support, and remote supervision. The goal should be to make the test not only portable, but usable, reliable, and safe in real-world settings. Cost is another barrier. Point-of-care testing can have a higher cost per test than centralised laboratory testing, especially when device costs, consumables, maintenance, quality assurance, and connectivity are included. Value-based payment models, bundled screening programmes, and outcome-linked reimbursement can help scale decentralised tests that demonstrate clinical and economic value by reducing delays, preventing complications, or lowering downstream treatment costs. Though the innovations are focused on early diagnosis, decentralisation, and democratisation, one of the biggest risks is poorly designed diagnostics, especially digital diagnostics, which still exclude the most vulnerable and widen the inequalities.  Patients without smartphones, broadband access, digital literacy, insurance coverage, or follow-up care still remain outside the system.  Diagnostic results must be designed for action (treatment, monitoring, follow-up), not just information. Public and private healthcare systems should work toward closing the care loop by integrating these diagnostics into broader care programmes and connecting patients to physicians, counselors, and follow-up services.   Debarati Sengupta, Research Manager, Everest Group  ]]> https://biospectrumindia.com/news/92/28159/bpl-medical-technologies-strengthens-respiratory-diagnostics-portfolio-with-jaeger-medical.html https://biospectrumindia.com/news/92/28159/bpl-medical-technologies-strengthens-respiratory-diagnostics-portfolio-with-jaeger-medical.html Mon, 20 Jul 2026 13:07:26 +0530 Bengaluru-based BPL Medical Technologies has announced its appointment as the authorised sales and service partner for Jaeger Medical's respiratory diagnostics portfolio in India. The appointment represents a strategic expansion of BPL MedTech's respiratory diagnostics portfolio, enabling hospitals and healthcare providers across the country to access globally trusted pulmonary diagnostics solutions supported by BPL's robust nationwide sales and service network. As respiratory diseases continue to place a growing burden on India's healthcare system, the need for accurate and timely diagnosis has become increasingly important. Through this collaboration, BPL Medical Technologies will offer Jaeger Medical's comprehensive portfolio of respiratory diagnostics solutions, including spirometry, pulmonary function testing (PFT) and cardiopulmonary exercise testing (CPET), supporting clinicians in the diagnosis, assessment and monitoring of a wide range of respiratory conditions. Germany-based Jaeger Medical's solutions are already used by leading healthcare institutions across India, including Apollo Hospitals, Manipal Hospitals, AIIMS and JIPMER. With BPL Medical Technologies now providing nationwide sales, installation, application support and after-sales service, hospitals can expect faster response times, dependable technical expertise and enhanced customer support throughout the product lifecycle. Together, Jaeger Medical's internationally trusted respiratory diagnostics portfolio and BPL Medical's pan-India reach will strengthen respiratory diagnostics capabilities across hospitals and diagnostic centres nationwide.   ]]> https://biospectrumindia.com/news/92/28090/redcliffe-labs-expands-national-footprint-with-strategic-entry-into-imphal.html https://biospectrumindia.com/news/92/28090/redcliffe-labs-expands-national-footprint-with-strategic-entry-into-imphal.html Thu, 09 Jul 2026 16:19:16 +0530 Redcliffe Labs, one of India's fastest-growing omnichannel diagnostic service providers, has announced the launch of its first state-of-the-art diagnostic laboratory in Imphal, marking the company's entry into Manipur and further strengthening its commitment to expanding quality healthcare infrastructure across underserved regions of the country.  With this expansion, Redcliffe Labs becomes one of the first three national diagnostic brands to establish a laboratory footprint in the state, bringing reliable, affordable, and high-quality diagnostic services closer to communities across Manipur. Located at RIMS Road, Lalambung Makhong, Thangmeiband, the new facility aims to improve access to advanced diagnostics and reduce reliance on sending samples outside the region for testing. While healthcare infrastructure continues to evolve across the country, access to advanced diagnostic services remains a challenge in several regions, particularly in remote and geographically complex terrains. By establishing a presence in Imphal, Redcliffe Labs aims to strengthen diagnostic access in the region. Every test comes with 4X value benefits, including doctor-verified Smart Reports, expert consultation, personalized diet consultation, and 24x7 AI assistance, enabling individuals to make more informed health decisions with actionable insights along with a digital-first healthcare ecosystem. The state-of-the-art laboratory will offer a comprehensive range of pathology services across Biochemistry, Hematology, Immunoassays, Clinical Pathology, Serology, Hormone, and Microbiology testing, including automated cultures. Patients can conveniently access these services through both laboratory walk-ins and home sample collection, ensuring greater comfort and flexibility, especially for elderly individuals, patients with mobility constraints, and working professionals. Beyond pathology services, patients will also have access to a wider range of diagnostic services through Redcliffe Labs' collaboration with Padma Diagnostic Center. These include X-Ray, Ultrasound, Portable ECG with tele-reporting, EEG, Spirometry, 24-hour, 48-hour and 72-hour Holter ECG monitoring, and DEXA Scan services.   ]]> https://biospectrumindia.com/news/92/28083/admi-and-iit-kanpur-forge-strategic-partnership-to-propel-indias-in-vitro-diagnostics-ecosystem.html https://biospectrumindia.com/news/92/28083/admi-and-iit-kanpur-forge-strategic-partnership-to-propel-indias-in-vitro-diagnostics-ecosystem.html Wed, 08 Jul 2026 21:22:20 +0530 The Association of Diagnostics Manufacturers of India (ADMI) and the Indian Institute of Technology Kanpur (IIT-K) have enacted a landmark Memorandum of Understanding designed to accelerate innovation within the nation In Vitro Diagnostics (IVD) sector. This partnership creates a powerful conduit between academic excellence and commercial diagnostic manufacturing. Spearheaded on behalf of IITK by the National Centre for Flexible Electronics (NCFlexE), this collaboration establishes a robust framework for joint project development and the commercialisation of next-generation IVD solutions. By leveraging NCFlexE’s specialised expertise in flexible electronics and advanced biosensors, the alliance serves as a dynamic platform for technological integration. For ADMI members, this agreement provides crucial access to world-class lab-to-piloting facilities, empowering domestic enterprises to successfully scale and manufacture sophisticated diagnostic technologies. Beyond immediate collaborative research, this MoU is a strategic investment in India’s healthcare infrastructure and national development. It actively drives industry-academia synergy through the exchange of academic materials, the formulation of joint research proposals, and comprehensive capacity building. Together, ADMI and IIT Kanpur will co-develop cutting-edge technology frameworks, publish authoritative white papers, and design resource development programmes tailored to fortify India's self-reliance in medical technology. Grounded in mutual interest, this alliance marks a definitive step toward technological sovereignty, equipping India's diagnostics industry with the foundational research and strategic insights required to deliver high-quality, indigenous healthcare solutions. ]]> https://biospectrumindia.com/news/92/28085/strand-life-sciences-secures-indian-patent-for-blood-based-early-cancer-detection-technology.html https://biospectrumindia.com/news/92/28085/strand-life-sciences-secures-indian-patent-for-blood-based-early-cancer-detection-technology.html Wed, 08 Jul 2026 21:44:20 +0530 Bengaluru-based Strand Life Sciences has announced the grant of an Indian patent covering its integrated platform for early cancer detection using cell-free DNA (cfDNA) analysis. The patented platform brings together high-quality sequencing, rigorous quality control, biologically informed methylation and fragmentomic feature extraction, and machine learning to enable cancer detection and tissue-of-origin prediction from just a blood sample. Widespread methylation pattern changes across the genome are a hallmark of cancer. A key innovation in the patent, among others, is obtaining these methylation patterns using genome sequencing with minimal loss or failure, thus enabling sensitive early cancer detection.  "We believe this innovation represents an important step towards making precision cancer screening more accurate, scalable, and accessible," said Ramesh Hariharan, CEO, Strand Life Sciences.  The granted patent further strengthens the company's intellectual property portfolio in liquid biopsy and reinforces its strategy of developing integrated, AI-enabled molecular approaches for early cancer detection and precision oncology. ]]> https://biospectrumindia.com/news/92/28079/iit-d-launches-national-translational-platform-for-advancing-medical-device-and-diagnostics-innovation.html https://biospectrumindia.com/news/92/28079/iit-d-launches-national-translational-platform-for-advancing-medical-device-and-diagnostics-innovation.html Mon, 06 Jul 2026 19:20:20 +0530 The Indian Institute of Technology (IIT) Delhi has announced the inauguration of a state-of-the-art CNC and Sterilisation & Packaging lab at mPragati, IIT Delhi, a national translational platform dedicated to advancing medical device and diagnostics innovation. Dr Rajiv Bahl, Secretary to Government of India, Department of Health Research and Director General, Indian Council of Medical Research, inaugurated the facilities. The CNC facility provides state-of-the-art precision machining for medical implants, surgical instruments, dental devices, and diagnostic components — enabling indigenous manufacturing with certified biocompatible materials. With advanced multi-axis machining, Swiss-type turning, and high-speed milling, the CNC facility supports both patient-specific and standardised components. It bridges a critical gap in India’s MedTech value chain by reducing reliance on imports and accelerating translation of prototypes into clinically deployable products. The Sterilization & Packaging Facility provides an end-to-end infrastructure for the development, validation, sterilisation, and packaging of medical devices, diagnostics, and biomedical products. The facility is equipped with advanced sterilisation systems, including Ethylene Oxide (EtO) and steam autoclaves, precision device assembly workstations, automated reagent dispensing systems, stability chambers for reagent and product shelf-life validation, a high-precision laser welding system, laser marking, and secure vacuum packaging integrated with batch coding and product traceability. Complementing these capabilities is a comprehensive biological and molecular testing infrastructure comprising thermal cyclers, real-time PCR systems, Trans-Blot systems, gel electrophoresis and gel documentation systems, high-speed ultracentrifuges, HPLC, CO₂ incubators, fluorescence microscopy, biosafety cabinets for mammalian cell culture, and ultra-low temperature storage. ]]> https://biospectrumindia.com/news/92/28070/apollo-cancer-centre-becomes-first-to-launch-guardant-healths-shield-multi-cancer-detection-test-in-india.html https://biospectrumindia.com/news/92/28070/apollo-cancer-centre-becomes-first-to-launch-guardant-healths-shield-multi-cancer-detection-test-in-india.html Sat, 04 Jul 2026 08:37:40 +0530 As early detection remains the most powerful ally in improving survival and quality of life, Apollo Cancer Centres (ACCs), India’s leading and dedicated provider of comprehensive cancer care, has signed a Memorandum of Understanding with Zydus Lifesciences to offer the Shield™ Multi-Cancer Detection (MCD) laboratory developed test by precision oncology company Guardant Health in India. With this launch, ACCs becomes the first healthcare institution in India to offer access to the test. With India’s cancer burden projected to rise to 2.08 million cases by 2040 – a 57.5% increase from 2020 – the need for timely support, early intervention, and reliable information is a crucial requirement. In 2022, more than 1.41 million Indians were diagnosed with cancer. Breast cancer remains the leading cause of cancer-related mortality among women, while oral cancer is the most prevalent cancer among men. Despite the growing burden, cancer screening rates remain low and uneven across the country.  The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types including bladder, colorectal, breast, prostate, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older who are at typical average risk for cancer. In the United States, the Shield MCD test has received Breakthrough Device Designation from the US Food and Drug Administration based on its strong performance in predicting the presence of cancers and cancer tissue of origin in the National Cancer Institute Vanguard Study evaluating emerging MCD technology. Over the years, Apollo Hospitals has consistently pioneered several firsts in Indian healthcare, including advanced robotic surgery, CyberKnife radiosurgery, Proton Therapy, precision oncology, genomics, and AI-enabled healthcare solutions. The introduction of the Shield MCD test further strengthens its leadership in cancer care and innovation. ]]> https://biospectrumindia.com/news/92/28012/reliance-owned-karkinos-healthcare-crosses-one-lakh-hpv-dna-tests.html https://biospectrumindia.com/news/92/28012/reliance-owned-karkinos-healthcare-crosses-one-lakh-hpv-dna-tests.html Wed, 24 Jun 2026 22:14:37 +0530 Karkinos Healthcare, a 100% step-down subsidiary of Reliance Industries Limited, has completed HPV DNA screening for over one lakh women across India, marking an important milestone in expanding access to high-quality cervical cancer screening and follow-up care. Cervical cancer prevention is often limited not only by access to screening, but also by loss to follow-up after a positive result. Mumbai-based Karkinos Healthcare’s model addresses both challenges through World Health Organization-recommended HPV DNA testing and a digitally enabled continuum of care that integrates awareness, screening, tracking, triage, navigation, and follow-up. The milestone has been achieved through multiple implementation models across diverse geographies, including public-health programmes, public-private partnerships, CSR supported initiatives, nurse-assisted and self-sampling programmes, district-level screening efforts, and focused outreach for underserved and high-risk communities. A large share of the women reached are those who, by circumstance or distance, may not otherwise have had access to screening. The achievement demonstrates that high-quality HPV DNA testing can be delivered at scale in India through technology-driven care pathways. The learnings and infrastructure developed through this programme can support wider adoption of organised cervical cancer screening and contribute to India’s cervical cancer elimination efforts. Commenting on this milestone, Dr Neerja Bhatla, Consultant, Early Detection and Women Wellness, Karkinos Healthcare, who is also a Padma Shri awardee and globally acclaimed leader in women’s health and oncology, said, “The evidence has been clear for some time that HPV DNA testing is the most reliable primary screen we have for cervical cancer. What matters now is not testing at scale alone but also ensuring that every woman who tests positive is carried through to diagnosis and treatment across the care continuum. A programme that can demonstrate that linkage at this volume, and well beyond the big cities, is exactly the direction India’s cervical cancer elimination effort needs.” ]]> https://biospectrumindia.com/news/92/27977/admi-and-cliniminds-partner-to-accelerate-diagnostic-manufacturing-capabilities-and-workforce-readiness-.html https://biospectrumindia.com/news/92/27977/admi-and-cliniminds-partner-to-accelerate-diagnostic-manufacturing-capabilities-and-workforce-readiness-.html Tue, 16 Jun 2026 17:18:16 +0530 The Association of Diagnostics Manufacturers of India (ADMI) has announced the signing of a Memorandum of Understanding (MoU) with Cliniminds, a premier health sciences training and educational institute. This strategic alliance is designed to address the core manufacturing, regulatory, and talent acquisition challenges faced by India’s diagnostic startups and SMEs. Central to the MoU is the creation of a specialised manufacturing workforce pipeline. By aligning curriculum with industry needs—specifically in cleanroom operations, quality assurance, and molecular diagnostic assembly—the initiative will provide manufacturers with a pre-trained talent pool, significantly reducing onboarding time and recruitment costs. Key strategic benefits by this include: Regulatory Compliance Upskilling: Specialised certification programmes to help technical teams navigate complex regulations, thereby reducing product approval timelines. Exclusive Corporate Training Discounts: Preferential pricing on Cliniminds’ certification programmes, offering an immediate financial return on ADMI membership by lowering internal training budgets. Industry-Integrated Internships: A formal framework deploying Cliniminds students onto live operational and market research projects, granting manufacturers cost-effective manpower. Domestic Procurement Intelligence: Real-time, localised insights into Public Procurement guidelines, GeM updates, and local content criteria to help members successfully secure government tenders. ]]> https://biospectrumindia.com/news/92/27962/siemens-healthineers-expands-make-in-india-portfolio-with-manufacturing-of-atellica-chemistry-reagents-at-vadodara-factory.html https://biospectrumindia.com/news/92/27962/siemens-healthineers-expands-make-in-india-portfolio-with-manufacturing-of-atellica-chemistry-reagents-at-vadodara-factory.html Mon, 15 Jun 2026 15:40:03 +0530 In an effort to elevate healthcare in India, Siemens Healthineers has begun local manufacturing of Atellica chemistry reagents at its Vadodara facility, a milestone for the Make in India initiative that will benefit patients and healthcare professionals across the country.  These chemistry reagents are used in routine blood tests that detect conditions such as infections, diabetes, and organ function abnormalities. Local production aims to strengthen better access to quality care for patients and supports early detection and preventive care, enabling clinicians to monitor risk factors in time. “Bringing the expertise and legacy of over 50 years, our Vadodara facility will play a pivotal role in producing diagnostic solutions tailored to the needs of Indian laboratories and healthcare providers. This move also aligns with national priorities to boost domestic manufacturing in critical healthcare segments, advancing preventive healthcare and contributing to India’s vision of self-reliance in healthcare technologies", said Hariharan Subramanian, Managing Director, Siemens Healthcare. The Atellica Solution is widely recognised for its innovation, sustainability and efficiency in laboratory diagnostics, and the availability of locally manufactured reagents will further strengthen its value for healthcare providers and patients in India. ]]> https://biospectrumindia.com/news/92/27969/redcliffe-labs-strengthens-footprint-in-rajasthan-with-new-acquisition.html https://biospectrumindia.com/news/92/27969/redcliffe-labs-strengthens-footprint-in-rajasthan-with-new-acquisition.html Mon, 15 Jun 2026 17:11:00 +0530 Redcliffe Labs, India's fastest-growing diagnostics network, has further strengthened its leadership position in Rajasthan and North India through the strategic acquisition of a leading diagnostic centre in Ajmer. As part of its inorganic roll-up strategy, the acquisition marks a significant milestone in the company's vision of building integrated diagnostic ecosystems that bring radiology, pathology, and preventive healthcare together under one roof. The facility will now operate as Redcliffe Medicentre Imaging & Labs, expanding access to advanced diagnostic services for patients across Ajmer and central Rajasthan. With a network of 16 laboratories and over 150 collection centres across Rajasthan, Redcliffe Labs has built one of the state's most extensive diagnostic networks. The acquisition strengthens its presence in Ajmer, a key healthcare hub serving a population of approximately 2.6 million. The centre is strategically positioned to serve patients not only from Ajmer but also from neighboring districts like Talwandi, Indra Vihar, Jawahar Nagar, Mahaveer Nagar, Vigyan Nagar, Keshavpura, Rajeev Gandhi Nagar, Dadabari, Shastri Nagar, Basant Vihar, and more, seeking access to high-quality diagnostics closer to home. Redcliffe Medicentre Imaging & Labs is equipped with a 1.5 Tesla MRI, 128-slice CT Scan, Color Doppler, ECHO, TMT, Ultrasound, and X-Ray services, with the capacity to perform more than 1,200 MRI scans and 1,500 CT scans every month. Combined with Redcliffe Labs' portfolio of over 3,600 pathology tests spanning biochemistry, hematology, immunoassays, clinical pathology, serology, hormones, genetics, and specialized diagnostics, the facility delivers a comprehensive end-to-end diagnostic experience. Redcliffe now has a presence across multiple cities in Rajasthan, including Udaipur, Kota, and Ajmer.  ]]> https://biospectrumindia.com/news/92/27950/indias-validated-hpv-test-to-offer-cervical-cancer-screening-model-for-low-resource-countries.html https://biospectrumindia.com/news/92/27950/indias-validated-hpv-test-to-offer-cervical-cancer-screening-model-for-low-resource-countries.html Fri, 12 Jun 2026 19:12:48 +0530 India has achieved a significant milestone in cervical cancer prevention with the successful validation of the country's first indigenous HPV DNA tests which meet international standards for cervical cancer screening. Published in the International Journal of Cancer, a multicentre study involving leading Indian and international institutions found that Molbio Diagnostics' Truenat HPV-HR Plus met the validation criteria established by the International Agency for Research on Cancer (IARC), the specialised cancer research agency of the World Health Organization (WHO). Cervical cancer remains one of the leading causes of cancer-related deaths among Indian women. The World Health Organization recommends HPV DNA testing as the preferred screening approach for cervical cancer because of its higher sensitivity in detecting high-risk HPV infections compared with conventional cytology-based methods such as the Pap smear. The validation comes at a crucial time for India's cervical cancer elimination efforts, as the country expands HPV vaccination and strengthens screening programmes for women above 30 years of age.  Importantly, the study marks the world's first formal validation of a reduced-valency HPV test— one that deliberately targets only the eight most cancer-causing strains rather than the usual 14 — setting a global scientific benchmark for evaluating this new class of affordable, point-of-care screening tools. The study was conducted through collaboration between leading Indian and international institutions, including AIIMS New Delhi, ICMR-National Institute of Cancer Prevention and Research, ICMR-National Institute for Research in Reproductive and Child Health, the International Agency for Research on Cancer, France, and the Biotechnology Industry Research Assistance Council under the Department of Biotechnology, Government of India. By narrowing its targets to 8 high-risk types, the assay avoids detecting transient, low-risk infections that 14-valent tests often detect. It successfully maintained an exceptional relative clinical specificity (0.99), demonstrating its potential to drastically reduce unnecessary secondary referrals, costly over-triage, and patient anxiety. This targeted approach offers a highly sustainable model for primary cervical cancer screening, particularly within low- and middle-income countries where optimising limited healthcare resources is paramount.  ]]> https://biospectrumindia.com/news/92/27949/avio-smart-market-stack-strengthens-diagnostics-healthcare-vertical-in-discussion-with-mediciti-institute.html https://biospectrumindia.com/news/92/27949/avio-smart-market-stack-strengthens-diagnostics-healthcare-vertical-in-discussion-with-mediciti-institute.html Thu, 11 Jun 2026 19:48:44 +0530 As part of its strategy to build a scalable Diagnostics & Healthcare business, Avio Smart Market Stack (formerly Bartronics India) has initiated strategic discussions with Mediciti Institute of Medical Sciences (MIMS), Hyderabad, to explore opportunities for research collaboration, clinical validation, and adoption of advanced molecular diagnostic technologies. As part of the interaction, Huwel Lifesciences, ASMS' strategic molecular diagnostics partner, showcased its portfolio of indigenous diagnostic technologies and ongoing innovations in molecular diagnostics. The discussions brought together leadership teams, clinicians, researchers, and academic experts to examine how innovative molecular diagnostic solutions can strengthen disease detection, improve clinical decision-making, and enhance healthcare outcomes across India. During the discussions, Huwel Lifesciences showcased its comprehensive portfolio of indigenous molecular diagnostic technologies, including solutions for tuberculosis, multidrug-resistant tuberculosis (MDR-TB), sepsis, HPV screening, hepatitis, antimicrobial resistance (AMR) detection, respiratory diseases, and environmental surveillance. The discussions focused on collaborative research, clinical validation studies, real-world evidence generation, and opportunities for adoption and deployment of Huwel's diagnostic technologies within Mediciti's healthcare ecosystem. The organisations also explored the possibility of pilot programmes and product evaluations across selected departments to assess their impact on routine diagnostic workflows.     As part of its Diagnostics & Healthcare growth strategy, ASMS is actively building market access channels for advanced diagnostic technologies through partnerships with healthcare institutions, government programs, research organisations, and industry stakeholders. Through its partnership with Huwel Lifesciences, the company is working to accelerate validation, adoption, procurement, and large-scale deployment of indigenous diagnostic solutions across India and international markets. ]]> https://biospectrumindia.com/news/92/27935/remidio-receives-grant-from-gates-foundation-to-advance-maternal-healthcare.html https://biospectrumindia.com/news/92/27935/remidio-receives-grant-from-gates-foundation-to-advance-maternal-healthcare.html Wed, 10 Jun 2026 11:58:05 +0530 Bengaluru-based Remidio Innovative Solutions has received a grant from the Gates Foundation to advance its Oculomics platform, which uses retinal imaging and AI to detect signs of systemic disease, for maternal health applications in low- and middle-income countries (LMICs). The initiative will focus on improving early risk assessment for major pregnancy complications, including pre-eclampsia (PE), anemia and gestational diabetes mellitus (GDM). The program will be carried out across countries in Africa and India, regions that together bear the overwhelming share of the global maternal and perinatal disease burden. "The women most at risk from pre-eclampsia and gestational diabetes are often the least likely to reach a laboratory or a specialist in time," said Dr Anand Sivaraman, Chief Executive Officer and Founding Director, Remidio. "A retinal image takes seconds and can be captured by a frontline worker with minimal training. This grant allows us to ask a clear question with real rigour: can the platform already deployed widely for diabetic retinopathy also help identify pregnancies at risk, in the places where that information is needed most." The biological link between retinal microvascular changes and systemic vascular and metabolic disease is now well established. Yet in the primary care and community settings where maternal mortality is concentrated, the diagnostic tools that currently support early risk stratification, namely complex laboratory assays, biochemical biomarkers and Doppler-based assessments, are largely unavailable at the point of care, requiring laboratory infrastructure, trained personnel and referral pathways that simply do not exist for most pregnant women in LMICs. Non-invasive retinal imaging, by contrast, is quick, easy to perform by frontline health workers with minimal training, and inherently scalable, making it uniquely suited to bringing advanced risk assessment to the front lines of antenatal care. Remidio's portable, smartphone-based retinal imaging platform is already widely deployed across primary care and community screening programmes for diabetic retinopathy, glaucoma and AMD. The grant will extend this platform into maternal health, with implementation across partner sites in Africa and India. ]]> https://biospectrumindia.com/news/92/27936/thyrocare-sets-up-new-diagnostic-lab-in-up-in-association-with-secondmedic.html https://biospectrumindia.com/news/92/27936/thyrocare-sets-up-new-diagnostic-lab-in-up-in-association-with-secondmedic.html Wed, 10 Jun 2026 14:56:28 +0530 Thyrocare Technologies has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh (UP), in association with SecondMedic.  The new facility was inaugurated by Rajdeep Panwar, Chief Commercial Officer, Thyrocare Technologies. Prior to this launch, Thyrocare operated three laboratories in Uttar Pradesh, located in Lucknow, Noida, and Varanasi. With the addition of Prayagraj, the company further strengthens access to diagnostic services across the state.  The new laboratory is equipped  with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised as well as routine testing requirements, offering support to ongoing and  preventive healthcare needs.  This expansion aligns with the consistent focus of Thyrocare  towards meeting the increasing demand for reliable diagnostic services in emerging markets and bolstering its network. The Prayagraj diagnostic lab further expands the presence of the company in the northern part of the country. With this launch, Thyrocare continues to expand its presence in Uttar Pradesh, with an emphasis on growing the accessibility of diagnostic services  across cities beyond the metro markets. Thyrocare remains committed to strengthening its network and bringing reliable healthcare services closer to patients. ]]> https://biospectrumindia.com/news/92/27928/agilus-diagnostics-launches-idylla-system-for-rapid-detection-of-cancer-mutations.html https://biospectrumindia.com/news/92/27928/agilus-diagnostics-launches-idylla-system-for-rapid-detection-of-cancer-mutations.html Tue, 09 Jun 2026 19:44:30 +0530 Agilus Diagnostics, subsidiary of Fortis Healthcare, has launched the automated Idylla molecular diagnostics system at its Goregaon laboratory in Mumbai, enabling rapid detection of cancer-related genetic mutations within 2.5 to 3 hours. The launch marks a significant advancement in accelerating clinical decision-making and expanding access to precision oncology in India. The Idylla system is a fully integrated, cartridge-based molecular testing platform that combines sample processing, nucleic acid extraction, amplification and detection into a single automated workflow. By minimising manual intervention and pre-analytical variability, the system delivers highly accurate and reproducible results in a significantly shorter timeframe compared to conventional molecular testing methods, which can take several days. This capability is particularly critical in oncology, where timely identification of actionable biomarkers plays a decisive role in guiding targeted therapies. The platform enables rapid detection of clinically relevant mutations, including: EGFR – commonly associated with lung cancer in Indian and Asian populations KRAS and NRAS – key markers in colorectal and pancreatic cancers BRAF – present across multiple tumor types, including melanoma and colorectal cancer Additionally, the system supports detection of emerging biomarkers such as MSI (Microsatellite Instability) and IDH1/IDH2, which are increasingly important in determining eligibility for advanced targeted and immunotherapies. With this addition, Agilus Diagnostics further enhances its integrated oncology diagnostics ecosystem, enabling faster, more efficient biomarker-driven treatment pathways and improved access to advanced cancer care. ]]> https://biospectrumindia.com/news/92/27910/molbio-diagnostics-deploys-decentralised-molecular-testing-solution-amid-ongoing-ebola-outbreak.html https://biospectrumindia.com/news/92/27910/molbio-diagnostics-deploys-decentralised-molecular-testing-solution-amid-ongoing-ebola-outbreak.html Thu, 04 Jun 2026 19:17:52 +0530 Goa-based Molbio  Diagnostics has developed a real-time PCR test capable of detecting Ebola disease caused by all three outbreak-associated viruses — Ebola virus, Sudan virus, and Bundibugyo virus. Designed for decentralised settings, the test runs on Molbio’s near-patient portable Truenat platform and delivers results in approximately one hour, enabling faster clinical decision-making and timely public health intervention.  The company is currently working closely with the World Health Organization (WHO), the Africa Centres for Disease Control and Prevention, and local authorities to validate the test on clinical specimens urgently. Initial deployment has commenced, and test kits have already reached affected regions in Uganda and the DRC. On 17 May, the WHO declared the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda a Public Health Emergency of International Concern. As of 21 May, 746 suspected cases and 176 deaths among suspected cases had been reported in the DRC. On 22 May, Molbio Diagnostics participated in the emergency consultation convened by the World Health Organization and the Africa Centres for Disease Control and Prevention (Africa CDC), bringing together key stakeholders to accelerate the research, development, and deployment of decentralised diagnostic solutions to support outbreak response efforts. The consultation highlighted significant challenges arising from the limited availability of appropriate decentralised testing solutions for the disease caused by the Bundibugyo virus. ]]> https://biospectrumindia.com/features/92/27861/indias-diagnostics-shifts-to-self-reliance-and-innovation.html https://biospectrumindia.com/features/92/27861/indias-diagnostics-shifts-to-self-reliance-and-innovation.html Mon, 01 Jun 2026 11:42:55 +0530 India's diagnostics and MedTech sector is becoming an increasingly important component of the country's healthcare ecosystem, public health preparedness and manufacturing strategy. India's diagnostics supply ecosystem spans in-vitro diagnostic reagents and instruments, diagnostic imaging equipment, and related software and services.  The Indian MedTech market is currently valued at approximately $18.3 billion in 2026, up from $16.97 billion in 2025. Within this, the In-Vitro Diagnostics (IVD) segment represents a significant share and was valued at approximately $5.60 billion during FY2025–26, according to Association of Diagnostics Manufacturers of India (ADMI)). Within the IVD segment, reagents and diagnostic kits account for nearly 65–70 per cent of revenues.  Diagnostic imaging equipment market, comprising CT scanners, MRI machines, X-ray systems and ultrasound equipment, is valued at nearly Rs 20,968 crore, growing at a 9.8 per cent CAGR. The industry structure, however, remains divided between multinational players and domestic manufacturers. India currently has nearly 171 IVD manufacturers as of January 2026, according to Tracxn. Domestic manufacturers are largely focused on rapid test kits, lateral flow assays, reagents and semi-automated instruments, where local service networks and cost advantages remain key differentiators. The high-end imaging segment continues to be dominated by multinational OEMs. Nearly 98 per cent of CT scanner sales and over 91 per cent of MRI revenues are controlled by five global companies, while around 80 per cent of diagnostic imaging equipment continues to be imported.  This dependence on imported technologies has increased the focus on strengthening domestic manufacturing and innovation, bringing diagnostics into broader discussions around healthcare infrastructure and self-reliance. Why Diagnostics Has Become a National Priority Several factors are driving the increased focus on diagnostics in India. The country faces a rising burden of both chronic and infectious diseases, making early diagnosis increasingly important for improving treatment outcomes, reducing healthcare costs and strengthening preventive care. The COVID-19 pandemic further highlighted the role of accessible diagnostics and decentralised testing networks in healthcare delivery, bringing greater attention to testing infrastructure and preparedness. These factors have gradually shifted diagnostics from a healthcare support function to an important component of healthcare planning and public health systems. Government programmes such as the Free Diagnostics Service Initiative under the National Health Mission (NHM) have expanded access to testing through in-house, public-private partnership and hybrid models across states and Union Territories. Similarly, Ayushman Bharat-Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) has widened healthcare coverage and increased patient access to formal healthcare systems, indirectly supporting demand for diagnostic services. The focus has also expanded beyond healthcare access toward technology and system strengthening. India's digital health agenda increasingly incorporates AI-enabled diagnostics, electronic health records and integrated healthcare platforms. Recent discussions under the 17th Common Review Mission (CRM) also highlighted the need to strengthen the availability of essential diagnostics and improve healthcare access in underserved regions. New Government Initiatives and Partnerships Fueling Growth  While the country does not yet have a dedicated National Diagnostics Policy, diagnostics is being integrated into the broader MedTech framework through the National Medical Devices Policy and Medical Devices Rules, particularly for IVDs, with emphasis on reducing import dependence, boosting domestic manufacturing and improving testing and certification infrastructure. Simultaneously, government support is moving toward diagnostics innovation through initiatives such as Promotion of Research and Innovation in Pharma-MedTech (PRIP), Maha MedTech and broader R&D funds supporting molecular diagnostics, indigenous test development and translational research. The push toward preventive and digital healthcare is also accelerating, with Artificial intelligence (AI)-enabled programmes under the National TB Elimination Programme, National Diabetic Retinopathy Screening Programme and disease surveillance systems improving screening and early detection capabilities. Recent GST reductions on diagnostic kits, reagents and certain diagnostic equipment to 5 per cent  have been welcomed by the industry, as the move is expected to reduce testing costs, improve affordability for patients and ease operational and cash-flow pressures for laboratories and manufacturers. Initiatives such as Patent Mitra, launched in 2025 under the guidance of NITI Aayog in collaboration with the Department of Pharmaceuticals and the Department for Promotion of Industry and Internal Trade (DPIIT), are helping streamline patenting processes, intellectual property support and the transfer of publicly funded innovations to industry for commercialisation. The initiative has already facilitated technology transfers for several healthcare innovations, including diagnostic ELISA kits for Japanese Encephalitis, Dengue and Chikungunya, immunodiagnostic technologies and rapid detection platforms for emerging infectious diseases such as Monkeypox and Nipah virus, accelerating the movement of innovations from laboratories to large-scale implementation. One of the leading supporters of diagnostics innovation in India is C-CAMP (Centre for Cellular and Molecular Platforms), a government-supported initiative that has played a crucial role in strengthening indigenous diagnostic capabilities. Through its National Diagnostics Catapult (NDxC), evolved from the Indigenisation of Diagnostics (InDx) programme launched during the COVID-19 pandemic, C-CAMP has emerged as a key driver of diagnostics development and self-reliance. During the pandemic, the programme enabled manufacturing of nearly one million RT-PCR kits daily, while 62 of the 102 the Indian Council of Medical Research (ICMR) and the Central Drugs Standard Control Organisation (CDSCO)-approved RT-PCR kits and 21 rapid antigen and antibody kits in India were linked to the C-CAMP-InDx ecosystem. The programme has since expanded beyond COVID-19 into diagnostics for diseases including tuberculosis, malaria, dengue, chikungunya, influenza and RSV. Today, NDxC operates through six Centres of Excellence and an eight-site clinical validation network, supporting more than 300 India-based IVD innovators, product developers and manufacturers. It has also significantly contributed to India's self-reliance goals, with three of the four ICMR-approved tuberculosis diagnostic assays currently in use in the country emerging through the ecosystem. Together, these developments underscore the growing shift of diagnostics from a support function to a strategic pillar of India's healthcare, innovation and manufacturing ambitions.  The government is also extending support to diagnostics innovation and indigenous technology development. Recent examples include support for Acrannolife Genomics for indigenous manufacturing of advanced IVD diagnostic kits, Prante Solutions for commercialisation of its renal diagnostics platform Proflow-U, and BabyCue for the development of rapid diagnostic equipment for childhood diarrhoea. How’s the industry responding  The government's growing focus on diagnostics is also reflected in industry activity, with companies increasing investments across molecular diagnostics, genomics, AI-based tools, automation and domestic manufacturing. Recent investments indicate growing confidence in the sector. Bartronics India announced a strategic investment of up to Rs 50 crore in molecular diagnostics company Huwel Life Sciences, acquiring an initial 15 per cent stake with an option to increase its holding further. Similarly, government-backed support for companies such as Acrannolife Genomics, Prante Solutions and BabyCue reflects growing momentum around indigenous diagnostic innovation and commercialisation. Indian diagnostics companies are also increasing investments in R&D and technology development. Molbio Diagnostics has strengthened India's molecular diagnostics capabilities through its Truenat platform, a portable real-time PCR system designed for point-of-care testing. Companies including Transasia Bio-Medicals, J Mitra & Co. and Agappe Diagnostics are investing in advanced manufacturing facilities, automated laboratory systems, diagnostic reagents and next-generation testing technologies to strengthen domestic capabilities and global competitiveness. Precision medicine and genomics are emerging as another major area of focus. MedGenome recently expanded its footprint through a majority investment in Siddhi Diagnostics & Research Centre, while Datar Cancer Genetics received US FDA clearance for its tissue-based comprehensive genomic profiling assay, CellDx-Tissue, marking an important milestone for Indian diagnostics innovation in international markets. AI is increasingly becoming central to healthcare partnerships, with 4baseCare collaborating with the Maharashtra government to establish a Centre of Excellence for Precision Oncology, and AstraZeneca India partnering with the Telangana government for AI-powered lung cancer screening in public hospitals. Industry efforts are also extending toward developing affordable, locally manufactured technologies. The India Health Fund-supported ASSURED rapid multi-diagnostic test, developed by Bengaluru-based Ameliorate Biotech, recently received CDSCO approval for manufacturing and commercialisation. Cipla launched Ciposcillo, an advanced respiratory diagnostics platform designed for early detection of COPD and asthma. The Industry Wishlist As India strengthens its diagnostics ecosystem, industry stakeholders broadly agree that recent policy initiatives have helped create an important foundation. However, the next phase of growth will need to move beyond capacity creation toward building an innovation-led and globally competitive ecosystem.  “Many of the existing schemes and infrastructure initiatives operate in silos. India has multiple medtech parks, multiple incentive schemes, and several institutions working toward similar goals. Still, there is a need for a more integrated national strategy with a clearly defined long-term vision. Funding, infrastructure, regulatory support, academia, and industry participation all need to be aligned toward common national objectives. The biggest challenge is that while there is strong policy intent to promote manufacturing, the ecosystem for deep-tech medtech innovation is still evolving. India continues to rely heavily on imports for critical components, technologies, reagents, electronics, and advanced manufacturing inputs. The need of the hour is to build a complete ecosystem that supports both innovation and scale-up,” said Sriram Natarajan, Founder, Director and CEO at Molbio Diagnostics.  The conversation is also increasingly shifting toward strengthening foundational capabilities that can support long-term growth and competitiveness. “The sector is now entering a phase where strengthening foundational capabilities will be key to unlocking its next stage of growth. Continued focus on improving quality and standards consistency across the broader manufacturing ecosystem, particularly among smaller players, will further enhance product confidence and global competitiveness. At the same time, expanding specialised testing infrastructure and advanced manufacturing capabilities presents a significant opportunity to accelerate innovation and scale. Greater collaboration between technical institutions and industry can also help fast-track the commercialisation of research and emerging technologies. Additionally, while dependence on imported specialised components and raw materials continues in certain high-end segments, ongoing investments in domestic manufacturing are steadily building a stronger and more self-reliant ecosystem,” said Anish Bafna, CEO & MD-Healthium Medtech. Regulation and market access also continue to emerge as key priorities, particularly for companies targeting international markets. “Regulatory frameworks need to become more streamlined and supportive. Regulatory approvals, validation studies, certifications, and international compliance requirements involve significant investment, particularly for Indian companies building products for global markets. Financial and process-level handholding mechanisms can play a major role here. India can also explore models similar to EPCG schemes, where support for certifications, registrations, and regulatory approvals is linked to export commitments and performance,” said Natarajan. Industry stakeholders also point to procurement reforms as an area that requires attention. “Procurement reform is key. Quality, reliability, and innovation must be valued over just the lowest price, especially in healthcare, where outcomes depend on precision and performance,” said Chandra Ganjoo, Group Chief Executive Officer, Trivitron Healthcare. The next phase of diagnostics is also expected to be shaped by digital technologies and AI-enabled tools. “A key shift is the rise of clinically meaningful AI, not just as a buzzword, but as a tool to improve screening, workflow efficiency, and access, especially in underserved regions. Companies are increasingly integrating AI, telemedicine, and digital platforms into their offerings,” said Chandra Ganjoo.  However, broader adoption will depend on addressing infrastructure and data challenges. “Infrastructure readiness across healthcare institutions continues to be highly uneven, particularly outside major urban centres. Many facilities still lack standardised imaging systems, interoperable digital infrastructure, and adequately trained personnel required to fully utilise AI-enabled diagnostics at scale. There is also a need for clearer regulatory and reimbursement frameworks, especially around preventive and AI-assisted diagnostics, so that adoption moves beyond limited pilots into mainstream healthcare delivery. In parallel, building stronger India-specific clinical datasets will be critical, both from a validation and public health perspective, because AI models ultimately become far more effective when trained on diverse local population data,” said Ankit Modi, Founding Member and Chief Strategy & Growth Officer at Qure.ai.  The larger message across the industry remains consistent: “India doesn’t just need to manufacture more; it needs to build trust, quality, and innovation at a global level,” signs off Ganjoo.    Ayesha Siddiqui ]]> https://biospectrumindia.com/news/92/27860/nura-expands-south-india-presence-with-launch-of-preventive-health-screening-centre-in-chennai.html https://biospectrumindia.com/news/92/27860/nura-expands-south-india-presence-with-launch-of-preventive-health-screening-centre-in-chennai.html Wed, 27 May 2026 18:08:33 +0530 NURA, an advanced diagnostic venture between Fujifilm Healthcare and Dr Kutty’s Healthcare, has expanded its footprint in South India with the launch of its preventive health screening centre in Chennai. Located in Egmore, the facility marks NURA’s sixth centre in India and reflects the company’s continued focus on expanding access to advanced preventive healthcare and early disease detection services. The Chennai launch marks an important milestone in NURA’s India expansion journey. Designed to offer AI-enabled full-body health screenings, the Chennai facility integrates advanced imaging and diagnostic technologies to support faster detection of diseases at early stages. The centre has the capacity to screen up to 40 guests per day. Following the Chennai launch, NURA continues to pursue an ambitious expansion roadmap focused on strengthening its presence across Tier 1, Tier 2, and emerging urban areas in India. Internationally, the company is also exploring opportunities across Middle East and Africa,  South Asia, ASEAN as part of its larger vision to establish a strong and accessible global preventive healthcare network. ]]> https://biospectrumindia.com/news/92/27830/medgenome-makes-majority-investment-in-mumbais-siddhi-diagnostics-research-centre.html https://biospectrumindia.com/news/92/27830/medgenome-makes-majority-investment-in-mumbais-siddhi-diagnostics-research-centre.html Mon, 18 May 2026 14:52:24 +0530 Bengaluru-based MedGenome, India’s leading genomics-driven diagnostics and research services company, has joined hands with Siddhi Diagnostics & Research Centre (SDRC), a well-established diagnostic imaging service provider with a strong presence across Mumbai’s extended western suburbs. This marks a strategic step in strengthening MedGenome’s presence in the region, while expanding access to advanced, integrated diagnostics across suburban belts. Founded in 1995, SDRC is led by Dr Ajit Pungavkar and Dr Sona Pungavkar. Under their leadership, SDRC has built over 30 years of clinical expertise in diagnostic imaging and a strong reputation for delivering high-quality services, including MRI, CT, X-ray, Sonography, Mammography, Interventions, Cardiac investigations, HSG, OPG, and BMD. The network operates five centres across Nalasopara (East and West), Vasai, Virar and Thane supported by advanced infrastructure comprising four MRI and five CT systems. Positioned as a full-spectrum imaging provider, SDRC offers strong accessibility across the Naigaon–Palghar and Thane belt, serving a wide network of hospitals and clinicians in the region. SDRC caters to a large and diverse patient base through a mix of walk-in services, home collections, and partnerships with hospitals and laboratories, in an all-under-one-roof concept. Its strong reporting and analytical expertise have helped build long-standing clinical trust, particularly in regions beyond Greater Mumbai where access to high-quality diagnostic infrastructure has traditionally been limited.   ]]> https://biospectrumindia.com/news/92/27827/ameliorate-biotechs-multi-diagnostic-test-receives-cdsco-manufacturing-approval.html https://biospectrumindia.com/news/92/27827/ameliorate-biotechs-multi-diagnostic-test-receives-cdsco-manufacturing-approval.html Sat, 16 May 2026 22:13:25 +0530 India Health Fund (IHF)-supported rapid multi-diagnostic test, ASSURED, developed by Bengaluru-based Ameliorate Biotech, has received approval for manufacturing and marketing from the Central Drugs Standard Control Organisation (CDSCO). The first-of-its-kind “Made in India” test can swiftly and simultaneously detect dengue, malaria (including vivax and falciparum differentiation), chikungunya and their co-infections using a single blood sample in under 15 minutes and can be easily used by a minimally trained workforce at the primary care level. This approval now paves the way for large-scale product manufacturing and launch in the market. India Health Fund supported Ameliorate Biotech to conduct an open label, multicentric, performance and cost-effectiveness evaluation of the rapid antigen-based diagnostic kit. This multicentric evaluation was completed across three CDSCO-approved centres, namely RMRIMS (Patna), Rajiv Gandhi Institute (Srikakulam), and KLES’s Dr. Prabhakar Kore Hospital (Belagavi).  With sensitivity and specificity being 99.34% and 100% respectively, ASSURED is now gearing up for manufacturing scale-up, setting up stringent quality control processes, distribution pipelines, and supply chain logistics. It also addresses critical healthcare inequities by being accessible, affordable, widely available, and acceptable, thereby optimising healthcare delivery. ]]> https://biospectrumindia.com/news/92/27828/datar-cancer-genetics-receives-landmark-us-fda-clearance-for-celldx-tissue-assay.html https://biospectrumindia.com/news/92/27828/datar-cancer-genetics-receives-landmark-us-fda-clearance-for-celldx-tissue-assay.html Sat, 16 May 2026 22:17:39 +0530 Nashik-based Datar Cancer Genetics (DCG), a global precision oncology company, has announced that its tissue-based comprehensive genomic profiling (CGP) assay for all solid tumours, CellDx-Tissue, has been cleared by the US Food and Drug Administration (US FDA). CellDx-Tissue is a qualitative in vitro diagnostic (IVD) test that uses targeted Next-Generation Sequencing (NGS) of DNA and RNA isolated from formalin-fixed paraffin-embedded (FFPE) tumour tissue of patients diagnosed with solid tumors. The assay analyses 517 cancer-associated genes and is intended to provide information on somatic single nucleotide variants (SNVs), small insertions and deletions (InDels), ERBB2 gene amplification, and gene fusions involving ALK, RET and ROS1. CellDx-Tissue is a single-site assay performed at Datar Cancer Genetics' CAP- and CLIA-accredited laboratory. Comprehensive genomic profiling has become a central component of clinical management of solid tumours, supporting clinicians in characterising tumor genomic alterations across a broad spectrum of cancer types. ]]> https://biospectrumindia.com/news/92/27790/sebia-india-collaborates-with-caho-to-launch-autoimmunity-masterclass-series.html https://biospectrumindia.com/news/92/27790/sebia-india-collaborates-with-caho-to-launch-autoimmunity-masterclass-series.html Mon, 11 May 2026 15:07:51 +0530 Sebia, in collaboration with CAHO Diagnostic Division, has announced the launch of the Autoimmunity Masterclass Series—a six-part academic webinar initiative aimed at advancing the understanding, early diagnosis, and clinical management of autoimmune diseases. In recent years, particularly in the post-COVID era, there has been a noticeable rise in autoimmune conditions, often presenting with complex and overlapping clinical manifestations. A matched cohort study published in Clinical Rheumatology journal in  2023 involving over 640,000 patients reported approximately a 40–45% increased risk of developing autoimmune diseases within the first year following COVID-19 infection.  Addressing this growing challenge, the Masterclass Series is designed as a comprehensive platform bringing together clinicians, laboratory specialists, and healthcare professionals across disciplines. The series will cover key areas including autoimmune  connective tissue diseases , Antiphospholipid syndrome (APS), Systemic lupus erythematosus (SLE), Gastroenterological autoimmune disorders, Celiac disease, Rheumatoid Arthritis (RA) and related conditions. Each session is curated by expert panel to provide a balanced perspective on disease spectrum, diagnostic challenges, and evolving clinical practices, ensuring meaningful knowledge exchange and practical insights. The initiative comprises six webinars spread across the year, aligned with relevant medical awareness themes to maximize engagement and clinical relevance. Commenting on the initiative, Nitin Wadhwa  General Manager, Sebia India, said "This collaboration reflects our commitment to strengthening clinical and lab  awareness in improving diagnostic pathways in autoimmunity. Through this structured masterclass series, we aim to bridge knowledge gaps and support clinicians in managing increasingly complex autoimmune cases more effectively." Dr Aparna Jairam, Chairperson, CAHO  Diagnostic Division added, "Autoimmune diseases require a multidisciplinary approach for timely diagnosis and management. This series is a step towards creating a unified learning platform where experts can share insights and enhance patient care outcomes across the healthcare ecosystem." ]]> https://biospectrumindia.com/news/92/27772/cipla-launches-next-generation-oscillometer-device-ciposcillo-for-respiratory-diagnostics.html https://biospectrumindia.com/news/92/27772/cipla-launches-next-generation-oscillometer-device-ciposcillo-for-respiratory-diagnostics.html Thu, 07 May 2026 22:07:02 +0530 Mumbai-based pharma firm Cipla has announced the launch of Ciposcillo®, an advanced oscillometer designed for accurate and precise assessment of respiratory mechanics. The device enables early diagnosis of obstructive airway diseases such as Chronic Obstructive Pulmonary Disease (COPD) and Asthma. Built on US FDA cleared technology and engineered for Indian clinical practice, Ciposcillo® is CDSCO approved and ISO certified. With respiratory diseases on the rise in India, early detection and diagnosis of lung health conditions remains critical. Ciposcillo® combines precision, portability and clinically validated technology to better enable clinicians to assess patients across diverse healthcare settings. Importantly, the oscillometer can assess respiratory functions using normal, tidal breathing, eliminating the need for forceful patient effort. This makes it particularly suitable for use in elderly patients, young children, and others who may not be able to perform effort-dependent tests such as spirometry. Ciposcillo® incorporates India-specific reference values and is supported by Z-score–based interpretation for more individualized assessments, with a user-friendly interface for easy, seamless use. Speaking on the launch, Achin Gupta, MD and Global CEO, Cipla said, “At Cipla, innovation is central to how we address patient needs across the healthcare continuum – from therapies to diagnostics. With Ciposcillo®, we are not only bringing advanced diagnostic technology closer to clinicians to empower better decision-making, but also enabling a simpler, effort-independent approach that makes it accessible across age groups and care settings. This is another step in our journey to improving lung health outcomes and delivering on our purpose of Caring for Life.”  Ciposcillo® expands Cipla’s diagnostic toolkit available to physicians, reinforcing the company’s broader commitment to advancing disease detection and management, especially in high-burden areas such as respiratory health. ]]> https://biospectrumindia.com/news/92/27744/asms-and-huwel-to-launch-indias-revolutionary-point-of-care-molecular-diagnostics-platform-cubo.html https://biospectrumindia.com/news/92/27744/asms-and-huwel-to-launch-indias-revolutionary-point-of-care-molecular-diagnostics-platform-cubo.html Wed, 29 Apr 2026 00:00:00 +0530 Avio Smart Market Stack Limited (ASMS) (formerly known as Bartronics India Limited) and Huwel Lifesciences have announced the upcoming launch of Cubo, an ultra-compact, affordable RT-PCR platform developed to expand access to molecular diagnostics across India and global healthcare systems. Positioned as a first-of-its-kind indigenous innovation, Cubo combines laboratory-grade RT-PCR capabilities with a highly portable, cost-efficient deployment model. The platform is expected to provide both companies with a meaningful early-mover advantage in one of the fastest-growing segments of healthcare technology. Designed as a breakthrough in decentralised healthcare, Cubo enables advanced molecular testing within a compact form factor that can be deployed far beyond traditional laboratory environments. The platform has the potential to bring sophisticated diagnostics to rural clinics, district hospitals, mobile health units, industrial sites, border areas, and remote regions where access to centralised labs remains limited. In many healthcare systems, diagnostic samples must travel long distances to centralised facilities, resulting in delays and logistical inefficiencies. Cubo addresses this challenge by enabling accurate RT-PCR testing at or near the point of care, reducing turnaround times and operational complexity. This capability aligns with the global shift toward localised diagnostic models and may establish a strong strategic advantage for early adopters. Cubo features a simplified workflow and intuitive user interface, making it suitable for use by physicians and healthcare teams across diverse settings. Its ease of use and portability are expected to support faster adoption compared to conventional systems that require extensive infrastructure and specialised environments. The platform is being developed as a versatile diagnostic solution capable of supporting a wide range of assays, including tuberculosis, respiratory infections, influenza, viral panels, women’s health diagnostics, sexually transmitted infections, fever panels, and future outbreak-response applications. This broad testing menu positions Cubo to build a substantial installed base over time. With its first-mover advantage, affordability, and wide deployment potential, Cubo is expected to emerge as a leading solution in compact decentralised molecular diagnostics.   ]]> https://biospectrumindia.com/news/92/27785/experts-call-for-stronger-ecosystems-to-scale-indian-diagnostics-innovation.html https://biospectrumindia.com/news/92/27785/experts-call-for-stronger-ecosystems-to-scale-indian-diagnostics-innovation.html Fri, 08 May 2026 18:08:33 +0530 The panel discussion titled “Making it Happen: Enabling Diagnostics Developers and Manufacturers for Impact” was one of the key sessions at the National Diagnostics Conclave organized by the Centre for Cellular and Molecular Platforms (C-CAMP) recently. Conducted under the broader National Diagnostics Catapult (InDx 2.0) initiative, the session brought together leaders from India’s diagnostics ecosystem to deliberate on the challenges, opportunities, and structural requirements for building globally competitive indigenous in-vitro diagnostics (IVD) solutions. The conclave was supported by the Office of the Principal Scientific Adviser (PSA) to the Government of India, the Rockefeller Foundation, and the Gates Foundation. The discussion was moderated by Dr Nikhil Phadke, Founder & CSO, GenepathDx and featured distinguished panellists including Dr Chandrasekar Nair, Director & CTO, Molbio Diagnostics; Co-founder, Bigtec Labs; Dr Rachana Tripathi, CEO, Huwell Lifesciences; Dr Manoj Chugh, Vice President, R&D, Transasia Bio-Medicals Ltd and Harkaran Dhingra, CEO, DSS Takara Bio India. The session focused on the transition from innovation to commercialisation, highlighting the realities of scaling diagnostic technologies in India and the systemic interventions required to enable sustainable growth. A major theme that emerged throughout the discussion was that diagnostics manufacturing is fundamentally different from conventional manufacturing sectors. Dr Manoj Chugh emphasized that scaling in diagnostics is not merely about increasing production volumes, but about ensuring precision, reproducibility, repeatability, reliability, and compliance over time. He stressed that quality in diagnostics cannot remain a regulatory checkbox; instead, it must evolve into an organizational culture deeply embedded across all functions. According to him, Indian diagnostics companies often face a gap between entrepreneurial urgency and regulatory timelines, where founders expect products to reach markets in months while actual approvals may take years. He highlighted the need for a more flexible and practical regulatory framework, particularly regarding predicate devices and acceptance of internationally approved reference kits for validation studies. The panel also shed light on the entrepreneurial struggles faced by Indian diagnostics startups. Dr Rachana Tripathi shared the journey of building molecular diagnostic capabilities in India from scratch during the late 2000s, when the ecosystem lacked infrastructure, mentorship, organized markets, and funding mechanisms. She described how indigenous developers often faced challenges in accessing equipment, optimizing manufacturing processes such as lyophilization, and navigating regulatory pathways without institutional support. Despite these constraints, she noted that persistence, adaptability, and collaborative support from organizations such as the Gates Foundation enabled gradual progress toward commercialization. Her reflections highlighted the resilience required to build indigenous technologies in an ecosystem that is still maturing. Another significant issue discussed was the fragmentation of the diagnostics ecosystem. Dr Chandrasekar Nair pointed out that modern diagnostics platforms require convergence across multiple disciplines including biology, chemistry, electronics, optics, mechanical engineering, polymer sciences, and software systems. However, innovation ecosystems in India often function in silos, preventing the kind of interdisciplinary collaboration necessary for globally scalable products. He argued that industry must take a more collaborative approach and work collectively to solve shared challenges instead of functioning in isolation under investor-driven competitive pressures. The discussion further emphasized that developing a successful diagnostic platform requires far more than scientific innovation alone. Dr Nair described the “shiny new toy” problem, where many entrepreneurs focus on creating technologically impressive prototypes without adequately addressing the difficult transition from laboratory proof-of-concept to scalable manufacturing and global deployment. He explained that the real challenge lies in rebuilding prototypes into robust, scalable, validated products capable of surviving real-world variability, global regulatory scrutiny, and market expectations. The panel agreed that translating innovation into impact requires structured support systems for validation, manufacturing, quality systems, evidence generation, and international partnerships. Global regulatory alignment emerged as another critical topic. The speakers noted that Indian diagnostics companies aiming for large-scale public health deployment must eventually satisfy international standards such as WHO prequalification. Dr Nair explained that generating globally acceptable evidence requires substantial funding, multinational clinical collaborations, and protocol standardization. He advocated for India to assume a leadership role for the Global South by creating regulatory ecosystems that can support low-cost, high-quality diagnostics designed specifically for emerging markets. Such an approach, according to the panellists, could help Indian companies scale internationally while simultaneously strengthening public health systems across low-resource regions. The panel also highlighted the importance of long-term ecosystem support in nurturing innovation. Dr Nair reflected on the role played by institutions such as CSIR, ICMR, FIND, WHO, and philanthropic organizations in supporting Molbio Diagnostics through various stages of technology development and validation. He emphasized that early institutional support, especially during periods of zero revenue, was instrumental in enabling the company’s eventual success. The discussion reinforced the idea that diagnostics innovation requires patient capital, sustained public-private partnerships, and coordinated ecosystem development rather than short-term commercialization expectations. A recurring concern among the panellists was the shortage of industry-ready skilled manpower. Dr Tripathi explained that startups frequently struggle to recruit trained professionals who understand industrial workflows, regulatory documentation, manufacturing systems, and product development processes. Many companies are forced to train employees from scratch, only to lose them to larger organizations offering higher salaries. The panel stressed the importance of industry-oriented training programs that bridge the gap between academic learning and practical industrial requirements. Building a robust talent pipeline was considered essential for sustaining innovation and improving operational efficiency across the diagnostics sector. The importance of backward integration and supply-chain resilience was also discussed extensively. Dr Tripathi recounted how the COVID-19 pandemic exposed vulnerabilities associated with dependence on imported enzymes, plastics, primers, probes, and consumables. Delays in customs clearance and supply disruptions often jeopardized manufacturing timelines and product consistency. In response, companies began investing in local manufacturing capabilities for critical components such as enzymes and plastic consumables. The panellists agreed that while every company need not manufacture every component independently, India must develop a supportive local ecosystem where critical inputs are readily available through domestic suppliers and collaborative networks. Moderator Dr Nikhil Phadke summarized many of the core insights by emphasizing that scientific invention constitutes only a small fraction of the total effort required to build impactful diagnostic products. Drawing from his own entrepreneurial experience, he highlighted that successful commercialization demands extensive work in scaling, regulatory approvals, funding, partnerships, manufacturing, and market access. He also pointed out that unlike many Western innovation ecosystems, where universities and larger corporations often share the commercialization burden, Indian entrepreneurs frequently attempt to build companies from ideation to full-scale deployment entirely on their own. This increases both operational complexity and financial risk for startups. Overall, the panel underscored that India has made substantial progress in diagnostics innovation over the last two decades, but several systemic gaps continue to hinder the sector’s full potential. The discussion called for stronger industry-academia collaboration, regulatory modernisation, global market integration, manufacturing infrastructure development, organized market access, skilled workforce creation, and sustained funding support. The collective sentiment among the speakers was optimistic yet realistic: India possesses the scientific talent and entrepreneurial spirit necessary to become a global diagnostics leader, but achieving this vision will require coordinated ecosystem-level transformation and long-term commitment from industry, government, academia, and philanthropic stakeholders alike. ]]> https://biospectrumindia.com/news/92/27739/bpl-medical-technologies-launches-new-gen-glucose-meter-for-home-testing-.html https://biospectrumindia.com/news/92/27739/bpl-medical-technologies-launches-new-gen-glucose-meter-for-home-testing-.html Tue, 28 Apr 2026 00:00:00 +0530 BPL Medical Technologies, India’s leading medical equipment brand with a 50-year legacy under the BPL Group, has announced the launch of its latest, the BPL Blood Glucose Meter 582, aimed at simplifying daily diabetes monitoring through faster, more reliable, and user-friendly testing. With the growing shift towards home-based healthcare and rising diabetes prevalence in India, the need for easy-to-use and dependable monitoring devices has become more critical than ever. The newly launched glucometer is designed to meet this need by combining accuracy with convenience. The Blood Glucose Meter 582 is built to keep testing simple and quick. It delivers results in under 10 seconds and needs only a small 1µL blood sample, making the process far less cumbersome for daily use. With auto coding in place, users don’t have to worry about manual setup, which also helps minimise errors; especially useful for first-time users or seniors . Keeping everyday practicality in mind, the device features a large, easy-to-read display that shows results along with the date and time. It has a storage capacity of 250 readings, so users can view previous readings and track their levels with time. There is also an average reading in various periods, i.e., 7 days, 14 days, and 3 months, which makes it  easier to identify the patterns and keep track of the glucose levels. To enhance hygiene and usability, the glucometer includes a strip ejector button that allows for safe and contactless disposal of used strips. Built to perform across varying temperature conditions, the device is suitable for use in diverse Indian environments. Dr Shravan Subramanyam, Managing Director of BPL Medical Technologies, said, “Managing diabetes well really comes down to regular and reliable monitoring. With the Blood Glucose Meter 582, our focus has been on making everyday testing straightforward, quick, and something people can easily keep up with. This is part of our larger effort to provide  healthcare solutions that are  practical and accessible at home. As more people take charge of their own health, we want to support that shift with medical technology  that is  dependable and easy to live with, while continuing to improve access to quality home healthcare across the country." ]]> https://biospectrumindia.com/news/92/27729/metropolis-healthcare-introduces-advanced-blood-based-alzheimers-screening.html https://biospectrumindia.com/news/92/27729/metropolis-healthcare-introduces-advanced-blood-based-alzheimers-screening.html Mon, 27 Apr 2026 00:00:00 +0530 Metropolis Healthcare has announced the launch of an advanced blood-based test designed to support earlier detection and more informed clinical decisions in Alzheimer’s disease. Alzheimer’s disease (AD) is defined by its unique neuropathologic findings; hence diagnosis is based on clinical context, neuroimaging findings, and presence of accurate biomarkers in the intended population by which AD staging is done. Alzheimer’s disease remains significantly underdiagnosed in its early stages, particularly among individuals over the age of 50, where cognitive decline is often overlooked or misattributed.  Metropolis’ newly introduced blood-based test enables minimally invasive screening through a simple blood sample, allowing clinicians to assess the likelihood of Alzheimer’s-related changes and guide next steps in care. This approach aligns with 2025 clinical practice recommendations from the Alzheimer’s Association, which support the use of blood-based biomarkers such as pTau217 and the β-amyloid 1–42 ratio in individuals with cognitive impairment.  By identifying key disease-related markers, it provides a more convenient alternative to traditional diagnostic approaches such as PET scans or cerebrospinal fluid (CSF) testing. Backed by strong clinical evidence, including diagnostic accuracy of over 90% and strong alignment with amyloid PET imaging, the test provides reliable risk assessment. The test can be used as an initial step in the clinical evaluation process. Based on the results, doctors can determine whether more advanced tests, such as PET scans or CSF analysis, are required, enabling timely decisions and appropriate care. With this launch, Metropolis offers one of the most comprehensive Alzheimer’s diagnostic pathways in India, spanning early blood-based screening, confirmatory CSF testing, and genetic risk assessment, including APOE genotyping. This integrated approach enables clinicians to access a complete diagnostic pathway within a single network, supporting coordinated and efficient patient management. ]]> https://biospectrumindia.com/news/92/27703/kotak-mahindra-bank-supports-upgraded-diagnostic-infrastructure-at-k-j-somaiya-hospital-research-centre-in-mumbai.html https://biospectrumindia.com/news/92/27703/kotak-mahindra-bank-supports-upgraded-diagnostic-infrastructure-at-k-j-somaiya-hospital-research-centre-in-mumbai.html Wed, 22 Apr 2026 00:00:00 +0530 For many patients at K J Somaiya Hospital & Research Centre a timely and accurate diagnosis can determine the course of treatment and in some cases, the outcome of care. With that reality in mind, the hospital has strengthened its diagnostic infrastructure with the support of Kotak Mahindra Bank’s CSR initiative, adding a 1.5 Tesla MRI unit, ventilators for the pediatric NICU.  The MRI unit was inaugurated by Dipak Gupta, Former MD & CEO, Kotak Mahindra Bank alongside Samir Somaiya, Chairman of K J Somaiya Medical Trust, and other dignitaries.  The shift from an outsourced MRI model to a hospital‑operated facility is more than an infrastructure upgrade. It means shorter waiting times, reduced costs for patients and greater reliability in care- benefits that matter most to those who can least afford delays and disruptions. The unit will also support the hospital academic and research work by integrating directly into clinical workflows.  Himanshu Nivsarkar, Head of CSR & ESG, Kotak Mahindra Bank, said, “Advanced diagnostics should not be a privilege. By supporting K J Somaiya Hospital’s move to an in-house MRI facility, we hope to make high-quality imaging more accessible and reliable, particularly for patients who would otherwise have limited recourse.” K J Somaiya Hospital & Research Centre has long been committed to making world-class healthcare available to all sections of society. This partnership with Kotak Mahindra Bank is a step further in that direction – grounded not in gesture, but in the practical reality of what better diagnostics make possible for patients every day.  ]]> https://biospectrumindia.com/news/92/27706/omron-healthcare-and-tricog-health-strengthen-collaboration-in-india-with-tricog-cardiocheck.html https://biospectrumindia.com/news/92/27706/omron-healthcare-and-tricog-health-strengthen-collaboration-in-india-with-tricog-cardiocheck.html Wed, 22 Apr 2026 00:00:00 +0530 OMRON Healthcare Co., a global leader in clinically proven medical devices for home health monitoring and treatment, has announced the integration of its ECG-enabled upper arm blood pressure monitors with Tricog Health’s clinically validated AI-powered cardiac triage service, Tricog CardioCheck (TCC). The service is scheduled for rollout at health centers across India from April 2026. Tricog CardioCheck (TCC) enables ECG data recorded using OMRON Healthcare’s Complete™ blood pressure monitors with integrated ECG monitoring to be transmitted to the cloud and analyzed by Tricog’s AI algorithms. Within approximately 10 seconds, the system provides a three-level risk assessment, supporting patient triage and timely clinical evaluation. Results are displayed via a dedicated smartphone application designed for healthcare professionals, allowing front-line care providers to review patient risk levels in real time and quickly determine the need for further examination, even where a cardiology specialist is not immediately available. Since its initial investment in Tricog in fiscal year 2023, OMRON Healthcare has continued to strengthen its partnership with the company in order to address key healthcare challenges in India. Through ongoing collaboration, both companies aim to expand access to innovative diagnostic solutions and contribute to improving cardiovascular health outcomes across the country. ]]> https://biospectrumindia.com/news/92/27691/national-and-international-experts-convene-for-national-diagnostics-conclave-in-bengaluru.html https://biospectrumindia.com/news/92/27691/national-and-international-experts-convene-for-national-diagnostics-conclave-in-bengaluru.html Mon, 20 Apr 2026 00:00:00 +0530 The Centre for Cellular and Molecular Platforms (C-CAMP), hosted the first edition of National Diagnostics Conclave, at its Bengaluru campus on 20 April, in the presence of senior leadership including Dr Parvinder Maini, Scientific Secretary, Office of Principal Scientific Advisor (OPSA) to the Government of India; Dr Nivedita Gupta, Scientist G & Head, Communicable Diseases Division, Indian Council of Medical Research (ICMR) and Dr Harish Iyer, Health R&D, Digital Innovations and AI, Gates Foundation. The event was convened to chart out a collective vision and strategy for diagnostics innovation and implementation towards greater health equity for India and low and middle income countries (LMICs). The event launched the National Diagnostics Catapult Impact Report, capturing the programme’s genesis, evolution, and impact. It also unveiled environmental surveillance kits for Real time detection of SARS CoV2, Respiratory syncytial virus, Influenza viruses and Carbapenemase resistance in wastewater. The InDx Guidance Manual, which highlights key design principles and outlines India’s regulatory pathway for IVD devices was also released. Panel discussions throughout the day highlighted the strategic pillars of the National Diagnostics Catapult (NDxC) including strengthening the national validation and innovation infrastructure and diagnostics development with priority diseases and public health impact. Dr Taslimarif Saiyed, Director & CEO, C-CAMP reflected, “In February 2023, we launched the C-CAMP InDx National Diagnostics Catapult in collaboration with Rockefeller Foundation, Gates Foundation and FIND under the guidance of the OPSA with an aim to establish India’s much needed capacity for diagnostics and disease surveillance capabilities in infectious disease domain, beyond and over COVID." Dr Parvinder Maini, Scientific Secretary, Office of Principal Scientific Adviser to the Govt. of India said, “The C-CAMP InDx initiative was conceptualised with support from the Office of the Principal Scientific Adviser, reflecting a national vision for diagnostics self-reliance. This programme has brought together diagnostic manufacturers and India’s leading research centres of excellence onto a single platform, enabling the identification and bridging of key regulatory and R&D gaps. It has also fostered innovation by facilitating access to reference standards and strengthening evidence generation systems, particularly for infectious diseases where data infrastructure has traditionally been limited.” Dr Nivedita Gupta, Scientist G and Head of the Communicable Diseases Division, ICMR, appreciated C-CAMP's work and highlighted the ongoing collaboration to develop India-specific, cost-effective multiplex diagnostic panels tailored to local clinical syndromes. She emphasised that such panels will address the significant number of pathogens often overlooked in current International diagnostic frameworks. ]]> https://biospectrumindia.com/news/92/27633/redcliffe-labs-divests-crysta-ivf-to-moon-care-to-strengthen-focus-on-diagnostics.html https://biospectrumindia.com/news/92/27633/redcliffe-labs-divests-crysta-ivf-to-moon-care-to-strengthen-focus-on-diagnostics.html Wed, 08 Apr 2026 00:00:00 +0530 Noida-based Redcliffe Labs has announced the strategic divestment of its fertility services business, Crysta IVF, to DElhi-based Moon Care, the healthcare arm of MMG Group. The transaction reflects Redcliffe Labs' continued focus on strengthening its diagnostics capabilities and expanding its presence in preventive and advanced diagnostic services across India. The move allows the organisation to consolidate further its efforts to deliver technology-led accessible, accurate, and affordable diagnostic solutions at scale. At the same time, Crysta IVF, which achieved EBITDA profitability at the start of FY26, is well-positioned to continue its growth journey under the dedicated leadership of Moon Care, which will further strengthen its focus on delivering specialized fertility care and expanding access to reproductive health services. Speaking on the development, Aditya Kandoi, Founder & CEO, Redcliffe Labs, said: “Our priority has always been to build a strong, accessible diagnostics ecosystem rooted in preventive healthcare - with the goal of adding healthier years to people’s lives. This divestment allows us to sharpen that focus even further."  For patients already served by Crysta IVF, the transition will be seamless, with no change to ongoing operations. The existing Crysta IVF team and leadership will continue to lead the business, working closely with Moon Care, which will provide strategic guidance and mentorship. This ensures continuity of care without disruption, while also enabling the introduction of new initiatives to further enhance patient outcomes. For Redcliffe Labs, the deal signifies a sharpened focus on the diagnostic segment. This will enable the company to accelerate expansion, increase testing volumes, and deepen its presence in preventive healthcare, driving greater impact through early detection and accessible care. Alvarez & Marsal acted as the exclusive advisor to the transaction. ]]> https://biospectrumindia.com/news/92/27620/astrazeneca-india-signs-mou-with-telangana-govt-to-bring-ai-powered-lung-cancer-screening-to-public-hospitals.html https://biospectrumindia.com/news/92/27620/astrazeneca-india-signs-mou-with-telangana-govt-to-bring-ai-powered-lung-cancer-screening-to-public-hospitals.html Tue, 07 Apr 2026 00:00:00 +0530 AstraZeneca Pharma India has signed a Memorandum of Understanding (MoU) with the Government of Telangana to introduce artificial intelligence (AI)-enabled lung cancer screening across public healthcare facilities in the state. The collaboration aims to strengthen early detection and improve outcomes for patients in both urban and rural areas. Lung cancer is among the most pressing public health challenges in India today. National incidence is projected to rise from approximately 63,700 cases in 2015 to over 81,200 by 2025, a 27% increase over the decade, driven by tobacco use, environmental pollution, and critically, the near absence of routine screening.  Telangana reflects these national pressures acutely. The state is projected to record 46,762 new cancer cases among adults in 2026, rising to 47,314 by 2030, an estimated 13% increase by 2027. Women bear a disproportionate share, with 25,510 new cases expected this year against 21,252 in men.  Under the MoU, AstraZeneca will facilitate the deployment of Qure.ai's AI-powered chest X-ray solution to be integrated into routine workflows at public health facilities across Telangana. The technology helps clinicians flag the high-risk pulmonary nodules, a predominant precursor of lung cancer along with 29 other lung conditions. The high-risk patients will be triaged for lung cancer confirmation or future follow up to ensure stage-shift of lung cancer at diagnosis. A similar model has already been adopted in Goa, Tamil Nadu, and Karnataka.  The initiative is expected to roll out across 20 public health facilities, covering urban and rural health systems. It includes training and upskilling of healthcare professionals to support effective and sustainable adoption, as well as infrastructure enhancements where needed to ensure seamless integration into the public health system. ]]> https://biospectrumindia.com/news/92/27621/medgenome-unveils-indias-first-study-on-clinical-impact-of-rna-based-ngs-in-sarcoma-diagnosis.html https://biospectrumindia.com/news/92/27621/medgenome-unveils-indias-first-study-on-clinical-impact-of-rna-based-ngs-in-sarcoma-diagnosis.html Tue, 07 Apr 2026 00:00:00 +0530 On the occasion of World Health Day, Bengaluru-based MedGenome has announced the outcomes of India's first prospective study assessing the clinical utility of RNA-based next-generation sequencing (NGS) for soft tissue and bone sarcoma diagnosis. Aligning with this year’s theme “Together for health. Stand with science,” the study highlights the importance of science-led, collaborative approaches in strengthening access to accurate diagnosis and improving cancer care. This study, conducted in collaboration with India’s leading hospitals between 2022 and 2025 and published in the Journal of Global Oncology, has demonstrated that introducing targeted RNA sequencing into a multidisciplinary team (MDT) workflow can substantially enhance diagnostic clarity and aid treatment decisions for Sarcomas, especially in patients with ambiguous or complex presentations. For this study, 68 patients with unclear diagnoses based on their pathological indications were considered for evaluation after an MDT review. All samples were analysed with MedGenome's CAP-accredited indigenous RNA fusion panel, which is custom-designed for sarcomas and implemented in concordance with the WHO 2021 classification. The study showed that the RNA-based NGS provided clinically informative findings in half of all evaluated cases. Notably, diagnostic refinement or reclassification could be achieved in over 40% of patients, while treatment decisions changed in more than a quarter of cases according to molecular results. The study also highlights the opportunity of implementing cost-effective genomic testing in low and middle-income countries. MedGenome's sarcoma panel enables the detection of both canonical and ultra-rare gene fusions, many of which could have gone undetected by universal testing methods. By integrating these results into MDT discussions, clinicians can avoid ineffective chemotherapy regimens, confirm rare histologic subtypes, and make more informed therapeutic decisions. Speaking about the importance of the research, an author of the study Charu Bahl, PhD, General Manager - Scientific Affairs, MedGenome Labs Ltd, said, "Sarcomas often sit at the crossroads of overlapping morphology and unpredictable clinical behaviour. For a large proportion of patients, conventional tools such as Histopathology, Immunohistochemistry (IHC), or Fluorescence In Situ Hybridization (FISH) are not enough to arrive at a definitive diagnosis. This prospective study distinctly shows that RNA-based NGS offers the resolution we need to classify difficult tumours correctly and, in many cases, course-correct treatment plans before precious time is lost."   ]]> https://biospectrumindia.com/news/92/27593/4basecare-signs-mou-with-maharashtra-govt-to-establish-centre-of-excellence-for-precision-oncology.html https://biospectrumindia.com/news/92/27593/4basecare-signs-mou-with-maharashtra-govt-to-establish-centre-of-excellence-for-precision-oncology.html Tue, 31 Mar 2026 00:00:00 +0530 Bengaluru-based startup 4baseCare has signed a Memorandum of Understanding (MoU) with the Government of Maharashtra to establish a Centre of Excellence for Precision Oncology in the state.  The MoU aims to integrate genomic-driven cancer care into Maharashtra’s public health system. As part of the collaboration, 4baseCare will deploy its OncoTwin platform, an artificial intelligence (AI)-based tool that enables oncologists to derive actionable treatment insights by mapping each patient’s genomic and clinical profile against large, real-world outcomes datasets. OncoTwin was recently selected for the MSK iHub programme of Memorial Sloan Kettering Cancer Centre, New York, USA. The MoU signing took place at PULSE 2026, India’s leading Healthcare and Medical Education Summit, that was held in Mumbai recently.  Commenting on the MoU, Hitesh Goswami, CEO & Co-Founder, 4baseCare, said, “This MoU marks an important step towards creating more effective and personalized cancer treatment approaches, and we are pleased to see Maharashtra taking the lead in making this easily accessible to a wider population. At 4baseCare, our aim is to integrate genomic insights into routine cancer care, enabling oncologists to make more informed, evidence-based treatment decisions.” The Centre of Excellence will focus on enabling access to precision oncology, building local clinico-genomic datasets, and supporting oncologists across government healthcare institutions in Maharashtra with data-backed treatment insights. The Centre will be equipped with Next Generation Sequencing (NGS) technology to enable comprehensive genomic profiling for cancer patients. This will support Oncologists in making more targeted, personalised treatment decisions based on each patient’s genomic profile.   ]]> https://biospectrumindia.com/news/92/27577/somniscan-brings-hospital-grade-sleep-diagnostics-home.html https://biospectrumindia.com/news/92/27577/somniscan-brings-hospital-grade-sleep-diagnostics-home.html Fri, 27 Mar 2026 00:00:00 +0530 SomniScan is transforming sleep diagnostics in India by bringing hospital-grade polysomnography (PSG) directly into patients’ homes, combining clinical accuracy with the convenience of at-home testing. Addressing a critical gap in the healthcare system, SomniScan enables full sleep studies without the need for hospital admission, helping patients and clinicians access reliable diagnostics more efficiently. “From sleep labs to living rooms, without compromising on accuracy.” Sleep disorders remain widely underdiagnosed in India, with nearly 80% of sleep apnea cases going undetected. As per a report by AIIMS, an estimated 10.3 million people in India are affected, highlighting the scale of the problem. Traditional sleep studies are often limited to major hospitals, require overnight stays, and can be costly and inconvenient. This leads to delayed diagnosis and increases the risk of serious health conditions such as hypertension, diabetes, and cardiovascular disease. SomniScan directly addresses these challenges by making comprehensive sleep diagnostics more accessible across geographies, including Tier 2 and Tier 3 cities. Unlike basic home sleep tests, SomniScan delivers a complete diagnostic system rather than a simplified screening tool. Accurate diagnosis—not just detection—is critical in managing sleep disorders effectively. It captures detailed physiological signals including brain activity (EEG), enabling true sleep staging (REM, light, and deep sleep)—a capability typically unavailable in most home sleep tests. The system uses gold-standard polysomnography with high-quality sensors and gold cup electrodes, ensuring precision comparable to in-lab studies. High sampling rates further enhance data accuracy and reliability. Each study is manually scored epoch-by-epoch by trained sleep technologists certified as RPSGTs, following AASM guidelines to ensure clinical rigor and trust. Reports are delivered within 24 to 48 hours, allowing for timely medical intervention. Patients benefit from sleeping in their natural environment, reducing the ‘first night effect’—a well-known phenomenon where unfamiliar lab settings alter sleep patterns—resulting in more natural and reliable data.   ]]> https://biospectrumindia.com/news/92/27565/neuberg-announces-launch-of-blood-test-for-early-alzheimers-detection-in-chennai.html https://biospectrumindia.com/news/92/27565/neuberg-announces-launch-of-blood-test-for-early-alzheimers-detection-in-chennai.html Thu, 26 Mar 2026 00:00:00 +0530 As India’s healthcare landscape evolves with cutting-edge diagnostic solutions, Chennai is set to witness a transformative development in Alzheimer’s screening. The Mispa i60, introduced at Neuberg Diagnostics, Chennai, offers a simple blood test to detect early signs of Alzheimer’s disease using only a blood sample, making it a non-invasive and cost-effective screening option. This test serves as an adjunct to clinical evaluation and does not replace neuroimaging or cerebrospinal fluid (CSF) testing. This technology leverages p-tau and amyloid proteins, which are strongly associated with Alzheimer’s disease, enabling the detection of early pathological changes well before noticeable cognitive decline begins. Early identification can significantly enhance treatment planning and help clinicians distinguish Alzheimer’s disease from other forms of dementia that present with similar symptoms. “Alzheimer's disease shares overlapping clinical features with other types of dementia, making diagnosis challenging. Studies have shown that a proportion of clinically diagnosed Alzheimer’s cases reveal non-Alzheimer’s pathology upon autopsy, further emphasizing the importance of accurate biomarker testing,” says Dr Asma Bibi, Chief of Laboratory, Neuberg Diagnostics. “This blood test can help differentiate Alzheimer’s from other dementia syndromes, ensuring that patients receive the correct diagnosis and appropriate treatment. We are excited about the possibilities this test brings for both clinicians and patients.” Among patients who underwent this test at Neuberg’s OMR centre in Chennai, 45% were found to have an elevated tau-to-amyloid ratio, suggestive of underlying Alzheimer’s pathology. These findings were further supported through neurologist assessment and clinical evaluation. This outcome highlights the test's high concordance with traditional diagnostic methods while offering a faster and non-invasive alternative. With Alzheimer’s disease affecting a significant proportion of the global population, early detection is critical for effective treatment and management. Innovations like these are poised to bring more timely and accurate Alzheimer’s screening to both urban and regional settings, enabling early intervention for patients across Tamil Nadu.   ]]> https://biospectrumindia.com/news/92/27559/livlong-365-enters-diagnostics-marketplace-eyes-24-market-share-by-fy28.html https://biospectrumindia.com/news/92/27559/livlong-365-enters-diagnostics-marketplace-eyes-24-market-share-by-fy28.html Wed, 25 Mar 2026 00:00:00 +0530 Mumbai-based startup Livlong 365, a leading OPD insurance and health-tech platform, has launched India’s first nationwide Labs Marketplace, a digital platform that enables users to discover, compare, and book diagnostic tests from multiple certified laboratory partners through a single interface. The launch comes as India’s diagnostics industry, currently valued at approximately $10 billion or Rs 865 billion in FY24, continues its strong growth trajectory. The sector has expanded at a CAGR of 9 to 10 percent since FY12 and is projected to grow at nearly 11 percent CAGR through FY28, reaching an estimated Rs 1,325 billion. Livlong aims to capture 2 to 4 percent market share by FY28, positioning itself as a technology-led player in the evolving diagnostics landscape. Diagnostic services in India have traditionally been fragmented, with consumers navigating multiple labs, inconsistent pricing, and disconnected booking systems. Livlong’s Labs Marketplace addresses this gap by centralising access and offering users the flexibility to choose tests based on location, pricing, and preferred lab partners. In its initial phase, the platform covers over 19,000 pin codes across more than 800 cities and has onboarded 35 plus certified laboratory partners. The company plans to expand into 2,000 to 2,500 locations in the near term, strengthening its presence across both metros and emerging towns. Users can book multiple tests from a single lab in one journey and opt for home sample collection or in-centre visits based on availability.   ]]> https://biospectrumindia.com/news/92/27527/thyrocare-launches-first-diagnostic-laboratory-in-gwalior.html https://biospectrumindia.com/news/92/27527/thyrocare-launches-first-diagnostic-laboratory-in-gwalior.html Sat, 21 Mar 2026 00:00:00 +0530 Thyrocare Technologies has announced the launch of its first diagnostic laboratory in Gwalior, Madhya Pradesh, in association with Excellence Diagnostics. The facility was inaugurated by Piyush Singh, Vice President, Thyrocare. Thyrocare now operates three laboratories in Madhya Pradesh, including its existing presence in Bhopal and Indore, further strengthening access to diagnostic services across the state.  The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling accurate and timely diagnostic results. It is designed to cater to both routine and specialised testing requirements, supporting preventive and ongoing healthcare needs.  This expansion is aligned with Thyrocare’s continued focus on strengthening its network and addressing the growing demand for reliable diagnostic services in emerging markets. The Gwalior facility further expands the company's presence in central India. Commenting on the launch of the new lab in Gwalior, Rahul Guha, MD and CEO, Thyrocare, said, “At Thyrocare, our focus is on making  high-quality and reliable diagnostic services accessible to every Indian household. The launch of our new facility reflects our continued efforts to expand our presence while addressing diagnostic gaps through a technology-led and patient-focused approach.”  Rajdeep Panwar, Chief Commercial Officer, Thyrocare, shared, “Our focus in markets like Gwalior is on improving last-mile access and ensuring that both patients and healthcare partners have access to consistent and timely diagnostic services. This facility allows us to strengthen our reach in the region while maintaining the quality and turnaround standards that Thyrocare is known for.” With this launch, Thyrocare continues to expand its presence in Madhya Pradesh, with a focus on making diagnostic services more accessible across cities beyond metro markets. The company remains committed to strengthening its network and bringing reliable healthcare services closer to patients. ]]> https://biospectrumindia.com/news/92/27513/redcliffe-labs-introduces-elecsys-amh-plus-blood-test-to-transform-pcos-diagnosis.html https://biospectrumindia.com/news/92/27513/redcliffe-labs-introduces-elecsys-amh-plus-blood-test-to-transform-pcos-diagnosis.html Thu, 19 Mar 2026 00:00:00 +0530 Redcliffe Labs has announced the launch of the Elecsys® AMH Plus blood test, in collaboration with Roche Diagnostics India, to support the timely identification of Polycystic Ovarian Morphology (PCOM) and aid in the diagnosis of Polycystic Ovary Syndrome (PCOS). This addresses a pressing need, given that global estimates suggest up to 70% remain undiagnosed. Nearly 1 in 5 women of reproductive age in India are affected, and to resolve this concern, Redcliffe Labs, with the Elecsys®AMH Plus, is redefining this experience.  Instead of an invasive scan, a simple blood draw measures Anti-Müllerian Hormone (AMH), a biomarker strongly linked to PCOM and present in nearly 4 out of 5 PCOS cases in India. This test eliminates the drawbacks of transvaginal ultrasound (TVUS). The Elecsys® AMH Plus test is backed by strong global and local validation. International guidelines released in 2023 now recognize AMH as a reliable alternative to ultrasound for assessing PCOM, while in India, FOGSI’s Good Clinical Practice Recommendations have endorsed its use in aiding PCOS diagnosis. Large clinical studies, including APHRODITE and HARMONIA, further confirm its accuracy - at a cut-off of 3.2 ng/mL, the test delivers 89% sensitivity and 85% specificity. Together, these endorsements position the Elecsys® AMH Plus test as a trusted, evidence-based solution for clinicians and a breakthrough in accessible care for women.  ]]> https://biospectrumindia.com/news/92/27493/acrannolife-genomics-receives-govt-support-for-indigenous-manufacturing-of-advanced-ivd-diagnostic-kits.html https://biospectrumindia.com/news/92/27493/acrannolife-genomics-receives-govt-support-for-indigenous-manufacturing-of-advanced-ivd-diagnostic-kits.html Tue, 17 Mar 2026 00:00:00 +0530 The Technology Development Board (TDB), Department of Science & Technology (DST), Government of India, has extended financial assistance to Acrannolife Genomics, Chennai for the project titled “Indigenising IVD Innovation: Establishing a State-of-the-Art Manufacturing Facility to Drive Scalable and Sustainable Growth of Trunome GrafAssure IVD Kits and TBFYND IVD Kits.” The project focuses on establishing an advanced manufacturing facility to support the large-scale production and deployment of indigenous in-vitro diagnostic (IVD) solutions developed by the company. Acrannolife Genomics is engaged in developing innovative non-invasive diagnostic technologies based on cell-free DNA and LAMP technology platforms, addressing critical healthcare needs such as infectious diseases and transplant diagnostics. Through this project, the company will establish a state-of-the-art manufacturing facility at the Tamil Nadu Small Industries Development Corporation Limited (TANSIDCO) Industrial Estate to scale up production of two key diagnostic products—Trunome GrafAssure and TBFYND. The company’s flagship product, Trunome GrafAssure, is a laboratory-developed blood test designed for the early detection of post-transplant organ rejection and infection in patients who have undergone solid-organ transplants.  The second product, TBFYND, is designed to address the urgent need for rapid and accurate detection of tuberculosis, one of the most significant public health challenges in India. With support from TDB, the project will enable the creation of a dedicated platform facility for manufacturing these IVD kits at scale, strengthening India’s domestic capabilities in molecular diagnostics and reducing dependence on imported diagnostic technologies. ]]> https://biospectrumindia.com/news/92/27485/fujifilm-strengthens-advanced-diagnostic-infrastructure-in-tamil-nadu.html https://biospectrumindia.com/news/92/27485/fujifilm-strengthens-advanced-diagnostic-infrastructure-in-tamil-nadu.html Sun, 15 Mar 2026 00:00:00 +0530 Fujifilm India has announced the installation of a comprehensive suite of advanced diagnostic and medical equipment at Porunai Hospitals, Tirunelveli, further strengthening the hospital’s diagnostic capabilities and reinforcing the role of technology in expanding access to quality healthcare in South India. The installation includes CT System Supria 32, Amulet Innovality Mammography which includes the state-of-the-art features available globally, FDR Smart F – 40 kW Digital Radiography, Bone Mineral Densitometry (BMD), along with EP 6000 Endoscopy video processor with Multi-LED light source and Dry Chemistry analyser DRI-CHEM NX 600, enabling Porunai Hospitals to enhance its diagnostic ecosystem across multiple clinical domains. At the centre of this deployment is the Supria 32 CT system, a 32-slice CT platform designed to deliver high-resolution imaging with optimized radiation dose and efficient workflows across routine and advanced diagnostics.  The installation marks the first deployment of the Supria 32 CT system in Tamil Nadu, reflecting Porunai Hospitals’ commitment to adopting advanced imaging technologies to support accurate diagnosis and improved patient outcomes.  Complementing the CT platform is the FDR Smart F digital radiography system, which enables high-quality imaging with fast acquisition speeds and dose-optimized performance across a wide range of radiography applications. Designed to support high-throughput clinical environments, the system enhances operational efficiency while ensuring reliable diagnostic performance for everyday clinical needs. The deployment also includes the Amulet Innovality mammography system, a digital mammography platform equipped with advanced detector technology and low-dose imaging capabilities. As the first installation of its kind in South Tamil Nadu, the system strengthens women’s healthcare services in the region by supporting early and accurate breast cancer detection through advanced imaging technology.  Further strengthening preventive diagnostic capabilities, an advanced Bone Mineral Densitometry (BMD) system has also been installed, enabling precise assessment of bone health and early detection of osteoporosis. This installation marks the first advanced BMD system in South Tamil Nadu, expanding access to specialized diagnostics and preventive screening in the region.  In addition to imaging technologies, the deployment also includes EP 6000 Endoscopy video processor with Multi-LED light source and Dry Chemistry analyser DRI-CHEM NX 600, helping Porunai Hospitals strengthen its diagnostic ecosystem across multiple clinical domains, including gastroenterology, pathology, and preventive screening.     ]]> https://biospectrumindia.com/news/92/27453/babycue-receives-govt-support-to-develop-rapid-diagnostic-equipment-for-childhood-diarrhoea.html https://biospectrumindia.com/news/92/27453/babycue-receives-govt-support-to-develop-rapid-diagnostic-equipment-for-childhood-diarrhoea.html Mon, 09 Mar 2026 00:00:00 +0530 The Technology Development Board of the Department of Science and Technology, Government of India, has provided financial assistance to Cuttack-based startup BabyCue for a project to develop a disposable paper analytical device for rapid detection of childhood diarrhoea. The project focuses on commercialising indigenous rapid diagnostic kits, which have been designed to detect the difference between bacterial and non-bacterial diarrhoea in children in a timely manner. The proposed product, DyCue Diagnostic Kit is an important indigenous innovation combining biotechnology and materials science to tackle the widespread problem of diarrhoea in the country. The kit is designed as a quick, non-harmless and cost-effective diagnostic tool that can also be used in rural health centres and temporary diagnostic centres. The device is based on lateral flow assay (LFA) technology, which rapidly identifies disease using disease-specific fecal biomarkers. The system uses gold nanoparticle-based colorimetric detection, allowing results to be visually understood without the need for specialised laboratory equipment. The use of proprietary biomarkers and specially designed reagents ensures high sensitivity and specificity, making it possible to make a reliable distinction between bacterial and non-bacterial infections. Proprietary biomarkers are patented, biological indicators (molecules, genes, or imaging characteristics) that are made by specialty pharmaceutical, diagnostic, or biotech companies to detect diseases, predict treatment efficacy, or drug efficacy.   The technology has been developed in collaboration with National Institute of Pharmaceutical Education and Research, Hyderabad and has been clinically validated at ESIC Hospital, Hyderabad.  Technology Development Board will help the company to accelerate product development, increase manufacturing capacity and deploy this diagnostic solution widely for the benefit of healthcare providers and patients. ]]> https://biospectrumindia.com/news/92/27417/medgenome-makes-majority-investment-in-mumbai-based-medcare-diagnostics.html https://biospectrumindia.com/news/92/27417/medgenome-makes-majority-investment-in-mumbai-based-medcare-diagnostics.html Mon, 02 Mar 2026 00:00:00 +0530 Bengaluru-based MedGenome has announced a majority investment in Mumbai-headquartered Medcare Management Services, a leading radiology and nuclear medicine provider specialising in PET-CT and advanced molecular imaging services. Medcare Management Services offers advanced imaging services, including PET-CT, CT, Mammography, Nuclear Medicine Scans, and theragnostic facilities. Over the past decade, through partnerships with over 50 hospitals and leading physicians across the city, Medcare has built credibility for its clinical excellence, accessibility, and patient care in the region.  Nuclear medicine plays a major role in the areas of Oncology, Cardiology, and Neurology for diagnosis as well as in treatment planning. PET-CT Imaging, complemented with genetic tests, enables early cancer detection and has a significant impact on the course of treatment and monitoring, delivering enhanced patient outcomes. Dr Atul Marwah, Founder, Medcare, added, “As a part of MedGenome, Medcare can unlock significant growth opportunities, enabling us to offer integrated imaging, pathology, and genomics solutions, which are especially critical in oncology and the management of complex diseases." Commenting on this alliance, Dr Amit Kakar, Managing Partner and Head of Asia at Novo Holdings, and Chairman of the Board of MedGenome, said, “MedGenome’s investment in Medcare marks an important step in strengthening its vision of building an integrated diagnostics ecosystem for India. By bringing together Medcare’s imaging and pathology expertise with MedGenome’s leadership in multi‑omics, this partnership expands access to earlier and more precise diagnostics for patients. As an investor, Novo Holdings is pleased to support this next phase of growth as the company continues advancing high‑quality, science‑led healthcare.” The collaboration fortifies MedGenome's strategy of evolving into a truly integrated diagnostics player, with a focus on multi-omics. By strengthening its capabilities across radiology, pathology, and genomics, the company is poised to deliver more comprehensive, technology-driven, and patient-centric solutions, expand its reach and footprint, and improve the accessibility of advanced precision diagnostics across India. ]]> https://biospectrumindia.com/news/92/27419/avio-smart-market-stack-and-huwel-target-large-scale-public-tb-diagnostics-opportunity.html https://biospectrumindia.com/news/92/27419/avio-smart-market-stack-and-huwel-target-large-scale-public-tb-diagnostics-opportunity.html Mon, 02 Mar 2026 00:00:00 +0530 Avio Smart Market Stack (ASMS) (formerly Bartronics India Limited) has signed a Share Subscription cum Shareholders’ Agreement with Hyderabad-based startup Huwel Lifesciences pursuant to and in furtherance of the MoU signed between the parties in September 2025. Under the agreement, Avio Smart Market Stack will acquire a minority stake in Huwel and collaborate on business development and project execution. Under this structure, ASMS is contractually entitled to receive a defined share of the net project revenues arising from orders secured and executed through its institutional engagement and business development efforts. Huwel Lifesciences’ tuberculosis (TB) diagnostic platform has recently undergone a Health Technology Assessment (HTA) conducted by the Department of Health Research under the Ministry of Health & Family Welfare, Government of India. The assessment evaluated molecular tuberculosis diagnostic platforms deployed nationwide. As per its findings, Huwel’s Quantiplus® MTB FAST platform enables testing at an approximate cost of Rs 340 per sample, whereas molecular testing systems currently used in government programmes typically range between Rs 700 and Rs 1,000 per test. A key differentiator for the Quantiplus platform is its compatibility with open RT-PCR systems. This enables the Government to leverage the thousands of RT-PCR machines installed across India during the COVID-19 response, facilitating rapid deployment of the platform without the need for proprietary hardware or significant additional capital expenditure.   ]]> https://biospectrumindia.com/news/92/27402/ayucryam-innovations-develops-ai-powered-hole-slide-imaging-diagnostic-system.html https://biospectrumindia.com/news/92/27402/ayucryam-innovations-develops-ai-powered-hole-slide-imaging-diagnostic-system.html Thu, 26 Feb 2026 00:00:00 +0530 The Technology Development Board (TDB), Department of Science and Technology (DST), Government of India, has announced support for "Otoscope: A Fully Automated Hole Slide Imaging Diagnostic System" by Delhi-based Ayukriyam Innovations. The Otoscope platform is fully automated combined with AI-powered diagnostic capabilities. The system aims to offer high-throughput, standardised, and scalable diagnostic workflows. By leveraging indigenous research and development and AI-enabled image analysis, this technology enhances diagnostic accuracy while reducing dependence on imported high-end imaging systems. The project is indigenously developed through in-house R&D and institutional linkages. It strengthens TDB's mandate to provide financial support for commercialisation of technologies and innovation-based in critical sectors such as healthcare and medical devices.  ]]> https://biospectrumindia.com/news/92/27380/sigtuple-announces-launch-of-ai-enabled-digital-morphology-analyser.html https://biospectrumindia.com/news/92/27380/sigtuple-announces-launch-of-ai-enabled-digital-morphology-analyser.html Tue, 24 Feb 2026 00:00:00 +0530 Bengaluru-based SigTuple has announced the launch of AS76, an AI-enabled digital morphology analyser designed to automate peripheral blood smear (PBS) microscopic review. AS76 combines automated digital microscopy with on-device, edge-AI computing to deliver faster, more consistent results while preserving data privacy. Powered by NVIDIA RTX, the AS76 analyser will perform high-throughput image analysis using advanced AI models, all running locally on the device. This allows the system to deliver near-instant results even for large sample batches, without dependence on internet connectivity. An AI-powered automated digital microscope with built-in computing, AS76 system can load up to six PBS slides simultaneously, scan them in full diagnostic detail, and generate an AI-assisted report for expert review — with all processing performed entirely on the device. The system automates key elements of manual PBS review, including generation of a 200-cell leukocyte differential, highlighting red blood cell morphology, and flagging platelet morphology, including detection of platelet aggregates. Equipped with 20×, 40×, and 100× objectives on an automated turret, AS76 launches with peripheral blood smear capabilities and is designed for future software upgrades to support tissues, fluids, bone marrow, and microbiology slides. This multi-application readiness positions AS76 as a digital replacement for the analog microscope in the laboratory. By applying AI-driven cell pre-classification, AS76 standardises smear review at scale and surfaces atypical findings quickly for expert confirmation. The system reduces manual effort and turnaround time. ]]> https://biospectrumindia.com/news/92/27368/srmist-and-core-diagnostics-partner-to-strengthen-future-ready-talent-in-oncology-and-genetic-diagnostics.html https://biospectrumindia.com/news/92/27368/srmist-and-core-diagnostics-partner-to-strengthen-future-ready-talent-in-oncology-and-genetic-diagnostics.html Sat, 21 Feb 2026 00:00:00 +0530 In a significant step towards advancing precision oncology and building future-ready healthcare talent, SRM Institute of Science and Technology (SRMIST) has signed a Memorandum of Understanding (MoU) with CORE Diagnostics, a global leader in cancer diagnostics and genomic testing. With cancer care increasingly moving towards personalised and precision-based treatment, expertise in genetic diagnostics and next-generation sequencing is becoming indispensable. This partnership is designed to bridge the gap between classroom learning and real-world oncology practice, providing students with direct exposure to cutting-edge diagnostic technologies, genetic counseling frameworks and industry-led research. The MoU is expected to significantly enhance student competitiveness in the rapidly evolving healthcare sector. By working alongside industry experts and engaging with advanced genomic technologies, students will graduate not only with academic knowledge but with applied clinical insight, a crucial differentiator in today’s job market. Beyond training, the collaboration also opens avenues for joint research initiatives aimed at advancing cancer diagnostics and improving patient outcomes. As oncology treatment continues to evolve towards data-driven, individualised care, this SRMIST–CORE Diagnostics partnership signals a forward-looking commitment to strengthening India’s healthcare talent ecosystem ensuring that the next generation of professionals is equipped to lead in precision medicine and cancer care innovation. ]]> https://biospectrumindia.com/news/92/27338/oxygen-times-launches-somniscan-indias-first-branded-athome-sleep-diagnostic-solution.html https://biospectrumindia.com/news/92/27338/oxygen-times-launches-somniscan-indias-first-branded-athome-sleep-diagnostic-solution.html Tue, 17 Feb 2026 00:00:00 +0530 New Delhi-based startup Oxygen Times has announced the launch of SomniScan, a branded at-home sleep diagnostic solution designed to bring advanced sleep testing directly into Indian homes. With growing awareness of sleep health and a large burden of undiagnosed sleep disorders, SomniScan aims to establish a new benchmark in diagnostic accuracy, clinical reliability, and patient convenience across India. SomniScan represents a significant evolution in sleep diagnostics by offering hospital‑grade sleep studies that are manually scored and clinically interpreted by certified sleep professionals. Unlike generic or local sleep tests that may rely solely on basic automated scoring, SomniScan adheres to the latest AASM 3.0 standards and incorporates detailed manual scoring to ensure high sensitivity in detecting even subtle abnormalities in breathing patterns, oxygen desaturation, airflow limitations, snoring severity, and body positions changes during sleep. The at-home sleep study under the SomniScan brand is offered at an accessible starting price, positioning it among the most affordable yet comprehensive sleep diagnostics available in India. The Level 3 sleep study, suitable for identifying conditions such as obstructive sleep apnea, is available at a price of Rs 1,899, while advanced polysomnography options for more complex or severe sleep disorders are offered at approximately Rs 6,000. Reports are delivered within 24 hours, enabling timely clinical decision-making and treatment planning.   ]]> https://biospectrumindia.com/news/92/27316/erlysign-gets-us-fda-breakthrough-device-designation-for-saliva-based-oral-cancer-detection-test.html https://biospectrumindia.com/news/92/27316/erlysign-gets-us-fda-breakthrough-device-designation-for-saliva-based-oral-cancer-detection-test.html Wed, 11 Feb 2026 00:00:00 +0530 ErlySign, an innovative biotech startup from Nagpur, has been granted the US Food and Drug Administration (FDA) Breakthrough Device Designation for its saliva-based oral cancer early detection kit.  The designation marks a significant global regulatory milestone for the company and underscores the potential of its technology to advance early cancer detection across international markets.  The FDA Breakthrough Device Designation is awarded to medical devices that demonstrate reasonable clinical evidence of providing more effective diagnosis or treatment of life-threatening or irreversibly debilitating diseases.  ErlySign’s oral cancer detection test is India’s first saliva-based, non-invasive diagnostic solution designed to identify precancerous conditions even before visible tumours or lesions appear in the oral cavity, lips, tongue, throat, or larynx. The test requires only a 2–5 ml saliva sample and delivers results within 10–15 minutes, making it quick, painless, and easy to deploy across diverse healthcare settings. The technology has been clinically validated through large-scale, multi-city trials conducted in collaboration with Healthcare Global (HCG) and the Regional Cancer Hospital (Rashtrasant Tukdoji Cancer Hospital), Nagpur. The studies, conducted across approximately 1,000 patients in Nagpur, Bengaluru, and Ranchi, demonstrated 98% sensitivity and 100% specificity, validating the test’s accuracy and effectiveness.     ]]> https://biospectrumindia.com/news/92/27285/medgenome-expands-infectious-disease-testing-portfolio-with-metaseq.html https://biospectrumindia.com/news/92/27285/medgenome-expands-infectious-disease-testing-portfolio-with-metaseq.html Thu, 05 Feb 2026 00:00:00 +0530 Bengaluru-based MedGenome, India’s leading genomics-driven diagnostics company, has announced the launch of MetaSeq, an advanced blood test designed to support faster and more comprehensive detection of bloodstream infections (BSI). MetaSeq uses metagenomic next-generation sequencing (NGS) to analyse microbial cell-free DNA (cfDNA) present in the bloodstream. This enables identification of more than 1,400 clinically relevant pathogens in a single test, including bacteria, fungi, parasites, and DNA viruses, without the need for multiple targeted assays. Traditionally, diagnosing bloodstream infections depends on blood culture tests that can take several days and may yield negative results if patients have been taking antibiotics. MetaSeq detects microbial DNA directly from blood samples, allowing infections to be identified even when traditional methods are inconclusive. The test delivers results in approximately five days and has demonstrated higher sensitivity compared to standard blood culture. This supports clinicians to identify infections with greater confidence, enabling earlier, more informed treatment decisions, especially in critically ill and immunocompromised patients. MetaSeq is CE-IVD validated for peripheral blood samples, which means that the test can also be performed on other clinical sample types such as cerebrospinal fluid, synovial fluid, and ascitic fluid. MedGenome partnered with Noscendo, a leading German company specialising in software-based pathogen diagnostics, to develop this test. MetaSeq is powered by Noscendo’s DISQVER® platform, which uses advanced bioinformatics algorithms for accurate pathogen identification. DISQVER® is recognised by the World Health Organization as the only clinically approved NGS platform for diagnosing invasive fungal diseases.   ]]> https://biospectrumindia.com/news/92/27280/neuberg-launches-advanced-cytogenetics-fish-karyotyping-in-mumbai-for-cancer-prenatal-diagnosis.html https://biospectrumindia.com/news/92/27280/neuberg-launches-advanced-cytogenetics-fish-karyotyping-in-mumbai-for-cancer-prenatal-diagnosis.html Wed, 04 Feb 2026 00:00:00 +0530 Neuberg Sehgal Path Lab, a leading name in diagnostic services, has announced the launch of cutting-edge cytogenetics testing technology at its facilities in Mumbai. This advanced diagnostic tool is poised to revolutionise the approach to both cancer diagnostics and prenatal testing, offering a higher level of precision and personalisation for patients. Cytogenetics, a specialised field that focuses on studying genetic material within cells, is now available at Neuberg Sehgal Path Lab, utilising two powerful techniques: Fluorescent In-Situ Hybridisation (FISH) and Conventional Karyotyping. This technology enables the precise identification of chromosomal abnormalities, including translocations, deletions, and insertions—key indicators of various genetic disorders and cancer types. A rare offering by standalone labs in India, Cytogenetics is primarily conducted in large, standardised labs such as Tata Medical Center in Kolkata, Tata Memorial in Mumbai, CMC Vellore, and SGPGI in Lucknow. genetic abnormalities. Cytogenetics offers highly accurate detection of chromosomal abnormalities, aiding in the diagnosis of conditions such as Down syndrome during prenatal testing, as well as a variety of cancers, including acute promyelocytic leukaemia (APML) and Burkitt’s lymphoma. The cost of cytogenetic testing is relatively affordable compared to high-end molecular genetics, offering significant value for both prenatal and cancer diagnostics. ]]> https://biospectrumindia.com/news/92/27282/truevis-neusoft-smc-clinics-sign-mou-to-establish-300-radiology-centres.html https://biospectrumindia.com/news/92/27282/truevis-neusoft-smc-clinics-sign-mou-to-establish-300-radiology-centres.html Wed, 04 Feb 2026 00:00:00 +0530 Truevis Technologies, a leading manufacturer in the med-tech sector, and Neusoft Medical Systems, have signed a strategic Memorandum of Understanding (MoU) with SMC Clinics, an initiative of Swadhin Trust powered by Tripura Santiniketan Medical College and Hospital.  In a landmark move to bridge India's widening med-tech gap especially amid the escalating cancer crisis and capitalise on the sector's post-Budget 2026 surge, this partnership aims to establish 300 clinician-owned diagnostic centres in Tier II, Tier II towns and beyond over the next five years, reaching over 1 million patients annually. India grapples with a surging cancer burden, with approximately 1.46 million new cases in 2022 (ICMR estimates), projected to exceed 1.5 million by 2026 and rise to around 1.57 million by 2030. Early detection through advanced imaging is critical, yet access remains limited in semi-urban and rural areas.  This MoU directly tackles the cancer crisis by deploying advanced imaging equipment (X-Ray, Mammography, Ultrasound, CT, MRI, PET-CT) across 300 centres. These clinician-owned facilities will enable early-stage cancer detection vital for improving survival rates while cutting costs by up to 30% through local supply chains. By empowering radiologists in Tier II/III towns and beyond, the initiative ensures affordable, high-quality diagnostics for over 1 million patients yearly, reducing treatment delays, easing hospital overload, and supporting India's goal of universal healthcare access. This partnership positions Truevis, Neusoft, and SMC Clinics at the forefront, offering a clinician-centric model where radiologists retain full ownership while partners handle backend hurdles like technology procurement and operations.   The initiative prioritizes urban and semi-urban expansion, reducing dependence on corporate chains and promoting affordable, high-quality diagnostics amid the sector's projected boom. ]]> https://biospectrumindia.com/features/92/27238/ai-fuels-new-era-of-cancer-detection.html https://biospectrumindia.com/features/92/27238/ai-fuels-new-era-of-cancer-detection.html Sat, 31 Jan 2026 00:00:00 +0530 Cancer continues to be a significant health issue in the country, which demands the invention of new methods for early detection, precise diagnosis, and personalised treatments. And artificial intelligence (AI) is rapidly becoming a groundbreaking component in the modern era of oncology, offering sophisticated tools across the range of cancer detection and care. As World Cancer Day is marked every year on February 4, it becomes pertinent to focus on the new developments taking place within the country to address this growing healthcare burden. According to the Indian Council of Medical Research (ICMR), 15.7 lakh new cancer cases were apparently reported in India in 2025. This projection indicates a 12.8 per cent increase in cancer incidence compared to levels seen in 2020. Reports have also suggested that India's lung cancer burden is projected to rise sharply by 2030, with the North-East emerging as the worst-affected region and women recording the fastest increase in cases. Additionally, a recent study warns that breast cancer cases in India are expected to climb by 5.6 per cent every year. As a result, we are now seeing a huge increase in technology deployment, especially the use of AI, across public and private sectors for early detection of cancer, to bring down this number as much as possible. India’s first government-run artificial intelligence (AI) clinic was recently inaugurated at the Government Institute of Medical Sciences (GIMS) in Greater Noida, marking a major step in integrating cutting-edge technology into public healthcare, to enhance early disease detection of cancer and other diseases. IndiaAI Independent Business Division (IBD), in collaboration with the National Cancer Grid (NCG), has launched the Cancer AI & Technology Challenge (CATCH) Grant Programme to support the development and deployment of innovative AI solutions to strengthen cancer screening, diagnostics, treatment support, and healthcare operations across India. The CATCH Grant Programme is providing up to Rs 50 lakh per project to selected teams comprising technology innovators and clinical institutions. Successful pilot projects may also be eligible for an additional scale-up grant of up to Rs 1 crore, facilitated by IndiaAI. The Department of Biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC) are supporting the establishment of Bio-AI Hubs, which focus on interdisciplinary collaborations to develop AI-guided platforms for cancer research, diagnosis and treatment. These hubs aim to improve scientific discoveries, optimise processes, and enhance decision-making in the field of cancer treatment.  Although AI shows promise for improving cancer screening and diagnosis, its adoption and understanding have often turned out to be challenging. For instance, the lack of large, representative datasets specific to India has hindered AI’s readiness for routine clinical application. Dr Jitendra Kumar, Managing Director, Biotechnology Industry Research Assistance Council (BIRAC) said, “AI must be leveraged to deepen core scientific capabilities before being widely deployed in public-facing healthcare applications. Premature use of AI in direct patient interfaces must be done cautiously, as misinterpretation, misuse and varying levels of public health literacy could undermine trust in both technology and healthcare systems. AI should act as an enabler for scientists, clinicians and manufacturers rather than a replacement, and robust validation frameworks are essential before large-scale deployment.” In order to address such challenges, the Central Drugs Standard Control Organisation (CDSCO) has now brought artificial intelligence driven cancer detection and diagnostic software under its regulatory oversight, placing it on par with medical devices. Such proactive approaches to regulation can stand to benefit both patients and developers, particularly the startups and scientists that are developing novel AI-based solutions for early cancer detection. “AI-driven startups are pivotal in addressing India’s cancer burden by democratising expertise. In a country facing a chronic specialist shortage, AI empowers clinicians in Tier-2 and Tier-3 cities with metro-level diagnostic accuracy, facilitating early-stage detection where survival rates are highest. However, the path forward involves navigating regulatory and data challenges. Classifying AI-powered diagnostic software as Class C medical devices is a critical step; it ensures clinical validity and patient safety while building the trust required for large-scale hospital adoption”, said Chirag Adatia, Partner, Health and Life Sciences and Private Capital Practices, Oliver Wyman. He further added, “By creating compounding returns across the healthcare value chain, from improved hospital utilisation to better actuarial outcomes for insurers, AI-driven diagnostics are not just improving survival rates; they are making the India healthcare system more economically resilient.”   Rise of intelligent cancer diagnosis The emergence of oncology-focused AI startups in India is marking a significant chapter in the ongoing battle against cancer. By harnessing the power of technology, these innovators are reshaping the way we used to look at the oncology landscape earlier. Experts suggest that the AI-based cancer diagnostics market in India is projected to reach $41.4 million by 2030, where startups are likely to hold a major share. Mumbai-based startup Qure.ai is currently utilising deep learning algorithms to analyse medical imaging, enabling faster and more accurate lung cancer detection. The company has recently joined hands with the global player Johnson & Johnson MedTech, to establish AI-led Incidental Pulmonary Nodule (IPN) detection clinics across leading hospitals in India. “AI helps to overcome healthcare bottlenecks, from imaging reporting backlogs and low screening uptakes. The future belongs to proactive, AI-enabled health systems that can scale care without compromising quality. AI isn’t here to replace humans, it’s here to amplify human judgment, deliver faster insights, and ultimately make healthcare more equitable”, said Prashant Warier, Founder and CEO of Qure.ai. Emerging as a game-changer in cancer diagnostics is Bengaluru-based startup SigTuple's AI100, an AI-driven smart robotic microscope. It automates the microscopic analysis of biological samples, including blood and urine, and delivers results in minutes. This technology has received US FDA approval for its blood smear application, making it the first Indian company to achieve this milestone. The company has forged crucial partnerships with diagnostic labs to secure annotated data, and with distribution partners like Horiba India, leveraging established networks for market penetration. At the other end, Punjab government has launched first-of-its-kind AI-enabled screening devices for early detection of breast cancer and cervical cancer, in partnerships with startups such as Niramai and Periwinkle. Within Punjab, RNT Health Insights is specialising in AI-assisted diagnostic solutions for the accurate detection of pathologies during endoscopic procedures. The startup has recently received US FDA Breakthrough Device Designation for its oesophageal cancer and gastric cancer detection tools. Adding to this list is Dr. Lal Path Labs that has made a significant leap in cancer diagnostics by adopting a deep learning-based AI module to detect lymph node metastasis, including micrometastasis, in cancer cases, in collaboration with Singapore-based startup Qritive. “India has the potential to become a global hub for AI-driven medical devices and diagnostics. AI is enabling earlier, more accurate, and more accessible detection of disease, reshaping preventive and precision medicine in India. AI tools can detect subtle abnormalities critical for cancer. In endoscopy, AI has significantly improved adenoma detection rates, lesion characterisation, and early cancer diagnosis”, said Koji Wada, Managing Director (Healthcare Division), Fujifilm India. Delhi-based startup Primary Healthtech has recently received support from Technology Development Board (TDB), Department of Science and Technology, Government of India, to build an AI-based point-of-care blood testing device for detecting cancer and other diseases. Around similar lines, researchers at the Indraprastha Institute of Information Technology (IIIT), Delhi, have developed cutting-edge artificial intelligence tools that can detect cancer at an early stage using a simple blood test. The test is based on Tumour Educated Platelets (TEPs), which carry molecular information altered by the presence of cancer. Using AI, the test can identify multiple cancer types from a small blood sample, offering a cost-effective alternative to invasive and expensive diagnostic procedures. “AI models have been shown to detect up to 13 different cancers with over 98 per cent accuracy in controlled studies when analysing tissue patterns that the human eye would find difficult to quantify. For India, the opportunity is particularly profound. With a large and diverse population and a limited number of specialists, AI can help bridge gaps by streamlining imaging interpretation and pathology analysis, reducing reporting times, and enabling remote diagnostics in areas with few specialists”, said Dr Mayanka Lodha Seth, Chief Pathologist, Redcliffe Labs. With these developments taking place in India, AI is no longer a secondary adjunct in oncology, it is becoming an essential, intrinsic component in advancing cancer detection. With regulatory frameworks for AI in cancer diagnostics taking shape now, there is an urgent need to unite AI researchers, oncologists and regulators to create transparent, and clinically valuable AI deployment standards, so that AI can usher in a transformative era within the oncology landscape.   Vrushti Kothari (vrushti.kothari@mmactiv.com) ]]> https://biospectrumindia.com/news/92/27251/intuitive-supports-iit-m-to-build-ultrasound-imaging-system-for-early-breast-cancer-detection-in-rural-india.html https://biospectrumindia.com/news/92/27251/intuitive-supports-iit-m-to-build-ultrasound-imaging-system-for-early-breast-cancer-detection-in-rural-india.html Thu, 29 Jan 2026 00:00:00 +0530 Intuitive Surgical, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, has partnered with the Indian Institute of Technology (IIT) Madras to support the development of a fully indigenous portable ultrasound imaging system through its CSR funding. The initiative is led by the Biomedical Ultrasound Lab (BUSi) in the Department of Applied Mechanics and Biomedical Engineering at IIT Madras and focuses on strengthening early breast cancer detection for women in rural and semi-urban regions. Beyond its on-ground healthcare impact, the initiative is also expected to open new opportunities for India’s health-tech innovation ecosystem. By creating an indigenous source of high-quality imaging data, the project can support development of AI-driven diagnostics, automated screening tools, telemedicine workflows, and new domestic intellectual property. Dr Arun Kumar Thittai, Professor, IIT Madras said, “India lacks indigenous medical imaging systems despite the widespread use of ultrasound in routine care. Our lab is addressing this gap by developing an advanced yet accessible screening device that allows frontline healthcare workers to perform reliable breast screening without specialized radiology training, extending early detection to villages, small towns and remote communities through mobile units and primary health centres. Built on our proprietary ultrasound platform, the system delivers high-quality images at higher frame rates than most existing commercial scanners.” In India, breast cancer survival rates remain around 66%, compared to nearly 90% in many Western countries, largely due to delays in diagnosis and limited access to screening especially in underserved regions. By offering a reliable, portable imaging solution that can be deployed in community-level healthcare settings, the project aims to bring early breast screening closer to where women live. ]]> https://biospectrumindia.com/news/92/27246/agilus-diagnostics-installs-illumina-novaseq-x-to-revolutionise-genomic-testing-in-india.html https://biospectrumindia.com/news/92/27246/agilus-diagnostics-installs-illumina-novaseq-x-to-revolutionise-genomic-testing-in-india.html Wed, 28 Jan 2026 00:00:00 +0530 Agilus Diagnostics, a subsidiary of Fortis Healthcare, has announced the installation of the Illumina NovaSeq X at its Mumbai reference laboratory—strengthening India’s capacity for next‑generation sequencing at scale. The launch was attended by Dr Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare; Dr Anand K., Managing Director & CEO, Agilus Diagnostics, and Deepak Narang, Chief Operating Officer, Agilus Diagnostics. The NovaSeq X strengthens Agilus Diagnostics’ molecular testing capabilities through high‑throughput sequencing and scalable analytics. Its multi‑omic capacity delivers rapid, high‑resolution results across diverse clinical needs. Through Agilus’ nationwide network, these advanced capabilities become accessible to clinicians and patients in both metro and emerging markets. Powered by high‑density flow cells and automation, the NovaSeq X enables whole exome sequencing (WES), whole genome sequencing (WGS), and multi‑omic analysis with exceptional speed and accuracy. Deployed for high‑fidelity clinical decision‑making—not just research—it provides physicians with actionable molecular insights and faster turnaround times. Dr Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare, said, “Integrating advanced platforms like the Illumina NovaSeq X into clinical diagnostics is a pivotal step for India’s healthcare ecosystem. High‑quality molecular insights are vital not only for oncology but also for diagnosing rare diseases, guiding targeted therapies, and advancing personalized and preventive care. Agilus’ investment brings cutting‑edge science closer to patients and equips clinicians with actionable information to improve outcomes across a broad spectrum of conditions.” For clinicians and researchers, the enhanced capacity translates into: Whole exome and whole genome testing for comprehensive variant detection Genetic evaluation of inherited and rare disorders Reproductive and maternal health applications, including carrier screening and prenatal testing Pharmacogenomic assessments to inform drug response and dosing Infectious disease sequencing for pathogen tracking and antimicrobial resistance insights Liquid biopsy (ctDNA) analysis and multi‑omic studies for longitudinal disease monitoring and deeper biological understanding     ]]> https://biospectrumindia.com/news/92/27237/ai-eye-scan-offers-new-way-to-detect-diabetes-without-blood-tests.html https://biospectrumindia.com/news/92/27237/ai-eye-scan-offers-new-way-to-detect-diabetes-without-blood-tests.html Tue, 27 Jan 2026 00:00:00 +0530 A team of researchers from Yenepoya (Deemed to be) University (Mangalore), Madras Diabetes Research Foundation (Chennai), and Emory University (Atlanta, USA) have detected a way to detect diabetes among Indians by taking a high-resolution photo of the retina (back of the eye). The retina is the only place in the entire body where doctors can see live blood vessels without any surgery or invasive tools, by clicking a photograph. The scientists have used artificial intelligence (AI) techniques to look at the feature of the blood vessels and found that in the veins in the eyes show considerable changes in people with diabetes.  This research study has been published in Diabetes Technology and Therapeutics journal on 23th Jan 2026. This study shows that AI can spot tiny warning signs in the eye’s blood vessels that are invisible to the human eye that can differentiate people with and without diabetes without a finger prick blood test.   "The study has utilised routine retinal images already captured during standard eye examinations. We noticed that there are subtle changes in the eye blood vessels that start, even before diabetes develops”, notes Dr R. Rajalakshmi, senior author, who is the Head of Medical Retina and Ocular Research at Dr. Mohan’ s Diabetes Specialities Centre and Madras Diabetes Research Foundation. Dr V. Mohan, Chairman of Dr. Mohan’ s Diabetes Specialities Centre and a senior diabetes expert in India, explains why this matters: "India has over 100 million people with diabetes, and very often, many do not even know, they have it. If use of AI tools with simple retinal photos can help early diagnosis of diabetes, it can be used real-time in future, to screen for diabetes. We have to validate these research findings in a larger population." ]]> https://biospectrumindia.com/news/92/27195/mahajan-imaging-labs-introduces-alzheimers-diagnostics-with-ai-integrated-testing.html https://biospectrumindia.com/news/92/27195/mahajan-imaging-labs-introduces-alzheimers-diagnostics-with-ai-integrated-testing.html Mon, 19 Jan 2026 00:00:00 +0530 Mahajan Imaging & Labs, a leading chain of advanced diagnostic centres in India, has expanded its Alzheimer’s diagnostic capabilities with the introduction of an artificial intelligence (AI)-integrated blood biomarker test, supported by a structured PET and MRI imaging pathway, offered under its Dementia Diagnostic Series, which includes Alzheimer’s blood biomarker testing using the pTAU217/βAmyloid1-42 ratio along with cognitive health and genetic risk panels, AI-enabled MRI brain imaging with dementia protocol, and FDG PET imaging where clinically indicated. The new pTAU/Aβ1-42 blood biomarker test, which is USFDA- and CDSCO-approved, enables the detection of Alzheimer’s-related biological changes well before severe cognitive symptoms become evident, supporting a shift from symptom-led assessment to a biology-first diagnosis in Indian clinical practice.   Recent estimates indicate that over 8.8 million Indians aged 60 and above are living with dementia, with Alzheimer’s disease accounting for the majority of cases. This number is projected to nearly double over the next decade, highlighting the growing need for early and accurate diagnostic tools that support timely intervention and care planning.    Until recently, Alzheimer’s biomarker testing relied on cerebrospinal fluid samples, which meant a more invasive procedure for patients. Today, with plasma-based testing, we can obtain the same critical information through a simple blood test. This makes diagnosis easier, safer, and far more acceptable for patients. Mahajan Imaging & Labs now performs the pTAU/Aβ1-42 blood biomarker test in its Reference Laboratory, enabling faster reporting, closer clinical integration with imaging findings, and improved affordability for both patients and clinicians.  Globally, Alzheimer’s diagnosis increasingly depends on amyloid PET imaging and cerebrospinal fluid (CSF) testing. Commenting on the Alzheimer’s diagnostics scenario in India, Dr. Harsh Mahajan, Padma Shri Awardee, Founder & Chairman of Mahajan Imaging & Labs, said, “In India, limited availability and high costs, as much as Rupees two lakhs per scan, have restricted widespread access to amyloid PET, leaving many clinicians dependent on symptom-based assessments. A key differentiator of Mahajan Imaging & Labs’ approach is the integration of laboratory diagnostics with imaging. The combination of blood biomarkers with 18F FDG can be a game-changer not only in early diagnosis of Alzheimer’s, but also in follow-up of patients on the new treatments to assess for treatment response. The conclusions of this symposium shall be sent to the Neurological Society of India to help in formulating guidelines for the diagnosis and treatment of Alzheimer’s in India. This may even have implications on the approach to early diagnosis of Alzheimer’s in other parts of the world.”   ]]> https://biospectrumindia.com/news/92/27148/cardio-diagnostics-aimil-and-dr-lal-pathlabs-partner-to-launch-precisionchd-test-in-india.html https://biospectrumindia.com/news/92/27148/cardio-diagnostics-aimil-and-dr-lal-pathlabs-partner-to-launch-precisionchd-test-in-india.html Thu, 08 Jan 2026 00:00:00 +0530 Cardio Diagnostics Holdings, Aimil Ltd. and Dr. Lal PathLabs have announced a strategic agreement to launch Cardio Diagnostics' PrecisionCHD™ Test for the identification and management of coronary heart disease (CHD) in India. This partnership marks Cardio Diagnostics' first expansion outside the United States and an official entry into the Indian market. It is also a major step towards making the advanced technology of Cardio Diagnostics available in India, where cardiovascular disease remains a major and growing health problem. The prevalence rate of coronary heart disease (CHD) in India varies depending on the population, with prevalence rates of up to 7.4% and 13% recorded in rural and urban areas, respectively. PrecisionCHD is a clinical blood test that can combine the science of epigenetics and genetics with AI technology to identify coronary heart disease (CHD) at the molecular level. This clinically accredited test helps physicians understand the main molecular cause of the disease, which is very important for personalized treatment and continued management. In addition to the prevented CHDs that can be detected with an angiogram, the PrecisionCHD test can also detect CHDs that are not normally detected by an angiogram. The data supporting the potential of PrecisionCHD include information on the detection of ischemia with no obstructive coronary arteries (INOCA) and myocardial infarction with no obstructive coronary arteries (MINOCA), two common types of nonobstructive disease. Recently it was presented at the scientific meeting of the American Heart Association held in New Orleans, Louisiana. The initial phase of this partnership has already begun. The focus is on scaling up and scaling up the test to Dr. Lal PathLabs' larger lab and clinical network so that it is in accordance with India's clinical and regulatory regulations. Once this process is complete, work will be done on a commercial scale on a large scale, which is expected in 2026. ]]> https://biospectrumindia.com/news/92/27092/zydus-lifesciences-partners-with-us-based-myriad-genetics-to-launch-cancer-risk-assessment-diagnostic-tests-in-india.html https://biospectrumindia.com/news/92/27092/zydus-lifesciences-partners-with-us-based-myriad-genetics-to-launch-cancer-risk-assessment-diagnostic-tests-in-india.html Fri, 19 Dec 2025 00:00:00 +0530 Ahmedabad-based Zydus Lifesciences has signed an agreement with US-based Myriad Genetics, a leader in molecular diagnostic testing and precision medicine company. Pursuant to the agreement, Zydus will be introducing MyRisk® Hereditary Cancer Test, MyChoice® HRD Plus, Homologous Recombination Deficiency (HRD) Test and Prolaris® Prostate Cancer Prognostic Test to patients, clinicians, and healthcare systems across India. With the increasing incidence of cancers globally, the MyRisk® Test can help people safeguard their health and take precautionary steps and lifestyle changes that can minimise the risk of cancer. In patients suffering from prostate and ovarian cancers, the Prolaris® Test and MyChoice® HRD Plus Test, respectively, can help patients understand the disease progression and inform the right treatment path. As part of this agreement, Zydus will exclusively market, create awareness, access and engage clinicians on three of Myriad Genetics’ broadly validated diagnostic platforms, MyRisk® Hereditary Cancer Test, MyChoice® HRD Plus Test for ovarian cancer, and Prolaris® a gene expression Prostate Cancer Prognostic Test. These tests have been widely adopted in the North America, Europe, and major global cancer centres, and will now empower Indian oncologists with cutting-edge genomic decision-support tools. The MyRisk® Test is a germline multigene panel for individuals with personal or family history suggestive of hereditary cancer. It detects pathogenic variants in high, moderate and emerging-risk genes to estimate lifetime cancer risk and inform personalised prevention strategies. ]]> https://biospectrumindia.com/news/92/27010/cipla-opens-lung-health-diagnostics-centre-in-delhi.html https://biospectrumindia.com/news/92/27010/cipla-opens-lung-health-diagnostics-centre-in-delhi.html Sun, 30 Nov 2025 00:00:00 +0530 Cipla has announced the launch of its first Breathefree Lung Wellness Center in Lajpat Nagar in New Delhi. This will be India’s first-of-its-kind integrated lung diagnostics and wellness center, set to redefine respiratory care by making world-class, advanced standardised lung diagnostics both accessible and affordable for doctors and patients across the country. Respiratory diseases have been on the rise in India, with millions remaining undiagnosed or misdiagnosed due to limited access to advanced pulmonary function testing and comprehensive diagnostic infrastructure in the respiratory domain. The Breathefree Lung Wellness Center is designed to be a one-stop solution for comprehensive lung health diagnostics, leveraging Cipla’s decades of expertise and commitment to respiratory diseases and health. The center brings together cutting-edge technology, globally recognised diagnostic protocols, and a team of highly trained technical professionals who perform tests with precision, enabling doctors to detect respiratory diseases early and accurately. The center will provide a comprehensive gamut of over 60 tests covering lung physiology, microbiology, immunology, blood chemistry and radiology. The aim is to enable a more comprehensive evaluation of the lungs for patients suspected of having a respiratory disease or those already diagnosed with a lung condition - ranging from common diseases like Asthma and COPD to more complex ones such as interstitial lung diseases (ILD). Tests include Spirometry, Oscillometry, FeNO, DLCO, Body Plethysmography, FnNO, CPET, X-Ray and CT scan, sleep studies, etc. which will be conducted by highly trained technicians to eliminate errors and inconsistencies. In addition, the center will also provide pulmonary nutrition and rehabilitation services, and counselling for smoking cessation to aid patients on their rehabilitation journeys. Dr Jaideep Gogtay, Global Chief Medical Officer, Cipla Limited, added, “India is estimated to have over 90 million people with chronic respiratory diseases. Early and accurate diagnosis is crucial for physicians to initiate appropriate treatment for their patients, reduce the risk for hospitalisation and improve the quality of life." ]]> https://biospectrumindia.com/news/92/26991/lords-mark-india-acquires-85-holding-of-renalyx-health-systems.html https://biospectrumindia.com/news/92/26991/lords-mark-india-acquires-85-holding-of-renalyx-health-systems.html Wed, 26 Nov 2025 00:00:00 +0530 In a strategic move to strengthen its presence in the medical diagnostics segment, recently listed Mumbai based Lords Mark India has acquired 85% holding in Bengaluru based Renalyx Health Systems. By March 2026, the acquisition will reach 92% holding. The company will continue to operate as an independent business unit of Lords Mark India. The acquired company, Renalyx Health Systems is the developer of Renalyx, the world’s first AI powered – Made in India sustained low efficiency dialysis machine (SLED).  The product represents a significant step toward India’s vision of becoming a global MedTech manufacturing hub. RxT 21, is an AI powered and IoT-enabled smart hemodialysis machine, offering remote monitoring, clinical connectivity, real-time data access, supports telenephrology platforms and enhances patient safety and quality of care. Features of the ISO and CE certified machine includes integration with DNP database for seamless dialysis centre operations and cloud based patient EMR management, one touch operation for streamlined dialysis sessions, SLED mode for intensive care environments, personalised dialysis prescriptions, Kt/V monitoring for dialysis adequacy and clearance validation, single needle dialysis support, Endotoxin removal filter for patient safety, advanced sodium and ultrafiltration profiling. The dialysis machine will be manufactured in collaboration with Bharat Electronics. Lords Mark recently received its manufacturing license on in September 2025.   ]]> https://biospectrumindia.com/news/92/26950/qure-ai-partners-with-microsoft-to-increase-access-to-lung-cancer-detection-and-management-suite-in-us.html https://biospectrumindia.com/news/92/26950/qure-ai-partners-with-microsoft-to-increase-access-to-lung-cancer-detection-and-management-suite-in-us.html Wed, 19 Nov 2025 00:00:00 +0530 Mumbai-based startup Qure.ai has announced its collaboration with Microsoft. Qure.ai will onboard its end-to-end lung cancer detection, measurement and management suite of artificial intelligence (AI)-powered solutions onto the Precision Imaging Network. This will streamline deployment of Qure.ai solutions to hospitals and health systems across the USA, driving digital healthcare transformation, improved tech integrations and ultimately enhance quality of patient care. The Qure.ai suite of lung cancer algorithms are built from Large Language Models (LLMs) and Agentic AI, the very latest forms of artificial intelligence. Qure.ai augments clinical workflows between radiologists, pulmonologists, interventionalists and thoracic surgery teams, to accelerate the patient pathway from early detection to diagnosis and treatment. It aims to answer the biggest cancer challenge in the US today, with lung cancer responsible for more deaths in the US than colon, breast and prostate cancers combined. The Qure.ai FDA-cleared lung cancer solutions can be deployed as individual products, or collectively as a suite for a unified and cohesive workflow.  ]]> https://biospectrumindia.com/news/92/26907/servier-india-inks-partnership-with-medgenome-and-strand-life-sciences.html https://biospectrumindia.com/news/92/26907/servier-india-inks-partnership-with-medgenome-and-strand-life-sciences.html Tue, 11 Nov 2025 00:00:00 +0530 Servier India, a subsidiary of the leading French pharmaceutical company Servier Group, has announced the launch of a patient-centric biomarker testing initiative in collaboration with leading genomic laboratories MedGenome and Strand Life Sciences. As part of this initiative, a customised panel of biomarker tests for Acute Myeloid Leukaemia (AML), an aggressive blood cancer and Cholangiocarcinoma (CCA), a rare bile duct cancer, is launched across India at subsidised rates making these advanced diagnostics more affordable and accessible. The panel will be available to healthcare professionals across private and government sectors. Specifically, IDH1 and IDH2 mutation testing for AML and CCA, will be available free of cost for the government sector.   The patient-centric biomarker testing initiative aims to address access to good quality molecular testing which remains largely concentrated to a small subset of Indian population, majorly in urban centers, leaving many patients without timely and accurate diagnosis.  This is the critical gap that Servier India aims to bridge. The biomarker testing initiative is launched under ‘Servier Care’ patient support programme which offers comprehensive support to eligible patients, including financial assistance, free drug support and subsidised diagnostics, ensuring holistic care for patients throughout the treatment journey, where legally permissible. ]]> https://biospectrumindia.com/news/92/26894/sciverse-and-bhat-biotech-forge-strategic-collaboration-for-next-gen-molecular-diagnostics.html https://biospectrumindia.com/news/92/26894/sciverse-and-bhat-biotech-forge-strategic-collaboration-for-next-gen-molecular-diagnostics.html Thu, 06 Nov 2025 00:00:00 +0530 Pune-based Sciverse Solutions, an artificial intelligence (AI)-first Point-of-Care Testing (PoCT) diagnostics company, has announced its strategic collaboration with Bengaluru-based Bhat Biotech, a leading Indian biotechnology and molecular diagnostics company. The partnership will focus on co-developing next-generation molecular diagnostic platforms designed to make testing faster, smarter, and more accessible at the point of care. This collaboration combines Sciverse’s deep expertise in AI, biosensors, microfluidics, and hardware design with Bhat Biotech’s proven capabilities in molecular assay development and manufacturing. Together, both organisations aim to accelerate the development of portable, high-accuracy diagnostic systems capable of delivering lab-quality results in real time — directly at the site of patient care. “Molecular diagnostics is shaping the future of healthcare — enabling faster, more precise, and accessible disease detection,” said Rahul Singh, Managing Director of Sciverse Solutions. “Our collaboration with Bhat Biotech reflects a shared commitment to redefining how molecular testing can be brought closer to patients, doctors, and healthcare workers everywhere.” Dr Shama Bhat, Founder of Bhat Biotech added, “By integrating Bhat Biotech’s assay chemistry expertise with Sciverse’s device and AI capabilities, we are confident this collaboration will lead to molecular platforms that are more robust, cost-effective, and scalable across global markets.” ]]> https://biospectrumindia.com/news/92/26877/medgenome-makes-majority-investment-in-leading-gujarat-based-diagnostics-chain-green-cross.html https://biospectrumindia.com/news/92/26877/medgenome-makes-majority-investment-in-leading-gujarat-based-diagnostics-chain-green-cross.html Tue, 04 Nov 2025 00:00:00 +0530 MedGenome, a leading global genomics-driven diagnostics and research services company, has announced a majority investment in Gujarat-headquartered pathology laboratory chain, Green Cross Genetics Lab. With a legacy of over 30 years of trust and quality excellence, Green Cross continues to expand its presence with 17 state-of-the-art laboratories and 35 collection centres operating across Gujarat today. Each facility operates under the supervision of senior experts dedicated to precision, reliability, and patient trust. Founded by renowned industry veteran Vinod Patel, the company has, for over three decades, been guided by a leadership team of accomplished pathologists and medical professionals. Most of the management team brings more than 30 years of clinical experience and has been instrumental in shaping the company’s strategy and growth journey to its current scale. The company’s promoters are committed to continuing to lead the business in this partnership as the company enters its next phase of growth. Green Cross’s operational capabilities, combined with the credibility it has earned over the years, complement MedGenome’s commitment to making genomics-led, affordable solutions accessible to the larger population. MedGenome operates South Asia’s largest CAP-accredited end-to-end multiomics laboratory, along with in-house developed AI/ML-enabled analysis pipelines, empowering clinicians with data-driven genetic insights to better diagnose and treat complex diseases. Commenting on the announcement, Dr Vedam Ramprasad, CEO, MedGenome, said, “This partnership will strengthen MedGenome's market presence in Gujarat, allowing us to better serve a broader population. It reiterates our commitment to improving access to affordable omics solutions, particularly in Tier 2 and Tier 3 cities. With Green Cross’s three-decade legacy of trust and high-quality diagnostics, this partnership perfectly aligns with our mission to harness genomics for early, accurate disease detection and management. As we work towards positioning Indian genomics on the global stage, we will continue to innovate and create solutions that meet the needs of diverse markets worldwide.” Vinod Patel, Promoter & Director, Green Cross Genetics Lab, added, “Combining our extensive portfolio of over 800 diagnostics solutions and a dedicated team of 500+ employees, with MedGenome’s world-class genomics capabilities, we can offer a more comprehensive menu of services across the country. The collaboration also enables more efficient integration of genomics into diagnostics, unlocking new opportunities to service our clinicians and patient base.”   ]]> https://biospectrumindia.com/news/92/26897/molbio-diagnostics-receives-kochon-prize-2024-by-stop-tb-partnership.html https://biospectrumindia.com/news/92/26897/molbio-diagnostics-receives-kochon-prize-2024-by-stop-tb-partnership.html Tue, 04 Nov 2025 00:00:00 +0530 Molbio Diagnostics, an innovative point-of-care diagnostics company, has been awarded the KOCHON Prize 2024 by the Stop TB Partnership. This recognition honours Molbio’s work in ensuring access to the latest tools, innovations, and approaches for people affected by Tuberculosis (TB) and in advancing progress toward the UNHLM targets. With this award, Molbio becomes the first private company globally—and only the third Indian entity after the Indian Council of Medical Research (ICMR) and Dr. L.S. Chauhan—to receive this distinction. Awarded annually by the Stop TB Partnership, the Kochon Prize recognises individuals and organisations that have made significant contributions to combating tuberculosis. Established by the Kochon Foundation in memory of its late chairman, Chong-Kun Lee, the award carries a prize of $65,000 and a medal, making it the world’s largest award specifically dedicated to TB. “We express our sincere gratitude to the Government of India and the Indian Council of Medical Research (ICMR) for their unwavering support and for endorsing the Truenat®️ platform. We also extend our thanks to the World Health Organization and the global TB community for their trust and continued support in endorsing and adopting the platform. As a gesture of appreciation, Molbio is contributing the prize money back to the Stop TB Partnership — reaffirming our shared commitment to ensuring that communities affected by TB have a strong voice and active role in shaping and advancing TB programs worldwide", said Sriram Natarajan, Executive Director and Chief Executive Officer, Molbio Diagnostics Limited. ]]> https://biospectrumindia.com/news/92/26844/fujifilm-brings-advanced-wet-chemistry-technology-to-india.html https://biospectrumindia.com/news/92/26844/fujifilm-brings-advanced-wet-chemistry-technology-to-india.html Tue, 28 Oct 2025 00:00:00 +0530 Fujifilm India, a leader in healthcare technology solutions, has announced the launch of its FW500 Clinical Chemistry Analyzer strengthening the company's In-vitro diagnostics portfolio by combining over four decades of dry chemistry expertise with Fujifilm’s Wako globally trusted biochemistry reagents. The FW500 has been engineered to deliver accuracy, speed, and ease of use, qualities essential for today’s diagnostic laboratories. With the ability to process up to 200 tests per hour, 95 sample positions, and 72 reagent positions, the analyzer offers efficiency in a compact design. Features such as continuous sample loading and temperature-controlled reagents ensure smooth, uninterrupted laboratory operations, making the FW500 an ideal fit for mid-sized labs across India. Speaking on the milestone, Koji Wada, Managing Director, Fujifilm India, said, “At Fujifilm India, we are committed to delivering innovative products and solutions that embody our Group purpose of ‘Giving Our World More Smiles.’ By blending diverse ideas, unique capabilities, and extraordinary people, we aim to create solutions that bring joy and smiles to the world. The goal is to continuously innovate and deliver solutions that strengthen the nation’s healthcare ecosystem while providing high-quality, reliable, and comprehensive diagnostic solutions that empower healthcare providers and benefit patients across India.” Beyond performance, the FW500 incorporates sustainability and smart connectivity. It uses only 1.5 litres of water per hour and reusable cuvettes to minimize waste. Its intelligent software supports real-time monitoring and remote access, enabling laboratories to enhance productivity while staying connected. With this launch, Fujifilm India now offers a comprehensive biochemistry portfolio spanning both dry and wet chemistry platforms, reaffirming its commitment to delivering innovations that empower healthcare professionals and improve access to high-quality diagnostics nationwide. ]]> https://biospectrumindia.com/news/92/26820/icici-bank-pledges-rs-625-cr-to-set-up-radiation-therapy-facilities-at-tata-memorial-centre-navi-mumbai.html https://biospectrumindia.com/news/92/26820/icici-bank-pledges-rs-625-cr-to-set-up-radiation-therapy-facilities-at-tata-memorial-centre-navi-mumbai.html Sun, 19 Oct 2025 00:00:00 +0530 ICICI Bank, along with Tata Memorial Centre (TMC), has announced the commencement of construction of a new cancer care building at TMC’s Advanced Centre for Treatment, Research & Education in Cancer in Navi Mumbai, Maharashtra. Funded through the Bank’s CSR contribution of Rs 625 crore, the facility will be among India’s largest radiation therapy centres, equipped with cutting-edge cancer treatment technologies. This is part of the Bank’s larger commitment of Rs 1,800 crore to TMC for setting up of three state-of-the-art cancer care buildings, one each at Navi Mumbai in Maharashtra, Mullanpur (New Chandigarh) in Punjab and Visakhapatnam in Andhra Pradesh. The 11-storey building with a ground floor and two basements will span across 3.4 lakh square feet. It will house 12 state-of-the-art Linear Accelerators (LINACs), and other advanced cancer care equipment. LINACs deliver precise radiation to cancer cells thereby minimising damage to surrounding healthy tissues. The ‘ICICI Foundation Block for Radiation Oncology’ will serve 7,200 patients with radiation therapies annually, offering over two lakh radiation sessions to these patients. In addition, the block will provide OPD consultations and diagnostics to 25,000 new patients a year. It is expected to be completed by 2027. ICICI Foundation for Inclusive Growth, the CSR arm of ICICI Bank, will oversee its implementation.                                                                                                                       ]]> https://biospectrumindia.com/news/92/26812/indias-first-microrna-based-blood-test-for-breast-cancer-screening.html https://biospectrumindia.com/news/92/26812/indias-first-microrna-based-blood-test-for-breast-cancer-screening.html Fri, 17 Oct 2025 00:00:00 +0530 PrecisionRNA Biotech (Prerna), a healthcare startup from Hyderabad, has announced the launch of Cantel™, India’s first microRNA-based blood test for breast cancer screening. This groundbreaking test is set to transform early detection by offering a simple, convenient, and highly accurate alternative to traditional methods, addressing the critical screening gap that has led to late-stage diagnosis of breast cancer in India. In a country where less than 2% of women are screened for breast cancer, Cantel™ offers a scalable solution. Unlike mammography, which is often hindered by cost, accessibility issues, and social stigma, Cantel™ is a minimally invasive blood test that can be performed at home or at a local diagnostic center. No compression, no imaging, and no radiation. This convenience is designed to significantly increase screening adherence and improve survival rates, which are currently among the lowest globally. The test utilises the power of microRNAs (miRNAs), small molecules that act as dynamic biomarkers for disease. The 2024 Nobel Prize in Medicine recognized the discovery of microRNAs and their role in gene regulation, highlighting their significance in modern diagnostics. Cantel™ leverages proprietary miRNA signatures, validated through extensive clinical trials, to detect early molecular signals of breast cancer with high sensitivity and specificity. "For far too long, breast cancer detection in India has been reactive. With Cantel™, we’re making it proactive, accessible, and designed around women’s real lives, empowering them to take control of their health with confidence and ease,” said Siddharth Reddy, Co-founder of CANTEL™ and a serial healthcare entrepreneur. "This is not just a diagnostic innovation. This is a step toward building a national health habit around early detection."   ]]> https://biospectrumindia.com/news/92/26784/thermo-fisher-introduces-new-diagnostic-system-to-aid-in-evaluation-of-lung-transplant-rejection.html https://biospectrumindia.com/news/92/26784/thermo-fisher-introduces-new-diagnostic-system-to-aid-in-evaluation-of-lung-transplant-rejection.html Thu, 09 Oct 2025 00:00:00 +0530 Thermo Fisher Scientific, the world leader in serving science, has introduced a new laboratory developed test for post-transplant biopsy assessment designed to improve the detection of lung transplant rejection and injury, delivering quantifiable results that may increase diagnostic confidence and guide timely treatment.  Due to the significant risk of rejection, lung transplant recipients often require routine biopsies to monitor the health of their new lungs. Yet, when assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a diagnosis of acute rejection. Thermo Fisher’s new Molecular Microscope® Diagnostic System for Lung (MMDx® Lung) leverages the power of machine learning to profile gene expression data from lung biopsies, comparing each new sample to a reference set of over 896 lung biopsies. The system assesses the probability of rejection and provides molecular scores associated with injury, graft dysfunction and rejection. The results may aid in a pathologist’s assessment, with the aim of enabling greater confidence in the diagnosis and treatment of a lung transplant recipient.  Lung transplantation, once considered experimental, has evolved to become a standard of care for patients with end-state lung disease. In the past decade, the number of annual lung transplants in the U.S. has nearly doubled. Despite medical advances, lung transplant recipients continue to face higher rates of rejection compared to other solid organ transplants, with a five-year survival rate of just under 60%. In the United States, MMDx Lung is delivered through a collaboration with Kashi Clinical Laboratories, a market leader in transplantation immunodiagnostic lab testing.  ]]> https://biospectrumindia.com/news/92/26790/neuberg-pulse-marks-entry-into-tripura-with-first-state-of-the-art-lab-in-dharmanagar.html https://biospectrumindia.com/news/92/26790/neuberg-pulse-marks-entry-into-tripura-with-first-state-of-the-art-lab-in-dharmanagar.html Thu, 09 Oct 2025 00:00:00 +0530 Neuberg Pulse Diagnostics, one of India’s fastest-growing diagnostic chains, has announced the launch of its first diagnostic laboratory in Agartala and Dharmanagar, North Tripura District. Neuberg Diagnostics entered into a joint venture with Kolkata-based Pulse Diagnostics to strengthen its footprint across the eastern region, including West Bengal, Odisha, Bihar, Jharkhand, and the North Eastern states. The launch is a milestone for healthcare in North Tripura, as Neuberg Pulse becomes the first national diagnostics company to establish a lab in the district. Until now, patients often faced delays, with even routine samples traveling over 150 km to Agartala for processing. The new 1500 sq ft facility in Dharmanagar addresses this challenge, ensuring faster, more reliable test results and improving access to timely care for the community. The laboratory is equipped with latest technology to conduct a wide variety of routine and specialized tests and is capable of processing more than 2,000 samples per day. The state-of-the-art centre provides over 6,000 tests across routine and super-specialty tests under one roof, including ultrasound and ECG, Echo, TMT, PFT, Genomics, Proteomics among others. Additional services include home sample collection across, health check-up packages, personalised genomics, digital smart reports, and consultation support. By maintaining global quality standards and delivering results within defined turnaround times, Neuberg Pulse aims to bridge the diagnostic gap for the people of Dharmanagar and surrounding areas. Neuberg Pulse already has a presence in Agartala through its partnership with Primecare Hospital, and the new Dharmanagar lab Neuberg Pulse aims to bridge the diagnostic gap for the people of Dhramanagar and surrounding areas, which include North Tripura & Unakoti Districts of Tripura, Karimgunj & Halaikandi Districts of Assam. ]]> https://biospectrumindia.com/news/92/26710/agilus-diagnostics-sets-new-benchmark-by-introducing-comprehensive-genomic-profiling-of-500-genes.html https://biospectrumindia.com/news/92/26710/agilus-diagnostics-sets-new-benchmark-by-introducing-comprehensive-genomic-profiling-of-500-genes.html Tue, 23 Sep 2025 00:00:00 +0530 Agilus Diagnostics, a leading provider of diagnostic services in India and a subsidiary of Fortis Healthcare, has announced the launch of its ground-breaking AgilusEDGE Comprehensive Genomic Profile (CGP) Rapid at its state-of-the-art Reference Laboratory in Gurugram. This innovative test marks a transformative leap in cancer diagnostics by providing oncologists and clinicians with comprehensive genomic profiling of over 500 cancer-related genes in just four working days. Traditionally, genomic profiling for cancer takes up to 30 days, often delaying critical treatment decisions. AgilusEDGE CGP Rapid, powered by advanced next-generation sequencing (NGS) technology, dramatically reduces this turnaround time, empowering oncologists with rapid, actionable insights to tailor personalised treatment plans. This establishes Agilus Diagnostics as the first commercial laboratory in India to deliver such lightning-fast, multi-gene profiling. On the occasion, Dr Anand K, Managing Director & CEO at Agilus Diagnostics, said, “By bringing down the turnaround time for comprehensive genomic profiling from nearly a month to just four working days, Agilus Diagnostics has taken a decisive leap forward in cancer care. Being the first lab chain in India to introduce this capability, we are not only redefining industry benchmarks but also ensuring that patients and oncologists have faster access to critical insights when every day matters. This breakthrough reflects our commitment to making advanced, precision diagnostics led personalized medicine a reality for patients across India." The AgilusEDGE CGP Rapid offers: Comprehensive profiling of 500+ genes relevant to targeted therapies and precision oncology. Turnaround time of 4 working days, compared to the industry standard of several weeks. Formalin-fixed paraffin-embedded (FFPE) tissue compatibility, ensuring easy integration into existing diagnostic workflows.   ]]> https://biospectrumindia.com/news/92/26696/iit-m-and-sun-life-global-solutions-join-forces-to-pioneer-early-detection-of-type-2-diabetes.html https://biospectrumindia.com/news/92/26696/iit-m-and-sun-life-global-solutions-join-forces-to-pioneer-early-detection-of-type-2-diabetes.html Thu, 18 Sep 2025 00:00:00 +0530 In a significant step toward combating India’s growing diabetes burden, Sun Life Global Solutions (SLGS), the Global Capability Centre of Sun Life—a leading international insurance and asset management company—has announced a groundbreaking research collaboration with the Indian Institute of Technology Madras (IIT-M).  The joint initiative is focused on transforming early diagnosis and management of type 2 diabetes through the identification of Pancreastatin as a novel biomarker, along with genetic testing.The research, led by Dr Nitish R. Mahapatra, Professor, Department of Biotechnology and BJM School of Biosciences at IIT Madras, aims to establish Pancreastatin as a reliable early indicator for pre-diabetes—a crucial step in preventing disease progression. The study will also investigate 10–12 genetic markers that may help predict diabetes risk years in advance, even in children. Dr Mahapatra has previously led international teams in identifying genetic and protein variations prevalent among South Asians that heighten risks of diabetes, hypertension, and heart disease. This partnership will build on that foundation, aiming for early diagnosis, personalized risk prediction, and better disease management. IIT Madras will lead the research through its state-of-the-art biomedical labs, ensuring the science translates into real-world, scalable healthcare solutions. The findings are expected to inform public health policy, improve clinical protocols, and lead to cost-effective diagnostics for integration into India’s primary healthcare system. ]]> https://biospectrumindia.com/news/92/26689/molbio-announces-collaboration-with-ue-lifesciences-to-expand-ibreastexam-globally.html https://biospectrumindia.com/news/92/26689/molbio-announces-collaboration-with-ue-lifesciences-to-expand-ibreastexam-globally.html Tue, 16 Sep 2025 00:00:00 +0530 Molbio Diagnostics, a Goa-based point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies, and UE LifeSciences, a Philadelphia-based innovator engaged in the business of developing and manufacturing health technology solutions, with a primary focus on enabling early cancer detection technologies, have announced an exclusive collaboration, seeking to make early breast cancer detection accessible to millions of women in over 50 countries across the developing world. Through this collaboration, Molbio will bring UE LifeSciences’ iBreastExam® —a radiation-free, painless, and FDA-cleared screening device across India, Africa, the Middle East, CIS countries, the Philippines, Indonesia, and Vietnam. Together, they aim to address the late detection of breast cancer, a leading cause of preventable breast cancer mortality. Molbio Diagnostics will leverage its global distribution network and expertise in expanding access to healthcare solutions to promote, market, sell, and distribute the iBreastExam® to public and private healthcare providers in these regions. Ultra portable and easy to operate, iBreastExam brings early detection directly to women in their communities, overcoming barriers to mammogram access in low-resource settings. Secure cloud storage ensures seamless patient follow-up, helping save lives through timely diagnosis and care. ]]> https://biospectrumindia.com/news/92/26663/redcliffe-labs-strengthens-presence-in-west-bengal-with-new-diagnostic-lab-in-midnapore.html https://biospectrumindia.com/news/92/26663/redcliffe-labs-strengthens-presence-in-west-bengal-with-new-diagnostic-lab-in-midnapore.html Wed, 10 Sep 2025 00:00:00 +0530 Redcliffe Labs, a purpose-driven pan-India omnichannel diagnostics service provider, has expanded its footprint in West Bengal with a new state-of-the-art diagnostic laboratory in Midnapore. With this addition, Redcliffe Labs strengthens its presence across East and West Midnapore and neighboring towns, further solidifying its commitment to providing India with access to quality diagnostics. The new facility in Midnapore, located in Sadar District's Miya Bazar, is aligned with the company's strategic focus on enhancing its reach in Tier II and Tier III regions. By combining advanced infrastructure with strong on-ground networks, Redcliffe Labs is addressing the growing demand for high-quality diagnostic services beyond major metropolitan centres. The advanced laboratory, equipped with the latest diagnostic technology, will bridge accessibility gaps and deliver accurate reports with minimal turnaround time. Redcliffe Labs offers a broad spectrum of diagnostic capabilities across biochemistry, hematology, immunoassays, clinical pathology, serology, and hormones. Patients can conveniently access these services through walk-ins and receive accurate reports, as per NABL & ISO guidelines, within the minimum possible turnaround time. Strategically located in Midnapore, the laboratory will extend services not only to residents of the city but also to surrounding areas, including Khargapur, Jhargram, Contai, Ghatal, Tamluk, and Haldia. The lab is headed by Dr. Manatosh Mandal, a seasoned pathologist with over 12 years of experience, whose expertise and leadership will ensure seamless diagnostic operations and reporting. Speaking about the launch, Aditya Kandoi, Founder & CEO, Redcliffe Labs, said, “Our purpose has always been to give every Indian the right to quality diagnostics. With the launch of our Midnapore laboratory, we are bridging the diagnostic gap that still exists beyond metros. People in Tier 2, Tier 3 cities, and smaller towns deserve the same level of accuracy, convenience, and preventive care as those in developed cities. This expansion is a step towards making advanced diagnostics truly inclusive and accessible for everyone across Bharat.   ]]> https://biospectrumindia.com/news/92/26648/admi-urges-centre-to-remove-inverted-duty-structure-in-diagnostics-kits-reagents-and-ivd-equipment.html https://biospectrumindia.com/news/92/26648/admi-urges-centre-to-remove-inverted-duty-structure-in-diagnostics-kits-reagents-and-ivd-equipment.html Thu, 04 Sep 2025 00:00:00 +0530 The Association of Diagnostics Manufacturers of India (ADMI) has requested the commerce ministry for an urgent intervention to rationalise duties and remove the inverted duty structure in diagnostics kits & reagents and IVD equipment in the larger interest of public health, Atmanirbhar Bharat, and economic growth. In a submission to the Secretary Ministry of Commerce & Industry Government of India, Rajat Kapoor Assistant Director – Secretariat, ADMI noted that currently diagnostics kits, reagents, and In-Vitro Diagnostic (IVD) equipment are subject to an inverted duty structure and differential GST rates. This anomaly has made imported products cheaper than those manufactured domestically, thereby discouraging investment under the Make in India programme. He further said “As a result, local manufacturing capacity is underutilised, employment opportunities are lost, and India’s dependence on foreign suppliers increases. This dependence poses a significant risk, as seen during global health crises, when disruptions in international supply chains directly threaten India’s healthcare preparedness.” Pointing out similar episodes in other sectors, Rajat Kapoor noted “Encouragingly, India has successfully undertaken similar corrections in other sectors. The 2025 Budget reforms in mobile phones, the 2022 GST rationalisation in manmade fibre textiles, and the 2024 Production-Linked Manufacturing Plan for medical devices all demonstrate that calibrated duty and GST restructuring can significantly boost local production, attract foreign direct investment, and enhance global competitiveness. These proven policy models offer a roadmap for the diagnostics sector as well.” In line with these lessons, he suggested a calibrated approach to duty rationalisation for diagnostics. Duties on raw materials, parts, and consumables may be reduced to 2.5%, while duties on finished kits and IVD equipment may be set slightly higher, with a phased increase in IVD equipment duties (5% in Year 1, 10% in Year 2, and 15% in Year 3). To address industry liquidity challenges, a time-bound GST/duty refund mechanism for input tax credits may also be introduced, with a commitment to clearance within 60 days. This would prevent working capital blockages while maintaining revenue flows to the exchequer. “Diagnostics kits, reagents, and IVD equipment are not mere commercial products — they are the backbone of India’s healthcare system and national security. If India can build a competitive manufacturing ecosystem in this field, we will not only serve our 1.4 billion citizens more effectively but also emerge as a reliable partner for the world in times of global health challenges,” Rajat Kapoor added. ]]> https://biospectrumindia.com/news/92/26629/canon-medical-systems-india-inks-agreement-with-rajiv-gandhi-cancer-institute-research-centre-for-advanced-cancer-diagnostics.html https://biospectrumindia.com/news/92/26629/canon-medical-systems-india-inks-agreement-with-rajiv-gandhi-cancer-institute-research-centre-for-advanced-cancer-diagnostics.html Tue, 02 Sep 2025 00:00:00 +0530 Canon Medical Systems India has announced the signing of a Memorandum of Understanding (MoU) with Rajiv Gandhi Cancer Institute & Research Centre, further strengthening its footprint in the medical segment. Under the agreement, the Centre will be using Canon’s new flagship 640-slice CT system, Aquilion ONE / INSIGHT Edition, for research on advanced cancer diagnostics. This collaboration reflects Canon Medical’s commitment to elevating healthcare standards in India through innovation rooted in its ‘Made for Life’ philosophy. The Aquilion ONE / INSIGHT Edition features CT imaging technology, blending wide-area (16-cm) coverage with deep learning-based artificial intelligence (AI) to transform diagnostic capabilities. Canon Medical’s Aquilion ONE / INSIGHT Edition continues to redefine the capabilities of a premium CT by integrating AI technology on a wide-area (16-cm) CT platform to maximise conventional and spectral CT capabilities to assist physicians in making more informed decisions across the patient care cycle. The system features several game changing technologies such as Precise IQ Engine (PIQE), Advanced intelligent Clear-IQ Engine (Ace), SilverBeam and INSTINX. Precise IQ Engine (PIQE) is Deep Learning AI Technology that makes images sharper to show finer details for better delineation of small anatomical structures for a more definitive diagnosis. The 1024 matrix allows images to be enlarged up to four times the size of a 512 image, without a loss of resolution. Advanced intelligent Clear-IQ Engine (AiCE) combined with the SilverBeam Filter technology delivers high-quality chest CT at lung cancer screening dose to minimize the dosage to screening candidates. With AI-assisted workflow support from the new INSTINX platform with features such as automatic scan planning and anatomical landmark detection, the new system makes high-quality scanning easier and more efficient than ever before. ]]> https://biospectrumindia.com/news/92/26584/medgenome-unveils-indias-first-whole-genome-test-for-precise-brain-tumour-classification.html https://biospectrumindia.com/news/92/26584/medgenome-unveils-indias-first-whole-genome-test-for-precise-brain-tumour-classification.html Mon, 25 Aug 2025 00:00:00 +0530 Bengaluru-based MedGenome, India’s leading genomic diagnostics and research services company, has announced the launch of the country’s first CNS Tumour Methylation Classifier Test. This diagnostic test can differentiate and classify over 90 classes of brain and central nervous system (CNS) tumours into accurate subtypes, enabling doctors to make optimal and accurate treatment decisions. The test was unveiled in the presence of nearly 200 oncologists, neuro-onco surgeons and pathologists, researchers, and doctoral students at a precision oncology symposium in Mumbai, hosted by MedGenome jointly with Illumina, the global market leader in DNA sequencing and life sciences technologies. Brain and CNS tumours are among the most complex cancers to diagnose. MedGenome’s new test complements traditional techniques, like Histology, by offering additional insights, as it studies the entire genome, identifying molecular changes and also predicting the tumor’s treatment response. The test uses DNA methylation profiling, a technique that examines chemical modifications across the genome, to create a unique profile of the tumour. This profile is then compared to a global reference database to identify the exact tumuor type, enabling treatment planning tailored to the tumor’s molecular profile. The test has been found to be efficient even in cases that are rare or difficult to classify accurately. The results offer comprehensive support for more precise treatment decisions and guide personalised care. MedGenome’s CNS Tumour Methylation Classifier Test aligns with the World Health Organization’s 2021 guidelines for CNS tumour classification. It delivers results within 21 days and includes WHO grade assignment, genome-wide copy number profiling, and key gene alteration detection in line with the best global practices. ]]> https://biospectrumindia.com/news/92/26582/admi-announces-new-managing-committee-following-successful-2025-elections-.html https://biospectrumindia.com/news/92/26582/admi-announces-new-managing-committee-following-successful-2025-elections-.html Sat, 23 Aug 2025 00:00:00 +0530 The Association of Diagnostics Manufacturers of India (ADMI), the leading representative body of India’s in vitro diagnostics (IVD) industry, has announced the formation of its new Managing Committee, following the successful completion of elections held in July 2025. The newly elected office bearers formally assumed charge during the Annual General Meeting (AGM) convened on August 23, 2025, in Kochi. President: Jatin Mahajan, Managing Director – J. Mitra & Co. Vice President: Sanjeev Lala, Senior Strategic Advisor – Advy Chemical Pvt. Ltd. Secretary: Dr Rajesh M. Patel, Chief Executive Officer – AGD Biomedicals Pvt. Ltd. Treasurer: Chirag Joshi, Chief Executive Officer – Beacon Diagnostic Pvt. Ltd.   Under their stewardship, ADMI will continue to champion regulatory and policy advocacy, promote innovation and self reliance, and enhance the accessibility, affordability, and quality of diagnostic solutions across the nation. The newly constituted Managing Committee brings together distinguished industry leaders with deep expertise and proven track records in advancing diagnostic technologies. Their collective vision and commitment will play a pivotal role in shaping India’s diagnostic ecosystem, fostering collaboration across stakeholders, and contributing to the growth of a robust and globally competitive IVD industry. ADMI also extends its heartfelt gratitude to all members for their active participation in the election process and their unwavering support during the AGM. ]]> https://biospectrumindia.com/news/92/26546/agilus-diagnostics-deepens-footprint-in-mysuru-with-launch-of-new-centre.html https://biospectrumindia.com/news/92/26546/agilus-diagnostics-deepens-footprint-in-mysuru-with-launch-of-new-centre.html Tue, 19 Aug 2025 00:00:00 +0530 Agilus Diagnostics, a subsidiary of Fortis Healthcare Limited, has announced the inauguration of its latest Diagnostic centre at Kuvempunagar, Mysuru. Chief Guest Lakshmikanth Reddy G., IAS – Deputy Commissioner of Mysore and Guest of Honour Seema Latkar, IPS – Commissioner of Police, Mysore City inaugurated the new centre in the presence of local dignitaries, healthcare professionals and community members, which followed by a lunch gathering at noon. With a legacy spanning over 30 years, Agilus Diagnostics stands as India’s largest diagnostics company, trusted by millions for its commitment to quality and innovation. Boasting 30+ crore tests conducted, 4000+ customer touchpoints, and a network extending across 30+ states and Union Territories, Agilus continues to set benchmarks in accuracy, reliability, and patient convenience. The new Kuvempunagar centre offers residents access to an extensive suite of diagnostic and preventive healthcare services, including: CT Scan Ultrasound Scan X-Ray OPG Mammography EEG & Audiometry ECG, ECHO & TMT Full-service Pathology Lab Preventive Health Check-ups This facility complements Agilus’ existing main branch, Agilus Diagnostics – KCDC, at No.L-25/2A, Irwin Road, further strengthening its Karnataka network and reinforcing the company’s mission of delivering diagnostic excellence closer to communities. Dr Anand K, Managing Director & CEO, Agilus Diagnostics, said, “With our new centre in Kuvempunagar, Mysuru, we reaffirm our commitment to making high-quality, reliable diagnostic services accessible to all. Our focus remains on empowering patients and healthcare providers through timely, accurate testing and supportive care, right in the heart of the community.”  ]]> https://biospectrumindia.com/news/92/26549/himedia-labs-secures-cdsco-manufacturing-licenses-for-advanced-hepatitis-b-c-detection-kits.html https://biospectrumindia.com/news/92/26549/himedia-labs-secures-cdsco-manufacturing-licenses-for-advanced-hepatitis-b-c-detection-kits.html Tue, 19 Aug 2025 00:00:00 +0530 Mumbai-based HiMedia Laboratories, a global leader in diagnostics and life sciences, has received manufacturing licenses from the Central Drugs Standard Control Organization (CDSCO) for two advanced molecular diagnostic kits: Hi-PCR® Hepatitis B Virus (HBV) Detection and Quantitation Probe PCR Kit Hi-PCR® Hepatitis C Virus (HCV) Detection and Quantitation Probe PCR Kit These regulatory approvals empower HiGenoMB - HiMedia to manufacture these highly sensitive and specific diagnostic tools on a large scale, developed indigenously as part of the Make in India initiative to tackle two of the most significant viral infections impacting both the global and Indian populations. This achievement aligns strongly with HiGenoMB's vision to help make India hepatitis free by enabling early, accurate diagnosis and effective management of hepatitis B and C. Hepatitis B and C are leading causes of chronic liver disease, cirrhosis, and liver cancer. Early diagnosis is vital for timely treatment and preventing transmission. Hi-PCR® HBV Kit (MBPCR181) Detects HBV DNA across all genotypes (A–J) with 100% specificity. Analytical Sensitivity ≈15 IU/mL Includes quantitative standards for precise viral load measurement Includes endogenous internal control Compatible with various RT-PCR instruments Based on TaqMan chemistry Quantitative standards calibrated against 5th WHO International Standard (NIBSC Code: 22/120)   Hi-PCR® HCV Kit (MBPCR182) Detects HCV RNA across all genotypes (1–7) with 100% specificity. Analytical Sensitivity ≈43 IU/mL Includes quantitative standards for precise viral load measurement Includes endogenous internal control Compatible with various RT-PCR instruments Based on TaqMan chemistry Quantitative standards calibrated against 6th WHO International Standard (NIBSC Code: 18/184) Both kits are validated for EDTA plasma samples and intended for In vitro diagnostic use by trained clinical laboratory personnel. “This achievement underscores our commitment to delivering world-class affordable diagnostics from India to the world. These kits offer accuracy, speed, and accessibility, helping healthcare providers diagnose and manage hepatitis more effectively, even in resource-limited settings,” said Dr Rajas V. Warke, Director, Molecular Biology & Virology, HiMedia Laboratories. With CDSCO approval, HiMedia will supply these kits to hospitals, diagnostic labs, and public health programs across India, ensuring improved testing availability in both urban and rural regions. ]]> https://biospectrumindia.com/news/92/26541/govt-supports-indigenous-ai-powered-blood-testing-device-for-primary-healthcare.html https://biospectrumindia.com/news/92/26541/govt-supports-indigenous-ai-powered-blood-testing-device-for-primary-healthcare.html Mon, 18 Aug 2025 00:00:00 +0530 The Technology Development Board (TDB), Department of Science and Technology, Government of India, has signed an agreement with Primary Healthtech, New Delhi, for the project titled “IoT-enabled Point-of-care Blood Testing Device for Affordable and Accessible Healthcare powered by AI/ML algorithms.” The company's collaborative R&D, initially supported by BIRAC, led to the creation of the Mobilab device—a portable, battery-operated clinical chemistry analyzer, IoT-enabled and powered by artificial inteligence/ machine learning (AI/ML) algorithms, capable of testing over 25 parameters related to kidney, liver, heart, vitamins, and cancer. The company holds a patent for “A transmittance-based system/kit for point-of-care quantification” transferred from IIT Guwahati and has filed over six additional patent applications related to integrated mixers, assay development, centrifuges, and proprietary optical systems. The device has already undergone trials on 10,000 patients and recently received a CDSCO manufacturing license. The project will focus on enhancing the current prototype (M1) to perform five tests simultaneously, reducing patient waiting time, and setting up commercial-scale manufacturing. This next-generation Mobilab will include tests such as Hemoglobin, Creatinine, Bilirubin, Cholesterol, Triglycerides, Uric Acid, Glucose, and GGT, among others. ]]> https://biospectrumindia.com/news/92/26533/government-of-goa-to-implement-pricing-policy-for-innovative-lifesaving-therapies.html https://biospectrumindia.com/news/92/26533/government-of-goa-to-implement-pricing-policy-for-innovative-lifesaving-therapies.html Wed, 13 Aug 2025 00:00:00 +0530 In a progressive step toward making advanced, high-cost medical treatments more accessible, the Government of Goa is set to implement Pricing Policy for Innovative Lifesaving Therapies (PPILT). The policy aims to ensure fair and sustainable pricing for critical healthcare needs including medical devices, diagnostics, medicines etc, making them more affordable and within reach for all patients, especially those battling rare or complex diseases. The policy was announced at the CME event organised on the topic: AI’s use in diagnosing Lung Cancer Early in Goa. Goa will be the first state in India to adopt this policy framework, which enables confidential and outcome-linked pricing agreements between the government and pharmaceutical innovators. The rollout will begin with lung cancer treatment. This progressive approach allows the state to procure advanced therapies at significantly reduced costs, enabling many more patients to benefit from the existing public healthcare budget. “Innovative therapies for diseases like cancer, rare genetic disorders, and autoimmune conditions can cost upwards of Rs 50 lakh per year, placing them difficult for patients especially from underserved communities. Goa’s adoption of this pricing policy is vital and a timely step to advance health equity in the state.  A value-based approach to pricing will improve access for patients and marks a new era focusing on helping more and more patients”, said Vishwajit Rane, Health Minister of Goa. Since 2024, artificial intelligence (AI) has been embedded into Goa’s public healthcare system across 18 government hospitals and health centres, delivering measurable results at scale. Through Qure.ai’s qXR AI solution, more than 70,000 chest X-rays have been screened, detecting over 6,000 pulmonary nodules and flagging more than 500 individuals with high risk for lung cancer. This early detection has already led to confirmed lung cancer diagnoses and timely treatment, saving lives and reducing costs. The programme, led by the Government of Goa in partnership with Qure.ai and AstraZeneca, is a working example of how public and private sectors can combine technology and expertise to create systemic change and inform future health policy. By establishing a new age pricing framework, it encourages both global and Indian pharma organisation to introduce novel treatments in the state sustainable, backed by a predictable and collaborative procurement pathway. Proposed by Organisation of Pharmaceutical Producers of India (OPPI), an independent body representing research based global pharmaceutical companies in India, this critical policy is expected to strengthen Goa’s preparedness for future health challenges and ensure long-term resilience by integrating affordability, innovation, and public health priorities. ]]> https://biospectrumindia.com/news/92/26515/molbio-diagnostics-supports-philippines-to-accelerate-tb-elimination-drive.html https://biospectrumindia.com/news/92/26515/molbio-diagnostics-supports-philippines-to-accelerate-tb-elimination-drive.html Mon, 11 Aug 2025 00:00:00 +0530 The Philippines, one of the top five countries with the highest tuberculosis (TB) burden, faces the challenge of detecting and treating an estimated 190,000 missed TB cases each year. In line with the United Nations target to find and treat 2.1 million TB cases in the country by 2027, the Philippines Health Department is stepping up its commitment to strengthen community-level screening and diagnosis through India-made innovative Truenat systems and ultra-portable X-ray devices. Currently, there are 68 Truenat devices deployed across the Philippines, enabling rapid, multi-disease molecular testing for TB, HIV, HPV, Hepatitis B & C, and more. A pilot in the Bantayan Islands demonstrated the transformative potential of the platform, achieving a remarkable 1008% increase in TB case detection. Molbio’s WHO-endorsed and ICMR-approved solutions for TB detection, address critical barriers in the Philippines, such as geographic isolation, underutilisation of laboratory testing, and limited access in rural and island communities. The recent approval of the PRORAD Atlas Ultraportable X-ray by the Philippines FDA paves the way for integrated, end-to-end TB screening and diagnosis, ensuring immediate linkage to treatment. Health Secretary of Philippines Dr Theodore J Herbosa said, "As we intensify our efforts to combat tuberculosis (TB) in the Philippines, the collaboration with India stands as a beacon of innovation and partnership. The integration of India's indigenous diagnostic technologies, such as the Truenat® system, into our healthcare infrastructure is pivotal. Truenat®, known for its rapid and reliable molecular diagnostic capabilities, allows for swift and accurate TB screenings, enhancing our capacity to manage and eventually eliminate TB within our borders, especially in remote areas. This collaboration is part of a broader, strengthening bilateral relationship between India and the Philippines, which now exceeds $3 billion in trade. India is a key supplier of pharmaceuticals, medical equipment, and diagnostic technologies, contributing significantly to our healthcare advancements." With a portfolio spanning more than 40 tests for infectious and non-infectious diseases, Molbio combines portability, speed, and accuracy to strengthen public health systems worldwide. Molbio’s ongoing studies include a multi-country project funded by the R2D2 TB Network that is exploring novel tongue swab–based molecular diagnostics to improve TB detection among children and people living with HIV/AIDS. “By bringing testing closer to communities—whether on remote islands or underserved rural areas—we can close the gap in TB detection and treatment, helping the Philippines achieve its elimination targets. We are committed to strengthening the fight against infectious diseases across the globe, helping countries build more resilient and responsive health systems,” said Shiva Sriram, President of Molbio Diagnostics. ]]> https://biospectrumindia.com/news/92/26457/fortis-and-agilus-expand-rapid-genomic-testing-capabilities-with-launch-of-second-genexus-system.html https://biospectrumindia.com/news/92/26457/fortis-and-agilus-expand-rapid-genomic-testing-capabilities-with-launch-of-second-genexus-system.html Tue, 29 Jul 2025 00:00:00 +0530 In a significant advancement towards precision medicine, Fortis Memorial Research Institute (FMRI), Gurugram, in collaboration with Agilus Diagnostics, has launched its second Genexus system, further strengthening the nation’s fastest and most scalable rapid genomic testing programme. The Genexus platform enables Next-Generation Sequencing (NGS) with an unparalleled turnaround time - delivering crucial results such as Liquid Biopsy in 24 hours, Myeloid NGS in 72 hours, and Minimal residual disease (MRD) testing within 5 days. These timeframes significantly outperform traditional diagnostic methods, which often take weeks and offer limited insight into genetic complexity. Owing to the rapid NGS (Next-Generation Sequencing) programme at Fortis and Agilus, doctors can now uncover the genetic reasons behind a person’s cancer in just a few days - something that used to take weeks. This breakthrough has led to real and meaningful improvements in patient care: Patients start the right treatment much sooner - With faster test results, doctors can match patients to the most effective, personalised treatments based on their unique genetic profile. In fact, over 40% of patients received targeted therapies, compared to just 11% earlier when results took much longer. Life-saving transplants are happening earlier - For patients who need a bone marrow transplant, everyday counts. Before this program, most patients waited nearly 4 months before they could proceed. Now, with faster diagnostics, that wait has dropped to under 3 months - giving patients a better chance at recovery. Fewer patients are dying in the first month of treatment - Early treatment decisions are critical in blood cancers like leukaemia. With rapid test results, doctors can act quickly  cutting the number of early deaths (within 30 days of diagnosis) by more than half. More patients are living longer - After one year, survival rates were 8% higher among patients who benefited from the rapid NGS programme. That’s a significant improvement and offers new hope to patients and families battling aggressive cancers. As Fortis and Agilus accelerate the rollout of AI-enabled genomics and integrated tumour boards, the addition of this new system marks a leap forward in India’s journey toward precision oncology at scale. ]]> https://biospectrumindia.com/news/92/26419/max-lab-expands-to-bengaluru-through-strategic-partnership-with-stepcare.html https://biospectrumindia.com/news/92/26419/max-lab-expands-to-bengaluru-through-strategic-partnership-with-stepcare.html Tue, 22 Jul 2025 00:00:00 +0530 Max Healthcare’s diagnostic arm, Max Lab, has announced its expansion into Bengaluru, marking a significant milestone in its journey to strengthen healthcare access across India. The expansion is being carried out in collaboration with Stepcare, a specialty-led healthcare provider in the city, with Max Lab operating out of Stepcare’s advanced laboratory infrastructure. This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas, ensuring patients receive not just timely and accurate test results, but also coordinated care guided by primary and specialist physicians. The collaboration integrates cutting-edge diagnostic technology with patient-centric clinical care, offering a seamless healthcare experience. Max Lab will bring its extensive test portfolio, ranging from routine diagnostics to advanced genomics and oncology testing, to Bengaluru residents. Commenting on the partnership, Arpan Malhotra, Director and COO, Max Lab, said, “At Max Lab, we are eagerly looking forward to beginning operations at Bangalore and serving the patient needs with advanced and reliable Diagnostic testing services. Over 70% of clinical decisions are influenced by Diagnostic tests, which in turn play a pivotal role in delivering high-quality patient care. With rising burden of chronic diseases as well as increased awareness towards preventive testing, the need for diagnostic testing is on the rise." Parveen K Sikka, Chairman and Managing Director of Stepcare, said, “This collaboration with Max Lab is a milestone for Stepcare, to offer continuous access to quality healthcare at their specialty-led clinics. Our partnership reflects our shared belief that care must be integrated and coordinated, while offering a supportive, guided experience led by world-class clinicians. By combining Max Lab's advanced diagnostic capabilities and national reputation with our own patient-centric care model, we are confident that residents of Bengaluru will now have access to world-class care."   ]]> https://biospectrumindia.com/news/92/26410/medgenome-raises-series-e-funding-of-47-5-m-to-expand-access-to-genomics-offerings-in-india.html https://biospectrumindia.com/news/92/26410/medgenome-raises-series-e-funding-of-47-5-m-to-expand-access-to-genomics-offerings-in-india.html Mon, 21 Jul 2025 00:00:00 +0530 Bengaluru-based genomic diagnostics and research services company MedGenome has raised $47.5million in its Series E funding round, co-led by Maj Invest, a private equity firm joining as a new investor, along with existing investor Novo Holdings. The round also saw participation from Sofina, an existing shareholder in the company. This funding will enable the company to broaden access to its genomics and integrated diagnostics solutions across India and other emerging markets. The announcement also reiterates MedGenome’s mission to help reduce India’s disease burden through early detection and targeted disease management using genetic and integrated diagnostics tools with high affordability. Speaking about this funding aligning with the company’s vision, Dr Vedam Ramprasad, CEO of MedGenome, said, "India's healthcare ecosystem is increasingly recognizing the transformative potential of genomics, driving innovation and enhancing the country’s healthcare capabilities. This fundraise also reflects the growing adoption of genomics in personalized and preventive healthcare in India as well as other emerging economies. At MedGenome, we combine cutting-edge science with real-world application, bringing advanced omics solutions that bridge the unmet need in disease diagnosis and management. Early genomics-led intervention not only helps the patient but also helps families manage the economic and emotional burden of a disease." Dr Amit Kakar, Managing Partner and Head of Asia at Novo Holdings, and Chairman of the Board of MedGenome, commented, “Our reinvestment in MedGenome reflects our belief in the company’s potential to transform the landscape of genetic and integrated diagnostics in India and beyond. MedGenome stands out as a science-led platform with strong fundamentals, and this investment aligns with our conviction in the growing importance of genomics and personalised healthcare across emerging markets." "With its robust genomics portfolio, commitment to science and the transformative impact it has had on healthcare, MedGenome has consistently demonstrated its ability to drive innovation and precision diagnostics. We’re proud to support their next phase of growth, expanding their solutions to more markets in India and worldwide" Jannick Dam Mortensen, Partner, Maj Invest Minorities, added. ]]> https://biospectrumindia.com/news/92/26383/agilus-diagnostics-launches-new-anti-mcv-antibody-test-for-early-diagnosis-of-rheumatoid-arthritis.html https://biospectrumindia.com/news/92/26383/agilus-diagnostics-launches-new-anti-mcv-antibody-test-for-early-diagnosis-of-rheumatoid-arthritis.html Tue, 15 Jul 2025 00:00:00 +0530 Agilus Diagnostics, in collaboration with Sebia, has launched the cutting-edge Anti-MCV (anti–mutated citrullinated vimentin) antibody test in India. This advanced test significantly enhances the early detection of rheumatoid arthritis (RA), especially in patients who test negative for conventional markers like anti-CCP (cyclic citrullinated peptides) and rheumatoid factor (RF). Rheumatoid arthritis (RA), one of the most common autoimmune disorders, affects approximately 0.5–1% of the Indian population, with prevalence expected to rise due to increased awareness and improved diagnostic capabilities . A groundbreaking antibody test developed by Sebia, the anti-MCV (anti–mutated citrullinated vimentin) test, is redefining the early diagnosis and clinical management of rheumatoid arthritis (RA), especially in patients who remain undiagnosed using conventional methods. The anti-MCV test detects autoantibodies against a mutated form of the vimentin protein, commonly found in the synovial fluid of patients with rheumatoid arthritis (RA). It has emerged as a highly sensitive and specific biomarker, particularly valuable for identifying RA in individuals who test negative for conventional markers such as anti-CCP and rheumatoid factor (RF). Studies have shown that anti-MCV can be positive even in the absence of traditional markers, especially in patients presenting with clinical signs and symptoms of RA. Furthermore, anti-MCV positivity may precede the clinical onset of RA by up to 24 months, particularly in individuals with a strong family history, making it a powerful tool for early detection and intervention.  ]]> https://biospectrumindia.com/news/92/26388/himedia-receives-icmr-niv-validation-for-hi-pcr-monkeypox-virus-multiplex-probe-pcr-kit.html https://biospectrumindia.com/news/92/26388/himedia-receives-icmr-niv-validation-for-hi-pcr-monkeypox-virus-multiplex-probe-pcr-kit.html Tue, 15 Jul 2025 00:00:00 +0530 HiGenoMB, the Molecular Biology Division of Mumbai-based HiMedia Laboratories, has announced that its Hi-PCR Monkeypox Virus Multiplex Probe PCR Kit (MBPCR269) has been successfully validated by the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV), Pune. This recognition marks a significant milestone in HiMedia’s continued efforts to deliver high-quality, reliable molecular diagnostic solutions. The Hi-PCR® Monkeypox Virus Multiplex Probe PCR Kit is designed for the sensitive and specific detection of the Monkeypox virus in clinical samples. These samples may include skin lesion materials, exudates, lesion crusts, lesion surfaces & oropharyngeal swabs. This advanced real-time PCR system uses hydrolysis probe technology for precise identification of Monkeypox virus, effectively distinguishing it from other orthopoxviruses. The kit is capable of detecting both Clade I and Clade II of the Monkeypox virus. Developed for professional use, the kit is intended for trained clinical laboratory personnel skilled in real-time PCR and in-vitro diagnostic techniques. The system targets specific regions of the Monkeypox virus (MPXV) and orthopoxvirus gene (POPV), and includes a human internal control (IC) to ensure test reliability. Results are visualized through three fluorescent channels: FAM for MPXV, JOE for POPV, and Texas Red for the internal control. Dr Rajas Warke, the visionary behind HiGenoMB, emphasised the importance of accessible diagnostics in the global fight against emerging infectious diseases. He reaffirmed his commitment to providing high-quality, affordable Monkeypox PCR kits worldwide to support public health systems and clinical laboratories in tackling the spread of the virus. ]]> https://biospectrumindia.com/news/92/26336/suraksha-diagnostics-invests-rs-22-cr-to-establish-eastern-indias-largest-genomics-lab.html https://biospectrumindia.com/news/92/26336/suraksha-diagnostics-invests-rs-22-cr-to-establish-eastern-indias-largest-genomics-lab.html Sat, 05 Jul 2025 00:00:00 +0530 Suraksha Diagnostics, one of the leading diagnostics chains in Eastern India, has launched one of the largest and a state-of-the-art genomics labs in Eastern India with a grand inauguration event which was graced by Prof. Sukumar Mukherjee, a distinguished rheumatologist with more than 35 years of extensive experience in the field and a mentor at Suraksha Diagnostics. The global genetic testing market is valued at $38.77 billion (2024) and is projected to reach $186.64 billion by the year 2035 (CAGR: 22.5%). In a landmark move, Suraksha Diagnostics has invested Rs 22 crore in establishing its Genomics Lab. An additional Rs 46 crore investment is planned over the next 24 months to establish one of Asia’s most advanced Genomics Laboratories. This initiative is a significant leap forward for West Bengal, Eastern & North-Eastern India, and India’s future in precision diagnostics. This State-of-the-Art Genomics Lab is equipped with Cytogenetics, Microarray Technology, Sanger Sequencing, Multiple Next-Generation Sequencers (NGS). Together, these technologies enable the full spectrum of advanced genetic testing, offering predictive, preventive, and personalised care. Suraksha’s Genomics Lab enables the detection of chromosomal abnormalities like Down syndrome, Edwards syndrome, and Patau syndrome, as well as sex chromosome aneuploidies and microdeletions. These insights help expecting parents make informed decisions, supported by expert genetic counseling. Suraksha’s Genomics Lab also pioneers Onco-genomics with advanced hereditary cancer testing panels, enabling early detection of genetic predispositions to breast, ovarian, and colorectal cancers. The lab offers both germline and somatic mutation profiling, aiding in personalized cancer risk assessment and treatment planning. With targeted oncology panels powered by NGS, clinicians can now identify actionable mutations for precision therapies.   ]]> https://biospectrumindia.com/news/92/26292/abbott-introduces-lab-based-blood-test-in-india-to-help-evaluate-concussion.html https://biospectrumindia.com/news/92/26292/abbott-introduces-lab-based-blood-test-in-india-to-help-evaluate-concussion.html Thu, 26 Jun 2025 00:00:00 +0530 Abbott, the global healthcare company, has announced the launch of its laboratory-based blood test to evaluate mild traumatic brain injury (mTBI), commonly known as concussions. The traumatic brain injury (TBI) test runs on Abbott’s Alinity i and Architect i1000SR laboratory instruments, which are available in major hospitals and laboratories such as Apollo, Hyderabad and Neuberg Supratech Laboratory. The test offers a reliable result in 18 minutes to help clinicians quickly evaluate brain injury and triage mTBI patients. The diagnostic tool also helps eliminate the need for CT scans by up to 40% with a high degree of certainty eliminating wait time at the hospital and unnecessary exposure to radiation. The test measures two biomarkers in the blood - ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) - that, in elevated concentrations, are correlated to brain injury. The test can help streamline care benefiting both patients and the healthcare system. This is particularly important in areas where access to CT systems may be limited.  TBIs can be caused by a bump, blow or jolt to the head and can pose short- and long-term risks. In India, nearly one million people are estimated to experience it every year. People who experience a TBI may have impairment of memory, movement, sensation (e.g., vision and hearing), and emotional functioning (e.g., personality changes, psychological symptoms). People who sustain a TBI are more likely to have another one – similarly to how a sprained ankle or torn ligament is more susceptible to future injury. TBIs are among the most common neurological disorders worldwide, affecting millions each year. ]]> https://biospectrumindia.com/news/92/26289/dr-lal-pathlabs-strengthens-genomics-capabilities-with-illuminas-novaseq-x-series.html https://biospectrumindia.com/news/92/26289/dr-lal-pathlabs-strengthens-genomics-capabilities-with-illuminas-novaseq-x-series.html Wed, 25 Jun 2025 00:00:00 +0530 Dr. Lal PathLabs has expanded its genomics capabilities by adding Illumina’s NovaSeq™ X Series to its dedicated genomics division, Genevolve.  With the integration of Illumina’s latest technology, Dr. Lal PathLabs can now deliver faster and more accurate genomic research insights. The NovaSeq™ X system features Illumina’s cutting-edge XLEAP-SBS™ chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina’s previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what’s possible in genetic sequencing. And its powerful technology allows users to unlock previously unimaginable discoveries and advancements. Launched in 2019, Genevolve has swiftly emerged as a DNA-based center of excellence. The addition of Illumina products further strengthens Genevolve’s position as a pioneer in next-generation sequencing (NGS), enabling D tDr. Lal PathLabs deliver actionable, AI-powered insights with greater speed and sensitivity. “As Illumina continues to grow in India, we are committed to democratising access to sequencing technologies”, said Gregory Essert, General Manager, Emerging Markets, Illumina. "NovaSeq X Series represents our leadership in next-generation sequencing, and we are pleased to see it being adopted by institutions like Dr. Lal PathLabs, which are at the forefront of driving scientific discovery and access to genomic insights in India. We hope this empowers them to reach their goals more quickly.” Dr. Lal PathLabs Limited and Illumina aim to engage closely with India’s medical and scientific communities to build awareness and capacity for genomics-based decision-making. ]]> https://biospectrumindia.com/news/92/26280/amazon-india-launches-at-home-health-diagnostics-service.html https://biospectrumindia.com/news/92/26280/amazon-india-launches-at-home-health-diagnostics-service.html Mon, 23 Jun 2025 00:00:00 +0530 Amazon India has announced the launch of Amazon Diagnostics, a new at-home diagnostics service that enables customers to book lab tests, schedule and track appointments, and access digital reports instantly from the Amazon app. With Amazon Diagnostics, customers in 6 cities across 450+ PIN codes, can easily book from over 800 diagnostic tests, get doorstep sample collection in under 60 minutes and digital reports in as less as 6 hours, for routine tests. Currently, the service will be available across Bengaluru, Delhi, Gurgaon, Noida, Mumbai and Hyderabad. Amazon Diagnostics is currently being offered in collaboration with Orange Health Labs, a leading accredited diagnostic provider. Amazon Diagnostics addresses critical customer challenges where long wait times, inconsistent quality of service, and accessibility gaps often hinder preventive care. Amazon Diagnostics will enable customers to access diagnostics services quickly, reliably and without having to search or endure long wait times.  The service sets itself apart through rapid doorstep sample collection, timely reports delivery, and stringent data privacy and quality standards. The platform also incorporates intelligent features like real-time slot visibility, map-based address validation, secure digital report access via the Amazon Health dashboard, and automated test preparation instructions—all built into a seamless booking journey. With this launch, Amazon customers will now get access to a complete end-to-end healthcare services, spanning from tele-consultation, delivery of medicines, and accredited testing,  all under ‘Amazon Medical’.     ]]> https://biospectrumindia.com/news/92/26266/suraksha-diagnostics-announces-collaboration-with-united-imaging-technologies.html https://biospectrumindia.com/news/92/26266/suraksha-diagnostics-announces-collaboration-with-united-imaging-technologies.html Wed, 18 Jun 2025 00:00:00 +0530 Suraksha Diagnostics, a leading diagnostics service provider in Eastern India, has announced its collaboration with United Imaging, a global leader in advanced imaging technologies, with an aim to establish more than 20 new imaging centres across Eastern India. The collaboration involves a total investment of Rs 200 crore by Suraksha Diagnostics. This will focus on bringing advanced imaging solutions to Tier 2 and Tier 3 cities in Eastern India. The collaboration aims to enhance healthcare accessibility and affordability in smaller towns and semi-urban areas. Suraksha Diagnostics will be working closely with United Imaging by leveraging its existing network and reputation for delivering cost friendly and superior quality healthcare services. United Imaging will be offering its advanced imaging technologies such as MRI, CT, and PET CT solutions, in order to extend support for the diagnosis and treatment of various medical conditions. This partnership will enable Suraksha Diagnostics to provide an all-inclusive range of imaging services, further strengthening its position as a trusted healthcare provider in Eastern India.   ]]> https://biospectrumindia.com/news/92/26267/sciinv-biosciences-and-microbira-to-launch-cutting-edge-digital-diagnostics-for-combatting-superbugs-in-india.html https://biospectrumindia.com/news/92/26267/sciinv-biosciences-and-microbira-to-launch-cutting-edge-digital-diagnostics-for-combatting-superbugs-in-india.html Wed, 18 Jun 2025 00:00:00 +0530 In a decisive step to tackle one of the world’s most pressing public health threats, SCIINV Biosciences, a Hyderabad-based biotech startup incubated at ASPIRE BioNEST, University of Hyderabad (UoH), has announced a strategic partnership with Microbira Limited, a UK-based biotechnology firm. The collaboration aims to develop and deploy next-generation digital diagnostic solutions to strengthen India's fight against antimicrobial resistance (AMR).At the heart of this Indo-UK alliance lies a shared commitment to revolutionize microbial diagnostics by building a rapid, accurate, and affordable detection platform. The joint innovation AMRx and MAAP IR is focused on early and precise pathogen identification, thereby minimizing the misuse of broad-spectrum antibiotics—a major driver of AMR, particularly in high-disease-burden regions like India.Prof. Reddanna Pallu, Senior Professor (Retd.), School of Life Sciences, University of Hyderabad, underscored the clinical importance of this initiative, “This initiative is a crucial step in curbing inappropriate antibiotic use through timely pathogen detection. Such targeted interventions are fundamental in our fight against drug resistance.”Marianne Ismail, CEO of Microbira Ltd, emphasised the global relevance of the partnership, “This alliance underscores our shared commitment to tackling one of the most important global health challenges. It’s a meaningful example of innovation-driven collaboration between the UK and India.” ]]> https://biospectrumindia.com/news/92/26205/elucidata-and-sapien-biosciences-to-transform-biobank-assets-into-high-quality-ai-products.html https://biospectrumindia.com/news/92/26205/elucidata-and-sapien-biosciences-to-transform-biobank-assets-into-high-quality-ai-products.html Thu, 05 Jun 2025 00:00:00 +0530 US-based Elucidata, a leader in data-centric AI for drug discovery and translational research, and Hyderabad-based Sapien Biosciences, India's first and largest commercial biobank with 300,000+ patient samples founded in partnership with Apollo Hospitals, have announced a strategic partnership to convert Sapien’s extensive biobank assets into artificial intelligence (AI)-ready, multimodal data products for use in drug and diagnostic development. Through this collaboration, Sapien will harness Elucidata’s platform to integrate, standardise, and enrich its vast repository of biospecimens and curated clinical data, making them accessible for predictive modeling, synthetic data generation, and advanced genomics research. The partnership reflects a shared focus on turning real-world patient data into high-value actionable insights that drive precision medicine and improve outcomes worldwide. The first phase of the collaboration will focus on building AI models that infer genomic and transcriptomic insights from digital pathology images. By using NGS-annotated slides from Sapien’s cancer biobank, the project will enable the generation of synthetic multi-modal datasets essential for next-generation diagnostic tools and tissue-sparing research strategies. This is particularly valuable for rare cancers and limited biopsy specimens. In addition to oncology, the partnership will explore multi-disease use cases across Sapien’s biobank, including cardiovascular, autoimmune, and neurological disorders, building synthetic clinicogenomic datasets that support pharma R&D and companion diagnostic development. ]]> https://biospectrumindia.com/features/92/26156/how-ai-is-enhancing-medical-diagnostics.html https://biospectrumindia.com/features/92/26156/how-ai-is-enhancing-medical-diagnostics.html Sat, 31 May 2025 00:00:00 +0530 AI is rapidly transforming healthcare, particularly in diagnostics and imaging across the globe. The industry is continuously developing solutions in the form of new apps and devices using AI to ease out the burden on the healthcare setting. As a result, these solutions are improving diagnostic accuracy and enabling faster treatment decisions for conditions such as cancer, tuberculosis, diabetes, cardiovascular diseases etc. With India witnessing a rising burden of these diseases, coupled with a shortage of skilled healthcare professionals, AI-driven diagnostic solutions are emerging as a transformative force. By reducing diagnostic turnaround times, increasing accuracy, and enabling remote healthcare access, AI is playing a pivotal role in addressing the growing healthcare demand and disease burden, particularly in urban areas where non-communicable diseases (NCDs) are more prevalent. However, challenges persist in terms of high implementation costs, the lack of standardised AI regulations, a limited skilled workforce and concerns over data privacy and patient confidentiality. Furthermore, limited adoption of AI in rural healthcare facilities remains a significant barrier to widespread deployment in India. Despite these challenges, many new areas such as ophthalmology, dermatology, trichology, in vitro fertilisation, etc. are being touched upon by the industry where the use of AI can offer timely diagnosis and effective treatment plans.  “Diagnostics is undergoing a quiet revolution, one driven by artificial intelligence (AI). What was once a system dependent on reactive responses is now evolving into a proactive model that prioritises early detection, precision, and patient clarity. In a world where diagnostic errors contribute to 10 per cent of patient deaths, the stakes couldn’t be higher. AI brings a much-needed shift, enhancing accuracy, speeding up outcomes, and making care more understandable and accessible”, said Deepak Sahni, Founder & Chief Executive Officer, Healthians.   Setting the right vision with AI The growing number of cases of eye diseases such as diabetic retinopathy, glaucoma, cataract, and age-related macular degeneration (AMD), in the country has urged technology developers to increase the use of AI for their early detection. Studies have suggested that AI systems demonstrate strong diagnostic performance in detecting eye conditions such as diabetic retinopathy, with sensitivity and specificity comparable to or exceeding traditional clinicians. One notable example is Remidio Innovative Solutions, a Bengaluru-based healthtech startup focused on preventing avoidable blindness with the use of AI. The company has recently received regulatory approval from the State FDA, Karnataka (CDSCO), for its Medios HI (Humanising Intelligence) Glaucoma AI and Medios HI AMD AI tools. Following the success of the CDSCO-approved Medios DR HI, AI for diabetic retinopathy, which has impacted nearly 2,50,000 patients in the past year, the newly approved AI solutions are focused on early detection of glaucoma and AMD in diverse healthcare settings. A recent significant initiative leveraging Remidio’s AI technology is the announcement of Nayanamritham 2.0, India’s first government-led AI-assisted eye disease screening programme, launched by the Kerala government in February 2025. “India accounts for 12 million glaucoma patients, nearly one in eight globally. Yet over 90 per cent of these cases remain undiagnosed, often leading to irreversible vision loss. Early detection using portable, AI-enabled tools can drastically change this trajectory”, said Dr Anand Sivaraman, CEO and Founding Director, Remidio. Another example of fostering cutting-edge research in eye care is Zeiss India partnering with the Indian Institute of Science (IISc), Bengaluru, to establish a state-of-the-art research facility. This facility is focused on developing high-fidelity AI solutions for eye care and upskilling students in AI-based technologies. Supported by the Spectrum Lab at IISc, the collaboration aims to harness AI's potential to improve early diagnosis and patient outcomes in ophthalmology.  Zeiss India is also sponsoring students through its 'MTech Fellowship Programme,' further strengthening the research ecosystem and promoting advancements in AI-driven eye care solutions. Mumbai-based startup AND Healthcare Solutions is another player that is focused on delivering low-cost, AI-driven eye screening solutions to millions. The startup has partnered with Australian company TeleMedC to roll out advanced eye imaging and AI-powered diagnostics across India.  Mumbai-based institute Wadhwani AI is also emerging as another key player in this space. As a key partner, Wadhwani AI is supporting the development of multiple AI solutions for the screening of diabetic retinopathy, pulmonary and skin conditions at the All India Institutes of Medical Sciences (AIIMS). These solutions will now be scaled by the AIIMS Centre of Excellence (CoE), in collaboration with the Ministry of Health and Family Welfare, across primary and secondary healthcare settings to ensure timely care for all. “Diabetic retinopathy is a leading cause of preventable blindness, especially in India, where access to specialised eye care is limited, particularly in rural regions. Many individuals are unaware of their condition until severe vision loss occurs. AI-based solutions can empower optometrists and field investigators to screen patients, enabling early diagnosis and referral to specialists. We strongly believe in India’s ability to lead in AI innovation. With the right talent, ecosystem, and data, India can be at the forefront of AI applications”, said Nakul Jain, Director of Products and Design at Wadhwani AI. Further, Bengaluru-based startup NeuraSim Health, in collaboration with QWR, has introduced BeeVee, India’s first AI-powered VR therapy for amblyopia or lazy eye. This groundbreaking solution is transforming vision care with 3X faster recovery, making treatment more effective, engaging, and now available for at-home use. The application of AI in ophthalmology encompasses a wide range of innovations, from advanced diagnostic tools that can detect conditions like diabetic retinopathy, AMD and glaucoma with remarkable precision to personalised treatment plans that optimise therapeutic outcomes and reduce costs. Additionally, AI-driven surgical tools and teleophthalmology services are making high-quality eye care more accessible, particularly in underserved and remote areas.   Exploring dermatology and trichology AI is now also being used to detect numerous skin (eczema, acne, psoriasis, vitiligo) and hair (baldness, alopecia, scalp infection) conditions to offer better health solutions to millions across India.  For instance, in a revolutionary move set to transform the Rs 25,000 crore-worth Indian skincare market, Mumbai-based health-tech platform Skin Beyond Borders (SkinBB) has launched a pioneering Skincare Metaverse platform. This innovative digital ecosystem seamlessly integrates cutting-edge AI technology with clinical knowledge, creating a unique synergy between consumers, clinicians, and industry partners. Further, Kaya Clinic has launched a revolutionary AI app that offers an in-depth understanding of skin issues tailored to individual needs, making it the first app in India to leverage AI for personalised skin diagnosis. The app focuses on analysing acne, scars, pigmentation, fine lines, and anti-ageing concerns. Kaya holds the intellectual property, for the AI app, making it as the first AI-powered dermatology service in India. Also, Bengaluru-based startup Cureskin, a leader in AI-driven dermatology solutions, has developed the world's first AI-powered hair analyser. It is designed to accurately detect male pattern baldness and assess hairline health with advanced precision. Arshan Ommid, Founder and Chief Executive Officer of Dermose, said, “AI has the unprecedented ability to analyse the complexities of hair loss, from genetic predispositions to lifestyle factors, creating a holistic diagnostic framework. This precision equips clinicians to design truly tailored treatments, giving patients confidence in both the process and the outcome. AI tools such as computer vision and big data analytics are transforming the treatment of chronic conditions by allowing physicians to automate the identification of biomarkers for hair loss and combine thorough lab results with trichoscopic data. These developments significantly shorten diagnostic times while increasing precision, enabling patients to start receiving efficient treatments earlier.”   AI in IVF and birth management Another area where a rapid surge of AI integration is taking place is in vitro fertilisation (IVF). A type of assisted reproductive technology (ART), IVF has been revolutionising the field of infertility treatment over the past few years in India. With a market size of Rs 12000 crore, the IVF procedures are now offering better treatment plans with AI integration. A most recent example of this utilisation is the world’s first infant born (to an Indian couple in the US) using a fully automated and digitally controlled intracytoplasmic sperm injection (ICSI) process. After several failed IVF attempts, the couple was referred for ICSI treatment at a fertility clinic in Mexico, where four of the five eggs treated with AI-assisted ICSI were successfully fertilised, ultimately resulting in the first live birth. According to Dr Ramnath Babu T J, Co-founder, CEO, SpOvum Technologies, “The potential that AI and automation bring to IVF is unimaginable. They hold the possibility of increased success rates, customised treatment protocols, and lower costs, making fertility treatment affordable. The intersection of AI, automation, and IVF is a revolution in reproductive medicine. These advancements are hope in a country like India, where infertility is increasing.” Additionally, labour and delivery management is now also being handled using AI, by predicting birth times with precision and optimising hospital operations in real time. This groundbreaking AI-based obstetrics platform has been developed in a collaborative effort by US-based Birth Model with Pune-based Mindbowser. “What makes AI particularly valuable is its ability to quickly process large volumes of data and identify patterns that might be missed during routine evaluations. As the technology evolves, AI is expected to become a standard part of maternal care, not just in well-equipped hospitals but also in remote and underserved areas via mobile health tools and wearable devices. With continued research and thoughtful regulation, AI has the potential to make maternal care more personalised, accessible, and timely, ultimately improving outcomes for mothers and babies and reshaping the future of prenatal health”, said Ayush Jain, CEO & Founder, Mindbowser.   Way forward  While new avenues are opening for AI-based healthcare implementation and delivery, a strong and supportive ecosystem will need to be built in the coming years. The government is already on track to strengthen the skills for AI with its ongoing IndiaAI Mission. With Stanford University ranking India among the top four countries along with the US, China, and the UK in the Global and National AI vibrancy, AI-based innovations in India will cement the landscape further.    Vrushti Kothari (vrushti.kothari@mmactiv.com) ]]> https://biospectrumindia.com/news/92/26173/sir-h-n-reliance-foundation-hospital-launches-advanced-clinic-to-fight-pulmonary-disorders.html https://biospectrumindia.com/news/92/26173/sir-h-n-reliance-foundation-hospital-launches-advanced-clinic-to-fight-pulmonary-disorders.html Tue, 27 May 2025 00:00:00 +0530 In a significant stride towards elevating pulmonary healthcare in the city, Mumbai-based Sir H. N. Reliance Foundation Hospital has announced the launch of its Advanced Lung Disease Clinic, a dedicated centre of excellence for the diagnosis, treatment, and long-term management of rare and complex lung disorders. This clinic integrates advanced diagnostics, interventional pulmonology, and lung transplant expertise under one roof, offering patients comprehensive and personalised care. According to the Lancet Respiratory Medicine report, India is home to approximately 33 million asthma patients and 55 million individuals with chronic obstructive pulmonary disease (COPD), representing over 10% of the global burden for these respiratory illnesses. The Advanced Lung Disease Clinic aims to bridge this critical healthcare gap by delivering cutting-edge diagnostic and therapeutic interventions, including life-saving lung transplant services. The clinic specialises in managing severe and advanced lung diseases such as: Severe Interstitial Lung Disease (ILD); End-stage COPD and emphysema; Severe, treatment-resistant asthma; Occupational and environmental lung disorders; Progressive lung failure requiring ventilatory or ECMO suppor.t Equipped with state-of-the-art interventional pulmonology technologies-including high-precision bronchoscopy, cryotherapy, endobronchial ultrasound (EBUS)-guided biopsies, and airway stenting-the clinic also offers personalised pulmonary rehabilitation, oxygen therapy, and lifestyle support programs tailored to each patient’s needs. ]]> https://biospectrumindia.com/news/92/26145/asian-hospital-in-faridabad-launches-total-lab-automation-in-partnership-with-quidelortho.html https://biospectrumindia.com/news/92/26145/asian-hospital-in-faridabad-launches-total-lab-automation-in-partnership-with-quidelortho.html Thu, 22 May 2025 00:00:00 +0530 In a significant advancement for healthcare in the region, Asian Hospital, Faridabad has become the first hospital in the city to introduce Total Lab Automation (TLA) in collaboration with global diagnostics leader QuidelOrtho. This system, powered by the Vitros Automation Solution, represents a major step forward in diagnostic testing, bringing faster and more accurate results to patients. With the introduction of this technology, Asian Hospital is transforming the way laboratory tests are conducted. Automated processes significantly reduce turnaround times, which means that doctors can access test results quickly, especially in critical or emergency situations. This allows for faster diagnosis and treatment, improving patient outcomes, according to Dr. N K Pandey, Chairman & Managing Director, Asian Hospital. "The new system uses dry chemistry technology, eliminating the need for lab-grade water. This not only prevents water-related contamination but also ensures consistently reliable and precise results. It also makes the system more sustainable and eco-friendly, saving millions of litres of water each year and consuming less electricity", said Dr Pandey. The introduction of TLA is not only a technical advancement but also a patient-centric innovation that ensures faster, more reliable test results while contributing to environmental sustainability.  The innovation has been recognised by the Confederation of Indian Industry (CII) for its contribution to sustainable healthcare practices. The system’s advanced microfluidic technology ensures that the results are accurate the first time, minimising the need for repeat tests. Each sample is tracked throughout the testing process, ensuring full traceability and high standards of safety.   ]]> https://biospectrumindia.com/news/92/26148/redcliffe-labs-issues-preventive-healthcare-advisory-amidst-rise-in-covid-19-cases.html https://biospectrumindia.com/news/92/26148/redcliffe-labs-issues-preventive-healthcare-advisory-amidst-rise-in-covid-19-cases.html Thu, 22 May 2025 00:00:00 +0530 In light of the recent rise in COVID-19 cases in parts of India, Redcliffe Labs has issued a preventive healthcare advisory urging timely action and responsible practices. With reported cases crossing the 250 mark nationally in May 2025, the advisory encourages individuals to remain cautious, seek medical attention, and follow basic preventive measures to help curb the spread. Redcliffe Labs, after reviewing recent trends in respiratory infections, has advised that anyone experiencing symptoms like fever, cough, cold, or fatigue should consult a doctor and consider getting tested promptly. Even those without symptoms but who have had close contact with a confirmed or suspected case are urged to stay cautious and follow local health guidelines. While awaiting test results, it is recommended to wear a mask around others and limit close interactions, both indoors and outdoors. To support accurate diagnosis, the advisory recommends molecular testing such as RT-PCR, which detects the virus's genetic material and is highly reliable. Rapid Antigen Tests (RATs) are also available for quicker results, especially in symptomatic cases or high-risk exposures. Dr Mayanka Lodha Seth, Chief Pathologist, Redcliffe Labs said, “While there is a resurgence in a few regions, the situation remains manageable. There is no need for panic. What’s important is timely action. We advise individuals not to ignore early symptoms such as cough, fever, or severe body aches. Consult a doctor if you feel unwell, get tested if needed, and take basic precautions."     ]]> https://biospectrumindia.com/news/92/26138/remidio-unveils-new-device-pristine-for-innovating-ai-powered-eye-diagnostics-.html https://biospectrumindia.com/news/92/26138/remidio-unveils-new-device-pristine-for-innovating-ai-powered-eye-diagnostics-.html Wed, 21 May 2025 00:00:00 +0530 After a decade of transforming access to eye care in India and beyond, Bengaluru-based Remidio Innovative Solutions has announced a pivotal evolution in its journey, the launch of its dual brand strategy, Remidio and Pristine, to address the full spectrum of eye care needs, from last-mile screening to advanced clinical diagnostics. Over the past decade, Remidio has focused on expanding access to eye care. Through portable technology and artificial intelligence (AI), the company has facilitated over 16 million screenings across 40+ countries, addressing low awareness and limited access to early detection. Its Insta series of portable tools for frontline workers has built an ecosystem that now directs millions more patients to ophthalmology clinics annually. Pristine’s suite of in-clinic innovations is built to drive measurable efficiency. Pristine 1.5 reduces retina imaging time per patient through automated workflows. Pristine 5.0 offers true-color, wide-field imaging in seconds, maximizing throughput without compromising quality. The Pristine VX650 enables comprehensive, multimodal diagnostics in high-volume settings, streamlining the workup process across retina and refractive care. The soon to be launched Pristine OBM 12 delivers 12 essential eye measurements in just 25 seconds, empowering technicians to manage myopia and pre-operative evaluations with precision and minimal intervention.  Together, these devices enable clinics to ‘see more, do more’, boosting patient volumes, diagnostic confidence, and workflow efficiency. These platforms are redefining efficiency in clinical ophthalmology, allowing more patients to be seen per day, with better insights, and fewer delays. With validated AI for Diabetic Retinopathy, Glaucoma, and age-related macular degeneration (AMD), the company is also working on expanding screening capabilities into systemic conditions such as cardiovascular disease (CVD) and chronic kidney disease (CKD), leveraging the eye as a window into overall health. From outreach to in-clinic diagnostics, from retina to systemic health, Remidio’s dual brand strategy sets the stage for the next decade of transformation in eye care. ]]> https://biospectrumindia.com/news/92/26130/neuberg-diagnostics-and-star-imaging-announce-strategic-joint-venture-in-maharashtra.html https://biospectrumindia.com/news/92/26130/neuberg-diagnostics-and-star-imaging-announce-strategic-joint-venture-in-maharashtra.html Tue, 20 May 2025 00:00:00 +0530 Neuberg Diagnostics has announced a strategic joint venture with Star Imaging to expand integrated diagnostics centres combining advanced Pathology and advanced Radiology across Maharashtra. For over 13 years, Star Imaging has pioneered the introduction of next-generation radiology technologies in Pune. Under the visionary leadership of Dr Ashish Atre, a globally acclaimed radiologist, alongside a team of highly skilled, organ-specific radiologists has become a trusted name for high-end imaging services. Star Imaging currently operates state-of-the-art, fully integrated diagnostic centres across Deccan, Bund garden road, Wakad and Baner in Pune and in Akluj. Dr GSK Velu, Chairman and Managing Director of Neuberg Diagnostics, said “We see Maharashtra as a key market for growth and innovation, and this collaboration lays a strong foundation for long-term investment, infrastructure expansion, and the democratization of high-quality healthcare diagnostics. As part of the expansion strategy, we plan to launch new integrated diagnostic centres across Pune, Nashik, Nagpur, Aurangabad, and other key cities in Maharashtra over the next two years” In India, the growing burden of chronic diseases, rising demand for preventive healthcare, and the increasing complexity of clinical decision-making have created a strong need for integrated diagnostic services. Traditionally, radiology and pathology have operated in silos, often leading to fragmented information and delayed diagnoses. By bringing multiple diagnostic modalities radiology, pathology, wellness, and genomics under one roof, integrated diagnostics enhances accuracy, speeds up diagnosis, and enables more informed and timely treatment decisions. This model is particularly vital in India’s healthcare landscape, where early intervention can significantly reduce disease burden and improve patient outcomes. The Neuberg Diagnostics and Star Imaging partnership directly addresses this gap by offering a unified, patient-centric approach to diagnostics. ]]> https://biospectrumindia.com/news/92/26107/4basecare-inaugurates-new-genomics-lab-and-unveils-global-cancer-diversity-atlas.html https://biospectrumindia.com/news/92/26107/4basecare-inaugurates-new-genomics-lab-and-unveils-global-cancer-diversity-atlas.html Wed, 14 May 2025 00:00:00 +0530 4baseCare, a precision oncology company, has inaugurated its new genomics laboratory in Mahadevapura, Bengaluru, as a part of its consistent efforts to advance access to precision oncology in India. The highlight of the launch event was the unveiling of Global Cancer Diversity Atlas (GCDA) aimed at addressing the genomics data gap that exists in cancer care.  The launch event was presided over by N. R. Narayana Murthy, Chairman, Infosys, who also unveiled the Global Cancer Diversity Atlas. 4baseCare’s new genomics lab in Bengaluru will offer advanced genomic testing solutions including comprehensive gene panels, whole exome sequencing, and transcriptome analysis. These tools will enable oncologists to delve deeper into the genetic makeup of tumors, offering personalized and more effective cancer treatment options.  The Global Cancer Diversity Atlas (GCDA) is a pioneering initiative by 4baseCare designed to address a critical gap in global cancer research: the lack of genomic data from diverse populations. While most cancer genomic datasets are dominated by Western populations, GCDA is built on real-world data from India and the Global South, including South Asia, Southeast Asia, the Middle East, Central Europe, and Latin America. GCDA is the world’s most inclusive cancer genomics dataset, transforming how we develop diagnostics, conduct research, and deliver cancer care so that every patient, everywhere, is truly seen and understood. Commenting on the new lab and the unveiling of GCDA, Hitesh Goswami, CEO and Co-Founder, 4baseCare, said, “ Our new genomics lab and the unveiling of the GCDA are driven by a single goal of creating better access to precision oncology. One of the key challenges in cancer care today is the lack of genomic data from Indian and Asian populations. This data gap has a significant impact on the effectiveness of cancer diagnostics and treatment strategies for under-represented communities.”    ]]> https://biospectrumindia.com/news/92/26105/roche-announces-550-m-investment-to-expand-diagnostics-manufacturing-hub-in-us.html https://biospectrumindia.com/news/92/26105/roche-announces-550-m-investment-to-expand-diagnostics-manufacturing-hub-in-us.html Tue, 13 May 2025 00:00:00 +0530 Roche has announced plans to invest up to $550 million in its Diagnostics site in Indianapolis, US by 2030. The site will become a major hub for the manufacturing of Roche's continuous glucose monitoring (CGM) systems – marking a new milestone in Roche's long history of revolutionizing healthcare across the globe. Indianapolis serves as the North American headquarters for Roche Diagnostics, part of the Roche Group. "The challenges of diabetes are pervasive, with millions of Americans living with the constant vigilance and countless daily decisions the disease requires," said Brad Moore, President and CEO of Roche Diagnostics North America. "By expanding our manufacturing capabilities in Indianapolis, we ensure reliable access to innovative monitoring solutions for individuals living with diabetes in the US and worldwide." The Indianapolis campus houses key operations, including US research and development, laboratories, manufacturing, distribution, IT and administrative functions. It currently produces approximately 5.2 billion Accu-Chek diabetes test strips annually and serves as one of two global distribution hubs focused on serving the US market and supporting distribution to 53 countries worldwide. Building on more than $800 million in US investments made at Roche US sites since 2015, this new commitment reinforces Roche's longterm dedication to US operations and highlights the country's central role in the company's global strategy. The expansion is expected to generate hundreds of highly-skilled manufacturing jobs and thousands of construction jobs, providing a significant boost to Indiana's economy. It will also enhance domestic production capabilities and reduce dependency on imports – aligning with national efforts to strengthen local manufacturing. ]]> https://biospectrumindia.com/news/92/26093/redcliffe-labs-launches-indias-first-she-centric-diagnostic-platform-for-different-life-stages.html https://biospectrumindia.com/news/92/26093/redcliffe-labs-launches-indias-first-she-centric-diagnostic-platform-for-different-life-stages.html Fri, 09 May 2025 00:00:00 +0530 In a pioneering move to confront the long-standing gap in women’s preventive healthcare in India, Redcliffe Labs has launched Femcliffe, the country’s first diagnostic platform built exclusively for women. Introduced as part of Redcliffe’s ‘She the Women’ campaign for Mother’s Day, the initiative serves as a timely call to prioritise women’s health. Femcliffe provides comprehensive diagnostic support across all life stages, offering preventive, curative, and specialised testing tailored to women’s evolving health needs. Focusing on key physiological milestones, Femcliffe delivers condition-specific diagnostic packages designed to support women at every stage of life. From puberty and fertility to pregnancy, menopause, and active ageing, each package is structured to provide relevant, timely insights that help women make informed decisions about their health. The initiative, launched in the lead-up to Mother’s Day on May 11, brings attention to a widely recognised yet often unspoken truth. In many households, the woman who keeps the family running is often the last to care for her own health. Recent studies by Redcliffe Labs revealed that one in two women admits to postponing essential health checkups, often due to caregiving duties or household responsibilities. These delays can result in the late diagnosis of common yet serious conditions such as thyroid imbalances, PCOS, anaemia, vitamin deficiencies, reproductive disorders, and early-stage metabolic diseases. Femcliffe offers diagnostic packages to address these gaps, aligned with the distinct physiological changes women experience over time. These include hormonal assessments during adolescence, fertility and pregnancy screenings, as well as evaluations for pre- and post-menopausal health, bone density, and overall wellness. These services are available through Redcliffe’s extensive PAN India network of advanced laboratories and collection centres, with the added convenience of online booking and home sample collection. Femcliffe also focuses on simplifying the diagnostic experience. Diagnostic reports are presented in clear, easy-to-understand formats, with actionable insights and progress tracking to support long-term health management. This approach empowers women to take a proactive role in managing their health with clarity and confidence.   ]]> https://biospectrumindia.com/news/92/26095/bioheaven360-introduces-ai-driven-genomics-diagnostic-platform-for-early-disease-detection.html https://biospectrumindia.com/news/92/26095/bioheaven360-introduces-ai-driven-genomics-diagnostic-platform-for-early-disease-detection.html Fri, 09 May 2025 00:00:00 +0530 Bioheaven360 Genotec, a leading Delhi-based biotechnology startup, has has introduced its cutting-edge AI-powered genomics diagnostics platform in the Indian market. Designed to enable early disease detection and personalised treatment plans, the platform marks a significant shift from reactive to proactive healthcare. The platform has been developed through rigorous research and clinical trials in collaboration with the All India Institute of Medical Sciences (AIIMS), New Delhi. It integrates deep phenotyping to capture comprehensive patient data from multiple sources including genetic information, lifestyle factors, biomarkers, and environmental influences. Through this, the platform generates highly accurate cumulative risk assessments that can identify disease predispositions decades before symptoms appear. Commenting on the same, Dr Shailendra Vyas, Founder and CEO of Bioheaven360 Genotec, shared, "Our platform aims to revolutionise preventive healthcare by providing personalized recommendations to mitigate risks and improve overall health outcomes. With our cutting-edge technology, we strive to empower individuals to take proactive steps towards a healthier future. By leveraging the latest advancements in genetic testing and data analysis, our platform offers a comprehensive approach to preventive healthcare that goes beyond traditional methods. Our goal is to empower individuals with the knowledge and tools they need to make informed decisions about their health and well-being.” The platform leverages advanced machine learning algorithms that continuously refine in real-time, enhancing diagnostic precision with every new dataset.  It includes extensive phenotyping that captures patient data from various sources, cumulative risk assessments, AI-powered  diagnostic support, and self-learning capabilities. Initially designed for the early detection of osteoporosis, the platform’s applications will soon broaden to encompass a wider range of chronic and complex conditions. It is engineered to rapidly analyse intricate medical datasets including genomic sequences, imaging results, and biomarker profiles delivering insights far faster and more accurately than conventional diagnostic tools. ]]> https://biospectrumindia.com/news/92/26066/apollo-diagnostics-unveils-digi-smart-central-reference-laboratory-in-chennai.html https://biospectrumindia.com/news/92/26066/apollo-diagnostics-unveils-digi-smart-central-reference-laboratory-in-chennai.html Fri, 02 May 2025 00:00:00 +0530 Apollo Diagnostics has unveiled its Digi-Smart Central Reference Laboratory (CRL), in Chennai, a fully automated facility designed to dramatically accelerate diagnostic timelines with error free operations to enhance patient care. This pioneering initiative leverages cutting-edge technology to deliver a 60% reduction in Laboratory sample Turnaround Time (TAT), setting a new benchmark for efficiency in medical diagnostics by early delivery of patient’s reports. The state-of-the-art facility, spanning 45,000 square feet, integrates five major laboratory disciplines—Clinical Chemistry, Immunoassay, Serology, Hematology, and Hemostasis—into a unified, digitally monitored, and fully automated track. This seamless integration, powered by advanced robotics, high-definition cameras, bespoke algorithms, and machine learning technologies, optimises processes, mitigates errors, and significantly improves clinical outcomes. The Digi-Smart Lab’s sophisticated automation allows for the processing of over 100,000 samples daily, catering to clients across India and Southeast Asia. The laboratory will undergo rigorous clinical laboratory proficiency testing (PT) programmes and regular quality control (QC) reviews along with National and International accreditations.     ]]> https://biospectrumindia.com/news/92/26067/remidio-receives-regulatory-approval-from-karnataka-to-deploy-ai-based-tools-for-eye-care.html https://biospectrumindia.com/news/92/26067/remidio-receives-regulatory-approval-from-karnataka-to-deploy-ai-based-tools-for-eye-care.html Fri, 02 May 2025 00:00:00 +0530 Remidio Innovative Solutions has received approval from the State FDA, Karnataka (CDSCO), the regulatory authority for medical devices, for its Medios HI (Humanising Intelligence) Glaucoma AI and Medios HI AMD AI. This approval represents an important advancement in the use of artificial intelligence (AI) for early detection of glaucoma and age-related macular degeneration (AMD) in diverse healthcare settings. Following the success of the CDSCO-approved Medios DR HI, AI for diabetic retinopathy, which has impacted nearly 2,50,000 patients in the past year, the newly approved AI solutions for glaucoma and AMD are also designed to function offline. This offline capability allows real-time analysis without relying on internet access, making it useful for providing eye care in remote and underserved areas with limited access to specialised ophthalmic diagnostics. Medios HI Glaucoma AI exceeds conventional screening methods by analysing optic nerve head and RNFL structures, generating heat map–based reports to detect early signs of referable glaucoma. This is vital in a country like India, which accounts for 12 million glaucoma patients, nearly one in eight globally. Yet over 90% of these cases remain undiagnosed, often leading to irreversible vision loss. Early detection using portable, AI-enabled tools can drastically change this trajectory. The Medios HI AMD AI, detects early-stage age-related macular degeneration (AMD), a major cause of vision impairment among the elderly. With 2.1% of Indians over age 60 affected, amounting to nearly 6.7 million people at risk, this tool plays a crucial role in enabling timely referrals and preventive care by highlighting lesions with AI generated heat maps. Medios HI Glaucoma and Medios HI AMD Al has been clinically validated across tertiary hospitals, eye institute and vision centres showcasing high level of sensitivity and specificity. With Medios HI on Remidio’s FOP NM 10, a single tap delivers results for screening AMD, Glaucoma, and DR in few seconds.  Three critical insights, one seamless experience. Dr R. Kim, Chief Medical Officer, Senior Medical Consultant, Retina & Vitreous Services Director, Aravind Eye Hospital, Madurai said “The Remidio fundus camera isn't just an imaging device; it's a portable gateway to early detection and prevention of vision-threatening conditions, bringing quality eye care closer to those who need it most”  Dr Anand Sivaraman, CEO and Founding Director, Remidio said "The CDSCO's approval of our Medios HI Glaucoma AI and Medios HI AMD AI builds upon the foundation laid by our Medios HI DR AI, which was the first ophthalmic AI software to receive such approval in India."   ]]> https://biospectrumindia.com/news/92/26070/amr-challenge-2024-25-in-collaboration-with-gamrif-announces-9-winners.html https://biospectrumindia.com/news/92/26070/amr-challenge-2024-25-in-collaboration-with-gamrif-announces-9-winners.html Fri, 02 May 2025 00:00:00 +0530 The Centre for Cellular and Molecular Platforms (C-CAMP) Antimicrobial Resistance (AMR) Challenge 2024-25 supported by the UK Department of Health and Social Care’s Global AMR Innovation Fund (GAMRIF), under the aegis of India AMR Innovation Hub, has announced nine winners of its National Call in India. The winners shall be supported by C-CAMP in India in collaboration with the UK Department of Health and Social Care’s Global AMR Innovation Fund (GAMRIF) to foster the identification and development of world-class AMR-focused innovative solutions to tackle various aspects of AMR in the environment in India and for the benefit of low and middle income countries (LMICs). The winners include-  Foundation for Neglected Diseases Research (FNDR) - A device to deplete antimicrobial residues from wastewater, using a cartridge-based device with a patented mixture of activated charcoal and plant-based materials. Biomoneta Research: qAMI (Quantitative Airborne Microbial Index) - A singular technology combining detection of air-borne total microbial load and pathogenic microbes in hospital set-ups, using AI/ML platform and encompassing different microbial attributes, combined with the classic microbiological approach. D-NOME's pocket PCR device: Rapid and accurate on-field detection and identification of Antibiotic-Resistant Bacteria (ARB) & Antibiotic Resistance Genes (ARGs) in aquaculture farms and other wastewater sources. Vividew Innovations - A novel innovation to remove residual antibiotics & antibiotic-resistant bacteria from wastewater in hospital sewage treatment plants (STPs). A combination of technologies based on membrane filtration and advanced photo-catalytic oxidation. Diagopreutic - Detection of residual antibiotic and pathogen identification in water samples from aquaculture farm effluents, using a colorimetric method, based on the differential nitro-reductase activity of the bacteria and their ability to grow in presence of the specific antibiotic. Mylab Discovery Solutions - Rapid detection of pathogens from wastewater samples and detection of environment-related ARGs. The technology involves an in-house developed nucleic acid extraction kit and an advance multiplexed quantitative RT-PCR technology, capable of identifying a diverse array of pathogens as well as an extensive spectrum of ARGs. Huwel Life Sciences: Quantiplus® Environmental Surveillance Kit - Real-Time PCR detection for typhoid and ARGs in environmental samples. The RT-PCR kit detects a wide spectrum of ARGs, as well as the typhoid specific gene along with its resistance genes. Amrita Vishwa Vidyapeeth - Development of affordable POT (Point of Testing) device for monitoring of AMR in the environment, by an impedance-based microfluidic device, using a lytic phage-based detection technology. The innovation, as proposed by Dr. Bipin Nair and his team, is capable of detecting and identifying various pathogens of clinical relevance and can be used for rapid and accurate detection of specific bacteria. Indian Intitute of Science (IISc) - Tackling AMR emergence through effluent treatment using robust catalytic enzyme mimetics. The MONZymes based technology, as developed by Dr. Subinoy Rana and his team, is capable of effectively degrading residual antibiotics from effluent wastewater and also exhibit antibacterial activity, through advanced (photo)catalytic activity. ]]> https://biospectrumindia.com/news/92/26050/aiims-jammu-opens-centre-for-advanced-genomics-precision-medicine.html https://biospectrumindia.com/news/92/26050/aiims-jammu-opens-centre-for-advanced-genomics-precision-medicine.html Mon, 28 Apr 2025 00:00:00 +0530 The All India Institute of Medical Sciences (AIIMS) Jammu has officially initiated laboratory operations with the illumina NextSeq 2000 sequencing machine, at its newly established Centre for Advanced Genomics & Precision Medicine, marking a transformative step toward making affordable, precision-driven cancer care accessible to patients across India. Inaugurating the state-of-the-art facility were key dignitaries, including Prof. (Dr) Shakti Kumar Gupta, Executive Director and CEO of AIIMS Jammu; Lt Gen Dr Sunil Kant, Dean Research and Medical Superintendent; Prof. Dr Meeta Gupta, Dean (Academics); Prof. Dr Shabab L Angurana, Associate Dean (Research); Shailender Slathia, Registrar; Dr Poonam Sharma, Head, Department of Pathology; and Dr Sudharshan, Vice President – Global Operations at 4baseCare. The Centre, developed in collaboration with Bengaluru-based startup 4baseCare, is equipped with advanced Next Generation Sequencing (NGS) technology, offering comprehensive genomic profiling for cancer patients. This powerful capability enables clinicians to design highly personalised, targeted treatment plans tailored to each patient’s unique molecular profile. “By integrating cutting-edge genomic data with AI-powered diagnostics, the Centre is poised to significantly improve early disease detection, refine therapy choices, and minimize ineffective treatments — ultimately enhancing both patient outcomes and quality of life,” said Dr Sudharshan Elangovan , Vice President – Global Operations at 4baseCare. Traditionally, access to such advanced genomic testing has been prohibitively expensive for many patients. However, with this initiative, high-quality NGS-based tests will now be made available at affordable costs, paving the way for greater inclusivity in precision oncology across India. Further solidifying its role as a national referral hub, the Centre will accept samples from patients and healthcare providers across the country, ensuring that cutting-edge molecular diagnostics are accessible, regardless of geographical barriers. ]]> https://biospectrumindia.com/news/92/26028/researchers-in-nashik-develop-blood-test-to-detect-30-different-types-of-cancer.html https://biospectrumindia.com/news/92/26028/researchers-in-nashik-develop-blood-test-to-detect-30-different-types-of-cancer.html Thu, 24 Apr 2025 00:00:00 +0530 In a landmark advancement for global oncology, a multi-institutional research team led by Prof Dr Raj Nagarkar, Managing Director and Chief of Surgical Oncology & Robotic Services at HCG Manavata Cancer Centre (HCGMCC), Nashik, has developed a revolutionary blood test that can detect 30 different types of cancers including pancreatic, lung, and ovarian cancers across both genders, with an average accuracy of 98.4 per cent. The pioneering study, recently published in Cancer Reports, is the largest clinical trial of its kind in India. It utilised a novel serum metabolome-based diagnostic platform powered by machine learning to identify distinct metabolic signatures associated with cancer. The trial included 6,445 participants, with over 2,800 confirmed, treatment-naïve cancer patients across four stages of the disease. Remarkably, the platform showed consistent high sensitivity even in early-stage (Stage I/II) cancers, a feat rarely achieved by current diagnostic standards. The model’s robustness was validated across multiple age groups, showing detection sensitivity consistently above 96 per cent across all demographics and cancer stages. Unlike other multi-cancer early detection (MCED) tests that rely on detecting tumour DNA or cells that are often limited by low biomarker concentration, this test captures changes in metabolites, providing a more reliable and sensitive readout, especially for early-stage cancers. The serum samples were analysed using high-resolution mass spectrometry and the data was interpreted through a proprietary Cancer Detection Artificial Intelligence (CDAI) algorithm developed in collaboration with PredOmix Technologies. “Currently, plans are underway to initiate larger, multi-centre clinical trials and eventually work toward commercial deployment. There are also on-going efforts to integrate tissue-of-origin prediction capabilities, which would further support physicians in initiating precise follow-up diagnostics and treatment strategies,” said Dr Nagarkar. ]]> https://biospectrumindia.com/news/92/26030/molbio-diagnostics-enhances-cervical-cancer-screening-with-upgraded-truenat-hpv-hr-plus-in-india.html https://biospectrumindia.com/news/92/26030/molbio-diagnostics-enhances-cervical-cancer-screening-with-upgraded-truenat-hpv-hr-plus-in-india.html Thu, 24 Apr 2025 00:00:00 +0530 Molbio Diagnostics Limited, a pioneer in point-of-care molecular diagnostics, recently unveiled their latest innovation, Truenat HPV-HR Plus, which enables expanded high-risk genotype detection.  The chip-based RT-PCR test allows rapid and decentralized detection of eight high-risk genotypes of human papillomavirus (HPV) – which account for over 96% of cervical cancer cases globally.  The multicentric validation was supported by the Grand Challenges India, Biotechnology Industry Research Assistance Council (BIRAC) and the Department of Biotechnology (DBT), Government of India under its program “Validating Indigenous Human Papilloma Virus (HPV) Tests for Cervical Cancer Screening in India”, making it one of the most trusted, indigenously developed tools for cervical cancer screening in India. India continues to bear a disproportionate burden of cervical cancer, accounting for nearly 25% of global cases. With more than 1,23,000 new diagnoses and around 77,000 deaths each year, the disease remains the second most common cancer among Indian women — despite being preventable through timely screening. Highlighting the importance of developing homegrown solutions, Rajesh S. Gokhale, Secretary, Department of Biotechnology, Ministry of Science & Technology, Government of India said “Truenat HPV-HR Plus represents the kind of diagnostic innovation we need — dependable, scientifically rigorous, locally developed, and built to serve our public health system. It’s a huge step forward in strengthening cervical cancer screening across India.” Truenat HPV-HR Plus is a simple, fast, and reliable test that checks for high-risk HPV infections using a portable device. Designed to work with cervical swab samples collected by a clinician, it gives highly accurate results in just 60 minutes. Easy to use and with high stability at room temperature, it requires minimal biosafety and  is optimized for use at both the lab and near-patient settings. ]]> https://biospectrumindia.com/news/92/25999/sterling-accuris-buys-gujarat-pathology-laboratory-and-diagnostic-centre.html https://biospectrumindia.com/news/92/25999/sterling-accuris-buys-gujarat-pathology-laboratory-and-diagnostic-centre.html Wed, 16 Apr 2025 00:00:00 +0530 Sterling Accuris Diagnostics, one of the fastest growing chains of NABL accredited pathology laboratory in India with a leading presence in Gujarat, Rajasthan, and Madhya Pradesh, has announced the acquisition of Gujarat & Maha Gujarat Pathology Laboratories, a leading pathology service provider in Ahmedabad. This acquisition is poised to significantly increase the footprints of Sterling Accuris across the length and breadth of Ahmedabad and add value to service excellence across the diagnostics landscape. Sterling Accuris is a strong, customer-centric brand known for providing ethical and market-appropriate pathology diagnostic services. It offers reliable, accurate, and dependable solutions to individual patients, hospitals, and corporates. While Gujarat Pathology Laboratory has been serving Ahmedabad since 1998 and offering a comprehensive range of diagnostic services from Hematology, Biochemistry, and Immunology to Molecular Biology. With a network of 8 laboratories and more than 20 collection centres across Ahmedabad, it has served nearly 20 lakh patients so far. Rajiv Sharma, Managing Director of Sterling Accuris said, “Gujarat Pathology Laboratory has been serving Ahmedabad for the past 27 years, with a strong presence and reputation in the market. Our acquisition of Gujarat Pathology Laboratory will enable us to serve a larger patient base in Ahmedabad by leveraging their strengths in the B2C segment. This collaboration will not only strengthen our service network but also enhance the reach and quality of diagnostic services we offer across Ahmedabad & Gujarat.” Dr Niraj Kothari, Founder, and Vishnubhai Patel, Co-Founder of Gujarat Pathology Laboratory, along with Navinbhai Patel, Founder of Maha Gujarat Pathology Laboratory, stated, "Sterling Accuris brings a strong and established presence in the diagnostics market, and we see this partnership as a valuable opportunity to scale our services. Gujarat Pathology has a solid foundation in Ahmedabad, and with this acquisition, we will be able to leverage the high-end technology available with Sterling Accuris. This collaboration will enable us to offer a wide range of diagnostic tests, helping us expand our reach and improve accessibility." ]]> https://biospectrumindia.com/news/92/25986/dr-lal-pathlabs-first-to-launch-advanced-test-for-amyloidosis.html https://biospectrumindia.com/news/92/25986/dr-lal-pathlabs-first-to-launch-advanced-test-for-amyloidosis.html Tue, 15 Apr 2025 00:00:00 +0530 Dr. Lal PathLabs Limited (DLPL), a leader in diagnostic healthcare, has introduced Amyloid Typing by Laser Capture Microdissection & Mass Spectrometry – a breakthrough test for accurately identifying different types of Amyloid proteins. With this launch, DLPL becomes the first diagnostic chain in South Asia to offer this highly specialized test. Amyloidosis is a disease where the abnormal or misfolded amyloid protein accumulates in various vital organs leading to loss of function or even death in some cases. More than 40 types of Amyloid proteins are discovered till date, and precise knowledge about the type of Amyloid helps doctors in choosing the correct treatment or management plan for the patient. Kidney, Heart, Lungs, Skin are the most common involved, however any organ in the body can be affected.  Dr Alok Sharma, R&D Head & Director Renal Pathology & Electron Microscopy, stated, “Accurate typing of Amyloid proteins is essential for guiding treatment decisions. This gold standard advanced test, powered by Laser Microdissection & Mass Spectrometry allows us to precisely identify amyloid subtypes, helping clinicians provide targeted care. With this launch, we are bringing global standards of Proteomics based diagnostics to patients across India.” Dr. Lal PathLabs has launched this test, under the guidance of National Amyloidosis Centre, London (UK). ]]> https://biospectrumindia.com/news/92/25987/australias-telemedc-partners-with-indian-startup-and-healthcare-to-expand-ai-based-eye-disease-screening.html https://biospectrumindia.com/news/92/25987/australias-telemedc-partners-with-indian-startup-and-healthcare-to-expand-ai-based-eye-disease-screening.html Tue, 15 Apr 2025 00:00:00 +0530 TeleMedC, an Australia-based leader in artificial intelligence (AI)-powered retinal disease diagnostics is expanding its footprint in India, through a strategic partnership with Mumbai-based startup AND Healthcare Solutions to deliver low-cost, AI-driven eye screening solutions to millions. The move aims to tackle the growing burden of preventable eye diseases by enabling early detection and intervention. Through its AI-powered technology, the company enables early detection of conditions such as diabetic retinopathy, glaucoma, and macular diseases, helping to prevent vision impairment and blindness.  Supported by Trade and Investment Queensland (TIQ), the Queensland Government’s global business agency, TeleMedC and AND Healthcare Solutions will roll out advanced eye imaging and AI-powered diagnostics across India. This initiative is poised to strengthen India’s healthcare innovation ecosystem, making critical eye care more affordable and accessible to all.  TeleMedC aims to screen one billion eyes over the next decade, driving early detection, disease prevention, and affordable access to advanced diagnostics. The company is actively partnering with Indian healthcare institutions, research bodies, and non-profits to accelerate innovation in eye health. Recently, TeleMedC collaborated with leading Indian healthcare institutions, including Aravind Eye Hospital, through the Australia-India Strategic Research Fund. This partnership is advancing AI-driven eye health solutions, reinforcing the company’s commitment to cutting-edge diagnostics. Expanding its impact, TeleMedC is working with SMEs and large corporations to integrate AI-powered eye screening into Corporate Social Responsibility (CSR) initiatives, making preventive healthcare more inclusive in India.      ]]> https://biospectrumindia.com/news/92/25992/remidio-with-retinarisk-to-strengthen-ai-driven-diabetic-retinopathy-screening-in-india-and-iceland.html https://biospectrumindia.com/news/92/25992/remidio-with-retinarisk-to-strengthen-ai-driven-diabetic-retinopathy-screening-in-india-and-iceland.html Tue, 15 Apr 2025 00:00:00 +0530 Bengaluru-based Remidio Innovative Solutions, a global leader in artificial intelligence (AI)-powered ophthalmic diagnostics, has announced a strategic partnership with RetinaRisk, a leading health tech company from Iceland, to enhance risk-based diabetic retinopathy (DR) screening in India and Iceland. This partnership brings together two powerful innovations, Remidio’s Medios DR AI for automated DR detection and RetinaRisk’s personalised risk triaging algorithm for progression to sight-threatening DR. Medios DR is an edge-AI solution that runs entirely on a smartphone without the need for internet access or cloud connectivity, offering real-time DR grading at the point of care. RetinaRisk calculates a patient’s risk level and suggests a recommended screening interval using key clinical inputs such as HbA1c, blood pressure, diabetes type and duration, and DR status. From a public health perspective, this enables more cost-effective DR screening programmes by individualising screening intervals, extending the frequency for low-risk individuals while ensuring timely follow-up for high-risk cases. The urgency of this collaboration is highlighted by growing global and national public health concerns. Globally, an estimated 22.27% of people with diabetes have diabetic retinopathy, and the number of affected adults is projected to rise from 103.12 million in 2020 to 160.50 million by 2045. India alone accounts for over 9.2 million cases, highlighting the urgent need for scalable, personalized screening models. The partnership will kick off with pilot programmes targeting high-prevalence diabetic populations in India, aiming to create a scalable framework for prioritised referrals, longitudinal tracking, and reduced vision loss due to DR.   ]]> https://biospectrumindia.com/news/92/25994/dr-mohans-diabetes-specialities-centre-launches-ai-driven-diabetic-retinopathy-screening-software.html https://biospectrumindia.com/news/92/25994/dr-mohans-diabetes-specialities-centre-launches-ai-driven-diabetic-retinopathy-screening-software.html Tue, 15 Apr 2025 00:00:00 +0530 Taking yet another pioneering and life-changing step in the field of diabetic care, Dr. Mohan’s Diabetes Specialities Centre (DMDSC) has launched a first-of-its-kind artificial intelligence (AI)-driven Diabetic Retinopathy Screening Software. This initiative aims to harness the latest artificial intelligence technology to detect early-stage diabetic retinopathy and apply this technology to offer quick and precise analysis that will help doctors make informed decisions. This move further strengthens DMDSC's vision of offering holistic preventive care in the diabetic field. Set to be available across its 50 clinics nationally, the hospital has launched this initiative in its flagship Pondicherry and Thanjavur clinics in the first phase of the rollout. Diabetic retinopathy ranks among the primary causes of vision impairment in individuals with diabetes, frequently going unnoticed until substantial damage has taken place. With this AI-powered screening, DMDSC aims to bridge the gap between early detection and effective treatment by providing quick, highly accurate, and accessible diagnostic solutions. Dr R. M. Anjana, Managing Director of Dr. Mohan’s Diabetes Specialities Centre, said, “Diabetic retinopathy is a silent but severe complication that can lead to irreversible vision loss if left undetected. With diabetes cases on the rise, it is crucial to integrate preventive eye care into routine diabetes management. This AI-powered screening initiative is a game-changer, as it enables early detection and timely intervention, significantly reducing the risk of vision impairment. We have chosen Pondicherry and Thanjavur as the first locations for this rollout due to the high prevalence of diabetes in these regions and the need to strengthen accessible eye care solutions. Our goal is to ensure that patients receive proactive, high-quality care close to home.”   ]]> https://biospectrumindia.com/news/92/25950/fujifilm-india-launches-latest-csr-initiative-care-on-wheels-in-himachal-pradesh.html https://biospectrumindia.com/news/92/25950/fujifilm-india-launches-latest-csr-initiative-care-on-wheels-in-himachal-pradesh.html Mon, 07 Apr 2025 00:00:00 +0530 Fujifilm India, a leader in healthcare imaging technology, has announced its latest CSR initiative “Care on Wheels” in Himachal Pradesh on the occasion of World Health Day, on 7 April. Inaugurated by Dr (Col.) Dhani Ram Shandil, Minister of Health and Welfare, Government of Himachal Pradesh, this groundbreaking intervention features a dual approach with a static healthcare centre complemented by a fully equipped mobile van that will deliver X-Ray and clinical chemistry tests combined with tele-radiology and tele-health services directly to people’s doorsteps. Leveraging state-of-the-art diagnostic and imaging technology, this initiative ensures cutting-edge medical systems that strengthens healthcare infrastructure in Mandi and ensures access to proactive check-ups where population resides. With the CSR approach, the mobile van in its initial phase will cover the whole area of 3,950 km² covering the Mandi district, providing essential services like General Health Checkup, CBC Test, tuberculosis (TB) Screening, X Ray diagnosis, Tele-Radiology, 18+ Blood Tests, Chronic Obstructive Pulmonary Disease (COPD) diagnosis and Tele-Consultation with doctor. As part of this initiative, Fujifilm India is incorporating cutting-edge diagnostic technology to enhance healthcare delivery. The DRI-CHEM NX600, an automated clinical chemistry analyser and Portable X-ray Unit FDR Xair, will be deployed in the CSR programme, making advanced radiography possible along with quick clinical chemistry reports, even in the most remote locations. These innovations will play a critical role in delivering efficient and precise healthcare diagnostics on the go while covering wide ranges of diseases from COPD to TB.   ]]> https://biospectrumindia.com/news/92/25951/neuberg-diagnostics-opens-advanced-regional-reference-laboratory-in-madurai.html https://biospectrumindia.com/news/92/25951/neuberg-diagnostics-opens-advanced-regional-reference-laboratory-in-madurai.html Mon, 07 Apr 2025 00:00:00 +0530 Neuberg Diagnostics, a global leader in diagnostic healthcare, has unveiled its advanced regional reference laboratory and wellness centre in Madurai. As the only NABL-accredited standalone advanced reference laboratory in Madurai, Neuberg Bose is set to redefine diagnostic excellence in the region. The advanced facility was inaugurated by Dr S. Meenakshi Sundaram – Neurologist; Dr GSK Velu, Founder & Chairman, Neuberg Diagnostics; Dr Puratchimani.S, Founder Bose Labs in the presence of distinguished guests. Further strengthening its healthcare footprint, Neuberg Diagnostics has also inaugurated 10 new collection centres across Madurai district in locations including Sattur(Madurai), Avaniyapuram, Thirunagar, Theni, Kochadai, Nagamalaipudukottai, Ksalai Pudur, Gomathipuram, and Simmakkal. The inauguration of these centres was conducted virtually by Minister Thiru. P. Moorthy. This expansion aims to provide enhanced accessibility and convenience for patients seeking high-quality diagnostic services in the region.   Residents of Madurai will now have access for an extensive array of over 6000 routine and specialised tests and this advanced laboratory have a capacity to process a remarkable number of 300000 tests samples per month. Spanning over 15,000 square feet, the facility houses multiple specialised laboratory divisions, including- Haematology, Biochemistry, Clinical Pathology, Immunology, Histopathology, Immunohistochemistry, Molecular Genetics, Cytogenetics, Microbiology, serology, Flow Cytometry and Mass Spectrometry; A comprehensive radiology suite featuring Ultrasound, Audiometry, Ophthalmology, X-Ray, ECG, TMT, Spirometry, and Executive Medical Check-ups. ]]> https://biospectrumindia.com/news/92/25922/tvaster-genkalp-secures-1-25-m-funding-to-advance-liquid-biopsy-cancer-diagnostics.html https://biospectrumindia.com/news/92/25922/tvaster-genkalp-secures-1-25-m-funding-to-advance-liquid-biopsy-cancer-diagnostics.html Tue, 01 Apr 2025 00:00:00 +0530 Chennai-based molecular diagnostic startup Tvaster Genkalp has raised $1.25 million in a Pre-Series A funding round led by Ideaspring Capital. Existing investors include Invigo Softwares and Prof. Mohamed Rela, a globally renowned liver transplant surgeon. The fresh investment will accelerate expansion and commercialisation of Episcreen Liver, a pioneering methylation-based liquid biopsy test for early liver cancer detection. Co-founded in 2021 by Dr Srikar Raman and K Sreedurgalakshmi, Tvaster is transforming molecular diagnostics and precision oncology through advanced epigenetic screening technologies. The company develops proprietary, high-accuracy genetic solutions, setting a new benchmark in non-invasive cancer detection. Dr Srikar Raman, Co-founder of Tvaster Genkalp, said, “The funding will accelerate nationwide deployment of Episcreen Liver, offering a non-invasive, highly accurate diagnostic alternative for Hepatocellular Carcinoma (HCC), the most common form of liver cancer.” He further added that while Alpha-Fetoprotein (AFP), the current standard for HCC screening, has 50% sensitivity, Episcreen Liver achieves 90% sensitivity thus significantly improving early detection and increasing survival chances by over 70%. To achieve this, Tvaster is forging partnerships with leading diagnostic companies. Tvaster is also advancing its oncology diagnostics pipeline with Episcreen Bile, a novel test for Cholangiocarcinoma, an aggressive bile duct cancer with limited early detection options. Additionally, the company has developed Episcreen HBResist, the first-ever chemotherapy resistance test for pediatric hepatoblastoma, addressing a critical gap in childhood cancer treatment.  ]]> https://biospectrumindia.com/news/92/25908/lungs-alliance-launches-free-ngs-biomarker-testing-for-lung-cancer-patients-in-india.html https://biospectrumindia.com/news/92/25908/lungs-alliance-launches-free-ngs-biomarker-testing-for-lung-cancer-patients-in-india.html Mon, 31 Mar 2025 00:00:00 +0530 In a significant move to drive awareness about precision oncology as an essential, accessible and affordable treatment plan for lung cancer treatment, LuNGS Alliance, an initiative led by the Cancer Research and Statistic Foundation (CRSF), has announced free Lung NGS (Next Generation Sequencing) biomarker testing for lung cancer patients across India. This initiative is backed by leading pharmaceutical companies AstraZeneca, Pfizer, and Roche, with 4baseCare serving as the official lab partner. The TARGT First Solid test by 4baseCare offers a comprehensive analysis of 72 commonly mutated genes, identifying actionable biomarkers that enable personalized treatment plans based on a patient’s unique genomic profile. This cutting-edge test identifies mutations corresponding to approved therapies by FDA and NCCN (National Comprehensive Cancer Network), empowering oncologists to provide tailored, more effective treatments that can significantly improve patient outcomes. The primary goal of this initiative is to bridge the gap between innovative cancer care and its accessibility. By offering zero-cost biomarker testing, LuNGS Alliance ensures that financial constraints do not prevent patients from receiving the most advanced cancer treatment available. According to a study published in The Lancet Regional Health, lung cancer accounts for an estimated 72,510 new cases and 66,279 deaths annually in India. The high mortality rate highlights the urgent need for personalised treatment approaches over the conventional one-size-fits-all methods. Biomarker testing addresses this challenge by offering targeted therapies based on a patient’s unique genetic mutations.   ]]> https://biospectrumindia.com/news/92/25880/nura-launches-mobile-health-screening-facility-nura-express-in-kozhikode.html https://biospectrumindia.com/news/92/25880/nura-launches-mobile-health-screening-facility-nura-express-in-kozhikode.html Tue, 25 Mar 2025 00:00:00 +0530 NURA, an advanced diagnostic venture between Fujifilm Healthcare and Dr Kutty’s Healthcare, has announced the launch of its mobile health screening facility, ‘NURA Express’, in Kozhikode, Kerala. This marks a significant expansion of NURA’s health screening service business in Kerala for the first time. NURA’s global partner Fujifilm has been expanding the ‘NURA’ health screening centres, primarily in urban areas across several countries, to build an environment where more people can access high-quality health screening services. The newly-introduced NURA Express provides corporate health screenings in collaboration with local companies. The mobile unit will travel to the designated locations, offering cancer screenings and testing of lifestyle-related diseases through on-site CT scans for employees working in an office or factory or living in a particular residential area. The images captured in the NURA Express will then be remotely interpreted by the physicians stationed at the ‘NURA Global Innovation Centre’ in Kozhikode. The captured images and analyzed test results will be provided to people through a dedicated smartphone app. In the future, NURA/ Fujifilm aims to partner with local self-governments to establish a system through which the NURA Express can provide municipal health screenings to residents in remote areas. This initiative will contribute significantly to the early detection of cancer and lifestyle diseases for a large number of people. Commenting on the development, Dr Bilal Thangal T M, Medical Lead, NURA, said, “Cancer and lifestyle diseases, such as ischemic heart disease, remain among the leading causes of death worldwide. Health screenings play a crucial role not only in the early detection of these conditions—enabling timely intervention through treatment and health guidance—but also in disease prevention by fostering a deeper understanding of one’s health. However, in many emerging countries, access to health screening services remains limited, and the culture of preventive health checks is yet to be widely adopted." ]]> https://biospectrumindia.com/news/92/25871/american-institute-of-pathology-laboratory-sciences-expands-diagnostic-services-in-punjab.html https://biospectrumindia.com/news/92/25871/american-institute-of-pathology-laboratory-sciences-expands-diagnostic-services-in-punjab.html Mon, 24 Mar 2025 00:00:00 +0530 American Institute of Pathology & Laboratory Sciences (Ampath) has expanded its footprint in Punjab with the launch of a new pathology laboratory in Pathankot. This expansion is in collaboration with Star Path Lab, Pathankot furthering Ampath’s commitment to providing world-class diagnostic services to communities across the region. The new laboratory was inaugurated by Ashwani Sharma, MLA Pathankot on 23rd March, 2025. It is equipped with cutting-edge technology and a highly skilled team of pathologists and technicians, ensuring accurate, reliable, and timely diagnostic services. With a focus on patient-centric care, the facility will offer a comprehensive range of more than 2500 tests, including Clinical Biochemistry, Hematology, Flow Cytometry, Clinical Pathology, Serology, Immunology, Microbiology, Cytology, Histopathology, Immunohistochemistry, Molecular Diagnosis, NGS, and Cytogenetics, the lab is poised to deliver precise and timely diagnostic results. Dr Maneesh Bagai, Chief Operating Officer of Ampath Labs, said, "With rising healthcare awareness and the need for early disease detection, timely and precise diagnostics have become more crucial than ever. This expansion aligns with our vision of providing state-of-the-art pathology services closer to communities, ensuring they receive world-class diagnostics without having to travel long distances." Dr Ashneet Walia, Lab Head, Star Path Lab expressed enthusiasm about the collaboration, stating, "This collaboration will greatly benefit residents of Pathankot and surrounding areas, ensuring they have access to high-quality healthcare diagnostics right at their doorstep." Ampath operates a Central Reference Laboratory in Hyderabad and 22 satellite labs across various locations. As part of its expansion strategy, Ampath aims to set up additional labs and collection centres across the country, continuing its mission to deliver top-notch diagnostic services and support better healthcare outcomes. ]]> https://biospectrumindia.com/news/92/25848/icmr-strengthens-strategies-for-faster-and-more-accurate-diagnostics-of-tuberculosis.html https://biospectrumindia.com/news/92/25848/icmr-strengthens-strategies-for-faster-and-more-accurate-diagnostics-of-tuberculosis.html Tue, 18 Mar 2025 00:00:00 +0530 Union Minister of State for Health and Family Welfare, Anupriya Patel inaugurated the India Innovation Summit – Pioneering Solutions to End Tuberculosis (TB), at Bharat Mandapam Convention Centre, on 18th March in Delhi. The Summit is being organised jointly by the Department of Health Research-Indian Council of Medical Research (DHR-ICMR) and the Central TB Division (CTD), Ministry of Health & Family Welfare (MoHFW). The summit aims to accelerate India's progress towards TB elimination by 2025. Underlining the new innovations rolled out under the TB Mukt Bharat– 100 Days Intensified Campaign, the Minister stated that, “ICMR has validated three indigenous handheld X-ray devices, which makes it possible to reach vulnerable population groups for TB screening. Hand-held devices offer advantages of low weight, portability, and low radiation exposure and are being used in the 100-day accelerated programme.” She also added that “ICMR partnered with Institute of Plasma Research, Ahmedabad, to develop DeepCXR, a tool for artificial intelligence-based reporting chest X-ray films. ICMR has also validated CyTb skin test for detection of latent TB infection, developed by Serum Institute of India against Interferon gamma release assay (IGRA), which is the preferred test for latent TB detection. However, IGRA is expensive and it may not be feasible to be introduced in resource limited countries. Overall performance of CyTb was better than the currently used tuberculin skin test.” She further added that “ICMR conducted a multicentric validation of PathoDetect, an indigenous molecular diagnostic NAAT test which can perform 32 tests simultaneously, detects MTB complex and first line drug resistance to rifampicin (RIF) and Isoniazid (INH) simultaneously as a one step process. Overall, the performance of PathoDetect was comparable to other molecular assays. Deployment of this test in the 100-day programme, along with the already available TruNat test, has enhanced capacity of molecular diagnosis of TB and early detection of drug resistance. Moreover, the Quantiplus MTB FAST Detection Kit developed by Huwel Lifesciences is the first in world indigenous open system RTPCR kits developed in India and validated by ICMR. In comparison to the gold standard liquid culture, sensitivity of the kit is 86% and specificity is 96%. These kits are likely to be low-cost and have a potential to expand the outreach of TB molecular testing, including more than 3300 RTPCR machines used during the COVID-19 pandemic.” ]]> https://biospectrumindia.com/news/92/25820/haystackanalytics-secures-patent-for-cutting-edge-secure-genomic-analysis-technology.html https://biospectrumindia.com/news/92/25820/haystackanalytics-secures-patent-for-cutting-edge-secure-genomic-analysis-technology.html Tue, 11 Mar 2025 00:00:00 +0530 In a country like India, with a rapidly advancing healthcare landscape and a growing focus on equitable access to enhance disease diagnosis and personalized treatment, Mumbai-based startup HaystackAnalytics, a pioneer in genomics-based diagnostic solutions, has secured a patent for its groundbreaking invention, “Systems and Methods for Secure Genomic Analysis Using a Specialised Edge Computing Device.”  This patent marks a significant advance, enabling real-time genomic analysis at the point of use, reducing reliance on complex infrastructure and specialized personnel. It empowers laboratories and hospital labs with real time reporting capabilities with accurate, simplified and timely insights for enhanced patient diagnosis and treatment.  HaystackAnalytics holds exclusive rights to this patent for the next 20 years and is committed to integrating it into all its solutions while making it widely accessible. As genomic sequencing becomes more widespread, the lack of standardised analysis tools has been a major bottleneck. This patent allows real-time sequencing data analysis, minimizing dependence on bioinformatics experts and complex infrastructure. With rising concerns over antimicrobial resistance (AMR), tuberculosis (TB), and emerging infectious diseases, India urgently needs scalable genomic tools that can be seamlessly deployed in hospitals and labs without complex setup requirements. This milestone reinforces the company’s commitment to advancing genomic diagnostics, ensuring standardised, cutting-edge analysis is accessible across diverse healthcare settings. By collaborating with its network of 250+diagnostic labs, 100+ hospitals, and potential public and private healthcare partners, the IIT-B-based company aims to establish this technology as a cornerstone of precision medicine on a global scale. ]]> https://biospectrumindia.com/news/92/25779/metropolis-healthcare-to-acquire-agras-leading-diagnostic-chain-scientific-pathology.html https://biospectrumindia.com/news/92/25779/metropolis-healthcare-to-acquire-agras-leading-diagnostic-chain-scientific-pathology.html Tue, 04 Mar 2025 00:00:00 +0530 Metropolis Healthcare Limited has announced that its wholly owned subsidiary, Metropolis Clinical Pathology Private Limited, will acquire Agra-based Scientific Pathology, founded by Dr Ashok Kumar Sharma, through a Business Transfer Agreement (BTA). This strategic move strengthens Metropolis’ presence in Western Uttar Pradesh, accelerates its B2C expansion, and unlocks growth opportunities across the state and beyond. Under the agreement, Metropolis Clinical Pathology will acquire and operate all laboratories and collection centers of Scientific Pathology in Agra and neighbouring towns through a slump sale transaction. The consideration for the acquisition will range between Rs 55 crore and Rs 83 crore, determined at 12.2x of the adjusted EBITDA over a defined assessment period. The transaction will be executed through a Securities Subscription Cum Shareholders’ Agreement (SHA), backed by Metropolis Healthcare Limited. Upon completion, Metropolis Clinical Pathology will transition from a wholly owned subsidiary while continuing to be an integral part of the Metropolis Healthcare Group. Founded in 1984, Scientific Pathology is a well-established diagnostic brand in Agra, known for its quality, strong clinician relationships, and patient-centric approach. With three laboratories and eleven collection centres, including two NABL-accredited labs, Scientific Pathology is a market leader and was among the first automated laboratories in the region. With a strong B2C focus, 90% of its revenue is generated from walk-in patients. In FY24, the company recorded a turnover of Rs 26 crore. It also has a strong digital presence. ]]> https://biospectrumindia.com/news/92/25772/strand-life-sciences-launches-portal-to-help-doctors-with-rare-disease-diagnosis.html https://biospectrumindia.com/news/92/25772/strand-life-sciences-launches-portal-to-help-doctors-with-rare-disease-diagnosis.html Fri, 28 Feb 2025 00:00:00 +0530 On the occasion of Rare Disease Day on 28 Feb, Bengaluru-based Strand Life Sciences, a Reliance Industries subsidiary and leading genomics company, has launched the StrandOmics Portal to improve diagnosis of rare diseases. This new online portal gives clinicians quick and easy access to information on genetic variants, giving them a comprehensive view for each case. This means faster and more accurate diagnosis for patients. In addition to the portal, Strand Life Sciences will offer rare disease genetic testing at a reduced cost for patients from economically disadvantaged backgrounds, making these crucial tests more accessible. The StrandOmics Portal helps doctors by providing clear and quick genetic insights for better diagnosis; allowing doctors to independently review a broader set of genetic variants; and improving prenatal diagnosis through better collaboration between specialists. Dr Ramesh Hariharan, CEO & Co-Founder of Strand Life Sciences, said, “We will continue to innovate and invest in tools like the StrandOmics Portal to empower doctors in their fight against rare diseases.”   ]]> https://biospectrumindia.com/news/92/25705/crisprbits-develops-pathcrisp-for-early-detection-of-antibiotic-resistance-.html https://biospectrumindia.com/news/92/25705/crisprbits-develops-pathcrisp-for-early-detection-of-antibiotic-resistance-.html Thu, 20 Feb 2025 00:00:00 +0530 Bengaluru-based biotechnology startup CrisprBits has developed PathCrisp, a platform for CRISPR-based molecular diagnostics for early detection of antibiotic resistance in hospital-acquired infections. Antimicrobial resistance (AMR) is a critical global health challenge, requiring early and accurate detection of resistance markers in hospital-acquired infections, particularly in ICU settings. A recent analysis in The Lancet found that antimicrobial resistance (AMR) contributed to nearly 4.7 million deaths globally in 2021, with over a million directly caused by resistant infections. India alone has reported over a million AMR associated deaths in 2019. Carbapenems, a class of antibiotics, often serve as the last line of defense against multi-drug-resistant bacterial infections. However, New Delhi metallo-beta-lactamase (NDM) driven carbapenem resistance is a major concern in hospitals across India, contributing significantly to the antimicrobial resistance burden. This enzyme enables bacteria to break down carbapenems and other beta-lactam antibiotics, severely limiting treatment options and posing a significant challenge in clinical settings. CrisprBits' latest study, published in Nature Scientific Reports, showcases PathCrisp’s ability to detect carbapenem resistance in bacterial samples from patients. In the study, the PathCrisp platform was used to test the presence or absence of NDM in DNA isolated from 49 clinical bacterial samples. The data showed 100% concordance with other techniques used as the gold standard (PCR-Sanger sequencing) for the same. The study was a collaborative research between CrisprBits, with Sri Sathya Sai Institute of Higher learning, Puttaparthi, and Asoka University, NCR region.   Future R&D efforts will focus on adapting PathCrisp for low-resource settings by developing lyophilised reagents for room-temperature stability. Additionally, smart engineering approaches will be explored to create a multiplexed version, expanding its diagnostic capabilities. ]]> https://biospectrumindia.com/news/92/25699/leucine-rich-bio-expands-global-reach-with-new-partnership-in-brazil.html https://biospectrumindia.com/news/92/25699/leucine-rich-bio-expands-global-reach-with-new-partnership-in-brazil.html Wed, 19 Feb 2025 00:00:00 +0530 Bengaluru-based Leucine Rich Bio, South Asia’s first microbiome company, has announced a strategic partnership with Precision Diagnosticos, a leading diagnostics firm based in Brazil. This collaboration will bring BugSpeaks, Leucine Rich Bio’s flagship microbiome testing technology, to the Brazilian market, enhancing access to cutting-edge microbiome diagnostics and personalised health solutions across both regions. BugSpeaks is an advanced gut microbiome analysis tool designed to detect microbial imbalances that can contribute to conditions such as obesity, diabetes, and digestive disorders. Through this partnership, Precision Diagnosticos expertise and extensive distribution network will help expand the availability of microbiome testing in Brazil, empowering individuals to take proactive steps toward better health. In addition to expanding microbiome testing, the partnership will drive educational campaigns to raise awareness about gut health and its crucial role in overall well-being. Healthcare professionals will receive specialised training and resources to integrate microbiome testing into clinical practice, ensuring the technology’s widespread and effective use.     ]]> https://biospectrumindia.com/news/92/25703/first-in-india-academy-to-enhance-awareness-of-precision-diagnostics-in-cancer-care.html https://biospectrumindia.com/news/92/25703/first-in-india-academy-to-enhance-awareness-of-precision-diagnostics-in-cancer-care.html Wed, 19 Feb 2025 00:00:00 +0530 Zydus Lifesciences and Guardant Health have announced their support for the newly launched Liquid is Solid (LiS) Academy’s educational effort. Established and driven by leading oncologists, the LiS academy is an independent academic forum and a first-of-its-kind initiative in India, which is focused on increasing the awareness of precision medicine using liquid biopsies (minimally invasive blood-based tests) in transforming cancer care. With one in nine people likely to develop cancer in his or her lifetime in India1, cutting-edge diagnostic solutions can play a critical role in reducing the burden of cancer by helping clinicians to detect cancer early, monitor recurrence and identify targeted treatment strategies with a simple blood draw. "Our focus in oncology care is to help patients through a holistic approach right from accessing affordable therapies, to companion diagnostics, nutrition and counselling. The aim through LiS Academy is to support clinicians and bring in a greater understanding and awareness on precision oncology and enable better patient care." said Samir Desai, President, BU Biologics, Zydus Lifesciences Limited. "By fostering collaboration between clinicians, researchers, and industry leaders, we can accelerate the adoption of these life-saving technologies." "The launch of LiS Academy marks a pivotal step in bringing transformative cancer care to India. By empowering oncologists with the awareness of liquid biopsies, we can accelerate access to personalised treatment and improve outcomes for more patients across the cancer continuum in India," said Simranjit Singh, CEO of Guardant Health AMEA. "Structured programmes through the LiS Academy provide clinicians with a solid foundation in understanding and utilising liquid biopsy technologies," said Dr Nitesh Rohatgi, Senior Director Medical Oncology at Fortis Memorial Research Institute, Gurugram. "Peer mentoring also ensures that the learning goes beyond theoretical knowledge, empowering doctors to confidently integrate these innovations into their practice and improve patient outcomes.” ]]> https://biospectrumindia.com/news/92/25690/kerala-government-announces-first-ai-powered-screening-programme-for-chronic-eye-diseases.html https://biospectrumindia.com/news/92/25690/kerala-government-announces-first-ai-powered-screening-programme-for-chronic-eye-diseases.html Tue, 18 Feb 2025 00:00:00 +0530 The Government of Kerala, in collaboration with Remidio, a leader in artificial intelligence (AI)-driven ophthalmic screening solutions, has launched Nayanamritham 2.0, the world’s first government led AI-assisted chronic eye disease screening programme. This pioneering initiative leverages artificial intelligence to enhance early detection and streamline eye disease screening, making quality eye care more accessible and efficient across the state. Building on the success of Nayanamritham 1.0, which introduced diabetic retinopathy (DR) screening at Family Health Centers with expert interpretation by ophthalmologists at secondary and tertiary centres, Nayanamritham 2.0 takes a major leap forward. The new phase empowers optometrists with Remidio’s AI-enabled fundus cameras that instantly classify cases as referable or non-referable, ensuring faster diagnosis and timely referrals. In addition to DR, Nayanamritham 2.0 expands its scope to include screening for two major chronic eye diseases - Glaucoma and Age-related Macular Degeneration (AMD). The programme now extends across Community Health Centers, Taluk Hospitals, and District Hospitals, making comprehensive eye care available at all levels of the healthcare system. With Nayanamritham 2.0, Kerala is setting a global precedent for seamlessly integrating ophthalmic AI into clinical workflows, making screening programs more efficient, scalable, and cost-effective.   ]]> https://biospectrumindia.com/news/92/25675/iit-madras-centre-for-responsible-ai-teams-up-with-roche-diagnostics-for-rd.html https://biospectrumindia.com/news/92/25675/iit-madras-centre-for-responsible-ai-teams-up-with-roche-diagnostics-for-rd.html Fri, 14 Feb 2025 00:00:00 +0530 The Indian Institute of Technology Madras (IIT Madras) Centre for Responsible AI (CeRAI) is teaming up with Roche Diagnostics International Ltd, Switzerland, for collaboration in Research and Development (R&D). Roche is joining CeRAI as a Gold Consortium Member with a Memorandum of Understanding (MoU) signed between the two organisations.  CeRAI and Roche a global leader in in-vitro diagnostics and developer of digital health solutions, will engage in collaborative research activities in Analytics/ AI solutions as well as services for IVD diagnostics. Centre for Responsible AI (CeRAI) is a virtual interdisciplinary research centre at IIT Madras. The centre aims to pursue research in the domains of Ethical and Responsible AI and become the standard body in the country to recommend guidelines and policies to make deployable AI models/ systems more accountable, explainable and responsible. Speaking on ‘Responsible AI’, Prof. B Ravindran, Head, Centre for Responsible AI (CeRAI), IIT Madras, said, “Responsible development and deployment of AI systems requires close interaction between AI scientists and domain experts. Roche recognises this and has an active research program on ethical AI and data management. We look forward to working closely with their program in building more robust and ethical systems for AI in healthcare.” Manu Dev, Chapter Lead for IVD Analytics product domain, Roche Information Solutions said, “At Roche, we believe in the power of data. It helps healthcare providers and patients make informed decisions. The framework agreement with IIT Madras will enable us to collaborate on important research activities related to Analytics and AI in digital health solutions for in-vitro diagnostics. Sharing knowledge and expertise helps us get closer to a better healthcare system for all.” ]]> https://biospectrumindia.com/news/92/25640/nura-ai-health-screening-centre-in-bengaluru-to-expand-capacity.html https://biospectrumindia.com/news/92/25640/nura-ai-health-screening-centre-in-bengaluru-to-expand-capacity.html Wed, 05 Feb 2025 00:00:00 +0530 NURA AI Health Screening, a collaboration between Fujifilm Healthcare and Dr. Kutty’s Healthcare, recently celebrated the 4th anniversary of its Bengaluru facility. NURA aims to increase its capacity by 50%, enabling it to serve even more people every day. To further encourage the adoption of health screenings, NURA continues to run educational campaigns, social media initiatives, and on-ground activities, spreading awareness about the critical role of early diagnosis in saving lives. Since its inception, the centre has screened over 20,000 individuals, identifying critical health risks and saving more than 1,500 lives through the early detection of cancer and other lifestyle-driven diseases. NURA’s Bengaluru centre utilises REILI AI technology and Pixel Shine imaging with ultra-low-dose radiation to screen multiple organs, including the lungs, liver, kidneys, heart, pancreas, and bones, ensuring a comprehensive health assessment. Starting with 5 cancer parameters, the centre has now expanded its screening capabilities to include 10 cancer parameters, with plans for further advancements in the near future. ]]> https://biospectrumindia.com/news/92/25626/datar-cancer-genetics-launches-ai-driven-platform-providing-optimised-treatment-options-for-cancer-patients.html https://biospectrumindia.com/news/92/25626/datar-cancer-genetics-launches-ai-driven-platform-providing-optimised-treatment-options-for-cancer-patients.html Tue, 04 Feb 2025 00:00:00 +0530 Nashik-based Datar Cancer Genetics (DCG) has launched Exacta AI, a next generation multi-analyte artificial intelligence (AI)-driven platform providing optimised treatment options for cancer patients who have exhausted the standard options. It integrates a 360° tumour work-up and AI assisted data analysis to decode complex tumour interactome data-including molecular (NGS: DNA+RNA), proteomic, genomic, functional, and clinical insights—providing personalised treatment options with thorough risk-benefit analysis. Exacta AI processes real-time wet lab data and integrates it with knowledge from multiple sources to assess drug synergy, interactions, toxicity, and contraindications for Anti-body Drug Conjugates (ADC)s, Checkpoint Inhibitors (CPIs), targeted therapies, endocrine agents, chemotherapy agents and repurposed drugs. It can recommend up to 10 evidence-based multi-drug treatment combinations for evaluation by oncologists or molecular tumour boards (MTBs), offering new hope where no standard of care exists for refractory / recurrent cancer patients. "What makes Exacta AI truly unique is its ability to think like an entire team of multi-disciplinary experts, all at once," explains Dr Vineet Datta, Senior Director – Global Strategy and Business Development, DCG. "The platform processes information the way a molecular biologist, cancer cell expert, pharmacologist, and clinical oncologist would do, only in minutes instead of several days. By applying rational scoring steps to analyze vast datasets, Exacta AI delivers highly refined interpretations, offering an unprecedented level of precision in generating treatment options." ]]> https://biospectrumindia.com/news/92/25618/centre-for-advanced-genomics-precision-medicine-opens-at-aiims-jammu.html https://biospectrumindia.com/news/92/25618/centre-for-advanced-genomics-precision-medicine-opens-at-aiims-jammu.html Mon, 03 Feb 2025 00:00:00 +0530 The Centre for Advanced Genomics & Precision Medicine recently opened at AIIMS Jammu, inaugurated by Dr Jitendra Singh, Union Minister of State (Independent Charge) for Science and Technology, Government of India. Set up in collaboration with Bengaluru-based startup 4baseCare, the Centre aims to usher in a new era of personalised medicine, leveraging cutting-edge genomic research to provide targeted treatment based on individual genetic profiles. By integrating genomic data with artificial intelligence (AI)-driven diagnostics, the centre aims to enhance early disease detection, optimise treatment strategies, and reduce the trial-and-error approach in medical prescriptions. This facility is intended to play a pivotal role in advancing precision oncology, cardiovascular genomics, and genetic screening for rare disorders. While personalised treatments have traditionally been costly, AIIMS Jammu aims to leverage indigenous research and government-backed biotech initiatives to bring down costs and integrate precision medicine into public healthcare programmes. The Minister highlighted initiatives like Ayushman Bharat, which has provided health coverage to millions, and the recently launched Bio-E3 policy, which focuses on biotechnology for economic growth, environmental sustainability, and employment generation. He stated that the government’s National Research Foundation (Anusandhan) will play a crucial role in funding next-generation research in genomics and personalised medicine. ]]> https://biospectrumindia.com/news/92/25623/ddrc-agilus-diagnostics-opens-advanced-reference-laboratory-and-wellness-centre-in-thiruvananthapuram.html https://biospectrumindia.com/news/92/25623/ddrc-agilus-diagnostics-opens-advanced-reference-laboratory-and-wellness-centre-in-thiruvananthapuram.html Mon, 03 Feb 2025 00:00:00 +0530 DDRC Agilus Diagnostics, a subsidiary of Agilus Diagnostics Limited, has announced the launch of its state-of-the-art regional wellness centre and 24x7 reference laboratory in Thiruvananthapuram, marking a significant milestone as the first reference laboratory in South Kerala. The advanced facility was inaugurated by Pooyam Thirunal Gouri Paarvathi Bayi Thampuratty, in the presence of distinguished guests V.K. Prasanth (MLA) and Kadakampally Surendran (MLA) from the Kerala Legislative Assembly. As part of the launch, Dr Anand K, Managing Director & CEO of Agilus Diagnostics, donated a Life Support Ambulance to the Department of Health Services, Kerala, underscoring the company's commitment to community welfare. The new wellness centre and laboratory, operating 24x7, will cater to the growing healthcare needs of the region, providing access to an extensive test menu of 3,600+ diagnostic tests and a variety of preventive healthcare packages. The facility has the capacity to process over two lakh samples per month, covering routine, semi-specialised, and high-end specialised tests. Spanning over 18,000 square feet, the facility houses multiple specialised laboratory divisions, including: Haematology, Biochemistry, Clinical Pathology, Immunology, Histopathology, Immunohistochemistry, Molecular Genetics, Cytogenetics, and Microbiology. A comprehensive radiology suite featuring Ultrasound, Audiometry, Ophthalmology, Digital Radiography, ECG, TMT, Spirometry, and Executive Medical Checkups. The new facility will cater to various districts including Trivandrum city, Nemom, Balaramapuram, Neyyattinkara, Vizhinjam, Kazhakoottam, Nedumangadu, Attingal , Chirayinkeezhu, Varkala, Kollam, Nagercoil and Kanyakumari.   ]]> https://biospectrumindia.com/news/92/25624/metropolis-healthcare-roche-introduce-hpv-dna-testing-to-accelerate-cervical-cancer-screening-.html https://biospectrumindia.com/news/92/25624/metropolis-healthcare-roche-introduce-hpv-dna-testing-to-accelerate-cervical-cancer-screening-.html Mon, 03 Feb 2025 00:00:00 +0530 Metropolis Healthcare has announced its collaboration with Roche Diagnostics India and Neighbouring Markets to introduce the self-sampling human papillomavirus (HPV) DNA test for cervical cancer screening. The launch of this test aims to expand access to cervical cancer screening across India by addressing social and economic barriers, making early detection more convenient for women, including those in Tier 2, Tier 3, and Tier 4 towns. Cervical cancer is preventable and yet, India contributes to 21% of the world’s total cases of cervical cancer. Currently, it accounts for nearly 79,000 deaths among Indian women each year, which is roughly two thirds of diagnosed cases. This indicates late-stage intervention which can be avoided by taking precautionary measures such as early screening. The HPV DNA test, recognised by the World Health Organization (WHO) as a first-choice screening method for cervical cancer prevention, can help bridge the gap. This cutting-edge test detects 14 high-risk HPV types in a single tube and is a clinically validated, FDA-approved, and WHO-prequalified solution. It ensures reliable and accurate diagnosis, paving the way for early intervention and better outcomes. The self-sampling HPV DNA test empowers women to take control of their health by enabling them to self-collect their samples for testing comfortably and easily. It addresses significant barriers such as stigma, discomfort, and limited access to healthcare facilities. Commenting on the launch, Surendran Chemmenkotil, Chief Executive Officer, Metropolis Healthcare said, “Cervical cancer remains a major health challenge for Indian women, despite being preventable through early screening and vaccination. By introducing advanced screening tools like the HPV DNA test, in collaboration with Roche Diagnostics India, we aim to expand access to early detection across the country." “Our cobas HPV DNA test provides women with a solution that allows them to overcome the potential embarrassment and discomfort that some may feel about undergoing cervical cancer screening process. I am confident that Metropolis Healthcare’s vast and established laboratory footprint will allow India to adopt cervical cancer screening at a large scale, especially in underserved areas”, said Rishubh Gupta, Managing Director, Roche Diagnostics India and Neighbouring Markets.   ]]> https://biospectrumindia.com/views/92/25595/remote-diagnostics-greatly-influence-accessibility-and-quality-of-healthcare.html https://biospectrumindia.com/views/92/25595/remote-diagnostics-greatly-influence-accessibility-and-quality-of-healthcare.html Sat, 01 Feb 2025 00:00:00 +0530 The diagnostics industry in India is growing rapidly, driven by growing healthcare awareness, an increasing prevalence of chronic diseases and lifestyle disorders, and advancements in technology. It encompasses pathology labs, imaging centres, and specialised diagnostic services - all of which contribute significantly to the healthcare sector. Key trends in this area include the adoption of digital diagnostics, AI-powered tools, point-of-care testing, and a surge in home-based diagnostic services and telemedicine. Despite regulatory hurdles and infrastructure gaps, the Indian diagnostics market is poised for substantial growth, improving accessibility and quality of healthcare across the country. Recent technology developments, particularly in remote diagnostics, have significantly altered the healthcare landscape. These allow medical professionals to reach patients in even the most remote areas using digital tools and telecommunication technologies to deliver diagnostic services. Remote diagnostics will have a significant impact on healthcare accessibility and quality, but there are certain issues that need to be addressed to ensure widespread adoption.   Impact of Remote Diagnostics on Healthcare Accessibility One of the most significant benefits of remote diagnostics is improving accessibility of healthcare services to the underserved and vulnerable populations such as elderly people, immobile, disabled individuals, and residents of less economically developed areas. In many rural and remote regions of India, people have limited access to healthcare and specialised doctors. Distant diagnostics bridges the gap by providing patients with timely diagnostic services, eliminating the need to travel long distances in emergent situations. For instance, telemedicine platforms, driven by strong internet connectivity, can enable patients to consult healthcare professionals on video calls. Real-time transmission of medical images to a trained pathologist or radiologist, and of the test results back to the patient and the doctor is made possible through remote diagnostic tools. This accelerates the diagnostic process and reduces the burden on healthcare facilities, enabling them to allocate resources more effectively.   Enhancing Quality of Care In addition to accessibility, remote diagnostics may facilitate quality-of-care provision to patients. Through their application of AI and machine learning (ML), remote diagnostic tools become more accurate and efficient in data interpretation, leading to faster and more precise diagnoses. This proactive approach not only improves patient outcomes but also reduces the chance of complications from delayed diagnoses. Additionally, remote diagnostics facilitate real-time monitoring of chronic care patients. The continuous supervision has led to timely interventions and well-tailored plans to manage the chronic condition of the patients, ultimately providing better health outcomes. Challenges to Widespread Adoption Despite the many promising benefits of remote diagnostics, several challenges must be addressed to ensure its adoption in the healthcare system: Regulatory Framework: Currently, there is no regulatory environment governing remote diagnostics. The absence of guidelines or an enabling framework keeps the benefits of remote diagnostic technologies away from  those  who need it the most.  The  current  guidelines  necessitate clear standards to ensure  safety,  and security of data, and the quality of services rendered to patients. Policymakers must  collaborate  with healthcare providers and technology companies to devise a holistic regulatory framework that balances fast-moving  tech with patient interests. Infrastructure and Connectivity: For remote diagnostics to be truly effective, a robust, well-designed technology infrastructure along with reliable internet connectivity, is crucial. To fully leverage digital healthcare solutions, significant expansion is necessary in underserved regions. Increased investment in telecommunications is essential to ensure access for everyone, regardless of their geographic location.  Data Security and Privacy: Data security and privacy concerns are  of paramount importance, as remote diagnostics include the sharing of confidential patient  information. Healthcare  providers must ensure that strong safeguards are in place to prevent  breaches or unauthorised access to patient data. Additionally, setting up a single  governing  body that regulates data security processes in the medical field would  significantly increase the patients' confidence in their healthcare providers. Training and Education: Healthcare workers must be properly trained in the use of digital tools and technologies for remote diagnostics to be successful. Programmes for ongoing education and training are crucial for giving healthcare professionals the know-how to successfully traverse the digital landscape and provide superior remote diagnostic services. Patient Awareness and Acceptance: Although there are many advantages to remote diagnostics, its effectiveness depends on patient acceptance and awareness. Education can be used to increase adoption, alleviate worries, and educate the patient on the benefits of remote diagnostics and the utilisation of such services.   Potential Solutions Telepathology: This allows pathologists to examine and even diagnose tissue samples remotely. This can significantly accelerate diagnoses in India, especially in resource-constrained areas. Initiatives like the National Digital Health Mission will be important enablers of data sharing and interoperability between healthcare facilities and help enable seamless telepathology services. AI-powered Imaging: AI algorithms can analyse medical images (X-rays, CT scans, MRIs) faster and better than humans resulting in quick and accurate medical diagnoses. This is crucial in areas with a shortage of radiologists. Therefore, using AI-based tools for remote diagnostics for image interpretation can significantly improve its quality and speed, particularly in underserved areas. Public-Private Partnerships: There is a strong need for collaboration between the government, private sector, and tech companies, if remote diagnostics is to be successfully implemented. Such partnerships can encourage infrastructure development, technology deployment, and training programmes for healthcare professionals. Focus on Patient-centred Care: The provision of remote diagnostics service should be driven by the patient’s needs. Availability of open communication channels, comprehensive patient education programmes, and effective ways of addressing patient concerns are essential for building trust in these technologies and ensuring their widespread adoption. By addressing these considerations and leveraging the power of technology, India can harness the potential of remote diagnostics to transform its healthcare landscape, improve access to quality care, and ultimately improve the health and well-being of its citizens.   Future Potential This unlocks immense future potential to improve the accessibility and quality of healthcare in a changing world of remote diagnostics. With such technologies cutting across geographies, patients shall have timely diagnostic services, ensuring healthy outcomes. However, for this to be possible, stakeholders must tackle the challenges facing widespread adoption. A supportive regulatory framework, and investments in infrastructure, data security, training, and patient education, will enable the environment to steer the growth of remote diagnostics. As we look to the future, embracing digital transformation in healthcare is essential to realising the goal of Universal Health Coverage and to making quality healthcare universally accessible regardless of location. The journey to a more inclusive and efficient health system has begun, and remote diagnostics will undoubtedly be one of its defining features.    Dhrubaa Ghosh, Partner, Healthcare, Management Consulting, BDO India   Disclaimer - The views, thoughts and opinions expressed in the article are solely the author’s and are not representative of the author's employer/ organisation. ]]> https://biospectrumindia.com/views/92/25592/lack-of-population-specific-genomic-data-is-a-significant-challenge-in-the-field-of-precision-oncology.html https://biospectrumindia.com/views/92/25592/lack-of-population-specific-genomic-data-is-a-significant-challenge-in-the-field-of-precision-oncology.html Fri, 31 Jan 2025 00:00:00 +0530 With Infosys investing in 4baseCare, how do you plan to leverage this partnership to scale your operations, enhance technological capabilities, and drive growth? At 4baseCare, we drive innovation through two core solutions: Genomics and Digital Health. Our Genomics solutions focus on leveraging advanced genomic testing to identify actionable insights for personalised cancer care, while our Digital Health solutions encompass a comprehensive ecosystem designed to support patients and clinicians alike. This includes everything from a patient-centric app that provides guidance throughout the cancer journey, to sophisticated tools that generate insights for predictive modeling, enabling personalised treatment strategies. Collaborating with Infosys, a global leader in IT and digital transformation, we are enhancing the digital backbone of 4baseCare. Their expertise enables us to build a data-driven decision platform and develop pioneering solutions like the Clinico-Genomic Digital Twin (CG Twin)—a revolutionary model that integrates clinical and genomic data to create predictive insights for tailored cancer care. Together, we are bridging the gap between data, technology, and precision oncology to empower patients and healthcare providers with innovative, impactful solutions.    Besides this recent partnership, what were some of the other major developments at 4baseCare in 2024? The year 2024 has been a year of tremendous growth and significant milestones. We raised $6 million in Series A funding led by Yali Capital, which enabled us to set up a genomics lab at Dubai Science Park in partnership with Innovate Life Sciences. We are also preparing to launch labs in the Philippines and Nepal.  We welcomed two industry leaders to our advisory board this year. Francis deSouza, former CEO of Illumina, and Lip-Bu Tan, Chairman of Walden International, to our advisory board. Their expertise in genomics and technology will play a critical role in our mission to make genomics accessible to all.   Looking ahead to 2025, what are your key goals and initiatives, particularly in terms of expansion, partnerships, and impact on the precision oncology sector, in India and Asia? Collaborating with hospitals, research institutions, and pharmaceutical companies in Nepal, Bangladesh, and the Philippines remains central to our growth strategy. We aim to strengthen partnerships both in India and globally to bring advanced precision oncology solutions to patients. In the next 1-2 years, we plan to launch educational initiatives such as workshops, webinars, and training programmes to support oncologists and clinicians in adopting genomic testing for cancer care. We also intend to expand our laboratory infrastructure, enhance bioinformatics platforms, and build a multidisciplinary team of experts in genomics, oncology, and data science. This will enable us to handle larger data and sample volumes while maintaining the highest standards of accuracy and quality. With Series A funding from Yali Capital and Infosys Innovation Fund and the guidance of our esteemed advisors, we are well-positioned to expand our reach, drive innovation, and make precision oncology accessible to more cancer patients.   Are you planning to launch new products/technologies in India or globally in 2025 or beyond? Please share details. Cancer is not a single disease- it is a collection of many diseases, each with its own unique complexities. Understanding cancer biology requires addressing the heterogeneity that makes it so intricate and challenging to treat. At 4baseCare, we believe that a comprehensive and holistic approach is essential to truly unravel the molecular pathways of cancer. This means going beyond traditional core biopsies (solid biopsy) to include insights from cellular evolution by profiling circulating tumor DNA -ctDNA (liquid biopsy). This innovative approach allows us to capture the dynamic nature of cancer, identifying genomic signatures that evolve over time and enabling precision care at every stage of the disease. We recently launched our solution SoLiQ—our cutting-edge liquid biopsy technology that integrates genomic insights from both tissue and circulating tumour DNA, paving the way for more informed, personalised treatment strategies. With SoLiQ, we are redefining how cancer is understood and managed, ensuring no aspect of its complexity is overlooked.   What are the current challenges facing the precision oncology market in India & neighbouring areas, and how are you addressing those? A significant challenge is the lack of population-specific genomic data. Much of the existing research and strategies are based on Western populations, which often fail to address the unique genomic diversity of Indian patients. Precision oncology in India is progressing but still lags behind Western nations.  Cancer is fundamentally a genomic disease making it essential to understand its molecular details to improve treatments and achieve better patient outcomes. Precision oncology, which integrates genomic biomarkers into the treatment paradigm, has rapidly emerged as a cornerstone of contemporary cancer care. However, the major challenge to Precision Oncology is that it is mostly based on genomics research and data on Caucasian population which puts our and other non-caucasian populations at a disadvantage.  4baseCare’s vision is to bridge this data gap and push towards more evidence and data backed treatment for cancer patients.   What are your views on the growth of genomics startups in India? What does the future look like?  Precision Oncology has seen steady adoption over the last decade and it is pretty clear that it is set to become a core part of cancer care in India over the next decade. Costs will decrease and more hospitals will adopt it. This change will be primarily driven by startups.  There will be easier access to targeted therapies and immunotherapies as more pharmaceutical companies enter the Indian market with cost-effective options. And with early detection becoming more common, we’ll be able to identify high-risk individuals before cancer develops, shifting from treatment to prevention.  Technological advancements like artificial intelligence (AI) and big data integration will enhance genetic profiling, allowing oncologists to make faster and more precise decisions. With increased attention to clinical trials, India has the potential to emerge as a hub for precision oncology research.   Vrushti Kothari (vrushti.kothari@mmactiv.com) ]]> https://biospectrumindia.com/news/92/25574/aiims-jammu-and-4basecare-sign-mou-to-launch-centre-for-advanced-genomics-and-precision-medicine.html https://biospectrumindia.com/news/92/25574/aiims-jammu-and-4basecare-sign-mou-to-launch-centre-for-advanced-genomics-and-precision-medicine.html Wed, 22 Jan 2025 00:00:00 +0530 AIIMS Jammu and Bengaluru-based startup 4baseCare have signed a Memorandum of Understanding (MoU) to launch the Centre for Advanced Genomics and Precision Medicine. This state-of-the-art facility will offer cutting-edge genomic technologies to transform patient care across diverse medical fields, including cancer, rare diseases, reproductive health, and public health.  The Centre for Advanced Genomics and Precision Medicine will focus on the following areas- Precision Oncology The centre aims to redefine cancer care by focusing on targeted, biomarker-driven therapies. This approach ensures personalized treatment plans that improve outcomes and enhance quality of life for cancer patients. Rare Diseases Rare diseases often pose diagnostic challenges, leaving patients and families searching for answers. Through advanced genomics, the centre is committed to unlocking these mysteries and providing actionable insights for some of the world’s rarest conditions. Reproductive Medicine (NIPT/PGS/PGD) By integrating early genetic insights into prenatal and fertility care, the centre is revolutionizing reproductive medicine. Technologies such as Non-Invasive Prenatal Testing (NIPT), Preimplantation Genetic Screening (PGS), and Preimplantation Genetic Diagnosis (PGD) are empowering families with knowledge and options for a healthier future. Public Health – COVID and Beyond: The pandemic highlighted the critical need for precision-driven technologies in public health. This centre will continue to empower public health initiatives by providing genomic solutions for current and future health challenges.   ]]> https://biospectrumindia.com/news/92/25553/erlysign-raises-rs-16-cr-in-pre-series-a-funding-round-to-launch-oral-cancer-detection-kit.html https://biospectrumindia.com/news/92/25553/erlysign-raises-rs-16-cr-in-pre-series-a-funding-round-to-launch-oral-cancer-detection-kit.html Fri, 17 Jan 2025 00:00:00 +0530 Mumbai-based startup CURO Biosciences Private Limited, also known as ErlySign, has secured Rs 16 crore in pre-Series A funding from renowned investor Ashish Kacholia. This significant funding milestone is a testament to the company’s revolutionary approach to early cancer detection.   The investment, advised by DerivativeSaint, a boutique private equity and venture capital advisory firm, marks a pivotal moment for CURO Biosciences. The company is poised to disrupt the global diagnostics market, which is projected to reach $250 billion by 2030.   At the core of ErlySign’s innovation is a biomarker-based test kit capable of detecting oral precancerous conditions within just 15 minutes using a simple, non-invasive saliva sample. This groundbreaking solution addresses the limitations of current diagnostic methods, which are often painful, time-consuming, and expensive. ErlySign's test kit promises a painless, affordable, and immediate alternative for early cancer detection, offering hope for timely intervention and improved survival rates.   The company’s technology has achieved key milestones, including securing an Indian patent in 2022 and a US patent in 2023, underscoring its pioneering role in cancer diagnostics.   Speaking about the progress, Shubhendra Singh Thakur, CEO and Founder of ErlySign, said, “Our initial studies revealed exceptional results, achieving 100% specificity and 98.04% sensitivity. The product, now in the final stages of clinical trials across multiple HCG sites, promises to be a game-changer. Beyond early detection, it will serve as a critical screening tool to eliminate unnecessary biopsies and invasive procedures.”   The funding will be instrumental in finalising clinical trials, securing CDSCO approvals, and bringing ErlySign’s oral cancer detection kit to market. Additionally, it will support research and development, team expansion, and further patent filings.   Looking ahead, ErlySign has ambitious plans to leverage CRISPR miRNA-based testing technology to detect multiple types of cancer using the same saliva sample within 15–20 minutes. ]]> https://biospectrumindia.com/news/92/25522/brainsightai-raises-5-m-in-pre-series-a-funding-round-to-expand-presence-in-india-.html https://biospectrumindia.com/news/92/25522/brainsightai-raises-5-m-in-pre-series-a-funding-round-to-expand-presence-in-india-.html Wed, 08 Jan 2025 00:00:00 +0530 BrainSight AI, a Bengaluru-based deep-tech neuroscience startup, has raised Pre-series A funding with $5 million led by IAN Alpha Fund, with participation from IvyCap Ventures, Silver Needle, apart from existing investors. The funding is a significant milestone in BrainSightAI’s mission to revolutionise the diagnosis and treatment of complex brain disorders through its innovative neuroinformatics platform, VoxelBox. Currently, BrainSightAI collaborates with over 40 leading hospitals across India, particularly in neurosurgery and radiology departments, focusing on brain tumour cases. The company is now expanding its solutions to neurological and psychiatric disorders, paving the way for a more holistic approach to brain care. The funds from this round will be strategically utilised to expand BrainSightAI’s presence in India, increasing its reach in Tier 1 cities and extend to Tier 2 cities. The company also plans to pursue FDA certification, opening access to the US and allied markets. Additionally, the company is gearing up to explore opportunities in Africa and Southeast Asia, based on distributor interest. The funds will also support R&D for a caregiver-focused app, aimed at empowering families of patients with brain disorders. BrainSightAI is at the forefront of understanding how the physiology of the brain correlates to its functions by mapping macro-scale neural connections in the brain, to enable precise diagnosis and prognosis of neuro-oncological and neuropsychiatric disorders. Traditionally available only at leading global research institutions like Harvard and Stanford, the platform makes this cutting-edge technology accessible to hospitals and patients worldwide. ]]> https://biospectrumindia.com/news/92/25502/nura-plans-kerala-foray-to-launch-ai-driven-health-screening-centre-in-calicut.html https://biospectrumindia.com/news/92/25502/nura-plans-kerala-foray-to-launch-ai-driven-health-screening-centre-in-calicut.html Mon, 30 Dec 2024 00:00:00 +0530 NURA, an advanced diagnostic venture between Fujifilm Healthcare and Dr Kutty’s Healthcare, is all set to foray into Kerala by opening its artificial intelligence (AI)-driven Health Screening Facility in Calicut (Kozhikode). The facility was inaugurated by Kerala CM Pinarayi Vijayan in the presence of Teiichi Goto –President Fujifilm, V Abdurahiman, Ayisha Kutti. The debut in Kerala marks a significant milestone in NURA’s endeavour to provide early detection and comprehensive health screening services to the people of India. This Calicut centre is not just a screening facility, but it is a global training centre an experiential hub where people can experience the advantages of cutting-edge healthcare technologies, which NURA will be expanding globally. With this centre NURA aims its presence across the country and to strengthen its position as a global leader in the preventive healthcare market. The Calicut centre is designed to screen up to 50 people a day, offering world-class screening test experience with advanced technology, to facilitate faster and accurate detection of diseases at very early stages.  Currently, the centre offers Cancer and Metabolic syndrome screening but Locomotive syndrome screening and treatment plan for aging society will come up soon. In addition, NURA has an ambitious expansion plan, eyeing new centres in Chennai, Pune, Ahmedabad and other major Indian cities by the next year. By 2030, NURA envisions a network of 100 centers globally, making preventive healthcare accessible worldwide About NURA’s Kerala debut, Pinarayi Vijayan – Chief Minister – Kerala said “We welcome NURA’s entry into Kerala as the state has a dearth of advanced yet affordable screening facilities. The demand for such services is increasing exponentially in the state as the state-funded health agencies are deficient in serving a large pool of patients."    NURA has been on an ambitious expansion journey, establishing centres in India, East Asia and in ASEAN countries, the Middle East, and Africa in 2024. With the recent launch of the Calicut centre, joining other facilities in Gurugram, Mumbai, Bengaluru, and Hyderabad, NURA continues to deliver health screenings in just 120 minutes, leveraging Fujifilm’s leadership in healthcare IT and advanced screening test technology to ensure accurate, efficient, and hassle-free results. ]]> https://biospectrumindia.com/news/92/25454/pangia-biotech-announces-landmark-partnership-agreement-for-first-liquid-biopsy-prostate-cancer-assay-in-india.html https://biospectrumindia.com/news/92/25454/pangia-biotech-announces-landmark-partnership-agreement-for-first-liquid-biopsy-prostate-cancer-assay-in-india.html Fri, 13 Dec 2024 00:00:00 +0530 PanGIA Biotech, a pioneer in liquid biopsy technology, has announced its first international partnership, collaborating with Canary Oncoceutics (Canary Oncoceutics, Inc., Phoenix, AZ, and Canary Oncoceutics India, Tamil Nadu). This collaboration introduces the PanGIA Prostate Assay, the world’s first artificial intelligence (AI)-integrated urine-based liquid biopsy for prostate cancer detection, marking its commercial debut in India. PanGIA Biotech is actively advancing its R&D pipeline, targeting ten additional cancers including lung, pancreatic, ovarian, and breast. The company is also focused on validating its multi-cancer assay and expanding its global impact through continued innovation, offering long-term growth potential for partners. "Launching our patented PanGIA Prostate Assay in India marks an important milestone for our company and healthcare innovation. This non-invasive, accurate, and culturally sensitive diagnostic tool is poised to enhance early prostate cancer detection and improve patient outcomes," said Holly Magliochetti, CEO of PanGIA Biotech. "Partnering with Canary Oncoceutics enables us to bring life-changing technology to a population in need, reinforcing our commitment to saving lives, changing lives, and giving back by advancing healthcare equity." The PanGIA platform is a transformative solution for detecting, monitoring, and managing diseases, including cancers as early as Stage 1. Powered by machine learning, this urine-based platform profiles biomolecular patterns to deliver accurate diagnostic insights. ]]> https://biospectrumindia.com/news/92/25459/cosara-diagnostics-inaugurates-new-oligo-facility-in-ranoli-gujarat.html https://biospectrumindia.com/news/92/25459/cosara-diagnostics-inaugurates-new-oligo-facility-in-ranoli-gujarat.html Fri, 13 Dec 2024 00:00:00 +0530 US-based Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, has announced the inauguration of CoSara Diagnostics's oligonucleotide synthesis facility in Ranoli, Gujarat. In support of the "Make in India" initiative, the new facility is designed to manufacture the company's patented Co-Primers chemistry, which underpins Co-Dx's and CoSara's lab-based PCR diagnostic tests and which powers the test cups for the new Co-Dx PCR at-home and point-of-care testing platform. Qualifying under this initiative is anticipated to facilitate access to India's large and robust healthcare marketplace. "We are greatly pleased with the results of this growth stage as we look towards the future, which is expected to include additional facility expansion for manufacturing the Co-Dx PCR Pro instrument and the test cups for illnesses like TB, HPV and more, as we scale to meet the needs of the most populous country in the world," remarked Mohal Sarabhai, CEO of CoSara, the joint venture between Ambalal Sarabhai Enterprises Limited (ASE group) and Co-Diagnostics, Inc. "India is home to some of the world's best and brightest scientists, researchers and medical professionals who we believe will recognise the value of the Co-Primers PCR technology and of the forthcoming testing platform." Co-Diagnostics' CEO Dwight Egan added, "The new facility and the grantors who helped to fund it provide tangible evidence of the Company's foresight that partnering with Synbiotics Ltd. (an ASE group company) in 2017 to form CoSara would help lay the groundwork for introducing state-of-the-art Co-Dx technology to India's high-tech healthcare marketplace. We believe that synthesising Co-Primers in-house will play a vital role in enhancing manufacturing efficiency and removing barriers as we move towards regulatory approval and commercialisation of our new PCR testing platform in India."   ]]> https://biospectrumindia.com/news/92/25424/strand-life-sciences-launches-blood-based-test-for-early-detection-of-multiple-cancers.html https://biospectrumindia.com/news/92/25424/strand-life-sciences-launches-blood-based-test-for-early-detection-of-multiple-cancers.html Mon, 02 Dec 2024 00:00:00 +0530 Bengaluru-based genomics and bioinformatics company Strand Life Sciences, a subsidiary of Reliance Industries Limited, has launched a novel blood-based test for early detection of multiple cancers. Called CancerSpot, the test uses the latest globally accepted methylation profiling technology to identify cancer tumor DNA fragments. CancerSpot works off a simple blood sample and uses a proprietary genome sequencing and analysis process to identify DNA methylation signatures of cancer in the blood. CancerSpot’s signatures, derived from Indian cohorts, have been shown to be robust and applicable across global ethnicities. The test provides a simple and convenient option for proactive and routine cancer screening. Isha Ambani Piramal, Member of the Board, Reliance Industries Limited, said, "Reliance is committed to pioneering breakthroughs that reshape the future of medicine in service of humanity. Cancer in India is emerging as a major cause of morbidity and mortality.  It is a source of heavy financial, social and psychological burden on patients, families and communities. Therefore, Strand’s novel cancer early detection test exemplifies our vision of delivering transformative healthcare solutions." Speaking at the grand opening of Strand’s new state-of-the-art Genomics Diagnostics & Research Centre in Bengaluru, company CEO and Co-Founder Dr Ramesh Hariharan said, “Early warning is the key to battle cancer ─ and win it.  We are proud to launch an accessible early cancer detection test that will enable people to stay ahead of cancer. Over our 24-year history, Strand has been a pioneer in genomics, and this is another FIRST for India resulting from a rigorous multi-year research study.” He further added, “This new Genomics Diagnostics & Research Centre will drive the CancerSpot program and accelerate efforts to develop new solutions, support research efforts, and deliver novel life-saving diagnostics for both Indian and global populations.” The Genomics Diagnostics & Research Center was inaugurated today by Dr Charles Cantor, a global expert in genomics and biophysical chemistry, and previously Professor at Columbia University, UC Berkeley, and Boston University, in the presence of other luminaries in the field of genomics. This 33,000 square feet facility comprises a cutting-edge genomics laboratory with the latest sequencing technologies and workflows designed to foster collaboration among bioinformatics experts, molecular biologists, and clinical teams. ]]> https://biospectrumindia.com/news/92/25426/icmr-licenses-enviro-q-pcr-kit-to-molbio-diagnostics-for-enteric-virus-detection.html https://biospectrumindia.com/news/92/25426/icmr-licenses-enviro-q-pcr-kit-to-molbio-diagnostics-for-enteric-virus-detection.html Mon, 02 Dec 2024 00:00:00 +0530 The Indian Council of Medical Research (ICMR) has signed a technology transfer agreement with Molbio Diagnostics., licensing the commercialisation of EnViro-Q, India’s first multiplex real-time RT-PCR assay for detecting enteric viruses. Developed by ICMR-National Institute for Research in Bacterial Infections (NIRBI), Kolkata, this breakthrough diagnostic tool addresses a critical gap in managing viral gastroenteritis in children. Through this collaboration, Molbio Diagnostics aims to make EnViro-Q accessible worldwide, particularly in public health sectors, under a revenue-sharing model with ICMR. EnViro-Q will be made available at a cost-effective price, particularly for the public sector. As one of the leading causes of childhood mortality, viral gastroenteritis has posed persistent diagnostic challenges. Existing methods often misidentify viral infections as bacterial, leading to the irrational use of antibiotics. EnViro-Q, with comparable sensitivity and specificity to commercial imported assays, offers reliable results within 2-2.5 hours, ensuring timely diagnosis and treatment. By providing an effective method to detect co-infections and prevent repeated testing, EnViro-Q is poised to greatly enhance diagnostic capabilities in primary healthcare settings. ]]> https://biospectrumindia.com/news/92/25416/mahajan-imaging-and-labs-launches-ai-powered-lab-in-gurugram.html https://biospectrumindia.com/news/92/25416/mahajan-imaging-and-labs-launches-ai-powered-lab-in-gurugram.html Fri, 29 Nov 2024 00:00:00 +0530 Mahajan Imaging & Labs has announced its expansion into Gurugram with a new, fully-equipped lab and Home Collection services. This facility will bring enhanced multi-testing capabilities powered by artificial intelligence (AI) to the Gurugram region and beyond, ensuring greater accessibility and faster turnaround times for patients. The new lab is capable of processing thousand tests and offers cutting-edge diagnostic services with advanced systems designed for seamless, AI-driven analysis. This expansion reaffirms Mahajan Imaging & Labs’ commitment to providing high-quality healthcare, addressing community needs, and supporting healthcare providers across the region. Mahajan Imaging & Labs' Siemens' AI-Enhanced Multi-Testing Diagnostic System delivers faster, highly accurate results from a single vial, analyzing up to 206 parameters. Ideal for low-volume samples, especially in paediatric and complex cases, it reduces wait times drastically. Capable of performing complex diagnostics like preeclampsia screening with high precision, this system sets a new benchmark for patient comfort and rapid diagnostics in urgent care. The lab located on the ground floor of the Times Sqaure Building in downtown Sushant Lok , also boasts of highly qualified and trained phlebotomists who are able to cover all areas of Gurugram. This patient-centric approach allows individuals to book sample collections from the comfort of their homes, ensuring a seamless, hassle-free experience while maintaining the highest standards of accuracy and hygiene. The lab provides all services under one roof and is also fully equipped to cater to individuals who wish to come to the lab and get tests done.   ]]> https://biospectrumindia.com/news/92/25359/molbio-diagnostics-makes-30-m-investment-in-optrascan-to-advance-digital-pathology.html https://biospectrumindia.com/news/92/25359/molbio-diagnostics-makes-30-m-investment-in-optrascan-to-advance-digital-pathology.html Fri, 15 Nov 2024 00:00:00 +0530 Molbio Diagnostics, a molecular diagnostics solutions company, has announced its investment of $30 million in OptraSCAN, a San Jose-based global diagnostics company. This strategic partnership underscores Molbio's commitment to democratising healthcare by making advanced diagnostics accessible to underserved communities and healthcare providers worldwide. It enables OptraSCAN to accelerate the development and accessibility of digital pathology solutions powered by artificial intelligence. These solutions, which include cloud-based systems for slide scanning, image analysis, and secure data storage, aim to facilitate faster, more accurate diagnoses. This initiative aligns with Molbio's goal of providing advanced diagnostics to every healthcare provider, regardless of location or resource limitations. OptraSCAN's solutions are designed for various healthcare environments, from small laboratories to large medical facilities. With this partnership, OptraSCAN can expand its product portfolio and increase availability, making life-saving diagnostic technology accessible to facilities in rural and under-resourced regions in India. In addition to improved access to diagnostic tools, this collaboration will support AI-driven pathology solutions that aim to empower healthcare professionals to diagnose diseases more efficiently, leading to better patient outcomes. The strategic investment will further OptraSCAN's research and development, strengthen its global presence, and bring quality diagnostics to regions historically lacking access to advanced healthcare technology.   ]]> https://biospectrumindia.com/news/92/25288/boston-scientific-launches-avvigo-multi-modality-guidance-system-in-india.html https://biospectrumindia.com/news/92/25288/boston-scientific-launches-avvigo-multi-modality-guidance-system-in-india.html Wed, 23 Oct 2024 00:00:00 +0530 In line with its mission to transform the lives of patients around the world through innovative medical solutions, Boston Scientific Corporation announced the launch of AVVIGO™+ Multi-Modality Guidance System, a next-generation intravascular ultrasound (IVUS) and fractional flow reserve (FFR) system with advanced software and hardware features designed to provide high-quality IVUS vessel imaging and physiology experience during percutaneous coronary intervention (PCI) procedures.  Key features of the AVVIGO™+ system include:  Automates key procedural steps and provides precise vessel measurements through the use of artificial intelligence software called Automated Lesion Assessment. It is the first IVUS system that is AI enabled. Reduces procedure time significantly by acquiring IVUS images at a faster speed.  Provides enhanced guidance by drawing a physiology graph that helps to provide a roadmap to treat the diseased coronary artery. We are pleased to introduce physicians in India to the next generation AVVIGO™+ Multi-Modality Guidance System which provides fast, intuitive, and accurate vessel and lesion assessment capabilities for percutaneous coronary interventions,” said Madan R. Krishnan, vice president and managing director, India Subcontinent, Boston Scientific. “We believe this enhanced and automated tool will help them optimize these procedures to provide better outcomes for their patients with coronary artery disease. The fractional flow reserve (FFR) technology enables the system to assess the severity of coronary artery blockages inside the coronary arteries. It is a minimally invasive procedure that measures and analyzes the severity of coronary artery stenosis, with the help of pressure sensors, by comparing blood flow and pressure in the coronary arteries with and without a blockage.[1] These parameters help physicians assess the significance of coronary artery disease and make informed decisions about treatment options. IVUS is a specialized diagnostic procedure that uses an ultrasound probe to create high-resolution images of the heart's structures and function from inside the heart. Unlike traditional echocardiograms that use sound waves to produce images from outside the body, IVUS involves inserting a thin catheter with an ultrasound probe directly into the heart. The AVVIGO™+ system received approval from the Central Drugs Standard Control Organization (CDSCO) in July 2024. Boston Scientific manufactures a wide variety of catheters for coronary, peripheral, and cardiac conditions. The recommended use of each of these catheters may vary depending on the location of the disease. ]]> https://biospectrumindia.com/news/92/25285/redcliffe-labs-expands-its-network-in-gujarat-offering-quality-diagnostics-in-surat-and-vadodara.html https://biospectrumindia.com/news/92/25285/redcliffe-labs-expands-its-network-in-gujarat-offering-quality-diagnostics-in-surat-and-vadodara.html Tue, 22 Oct 2024 00:00:00 +0530 Redcliffe Labs, a purpose-driven PAN India omnichannel diagnostics service provider, has expanded its footprint in Gujarat with two more state-of-the-art diagnostic laboratories in Surat and Vadodara. The company now operates with a network of 3 laboratories and 30 collection centers across the state, and the latest expansion reinforces Redcliffe's commitment to Giving India its Right to Quality Diagnostics. Aligned with Redcliffe Labs’ strategic goal to extend its reach into Tier II and Tier III cities and beyond, this expansion ensures that accurate and reliable diagnostic services are not restricted to metropolitan regions but accessible to communities across the entire geography of Bharat. These advanced facilities are well-equipped with the latest diagnostic technology, enabling accurate reports within the minimum possible turnaround time. This development underlines Redcliffe Labs’ dedication to enhancing healthcare accessibility, considering the increasing demand for reliable and timely diagnostic services. Redcliffe Labs offers over 3,600 routine and specialized tests, covering a broad spectrum of diagnostic categories such as advanced pathology, biochemistry, hematology, immunoassays, histopathology, clinical pathology, cytopathology, molecular/genomic testing, hormones, microbiology, and infectious disease serology. The Vadodara lab, situated near Samruddhi Trade Centre in Kendranagar, will be operating under the leadership of seasoned consultant pathologist Shah Jigar Kiritkumar, with over 12 years of experience offering quicker access to diagnostic services for nearby communities, including Pal Gam, Adajan, Vesu, Hazira, Gopi Talav, Utran, Bardoli, Palsana, Kamrej, and Ichchhpur.  In Surat, the lab will be managed by Tejal Keyur Bhatt, Zonal Laboratory Head - West, who brings over eight years of industry expertise. Located at the Zenon Complex near Unique Hospital, it will efficiently serve residents surrounding Surat's Ring Road, Alkapuri, Bhayli, Manjalpur, Karelibaug, Gorwa, Vemali, Sardar Nagar, Akota, Harni, and Tarsali.  Dr. Geetanjali Gupta, Director-Technical Operations and Quality Assurance at Redcliffe Labs, said, “The opening of our two advanced diagnostic centers in Surat and Vadodara marks a key milestone in our journey to make high-quality diagnostic services accessible to everyone, surpassing all geographical limitations. We aim to provide timely, accurate, and reliable diagnostics to individuals in every corner of the country to drive better health outcomes across Bharat.  Redcliffe Labs maintains exceptional quality standards by strictly following NABL and ISO protocols, utilizing six-sigma methodologies, and performing more than 50 regular stringent quality checks across its diagnostic network.Furthermore, Redcliffe Labs’ temperature-controlled technology safeguards sample integrity, whether patients visit the lab in person or opt for the convenience of home sample collection through the app, website, or WhatsApp. ]]> https://biospectrumindia.com/news/92/25278/pathkind-diagnostics-expands-autoimmunity-testing-with-innovative-alegria-monotest-technology.html https://biospectrumindia.com/news/92/25278/pathkind-diagnostics-expands-autoimmunity-testing-with-innovative-alegria-monotest-technology.html Fri, 18 Oct 2024 00:00:00 +0530 Autoimmune diseases, which affect millions worldwide, often require complex diagnostic processes that can delay treatment and adversely affect patient outcomes. The partnership between Gurugram-based Pathkind Diagnostics and Sebia seeks to streamline this process, providing healthcare professionals with an efficient, user-friendly diagnostic tool that enhances patient care. By integrating this cutting-edge technology into Pathkind’s network, Pathkind aims to make advanced autoimmune disease diagnostics more accessible and efficient. Sebia’s Alegria system uses a monostrip format that simplifies the testing process while maintaining high accuracy and precision. This streamlined approach not only reduces the burden on laboratory resources but also empowers healthcare professionals to provide timely interventions. Alegria is a cutting-edge sample-to-result solution for autoimmunity that revolutionises diagnostics for Rheumatology, Thrombosis, ANCA & Vasculitis, Gastroenterology, Thyroid, and Stool testing. Each Alegria Monotest strip includes the complete set of reagents that are needed to perform the analysis for one individual patient result. Each test result is validated with its own integrated control for the highest reliability and quality in the lab. Post-COVID, India has seen a significant rise in autoimmune disorders, affecting millions of lives and creating an urgent need for advanced diagnostic solutions. These complex conditions often go undiagnosed or misdiagnosed, leading to delayed treatment and worsening patient outcomes. The introduction of Alegria Monotest technology aims to address this growing health crisis by offering precise, rapid, and reliable autoimmune testing, enabling earlier diagnosis and better patient care across the country.  ]]> https://biospectrumindia.com/news/92/25264/haystackanalytics-unveils-worlds-first-comprehensive-diagnostic-test-to-detect-bacterial-fungal-and-respiratory-rna-viruses.html https://biospectrumindia.com/news/92/25264/haystackanalytics-unveils-worlds-first-comprehensive-diagnostic-test-to-detect-bacterial-fungal-and-respiratory-rna-viruses.html Tue, 15 Oct 2024 00:00:00 +0530 Mumbai-based startup HaystackAnalytics has announced a significant milestone in precision medicine by expanding its infexn™ test using Next Generation Sequencing (NGS). The existing infexn™ test using NGS which has been in use for the comprehensive detection of bacteria, fungi and antimicrobial resistance (AMR) in a single test, has now been upgraded to also detect respiratory RNA viruses. Thus, by testing respiratory samples, such as VTM, BAL, etc. using the infexn™ NGS test, clinicians are further enabled towards antimicrobial stewardship (AMSP), wherein they may not choose a specific test for a specific suspected infection. Instead a single infexn™ - NGS test can screen for major RNA viruses, all bacterial and fungal human pathogens, and AMR. While there are very few well established antiviral treatment options, clinicians worldwide can make safer choices when supported by comprehensive diagnostic methods. The expansion of the scope of the infexn™ test using NGS, to include the detection of major respiratory RNA viruses, is a step in this direction of hypothesis free, universal infectious diseases testing paradigm. The next-generation sequencing test, infexn™, developed by HaystackAnalytics, is a genomics-based test capable of detecting pan-bacterial, pan-fungal, and now respiratory viral infections, along with identifying relevant rare and difficult-to-culture organisms, all within 24 hours. Developed in India and designed for global application, infexn™ using  NGS  emerges as the preferred test for detecting deadly infectious diseases. It holds the potential to promptly identify infections, empowering the healthcare ecosystem with advanced diagnostics to provide a customised care regime for patients. In the myriad of emerging infectious agents, infexn™ using NGS has now evolved into a versatile diagnostic tool for doctors. ]]> https://biospectrumindia.com/news/92/25260/city-imaging-clinical-labs-to-expand-services-to-50-hospitals-in-north-india-by-march-2027.html https://biospectrumindia.com/news/92/25260/city-imaging-clinical-labs-to-expand-services-to-50-hospitals-in-north-india-by-march-2027.html Mon, 14 Oct 2024 00:00:00 +0530 Delhi-based City Imaging & Clinical Labs, one of India's premier diagnostic chains, is set to make a profound impact on hospital laboratory management by expanding its services across North India. The company is currently associated with 10 hospitals, providing comprehensive lab management services, including 24/7 in-house phlebotomy and lab testing. Several of these labs are NABL accredited, ensuring the highest standards of care and diagnostics. City Imaging & Clinical Labs has ambitious plans to grow its network, offering world-class laboratory services to hospitals with 50 or more beds. The goal is to extend its footprint across North India over the next five years, supported by cutting-edge technology, a dedicated corporate quality assurance (CQA) team, highly experienced Pathologists, and an advanced Laboratory Information Management System (LIMS). "Our initiative will transform how hospital labs are managed in India. From existing numbers of Hospital Labs, we plan to offer the services to over 50 hospitals with 50 beds and above across north India by March 2027. In the next five years, we would take it to over 50 Hospitals. With our expertise, hospitals will be better equipped to deliver superior patient care and identify critical conditions before they become life-threatening," said Dr Aakaar Kapoor, CEO of City Imaging & Clinical Labs. The expansion of these services will provide hospitals with the tools and expertise needed to detect and treat conditions before they escalate, thus improving patient outcomes and saving lives. Further, it would ensure that the clinical team can focus on clinical work without having to bother about diagnostic services.   ]]> https://biospectrumindia.com/news/92/25235/agilus-diagnostics-unveils-pharmacogenomics-testing-service.html https://biospectrumindia.com/news/92/25235/agilus-diagnostics-unveils-pharmacogenomics-testing-service.html Mon, 07 Oct 2024 00:00:00 +0530 In a ground-breaking move that promises to transform patient care across the nation, Agilus Diagnostics has announced the launch of its Pharmacogenomics Testing Service. This innovative service empowers healthcare providers and patients with vital insights into how individual genetic profiles influence medication effectiveness and safety, paving the way for a more personalised approach to treatment. Commenting on the initiative, Dr Anand K, Managing Director & CEO of Agilus Diagnostics said, “With the increasing prevalence of diseases such as cancer, cardiovascular disorders and diabetes, our new service harnesses state-of-the-art genome sequencing technologies to provide tailored treatment strategies that can significantly enhance patient outcomes.” As we continue to explore the genetic underpinnings of psychiatric disorders and treatment responses, pharmacogenomics stands at the forefront of a new era in psychiatry. This approach holds the promise of not only better patient outcomes but also a more nuanced and individualized understanding of mental health. With its ability to guide medication selection and dosing, pharmacogenomics is paving the way for a future in which psychiatric care is more effective, efficient, and personalised than ever before. Agilus’ comprehensive pharmacogenomics panel based on whole exome sequencing covers 59 PGx genes and 194 drugs. It also covers 32 genes associated with clinical annotations & dosing guidelines. The reporting is based as per the standard dosing guidelines, which incorporates 191 CPIC, 108 DPWG and many others. The drug genomics panel includes 17 speciality, like cancer, cardiovascular disorders, depression, neurology, gastroenterology, paediatrics, endocrinology and immunosuppressant medications etc. ]]> https://biospectrumindia.com/news/92/25227/who-approves-first-mpox-diagnostic-test-by-abbott-for-emergency-use-.html https://biospectrumindia.com/news/92/25227/who-approves-first-mpox-diagnostic-test-by-abbott-for-emergency-use-.html Fri, 04 Oct 2024 00:00:00 +0530 The World Health Organisation (WHO) has listed the first mpox in vitro diagnostic (IVD) under its Emergency Use Listing (EUL) procedure, an important step in improving global access to mpox testing. The approval for emergency use of the Alinity m MPXV assay, manufactured by Abbott Molecular Inc., will be pivotal in expanding diagnostic capacity in countries facing mpox outbreaks, where the need for quick and accurate testing has risen sharply. Early diagnosis of mpox enables timely treatment and care, and control of the virus. Limited testing capacity and delays in confirming mpox cases persist in Africa, contributing to the continued spread of the virus. In 2024, over 30, 000 suspected cases have been reported across the region, with the highest numbers in the Democratic Republic of the Congo, Burundi, and Nigeria. In the Democratic Republic of the Congo, only 37% of suspected cases have been tested this year. The presence of the monkeypox virus is confirmed by nucleic acid amplification testing (NAAT), such as real-time or conventional polymerase chain reaction (PCR), as stated in the WHO Interim Guidance on Diagnostic testing for the monkeypox virus (MPXV). And the recommended specimen type for diagnostic confirmation of monkeypox virus (MPXV) infection in suspected cases is lesion material. The Alinity m MPXV assay is a real-time PCR test that enables detection of monkeypox virus (clade I/II) DNA from human skin lesion swabs. It is specifically designed for use by trained clinical laboratory personnel who are proficient in PCR techniques and IVD procedures. By detecting DNA from pustular or vesicular rash samples, laboratory and health workers can confirm suspected mpox cases efficiently and effectively.   ]]> https://biospectrumindia.com/news/92/25219/krsnaa-diagnostics-medikabazaar-united-imaging-join-hands-to-revolutionise-advanced-diagnostics.html https://biospectrumindia.com/news/92/25219/krsnaa-diagnostics-medikabazaar-united-imaging-join-hands-to-revolutionise-advanced-diagnostics.html Mon, 30 Sep 2024 00:00:00 +0530 In a landmark move set to redefine the landscape of diagnostics in India, Pune-based Krsnaa Diagnostics has entered into a strategic partnership with Mumbai-based Medikabazaar and United Imaging. This collaboration is poised to disrupt the industry with a Rs 300+ crore investment, targeting the establishment of over 30+ cutting-edge imaging centres across tier-2 and tier-3 cities across India. This partnership, which is one of the largest of its kind in the Indian diagnostics space, brings together the best of technology and healthcare expertise to significantly enhance patient care and accessibility. Aiming to bridge the gap in diagnostics in small towns and semi-urban areas, the collaboration will provide increased focus on advanced radiology imaging solutions by reaching the communities most in need, thus enhancing overall patient care to the masses. The partnership will see the deployment of world-class advanced imaging technologies made available by Medikabazaar across Krsnaa’s extensive network of diagnostic centres, primarily focusing on semi-urban and rural areas. This initiative aligns with the shared vision of both organisations to bridge the existing gap in access to quality healthcare services, ensuring that even the most remote populations benefit from timely, accurate diagnostic testing.  With the establishment of these imaging centres, Krsnaa Diagnostics and Medikabazaar aim to address the growing demand for high-quality diagnostics in smaller towns and cities. The collaboration is set to complement ongoing Public-Private Partnership (PPP) projects across various locations Pan India. ]]> https://biospectrumindia.com/news/92/25196/twist-bioscience-teams-up-with-medgenome-to-diagnose-rare-diseases.html https://biospectrumindia.com/news/92/25196/twist-bioscience-teams-up-with-medgenome-to-diagnose-rare-diseases.html Thu, 26 Sep 2024 00:00:00 +0530 To address the rare disease burden in India, Bengaluru-based MedGenome is partnering with Twist Bioscience, a leading and rapidly growing synthetic biology and genomics company based in the US., to establish the HOPE for Rare Diseases Programme in India. Within the programme, discounted whole exome sequencing is provided to the patients from economically disadvantaged families (with necessary documentation) and is a time limited programme. This collaboration coincides with MedGenome’s commemoration of a decade of pioneering genomics advancements in India. With this partnership, MedGenome reaffirms its commitment to democratize access to quality and affordable genetic solutions for all sections of society. MedGenome will continue to be guided by its vision to enhance healthcare affordability and accessibility and focus on its mission to leverage genomics to address the huge unmet need across emerging markets. Twist Bioscience is deploying the Twist Exome 2.0 to support this mission. Designed to enable researchers to detect rare and inherited diseases, as well as germline cancers, supporting researchers and clinicians in their ability to collect quality data with less sequencing. The partnership between MedGenome and Twist Bioscience is to bring this technology to economically disadvantaged people in the world, providing the genetic information they need to end their diagnostic odysseys and help clinicians pursue the management and treatment of the disease. Although this technology has been available for over a decade, it has not gained significant traction due to its cost, limited awareness, and the lack of insurance coverage, as healthcare in India remains an out-of-pocket expense. The HOPE for Rare Diseases programme, established in August 2024 aims to address this issue and provide whole exome sequencing for impoverished rare disease patients.  ]]> https://biospectrumindia.com/news/92/25165/neuberg-diagnostics-launches-personalised-genomics-platform-geniee.html https://biospectrumindia.com/news/92/25165/neuberg-diagnostics-launches-personalised-genomics-platform-geniee.html Thu, 19 Sep 2024 00:00:00 +0530 Chennai-based Neuberg Diagnostics, a global leader in cutting-edge healthcare diagnostics, has launched its ground-breaking personalised genomics platform, “Geniee – Decode your DNA”. This launch signifies a monumental shift in the future of personalised healthcare, positioning Neuberg Diagnostics at the forefront of genetic testing and tailored medicine. Neuberg's Geniee is designed to deliver highly personalised health insights, empowering users with the knowledge needed to make informed decisions about their health and wellness based on their unique genetic makeup. Geniee by Neuberg is more than just a risk prediction tool; it’s a personalised wellness revolution. This mobile platform provides insights into how your genes influence your body’s response to medications, dietary preferences, exercise routines, and nutritional needs. It enables users to take control of their health by offering comprehensive genetic insights into critical aspects of well-being. With Geniee, individuals can optimise their diets, identify nutrient deficiencies, enhance fitness plans, and take proactive steps to ensure a healthier future. The launch of the Complete Wellness Genetics Test along with the Geniee app is at the heart of this initiative. This advanced genetic analysis dives deep into a person’s DNA, offering clear guidance on how they can adjust their lifestyle to live longer, healthier lives. Whether it’s determining if you are prone to be obese, have nutritional deficiencies like vitamin A deficiency, and recommend the best foods for optimal nutrition or identifying potential health risks early on, Geniee empowers users to personalise their health strategy and transform their well-being. Considering the ever growing scientific advancement in genomics, Geniee customers will benefit from regular updates on the app that they will get based on their unique genetic make-up and recent updates. Geinee comprehensive genetic testing helps individuals and healthcare providers understand how their body processes and responds to drugs.   ]]> https://biospectrumindia.com/news/92/25162/city-imaging-launches-advanced-diagnostic-tool-fibroscan-for-early-screening-of-liver-diseases.html https://biospectrumindia.com/news/92/25162/city-imaging-launches-advanced-diagnostic-tool-fibroscan-for-early-screening-of-liver-diseases.html Wed, 18 Sep 2024 00:00:00 +0530 In response to the government's call for proactive measures to address the rising burden of liver diseases in India, City Imaging & Clinical Labs has taken a significant step by launching FibroScan, an advanced diagnostic tool designed for rapid, painless, and non-invasive liver assessment. This initiative aligns with the national focus on early detection and prevention, particularly in the context of non-alcoholic fatty liver disease (NAFLD), which is fast becoming a major health crisis in India. Union Minister Dr Jitendra Singh, during the recent launch of the Indo-French Liver and Metabolic Disease Network (InFLiMeN), emphasised the growing prevalence of NAFLD in India. “Every third Indian has fatty liver, which often predates Type 2 diabetes and other metabolic disorders,” said Dr. Singh, who himself is a nationally renowned diabetologist. He stressed the need for India-specific interventions to address this growing epidemic, given the country’s unique metabolic and genetic profile. The launch of FibroScan at City Imaging’s Dwarka branch is a direct response to this call for action. With this the City Imaging has extended its reach also. The device provides a Controlled Attenuation Parameter (CAP) and liver stiffness assessment, making it an essential tool for the early detection of liver conditions such as NAFLD and alcoholic liver disease (ALD). These conditions, if left undiagnosed, can progress to serious complications like cirrhosis and liver cancer. The FibroScan technology offers several key features, including its ability to deliver rapid results in just minutes. It is painless and non-invasive, eliminating the need for traditional biopsies or invasive procedures. Designed to be affordable, it ensures accessibility for a wide range of patients. ]]> https://biospectrumindia.com/news/92/25132/nucleome-informatics-launches-drseq-ird-test-for-comprehensive-genetic-diagnosis-of-inherited-retinal-diseases.html https://biospectrumindia.com/news/92/25132/nucleome-informatics-launches-drseq-ird-test-for-comprehensive-genetic-diagnosis-of-inherited-retinal-diseases.html Tue, 10 Sep 2024 00:00:00 +0530 Nucleome Informatics, a Hyderabad-based genomics services provider, has announced the launch of its DrSeq IRD panel, a revolutionary genetic test for diagnosing Inherited Retinal Diseases (IRDs). This test is among the most comprehensive available globally, designed to improve early detection and disease management, especially in individuals with a family history of blindness. IRDs represent a genetically diverse spectrum of disorders that affect the retina, leading to vision impairment or blindness. In India, the prevalence of IRDs ranges from 1 in 350 to 1 in 2000, varying by region and factors such as consanguinity. Accurate diagnosis of these conditions has been challenging due to their clinical and genetic heterogeneity, with over 300 genes associated with IRDs. However, most cases are caused by mutations in 20 key genes. Nucleome’s DrSeq IRD panel covers an extensive range of IRDs, including Leber Congenital Amaurosis (LCA); Cone Dystrophy; Cone Rod Dystrophy; Retinitis Pigmentosa (RP); Stargardt's Disease; Maclaren Dystrophy; Congenital Stationary Blindness; Vitelliform Macular Dystrophy; Bardet-Biedl Syndrome; Usher Syndrome; Choroideremia; Achromatopsia; and Bestrophinopathy The DrSeq IRD panel includes 850 genes and thousands of known and novel variants, providing superior diagnostic accuracy. The test helps identify the genetic mutations responsible for specific IRD types, which is critical for tailoring treatment options, including gene therapy.   In collaboration with LV Prasad Eye Institute (LVPEI), DST (Department of Science and Technology) of the Government of India and Korean partners, including Seoul Eye Hospital, Nucleome Informatics has developed the DrSeq IRD panel by sequencing 300 IRD patients and 200 healthy family members from India. One of the unique aspects of the DrSeq IRD panel is its saliva-based collection method, which eliminates the need for blood samples.  ]]> https://biospectrumindia.com/news/92/25083/redcliffe-labs-launches-mpox-testing-strengthens-national-preparedness.html https://biospectrumindia.com/news/92/25083/redcliffe-labs-launches-mpox-testing-strengthens-national-preparedness.html Thu, 29 Aug 2024 00:00:00 +0530 Noida-based startup Redcliffe Labs, a purpose-driven PAN India diagnostic service provider, has announced the launch of its advanced MPOX testing capabilities, reinforcing its commitment to national health security.  This strategic move is a significant step towards bolstering the nation’s preparedness against potential MPOX outbreaks. With its widespread network of 80+ in-house world-class labs, 2000+ collection centres, and presence in 220+ cities, Redcliffe Labs played a crucial role in combating the COVID-19 pandemic across both waves and is once again at the forefront of safeguarding public health. MPOX, a highly contagious viral disease increasingly recognised for its potential to cause localised outbreaks, poses significant public health risks if not detected and controlled promptly. With several cases reported in Africa, Europe, and parts of Asia, the urgency of this threat necessitates early preparedness and timely intervention to prevent the virus from spreading.  Redcliffe Labs has proactively assured key health authorities, including Noida's Chief Medical Officer (CMO) and the Indian Council of Medical Research (ICMR), of its readiness to manage the MPOX situation. Being prepared with advanced testing facilities not only ensures the rapid identification and isolation of cases but also guarantees that healthcare providers are fully equipped to handle increased demand. Additionally, it enables timely public communication and education, reducing misinformation and helping manage the community impact.   ]]> https://biospectrumindia.com/news/92/25009/j-mitra-launches-indias-first-dengue-ns1-antigen-self-test.html https://biospectrumindia.com/news/92/25009/j-mitra-launches-indias-first-dengue-ns1-antigen-self-test.html Fri, 09 Aug 2024 00:00:00 +0530 J Mitra & Company has revitalised its war against dengue by launching the Dengue NS1 Antigen self-test kit. This is the first self-test/home-test kit launched by any company in India. It detects dengue on the first day of fever; it is self-administrable – anyone can conduct the test on their own and in any location; Results are available within 20 mins. Using the Dengue NS1 Antigen self-test is a straightforward, 2-step process – add one drop of blood into the sample well; add one drop of assay buffer; allow the reaction to occur for 20 minutes and read the result. The Dengue NS1 Antigen self-test is a proactive tool that can detect the Dengue NS1 Antigen from Day One as soon as the symptoms appear in patients. This early detection capability empowers individuals to take control of their health and seek timely medical intervention. NS1 Antigen can be detected in both primary and secondary dengue infections. However, NS1 is challenging to detect once anti-NS1 Antibodies appear. NS1 Antigen is present at high concentrations in the sera of Dengue virus-infected patients during the early clinical phase of the disease. Dengue is amongst the top 10 most communicable diseases in India, and the most affected states include Uttar Pradesh, West Bengal, Bihar, Karnataka, Maharashtra, Kerala, Delhi, Rajasthan, Punjab and Odisha. ]]> https://biospectrumindia.com/news/92/24996/iit-kanpur-transfers-non-invasive-oral-cancer-detection-technology-to-scangenie-scientific.html https://biospectrumindia.com/news/92/24996/iit-kanpur-transfers-non-invasive-oral-cancer-detection-technology-to-scangenie-scientific.html Tue, 06 Aug 2024 00:00:00 +0530 To facilitate widespread adoption and commercial success, Indian Institute of Technology Kanpur (IIT-K) has transferred its unique technology, 'Munh Parikshak,' a portable device for detecting oral cancer, invented by Prof. Jayant Kumar Singh and his team from the Department of Chemical Engineering, to Scangenie Scientific, a Kanpur-based startup. The device uses special lights and a camera to examine the mouth, providing instant results by analysing mouth images and categorising them as normal, pre-cancerous, or cancerous. The results are displayed on a smartphone app and stored on cloud servers for continuous updates, making it ideal for self-testing. The technology licensing agreement was formally signed between IIT Kanpur and Scangenie Scientific in the presence of Prof. Tarun Gupta, Dean of R&D, IIT-K; Prof. Ankush Sharma, Professor-in-Charge of SIIC, IIT-K; Prof. Amitabha Bandyopadhyay, Head of BSBE Dept, IIT-K; Dr Prerana Singh, Head of Oral Pathology at MPDC and co-inventor; Prof. Jayant Kumar Singh, ChE Dept. & Inventor, IIT-K; and Dhirendra Singh, Licensee & Director of Scangenie Scientific. Munh-Parikshak is a user-friendly device having white and fluorescence light source that connects wirelessly to smartphones, tablets, iPads, etc. With a built-in power backup, it stores health history for tracking and provides instant oral health reports. The device offers quick and painless screening with 90% accuracy in clinical settings. It is safe, radiation-free, and does not require any additional chemicals or processes.  According to market research findings, the oral cancer diagnosis market is expected to reach $2.98 billion by 2032 with a 5% CAGR, while the rapid test kit market, currently at $736 million, is growing at a 7% CAGR until 2027.      ]]> https://biospectrumindia.com/views/92/24988/tavi-advanced-heart-care-for-complex-health-conditions-.html https://biospectrumindia.com/views/92/24988/tavi-advanced-heart-care-for-complex-health-conditions-.html Sat, 03 Aug 2024 00:00:00 +0530 1) Transcatheter Aortic Valve Implantation (TAVI) has emerged as a revolutionary treatment for severe aortic stenosis (AS), particularly benefiting patients with comorbidities like diabetes and hypertension. These patients face heightened surgical risks and complications, making TAVI's minimally invasive nature a crucial alternative. TAVI involves inserting a new aortic valve via a catheter, typically through the femoral artery (artery in the leg), thus avoiding the need for chest opening. This approach significantly reduces surgical trauma and accelerates recovery, making it an ideal choice for high-risk patients. For diabetic patients, TAVI’s reduced infection risk and faster healing times are particularly beneficial, as their condition often impairs wound healing and increases susceptibility to infections. Hypertensive patients also benefit from TAVI due to the procedure’s ability to minimize cardiovascular stress, resulting in fewer complications and a smoother recovery process. The advantages of TAVI extend beyond the operating room. Patients who undergo TAVI typically experience shorter hospital stays and quicker recoveries. This is especially important for those with comorbidities, as prolonged recovery can aggravate existing health issues. Post-TAVI, many patients report significant improvements in cardiac function and overall quality of life, with minimal impact on their other health conditions. India’s high prevalence of diabetes and hypertension underscores the necessity for advanced medical solutions like TAVI. With approximately 77 million adults living with diabetes, India ranks second globally, trailing only China. Urbanization, changing lifestyles, and genetic predispositions further intensify this health crisis. Therefore, the demand for safer, more effective treatments like TAVI is increasing. -By Dr Sharad Chandra, Professor, Lari Cardiology, Lucknow   2) Dealing with heart surgery in obese patients can be tricky because of extra tissue and other risks like prolonged recovery, heightened infection risk, and added strain on the cardiovascular system. TAVI, a less invasive procedure, offers a great solution. It involves inserting a new heart valve through a catheter, a thin flexible tube, typically via the femoral artery in the leg, and guiding it to the heart, reducing risks and speeding up recovery and improves outcomes for obese patients with Aortic Stenosis (AS). I recently encountered a particularly challenging case involving an obese patient with severe aortic stenosis (AS). Given the patient's condition, I chose Transcatheter Aortic Valve Implantation (TAVI) because of its minimally invasive nature, aiming to reduce the surgical risks significantly. This method allowed us to avoid large chest incisions, minimize the risk of infection, and reduce the stress on the heart. The patient's smooth recovery reaffirmed TAVI's effectiveness in such complex cases. The benefits of TAVI for obese patients are significant. By avoiding large incisions, it lowers the risk of wound infections and speeds up healing, which is crucial for those prone to slow recovery. This procedure also reduces the risk of heart attacks or strokes.  For obese patients, TAVI ensures quicker recovery, facilitating early hospital discharge and faster return to normal activities. This approach is vital in managing conditions like diabetes and hypertension. TAVI's minimal invasiveness minimizes surgical risks, ensuring safer procedures and better outcomes in treating severe heart problems among high-risk individuals.           -By Dr Naveen Jamwal, Professor (JR), RML Hospital, Lucknow     DISCLAIMER: The views/suggestions/opinions expressed in the article are the sole responsibility of the brand concerned this should not be considered a substitute for medical advise. Please consult your treating physician for more details.   ]]> https://biospectrumindia.com/news/92/24944/thyrocare-buys-polo-labs-pathology-diagnostic-biz-to-strengthen-northern-india-presence.html https://biospectrumindia.com/news/92/24944/thyrocare-buys-polo-labs-pathology-diagnostic-biz-to-strengthen-northern-india-presence.html Thu, 25 Jul 2024 00:00:00 +0530 Mumbai-based Thyrocare, a leading diagnostic and preventive healthcare service provider in India, has entered into a Business Transfer Agreement with Polo Labs to acquire their pathology diagnostic business. This strategic acquisition expands Thyrocare’s footprints into the Northern part of India, further solidifying its position as a dominant player in the Indian diagnostic industry. Polo Labs, based out of Punjab, is a well-established pathology diagnostic company with 14 laboratories across Punjab, Haryana, and Himachal Pradesh. Their robust network and expertise in the region make them a valuable addition to Thyrocare's operations. Currently, Polo Labs serves a substantial client base and has a significant market presence in Northern India, contributing to the region's healthcare infrastructure. The acquisition of Polo Labs aligns seamlessly with Thyrocare's overall business strategy in the healthcare sector, which focuses on enhancing diagnostic capabilities and extending its reach across India. By integrating Polo Labs' existing network with Thyrocare's advanced diagnostic infrastructure, the company aims to deliver improved service delivery, faster turnaround times, and unmatched patient convenience.   ]]> https://biospectrumindia.com/news/92/24933/neuberg-diagnostics-pathfinders-2024-highlights-future-of-integrated-diagnostics.html https://biospectrumindia.com/news/92/24933/neuberg-diagnostics-pathfinders-2024-highlights-future-of-integrated-diagnostics.html Mon, 22 Jul 2024 00:00:00 +0530 Neuberg Diagnostics, a leader in the field of medical diagnostics with a strong presence across India, South Africa, UAE, and the USA, organised its annual global pathology conference, Pathfinders 2024, on the 20th and 21st of July, 2024. The conference was a platform to bring together renowned speakers from the medical fraternity to discuss Integrated Diagnostics - Trends Defining the Future of Diagnostic Medicine in the post-pandemic world, innovative technology caters to a larger range of diseases and a faster implementation of the same. Pathfinders 2024 aimed to explore new age-integrated diagnostics advancements in the fields of Foetal Medicine, Oncology, Neurology, Transplant Immunology, Obstetrics and Gynecology, Inherited Genetics, and Cardiology. Dr GSK Velu, Chairman and Managing Director of Neuberg Diagnostics, said, "With advancements in proteomics and big data analytics, the role of AI is crucial in handling vast amounts of information. The partnership between clinicians and diagnosticians is vital, emphasising early diagnosis and wellness. India's potential as a leader in this field is immense, given its strong software industry and talented professionals. By collaborating, we can set a global standard in personalized medicine." Day 1 of the conference covered recent trends defining the future of diagnostics medicine, multiple myeloma epitomes of integrated diagnostics, Primary Immunodeficiency, Integrated Diagnostics in Tumours of Central Nervous System, Integrated Diagnostics in Colo-Rectal Malignancies, Integrated Diagnostics in Breast Carcinoma. While on day 2 of the conference, sessions were held on Foetal Medicine, Solid Organ Transplantation, and Transplant Pathology.   ]]> https://biospectrumindia.com/news/92/24925/neuberg-diagnostics-launches-centre-of-excellence-for-integrated-diagnostics-in-chennai.html https://biospectrumindia.com/news/92/24925/neuberg-diagnostics-launches-centre-of-excellence-for-integrated-diagnostics-in-chennai.html Fri, 19 Jul 2024 00:00:00 +0530 Neuberg Diagnostics, a leader in the field of medical diagnostics with a strong presence across India, South Africa, UAE, and the USA, has announced the launch of its Centre of Excellence for Integrated Diagnostics in Chennai.  This new centre offers a comprehensive range of diagnostic services under one roof, manned by experienced medical professionals committed to providing accurate diagnostic testing services. The facility is equipped with advanced Imaging, advanced foetal medicine, cardiology Services, pathology testing services. The Centre of Excellence for Integrated Diagnostics was inaugurated by Indira Kameswaran, Director with Madras Ent Research Foundation.  The Foetal Medicine Centre was inaugurated by Dr Mohan Kameshwaran, Managing Director of Madras ENT Research Foundation and Founder of MERF Institute of Speech & Hearing, in the presence of Dr GSK Velu, Chairman and Managing Director of Neuberg Diagnostics, Dr Bavaharan Rajalingam, Head of Radiology at Neuberg Diagnostics, and A Ganesan, Vice Chairman of Neuberg Diagnostics. Indira Kameswaran also launched specially curated Women’s Wellness Packages under the brand of “Neuberg for her” for various age groups and life events right from Puberty to Maternity to Geriatric Care. Dr GSK Velu, Chairman and Managing Director of Neuberg Diagnostics, said, "With the expansion of CT/MRI facilities and the addition of the foetal medicine centre, Neuberg OMR facility now houses all diagnostic modalities under one roof, serving both wellness and illness segments with designated areas. Our goal is to ensure that every patient receives timely and precise diagnoses, leading to better health outcomes. As part of our expansion, we have 10 integrated centres in West Bengal and Raipur, Chhattisgarh, and this will be our 11th integrated diagnostic centre. Neuberg also plans to expand its integrated diagnostics centre presence across Tamil Nadu in the next two years."   ]]> https://biospectrumindia.com/news/92/24922/apollo-diagnostics-launches-processing-lab-in-tirupati-to-enhance-healthcare-accessibility.html https://biospectrumindia.com/news/92/24922/apollo-diagnostics-launches-processing-lab-in-tirupati-to-enhance-healthcare-accessibility.html Thu, 18 Jul 2024 00:00:00 +0530 Apollo Diagnostics, a prominent unit of Apollo Health and Lifestyle Ltd., recently celebrated the grand opening of its cutting-edge processing lab, marking its 140th facility nationwide. Situated in Tirupati's NGO Colony, the inauguration ceremony was graced by Aranii Srenevasulu, MLA of Tirupati Assembly Constituency. The newly unveiled lab expands Apollo Diagnostics' footprint in Andhra Pradesh, complementing its existing network of 6 patient care centers in the region and 115 across the state. With a robust monthly capacity exceeding 25,000 samples, the facility offers a comprehensive range of diagnostic services, leveraging advanced technology for both routine and specialized tests, including home sample collection. Addressing the gathering, Aranii Srenevasulu underscored Apollo Diagnostics' commitment to bringing world-class healthcare standards to Tirupati, aligning with the vision of Dr Prathap Reddy, founder of Apollo Hospitals. The lab introduces over 3,000 tests and Xpert Health Checkup packages, catering to diverse medical needs. Devendra Singh Rajput, COO of Apollo Diagnostics, highlighted the facility's state-of-the-art infrastructure spanning 1500 square feet, equipped with automated analysers for precise diagnostic outcomes in fields such as Hematology, Biochemistry, and Microbiology.  ]]> https://biospectrumindia.com/news/92/24887/medgenome-expands-footprint-in-east-india-with-acquisition-of-stake-in-genx-diagnostics-.html https://biospectrumindia.com/news/92/24887/medgenome-expands-footprint-in-east-india-with-acquisition-of-stake-in-genx-diagnostics-.html Thu, 11 Jul 2024 00:00:00 +0530 MedGenome, Bengaluru-based genomics-driven diagnostics and research services company, has acquired a stake in GenX Diagnostics, a leading diagnostic lab chain in Odisha. Founded in 2017, GenX Diagnostics has established a robust regional presence in Odisha, with seven diagnostic centres and 60 collection centres across the state, including a flagship laboratory in Saheed Nagar, Bhubaneshwar, accredited by both NABL and NABH. MedGenome’s, state-of-the-art advanced science and technological capabilities, combined with GenX’s diagnostics leadership in the East, will empower the clinicians in Odisha with actionable insights from genetic data and enable them to prescribe targeted treatment for patients, improving healthcare outcomes. Commenting on the acquisition, Dr Vedam Ramprasad, PhD, CEO, MedGenome, said, "This acquisition further aims to expand our network in Tier 2 and Tier 3 cities in India by driving deeper penetration, new market development, and bringing new tests to the market. With a focus on positioning Indian genomics globally, we develop solutions that cater to diverse markets worldwide.” "This strategic collaboration aims to enhance healthcare services in the region, providing comprehensive and cutting-edge diagnostic solutions. We are committed to bringing sophisticated and advanced healthcare solutions to the people of Odisha. By combining our extensive product portfolio with MedGenome’s omics solutions, we will empower clinicians and consumers in Eastern India with the best diagnostic tools available,” said Dr Biswajit Mohanty, GenX Diagnostics, Bhubaneswar.    ]]> https://biospectrumindia.com/news/92/24855/abbott-and-yrgcare-open-outreach-centres-in-india-to-curb-spread-of-hiv-and-other-infectious-diseases.html https://biospectrumindia.com/news/92/24855/abbott-and-yrgcare-open-outreach-centres-in-india-to-curb-spread-of-hiv-and-other-infectious-diseases.html Wed, 03 Jul 2024 00:00:00 +0530 Abbott and YRGCARE, a leading non-profit offering non-stigmatising, high-quality services to those with or at risk for HIV (Human Immunodeficiency Virus), have opened two new facilities dedicated to helping stop the spread of HIV. The first facility, called “The Blue Shed,” is based in Delhi’s Yamuna Bazar, a hotspot for HIV transmission amongst its largely transient population. The new facility will offer testing, treatment and counselling, and other support services to provide holistic support for those who have or are at-risk for HIV and other known or emerging infectious diseases. In Mizoram, YRGCARE recently opened an adolescent center in Aizawl to serve at-risk youth who are vulnerable to HIV and other sexually transmitted infections. In addition to testing through the support of the Abbott Pandemic Defense Coalition, the Center offers access to treatment and other healthcare services, counselling and mental health services and guidance programs. Over 1600 young people have enrolled and this number is increasing.   The initiative aims to transform the lives of over 2500 people in these cities over the next year by taking a holistic approach for those who have or are at-risk for HIV and other known or emerging infectious diseases.   ]]> https://biospectrumindia.com/news/92/24819/xiaomi-india-announces-breast-cancer-screening-initiative-with-yuvraj-singh-foundation.html https://biospectrumindia.com/news/92/24819/xiaomi-india-announces-breast-cancer-screening-initiative-with-yuvraj-singh-foundation.html Tue, 25 Jun 2024 00:00:00 +0530 Marking a decade of innovation and contribution to community welfare in India, Xiaomi India, a global technology leader, has announced a landmark partnership with the Yuvraj Singh Foundation (YouWeCan), a non-profit organisation established by cricketer and cancer survivor Yuvraj Singh. The 'Swasth Mahila Swasth Bharat' project aims to screen 1,50,000 women for breast cancer over 12 months across 15 states, focusing on under-represented and under-resourced communities. This initiative represents Xiaomi's most extensive effort in India so far, in terms of impact and reach. Muralikrishnan B, President of Xiaomi India, said, "The stark reality that a woman in India dies of breast cancer every 6 minutes, with 70% of cases diagnosed in advanced stages due to lack of screening, underscores the urgency of our mission." The initiative aims to provide access to safe breast cancer screening, create awareness about risks and self-examination techniques, and ensure early detection and timely treatment. It aligns with UN Sustainable Development Goals, emphasizing health and gender equality. Yuvraj Singh Foundation (YouWeCan), with support from Xiaomi India, will implement this project by collaborating with grassroots organisations and leveraging existing healthcare infrastructure. The programme features: A community-based screening model using cost-effective, reliable technology Screenings in safe, accessible spaces like government schools and anganwadis Partnerships with local Primary Health Centres (PHCs), Community Health Centres (CHCs), and Government District Hospitals Comprehensive patient support, including education, counseling, and healthcare system navigation ]]> https://biospectrumindia.com/news/92/24814/mahe-roche-diagnostics-india-ink-mou-to-establish-coe-for-skill-development-.html https://biospectrumindia.com/news/92/24814/mahe-roche-diagnostics-india-ink-mou-to-establish-coe-for-skill-development-.html Mon, 24 Jun 2024 00:00:00 +0530 Manipal Academy of Higher Education (MAHE) and Roche Diagnostics India have signed a Memorandum of Understanding (MoU) to establish a Centre of Excellence (CoE). The Centre of Excellence aims to offer skill development and innovation in the field of diagnostics. Through this collaboration, both stakeholders are looking towards a significant step to strengthen the academia and industry to improve healthcare diagnostics.  This collaborative effort will focus on developing advanced diagnostic tools and training healthcare professionals to use cutting-edge technologies. Further,  MAHE experts will present their insights on advanced lab technologies and clinical assays at national and international Continuing Medical Education (CME) programmes and seminars. The Centre of Excellence will act as a medium for executing pioneering research, sharing knowledge and facilitating workshops to foster a culture of innovation and excellence in diagnostics. The collaboration will offer significant advancements in healthcare, eventually directing to better patient care and disease management. ]]> https://biospectrumindia.com/news/92/24764/fujifilm-india-deepens-commitment-to-tb-eradication-strengthens-csr-efforts-to-include-kutch-gujarat.html https://biospectrumindia.com/news/92/24764/fujifilm-india-deepens-commitment-to-tb-eradication-strengthens-csr-efforts-to-include-kutch-gujarat.html Wed, 12 Jun 2024 00:00:00 +0530 Fujifilm India, a leading healthcare company, has announce the extension of its Tuberculosis (TB) Screening under its CSR campaign to Kutch District of Gujarat with its implementation Partner Apollo Telemedicine Network Foundation, further broadening the scope of its community health initiatives that are already underway in Valsad and Banaskantha. This significant step aligns with the commitment to the national TB elimination campaign, "TB Harega Desh Jeetega," reinforcing the dedication to combatting TB across India. The National TB Elimination Programme's India TB Report 2024 reveals that 25.55 lakh TB cases were notified last year, marking the highest number since the programme's inception in the 1960s. Despite positive trends, the estimated number of TB cases remains high at 27.8 lakh in 2023. TB-related deaths remained unchanged at 3.2 lakh. These figures underscore the substantial TB burden in India and the need for sustained efforts to reduce both incidence and mortality. Building on their past initiatives, Fujifilm India has successfully conducted numerous screenings and awareness programmes in Valsad and Banaskantha, reaching thousands of individuals and providing critical support in the fight against TB. Since the inception of the TB screening CSR initiative in Gujarat, the company has been able to screen 8,218 individuals. Their innovative mobile TB diagnostic units, including the advanced FDR X-Air, have played a vital role in these efforts, ensuring that even the most remote communities get a comprehensive active case finding project of Tuberculosis. ]]> https://biospectrumindia.com/news/92/24750/trustlab-diagnostics-expands-footprint-in-chandigarh.html https://biospectrumindia.com/news/92/24750/trustlab-diagnostics-expands-footprint-in-chandigarh.html Tue, 11 Jun 2024 00:00:00 +0530 TRUSTlab Diagnostics, a startup in the healthcare diagnostics sector, has announced a significant expansion into the Chandigarh region, specifically in Sector 24. This move marks a major milestone in TRUSTlab's mission to provide accessible, precise, and top-quality diagnostic services across India. Founded in Hyderabad, TRUSTlab Diagnostics has rapidly become a leader in the healthcare diagnostics industry. With a commitment to excellence and innovation, TRUSTlab has successfully opened six new labs across the country in recent months, bringing its total number of laboratories to 20. The new Chandigarh facility is equipped to offer a comprehensive range of diagnostic services. Among the departments established in this state-of-the-art lab are Biochemistry, Hematology, Assay & Hormones, and Clinical Pathology. In addition to these core departments, the new lab will also perform specialised tests such as lipid profiles, liver function tests, renal function tests, glucose tolerance tests, and hormone assays including thyroid stimulating hormone (TSH), insulin, cortisol, and reproductive hormones. The expansion into Chandigarh is part of TRUSTlab's broader strategy to increase its footprint across India, ensuring that more people have access to the diagnostic services they need.  ]]> https://biospectrumindia.com/news/92/24733/innominds-and-sciinv-biosciences-unveil-ai-driven-solution-to-combat-amr.html https://biospectrumindia.com/news/92/24733/innominds-and-sciinv-biosciences-unveil-ai-driven-solution-to-combat-amr.html Thu, 06 Jun 2024 00:00:00 +0530 Innominds, a US-based digital transformation and product engineering company, has announced its partnership with Hyderabad-based startup SCIINV Biosciences to introduce AMRx, an advanced AI/ML-driven digital diagnostic tool designed to combat the growing threat of antimicrobial resistance (AMR).   This innovative tool promises to revolutionise the detection and treatment of antibiotic-resistant infections without the need for traditional cultures.   AMRx, developed by Innominds and SCIINV Biosciences, is a groundbreaking, culture-free companion diagnostic tool that utilises AI/ML to predict Urinary Tract Infections (UTIs) and determine antibiotic resistance patterns based on patient clinical history. This patented technology represents a significant advancement in the fight against AMR.   AMRx leverages patient clinical history to accurately predict UTIs, identify causative organisms (Enterobacteriaceae), and determine antibiotic resistance or susceptibility patterns without the need for traditional cultures.   By reducing unwarranted clinical investigations, AMRx saves valuable time, effort, and resources. This efficiency is particularly beneficial in resource-limited settings.   AMRx can be deployed as a clinical decision support tool, aiding healthcare professionals in making appropriate empirical antibiotic prescriptions, thereby enhancing the accuracy and effectiveness of treatment. ]]> https://biospectrumindia.com/news/92/24718/fujifilm-and-nm-medical-launch-skill-lab-for-full-field-digital-mammography-in-india.html https://biospectrumindia.com/news/92/24718/fujifilm-and-nm-medical-launch-skill-lab-for-full-field-digital-mammography-in-india.html Tue, 04 Jun 2024 00:00:00 +0530 Fujifilm India Healthcare Division, in collaboration with NM Medical Mumbai, has recently launched its first Fujifilm Skill Lab aimed at providing advanced training in FFDM (full-field digital mammography) technologies for radiologists and radiographers. The inaugural session witnessed the participation of eight candidates, comprising four radiologists and four radiographers. The Fujifilm Mammography Skill Development Programme is designed to empower radiographers and radiologists to enhance their skills and deliver improved diagnoses to their patients and customers using technologically advanced mammography machines by Fujifilm. Chander Shekhar Sibal, Vice President & HOD, Healthcare Business, FUJIFILM India, voiced, "The Fujifilm Mammography Skill Development Program represents a pivotal initiative aimed at empowering radiographers and radiologists to elevate their expertise and capabilities in mammography. Tailored specifically for professionals working in breast imaging, this comprehensive program is meticulously designed to harness the full potential of technologically advanced mammography machines developed by Fujifilm." Dr Shilpa Lad, Consultant Breast Imaging & Intervention, shared insights into the program, stating, “Fujifilm Mammography Skill Development programme in collaboration with NM Medical, Mumbai, will enhance patient care by providing radiologists with training in cutting-edge mammography technology. The comprehensive skill development programme provides hands-on training with practical applications covering all aspects of mammography, from patient positioning to advanced imaging procedures emphasising imaging techniques, technology overview, and hands-on experience, that will help radiologists and radiographers stay up to date with the latest advancements in mammography and advanced applications such as 3D Tomosynthesis. We work to improve women health care standards and provide training opportunities which benefits healthcare professionals and translates into high quality patient care.” ]]> https://biospectrumindia.com/news/92/24713/qiagen-and-myriad-genetics-design-oncology-test-to-analyse-homologous-recombination-deficiency.html https://biospectrumindia.com/news/92/24713/qiagen-and-myriad-genetics-design-oncology-test-to-analyse-homologous-recombination-deficiency.html Mon, 03 Jun 2024 00:00:00 +0530 German firm Qiagen and US-based Myriad Genetics will develop a globally distributable kit-based test for analysing Homologous Recombination Deficiency (HRD) status. This next-generation sequencing (NGS) test aims to support research into personalised medicine in multiple solid tumour types, including ovarian cancer and is expected to enhance decentralised testing capacities once a regulated product is developed with pharmaceutical partners. The project builds on the recently announced master collaboration agreement between the two companies. The test will be based on Qiagen’s QIAseq xHYB technology, Qiagen Digital Insight solutions, which creates a sample to insight HRD solutions, and Myriad’s proprietary US FDA-approved MyChoice CDx, a single-site PMA-approved centralised testing service for analysing HRD in certain tumours. MyChoice CDx assesses the HRD status by examining a tumor’s DNA repair capabilities, particularly focusing on BRCA1 and BRCA2 gene mutations and calculating a Genome Instability Score (GIS). The GIS aids in pinpointing ovarian cancer patients who are most likely to benefit from targeted treatments, such as LYNPARZA (olaparib) by AstraZeneca. The MyChoice CDx assay can identify 34% more tumors with HRD using the GIS score compared to other methods only using percent loss of heterozygosity (%LOH). Given that approximately 48% of ovarian cancer tumors exhibit HRD, often due to specific mutations within the tumour, expanding access to this assay is vital for advancing personalised medicine and ensuring that patients receive the most appropriate treatments. Qiagen will manage the development and distribution of the kit-based HRD test outside of the United States. The IP license grants Qiagen the capability to collaborate with pharmaceutical partners to create an IVD-validated test, intended for use as a companion diagnostic outside of the United States. The combined regulatory expertise of Qiagen and Myriad enables seamless compliance and integration in clinical and companion diagnostic applications.   ]]> https://biospectrumindia.com/news/92/24717/nashik-based-cupid-broadens-distribution-network-for-rapid-ivd-kits-in-india.html https://biospectrumindia.com/news/92/24717/nashik-based-cupid-broadens-distribution-network-for-rapid-ivd-kits-in-india.html Mon, 03 Jun 2024 00:00:00 +0530 Cupid has announced the introduction of its Rapid In Vitro Diagnostic (IVD) kits distribution network. This move is a key component of Cupid's overarching strategy to amplify its presence in the worldwide IVD market. The Nashik-based company has initiated the distribution of its IVD kits in various states across India, including Maharashtra, Goa, Gujarat, Rajasthan, Jammu & Kashmir, and Madhya Pradesh. The company is targeting a nationwide presence by the end of the fiscal year and has already established a strong sales team for this purpose. Cupid's current array of IVD products comprises 13 distinct kits, marketed under the brand names 'Cupikit' and 'Cupisure'. The company aims to position Cupikit in over 10,000 labs and distribute Cupisure pregnancy detection kits to more than 100,000 chemist outlets by the close of the financial year. Within three months of their launch, the pregnancy detection kits have already been placed in 25,000 chemist outlets. The company operates the state-of-the-art IVD manufacturing plant in Sinnar, Maharashtra, which boasts an annual production capacity exceeding 30 million kits. This facility, which has been operational for more than two years, is due for further capacity expansion in the upcoming quarters. In addition, Cupid has successfully exported IVD kits to nations like Tanzania, Liberia, Ghana, the Philippines, and Nepal. The company is currently in the process of product registration in Cameroon, Myanmar, Bhutan, Mozambique, Nigeria, Ethiopia, Zambia, and Sierra Leone. The present export orders total approximately Rs 1.25 crore. ]]> https://biospectrumindia.com/news/92/24665/g-knowme-collaborates-with-researchers-in-uk-to-automate-clinical-interpretation-of-whole-genome-sequencing-in-cancer-.html https://biospectrumindia.com/news/92/24665/g-knowme-collaborates-with-researchers-in-uk-to-automate-clinical-interpretation-of-whole-genome-sequencing-in-cancer-.html Mon, 27 May 2024 00:00:00 +0530 Bengaluru-based informatics startup G-KnowMe has entered into a partnership with researchers at the University of Cambridge and the Cambridge University Hospitals NHS Foundation Trust (CUH), United Kingdom (UK) to develop an automated workflow for interpreting data from sequencing the entire genome of cancers. “Whole genome sequencing (WGS) of cancers is emerging as the new paradigm in cancer management as Next Generation Sequencing (NGS) technology scales and the cost of sequencing drops. But timely interpretation of the data to make informed clinical decisions is the challenge. Clinical interpretation of WGS data for the breast cancer patient management will be developed under this collaboration’’, commented Professor Jean Abraham, Director of the Precision Breast Cancer Institute at the University of Cambridge. “To achieve this at scale,” she added, “we need to rely on cutting-edge automation and natural language processing tools powered by artificial intelligence." Tumour profiles carry information that can personalise treatment plans, predict response or resistance to approved therapies, suggest off-label therapies or relevant clinical trials for a patient, and at the same time identify any inherited basis for the cancer. “G-KnowMe is leveraging its combined expertise in AI and cancer biology to develop solutions that enable adoption of large panels in clinical management of cancer. While our platform G-KnowMiner is already in use by large diagnostics labs the Indian market to interpret data from NGS panels used for cancer diagnostics, expanding its scope to interpreting WGS data, within a clinically relevant time frame is what we aim to achieve through this partnership”, commented Nimisha Gupta’’, Founder, G-KnowMe. ]]> https://biospectrumindia.com/news/92/24654/core-diagnostics-to-expand-services-to-50-new-cities-in-2024.html https://biospectrumindia.com/news/92/24654/core-diagnostics-to-expand-services-to-50-new-cities-in-2024.html Wed, 22 May 2024 00:00:00 +0530 On the verge of completing 12 years of excellence in healthcare services this year, CORE Diagnostics has emerged as the fastest growing clinical laboratory focused on Next Generation Diagnostics for disease stratification and therapy selection. The company has established a central reference laboratory at Gurugram with satellite laboratories in New Delhi, Bengaluru, Lucknow, Guwahati and Bhubaneswar. CORE Diagnostics is also the largest high-end clinical laboratory in India with an international presence in UAE, Central Asia, various countries in South Asia and parts of Africa. During an exclusive chat with BioSpectrum, Dinesh Chauhan, Chief Executive Officer, CORE Diagnostics, revealed that during FY 23-24, the company has opened a new lab which is located in Secunderabad, to offer a larger range of thorough diagnostic solutions to a larger customer in Telangana and Andhra Pradesh and other parts of Southern India. “This 4000 square feet new lab has all the latest tools for Histopathology, Immunohistochemistry, Nephropathology, Flow Cytometry, in addition to essential services including Biochemistry, Immunology, Haematology, Clinical Pathology and Serology”, Chauhan said. Sharing the plans for FY 24-25, Chauhan said, “We plan to expand our reach within India and internationally. Within the country, we have identified around new 50 cities, where we will tie up with local labs and hospitals, and eventually set up our logistics there. We also plan to expand our genomics services across all specialities, i.e. besides oncology. We hope to explore areas such as neurology, mother & child care, endocrinology and much more.” With Rs 15-20 crore worth investment lined up to execute new plans this year, CORE Diagnostics is also venturing out into areas such as women’s health, and predictive diagnosis in reproductive health. “We are strengthening our focus on conditions like cervical cancer, by developing at-home tests for HPV”, added Chauhan. In addition, the company is planning to emerge as one of the largest diagnostics support and service provider for the clinical research organisations in the country. “Currently we are generating a business of more than Rs 100 crore, and hope to grow by 30-40 per cent with our new plans and opportunities”, Chauhan concluded. ]]> https://biospectrumindia.com/news/92/24641/ihridai-launches-ai-ml-based-diagnostics-tool-for-analysis-of-cardiac-mris.html https://biospectrumindia.com/news/92/24641/ihridai-launches-ai-ml-based-diagnostics-tool-for-analysis-of-cardiac-mris.html Mon, 20 May 2024 00:00:00 +0530 iHridAI, a Bengaluru-based healthcare technology startup focused on developing globally benchmarked and viable technology solutions for healthcare diagnostics, has launched its flagship product, HarmonyCVI, for detailed and accurate cardiovascular assessments. HarmonyCVI is a comprehensive artificial intelligence (AI)/ machine learning (ML)-based rapid diagnostics and insights tool that aids cardiologists and radiologists in enhanced analysis of cardiac MRI scans. Grounded on robust research, cardiothoracic models and extensive real-world cardiac imaging data, HarmonyCVI leverages deep learning AI/ML capabilities. It inputs the patient's MRI studies, learns respective metrics, and predicts various parameters, including dynamic contours and segmentation. The software uploads its comprehensive findings from processing and analysis into clinical data reports, which can be monitored and modified on a dashboard. The technology solution empowers radiologists and cardiologists with accurate and clinically reliable information, facilitating rapid and informed decision-making, typically within a few minutes. HarmonyCVI helps clinicians quickly assess the key parameters for comprehensive diagnosis, thereby aiding in practical assessment and treatments. The integrated platform offers real-time interactive report generation with automated report data analysis in the desired format. HarmonyCVI is the first product launched into this ecosystem, fully-tested and vetted with a critical mass of real-world datasets from various sources. iHridAI is simultaneously working towards developing a single integrated multi-model AI analytics platform which covers ECG, ECHO, CT and MRI. ]]> https://biospectrumindia.com/news/92/24630/cipla-announces-additional-investment-in-achira-labs.html https://biospectrumindia.com/news/92/24630/cipla-announces-additional-investment-in-achira-labs.html Thu, 16 May 2024 00:00:00 +0530 Mumbai-based pharmaceutical company Cipla has signed definitive agreements for further investment of up to Rs 26 crore (approx.) in Optionally Convertible Preference Shares of Bengaluru-based Achira Labs in four tranches, subject to completion of certain milestones. Achira is engaged in development and commercialisation of point of care (PoC) medical test kits in India. Since Cipla’s previous investment in June 2022, Achira has made significant developments in the Product Development and R&D space. Pursuant to the completion of the first tranche of investment, Cipla shall hold 27.27% of the total voting rights in Achira. Commenting on the development, Achin Gupta, CEO – One India Business, Cipla said, “Our decision to invest more in Achira is backed by Cipla's commitment to advance in the PoC diagnostics space. With the aim to reduce the existing gap in the ecosystem, our strategic financing will enable Achira to commercially launch and further develop test panels. We remain committed towards providing easy access to quality diagnostic services across India.” Achira aims to bring sophisticated medical tests closer to the point of diagnosis, treatment and management through its innovative solutions and cutting-edge research, by leveraging its state-of-the-art capabilities, strong collaborations, and deep expertise. ]]> https://biospectrumindia.com/news/92/24622/sanskritech-smart-solutions-ventures-into-africa.html https://biospectrumindia.com/news/92/24622/sanskritech-smart-solutions-ventures-into-africa.html Wed, 15 May 2024 00:00:00 +0530 Mumbai-based startup Sanskritech Smart Solutions has announced its expansion into Africa with a significant stride into the Republic of Malawi. In a landmark move, Sanskritech has formalised a Memorandum of Understanding (MoU) with the Republic of Malawi, aimed at introducing cutting-edge healthcare solutions to the country's healthcare sector. The formal signing ceremony of the MoU took place in the presence of Pritam Kumawat, CEO of Sanskritech Smart Solutions, and Dr Lazarus McCarthy Chakwera, President of the Republic of Malawi. The cornerstone of this collaboration is the introduction of Swandook, the world's first ultra-portable, ultra-smart Anytime Health Monitoring Bag. This novel product is poised to transform healthcare accessibility and efficiency in Malawi, addressing critical needs in remote healthcare management. Speaking on this occasion, Pritam Kumawat, CEO of Sanskritech Smart Solutions, expressed enthusiasm about the collaboration, stating, "Our expansion into Africa marks a pivotal moment for Sanskritech Smart Solutions. We are honored to partner with the Republic of Malawi in introducing Swandook, a revolutionary healthcare solution that embodies our commitment to innovation and accessibility in healthcare. We are confident that our collaboration will usher in a new era of healthcare excellence in Malawi, empowering healthcare professionals and improving outcomes for patients across the nation." Sanskritech plans to expand its footprint to other countries worldwide.  ]]> https://biospectrumindia.com/news/92/24613/molbio-diagnostics-deploys-new-age-technologies-to-launch-innovative-products-in-2024.html https://biospectrumindia.com/news/92/24613/molbio-diagnostics-deploys-new-age-technologies-to-launch-innovative-products-in-2024.html Sat, 11 May 2024 00:00:00 +0530 Diagnostics is expected to be more significant in the area of patient care in times to come. In particular, molecular diagnostics has undergone a period of rapid development and growth in the last decade with the implementation of new high complexity tests and integration of new technologies, not only in India, but across the globe. The use of molecular diagnostics has significantly improved the yield of detection. Numerous rapid multiplex PCR assays are now commercially available that can detect up to 18 or more viruses simultaneously. While there are numerous players in the molecular diagnostics market in India, Goa-based MolBio Diagnostics, which has developed a Truelab Real-Time quantitative micro PCR system, became the first molecular diagnostics company in India to be valued at over $1 billion.  After generating a group revenue of Rs 850 crore during FY 23-24, the company plans to strengthen its global presence this fiscal, along with launching new products in the Indian market. With these initiatives in mind, MolBio Diagnostics foresees a revenue collection of Rs 1200 crore in FY 24-25. During an exclusive chat with BioSpectrum, Sriram Natarajan, Director and Chief Executive Officer, Molbio Diagnostics revealed that the company is currently laying its focus on strengthening diagnostic testing for hepatitis C, B, HPV, and HIV, besides tuberculosis. “Our HCV test is undergoing WHO prequalification. The expectation is that hepatitis C and B screening will become a major public sector activity in the coming years. We are also increasing our focus on cervical cancer screening with HPV test. We are in the process to get the prequalification from WHO for our HPV test as well.” Providing recent updates on the company's landmark TB testing assay Trunat, Natarajan said, "Nigeria has now initiated the Truenat programme to address the challenges posed by tuberculosis (TB) diagnosis in the country. It is supported by the Stop TB Partnership and USAID’s introducing New Tools Project (iNTP) and it focuses on deploying Truenat systems in peripheral facilities across Nigeria." New launches MolBio is currently working on many pathbreaking point-of-care technologies in the areas of haematology, cancer, anti-microbial resistance (AMR), next-generation sequencing (NGS), syndromic testing etc. The company is also developing an artificial intelligence (AI)-enabled point-of-care test TruSight for various haematology applications including complete blood count (CBC). This platform could also be eventually used for PAP smear, malaria parasite, sperm counting, sickle cell disease, thalassemia etc. Focusing on the company’s major work on TB, Natarajan said, “We've acquired a majority stake in Prognosys Medical Systems, a manufacturer of a wide range of Digital X Ray machines including portable and ultra-portable machines. In addition to opening up Molbio's entry into the radiology segment, this enables us to provide end to end solutions for tuberculosis (TB) elimination, using the AI powered X-ray for screening high risk population and Truenat for same day confirmation and reporting.” Women’s Health MolBio has recently collaborated with Niramai Health Analytix, a Bengaluru-based deep-tech startup to accelerate the adoption of Niramai's innovative AI-based non-invasive breast cancer screening solution in developing countries around the world. “With this breast cancer screening tool, and our HPV test, we plan to strengthen the women’s healthcare sector, by offering a packaged cancer screening solution”, he said. Startups & Innovations Alongside developing new point of care diagnostic platforms, the company is also accelerating game-changing healthcare technologies by having launched ‘EDGE’- an innovative scaleup partnership programme, earlier this year. “We have just had the first round of applications globally, and are yet to screen those applications. We expect to have at least 2-4 technologies that can be taken forward. We will fund and mentor those selected technologies”, Natarajan stated. With multiple plans in place, the company is also exploring CSR funding support from various companies, to take diagnostic innovation to the next level.   Dr Manbeena Chawla (manbeena.chawla@mmactiv.com) ]]> https://biospectrumindia.com/news/92/24567/neuberg-diagnostics-forms-jv-with-sehgal-path-lab-to-expand-haemato-oncology-segment.html https://biospectrumindia.com/news/92/24567/neuberg-diagnostics-forms-jv-with-sehgal-path-lab-to-expand-haemato-oncology-segment.html Mon, 29 Apr 2024 00:00:00 +0530 Neuberg Diagnostics, one of the top 4 pathology laboratory chains in India, with more than 200 labs and 2000+ collection centres and having a presence in India, South Africa, UAE, and the USA has joined forces with Sehgal Path Lab in a strategic joint venture aimed at enhancing the Haemato-Oncology segment. Sehgal Path Lab has garnered acclaim for its exceptional services in the field of haematology. The collaboration will see Sehgal Path Lab rebranded as Neuberg Sehgal Path Lab soon, aligning with Neuberg's commitment to delivering superior diagnostic solutions. Dr Kunal Sehgal, a nationally acclaimed haematopathologist, will continue to lead as the Managing Director and Chief Pathologist of the joint venture (JV). Dr Sehgal's expertise and leadership will be instrumental in driving the expansion of the laboratory into a Global Centre of Excellence for the Haemato-Oncology segment, with a specific focus on Flow Cytometry Assays, Bone Marrow examination and developing a Myeloma Speciality Laboratory. Speaking about the JV, Dr GSK Velu, Chairman and Managing Director, Neuberg Diagnostics said, “With four entities based in Mumbai and AG Diagnostics, a Neuberg subsidiary, in Pune, Neuberg has significantly bolstered its presence in Maharashtra. This strategic consolidation reaffirms Neuberg's leadership position in Karnataka, Gujarat, Tamil Nadu, and Madhya Pradesh, while paving the way for further growth and innovation in Maharashtra's healthcare landscape." ]]> https://biospectrumindia.com/news/92/24538/strand-life-sciences-announces-launch-of-prenatal-genomic-diagnostics-portfolio.html https://biospectrumindia.com/news/92/24538/strand-life-sciences-announces-launch-of-prenatal-genomic-diagnostics-portfolio.html Wed, 24 Apr 2024 00:00:00 +0530 Bengaluru-based Strand Life Sciences has announced the launch of its prenatal screening and diagnostics portfolio with two breakthrough developments- CNSeq (sequencing based identification of aneuploidies and copy number variations) and MaatriSeq (Non-Invasive Prenatal Screening). CNSeq brings the latest Next Generation Sequencing technology to an important prenatal test marking a significant leap forward in prenatal diagnostics. Leveraging proprietary software, CNSeq delivers unmatched precision in identifying Copy Number Variations (CNVs), outperforming traditional cytogenetic and molecular techniques.  On the other hand, MaatriSeq is the first Non-Invasive Prenatal Screening (NIPS) solution validated on the latest high-throughput Illumina NovaSeq X Plus sequencing platform.This breakthrough offers a highly accurate and cost-effective solution, accessible to a wider community in India. These innovations underscore the company's commitment to innovate in genetic diagnostics and reduce the burden of rare diseases in India. "With these innovations in advanced genetic technologies, Strand wants to contribute to the efforts by the Indian Government in reducing the burden of rare diseases in India,” said Ramesh Hariharan, CEO and Co-founder of Strand Life Sciences. ]]> https://biospectrumindia.com/news/92/24502/agilus-diagnostics-opens-largest-24x7-reference-lab-and-wellness-centre-in-kottayam.html https://biospectrumindia.com/news/92/24502/agilus-diagnostics-opens-largest-24x7-reference-lab-and-wellness-centre-in-kottayam.html Mon, 15 Apr 2024 00:00:00 +0530 DDRC Agilus Diagnostics, a subsidiary of Agilus Diagnostics, has announced the launch of its regional wellness centre and laboratory in Kottayam. This wellness centre and laboratory will serve as a reference lab further strengthening the existing network of 35 labs and centres that DDRC Agilus has in Kottayam. The wellness centre and laboratory will be open 24X7 for all customers and will be especially invaluable for emergency services. The advanced laboratory has the capacity to process more than one and half lakh samples in a month ranging from simple routine tests to semi-specialised and high-end specialised tests.Recognising the rising demand for quality diagnostic services and wellness treatments, DDRC Agilus has expanded its capabilities by launching this 24X7 regional wellness centre and laboratory in Kottayam. The citizens of Kottayam will now have further access to DDRC Agilus’ extensive test menu comprising of 3,600+ tests and a range of well-curated preventive healthcare packages as well as access to the facilities at the wellness centre. This new DDRC Agilus regional wellness centre and laboratory in Kottayam will cater to the areas of Pathanamthitta, Idukki, Aleppey, Kottayam Medical College, Ettumanoor, Pala, Kumarakom, Kanjikkuzhy, Manarcadu and Changanaserry. The advanced wellness centre and  laboratory spread over 20,000 sq ft has multiple laboratory divisions including Haematology, Biochemistry, Clinical Pathology, Immunology, Histopathology, Immunohistochemistry, Molecular Genetics, Cytogenetics, Microbiology and full service radiology menu that includes ultrasound, audiometry, opthamology, digital radiography, ECG, TMT, Spirometry and Executive Medical Checkups.  ]]> https://biospectrumindia.com/news/92/24488/roche-diagnostics-india-launches-heart-failure-test-for-diabetics-as-point-of-care-device.html https://biospectrumindia.com/news/92/24488/roche-diagnostics-india-launches-heart-failure-test-for-diabetics-as-point-of-care-device.html Wed, 10 Apr 2024 00:00:00 +0530 Roche Diagnostics India has announced the launch of its point-of-care NT-proBNP test for screening diabetes patients who are at risk of cardiovascular diseases (CVD) such as heart failure (HF). This breakthrough innovation is designed to bring testing closer to clinics and revolutionise patient care. The claim extension of the NT-proBNP biomarker, available exclusively on the cobas h 232 system, aims to provide faster, more efficient diagnosis and management of HF in patients with type 2 diabetes (T2D). Although diabetes is a global health concern, its burden is more evident in developing countries like India.  Diabetes is associated with significant morbidity and mortality. Patients living with diabetes are at a higher risk of developing CVD: up to 46% of diabetic patients will develop CVD in their lifetime which is responsible for about 50% of mortality in T2D patients. Moreover, statistics indicate a staggering 30% of diabetic patients develop HF during their lifetime. Individuals with T2D and HF face up to an 8x increased risk of death compared to those without HF. Despite the number, approximately 80% of HF cases are only diagnosed following acute hospitalisaton, despite patients experiencing symptoms up to five years prior.  The challenge lies in the non-specific symptoms of HF, which often remain undetected until advanced stages. Recognising this critical gap, Roche Diagnostics India's NT-proBNP test on the cobas h 232 system facilitates early detection (screening) and intervention, enabling clinicians to identify high-risk T2D patients and initiate timely treatment discussions.   ]]> https://biospectrumindia.com/news/92/24474/institute-of-heart-lung-diseases-partners-with-krafton-india-for-active-tb-cases-detection.html https://biospectrumindia.com/news/92/24474/institute-of-heart-lung-diseases-partners-with-krafton-india-for-active-tb-cases-detection.html Mon, 08 Apr 2024 00:00:00 +0530 The Institute of Heart and Lung Diseases (IHLD), in collaboration with the Indian arm of South Korean firm Krafton, has embarked on a noble venture, aligning with the ambitious objectives of the Prime Minister's TB Mukt Bharat Abhiyan. This collaboration signifies a crucial stride in the fight against tuberculosis (TB), utilising the collective resources of Krafton India and IHLD for implementation. During its initial phase, the initiative is to conduct active case finding programmes in one district of Uttarakhand (UK) and one district of Uttar Pradesh (UP). Dr Rahul Chandola, Founder-Chairman of the Institute of Heart Lung Diseases (IHLD) Research Centre said, “Through this partnership, IHLD endeavours to screen approximately 1 lakh individuals over the next 12 months. Moreover, the aim is to increase TB detection by 10-15% in the target districts that are currently not accounted for in the existing system, significantly bolstering efforts towards disease surveillance and management.” Innovative approaches are integral to the success of TB Mukt Bharat. Dr Chandola highlighted the utilisation of artificial intelligence (AI)-supported X-ray machines for initial screening, enabling swift and accurate identification of potential TB cases, thereby enabling a huge chunk of the population infected with tuberculosis to be identified. This technological intervention not only streamlines the screening process but also enhances the effectiveness of early detection, a crucial aspect in combating the spread of tuberculosis.   ]]> https://biospectrumindia.com/news/92/24477/iit-jodhpur-develops-sensor-to-track-disease-progression-provide-rapid-medical-support.html https://biospectrumindia.com/news/92/24477/iit-jodhpur-develops-sensor-to-track-disease-progression-provide-rapid-medical-support.html Mon, 08 Apr 2024 00:00:00 +0530 Researchers at the Indian Institute of Technology (IIT) Jodhpur have developed a nanosensor that helps in the quick detection of cytokines, a group of proteins that regulate various cells. This development aims to reduce the mortality rate occurring due to delayed diagnosis and a lack of early warnings. Moreover, the technology has immense potential to be used as a rapid and point-of-care technique for health monitoring, disease diagnosis, prognosis, and immune response tracking.   Talking about the developed technique and its future scope, Prof. Ajay Agarwal, Department of Electrical Engineering, IIT Jodhpur, said, “This technique which is currently in its development stage has provided exciting and encouraging results for three biomarkers i.e. interleukin-6 (IL-6), interleukin-β (IL-β), and TNF-α which are key pro-inflammatory cytokines, released by inflammatory cells. As of now, the testing is done for controlled samples, but the team aims to take the technology to clinical trials soon. The group is also using this technique, to develop detection protocols for the early-stage and quick diagnosis of Sepsis and Fungal infections.” This novel sensor uses Surface Enhanced Raman Spectroscopy to detect analytes even at low concentrations, and is based on semiconductor process technology and works on the principle of Surface Enhanced Raman Scattering (SERS).  The most widely used techniques currently for cytokine detection are enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR). These methods are reliable but highly time-consuming, requiring trained personnel and a long sample preparation or analysis time of over 6 hours. However, the sensor developed by IIT Jodhpur takes only 30 minutes in comparison and is also cost effective. The developed sensor is used in conjuncture with artificial intelligence (AI) for quick and accurate data processing and analysis. By getting a faster and more robust diagnosis of a person’s autoimmune diseases and bacterial infections, this sensor possesses the capability to transform a patient’s medical treatment.   ]]> https://biospectrumindia.com/news/92/24465/sophia-genetics-and-strand-life-sciences-announce-new-strategic-partnership.html https://biospectrumindia.com/news/92/24465/sophia-genetics-and-strand-life-sciences-announce-new-strategic-partnership.html Thu, 04 Apr 2024 00:00:00 +0530 SOPHiA GENETICS, a cloud-native software company in the healthcare space and a leader in data-driven medicine, has announced a strategic partnership with Bengaluru-based Strand Life Sciences, a pioneer in bioinformatics and diagnostics, to deliver innovative solutions that will fuel the use of precision medicine globally.  The new collaboration will leverage the industry-leading strengths from both companies to provide access to advanced genomics technologies, cutting-edge bioinformatics services and innovative diagnostics solutions. Through the broad-ranging collaboration between SOPHiA GENETICS and Strand, the two companies will use their bioinformatics expertise to expand the ability to accurately analyse key healthcare data and facilitate the use of data-driven decision-making globally. SOPHiA GENETICS will provide support via the decentralised  SOPHiA DDM™ Platform and Strand via its curated variant databases and bioinformatics solutions expertise, and the companies will collaborate on strategic test co-development, among other initiatives, that will look to improve health outcomes in India and globally. The SOPHiA DDM™ Platform is designed to compute a wide array of genomic variants and continually hone machine learning algorithms. With their sophisticated technologies and bioinformatics expertise, SOPHiA GENETICS and Strand will jointly deepen their value propositions. ]]> https://biospectrumindia.com/news/92/24416/who-launches-new-guidance-on-use-of-targeted-ngs-tests-for-diagnosis-of-drug-resistant-tb.html https://biospectrumindia.com/news/92/24416/who-launches-new-guidance-on-use-of-targeted-ngs-tests-for-diagnosis-of-drug-resistant-tb.html Thu, 21 Mar 2024 00:00:00 +0530 The World Health Organisation (WHO) has just published recommendations on the use of a new class of diagnostic technologies i.e. targeted next-generation sequencing (NGS) tests for the diagnosis of drug-resistant tuberculosis (TB) in the third edition of the Consolidated guidelines on tuberculosis. Module 3: Diagnosis- Rapid diagnostics for tuberculosis detection. The recommendations provide a novel approach for the rapid detection of drug resistance to new anti-TB drugs using the latest technologies. The guidelines are accompanied by a WHO operational handbook, which provides laboratory personnel, clinicians and other clinical staff, as well as ministries of health and technical partners, detailed guidance on implementing the evidence-based recommendations, including recent updates on targeted NGS tests. It describes the WHO-recommended tests for the rapid bacteriological diagnosis of TB disease, including procedures for the tests, model algorithms, and the steps and processes required to implement and scale up new tests to diagnose TB and detect resistance to anti-TB drugs. To accompany the new guidance, WHO has also launched a new TB sequencing portal with more than 56,000 sequences. The portal, developed in partnership with FIND and Unitaid, represents the most advanced sequencing and phenotyping knowledgebase for Mycobacterium tuberculosis. The portal includes a dashboard visualising the data used in the WHO mutation catalogue published in November 2023.  The WHO TB sequencing portal will greatly contribute to the collective understanding of mutations in the Mycobacterium tuberculosis genome and their association with drug resistance. ]]> https://biospectrumindia.com/news/92/24408/medgenome-partners-with-darshan-giva-foundation-for-tb-diagnosis-using-whole-genome-sequencing.html https://biospectrumindia.com/news/92/24408/medgenome-partners-with-darshan-giva-foundation-for-tb-diagnosis-using-whole-genome-sequencing.html Wed, 20 Mar 2024 00:00:00 +0530 Bengaluru-based genomics company MedGenome has partnered with Darshan GIVA Foundation, a non-governmental organisation, to pioneer a transformative approach to tuberculosis (TB) diagnosis and treatment. The partnership aims at an access intervention pilot for offering Whole Genome Sequencing (WGS) testing free of cost to pre diagnosed drug-resistant TB (DRTB) patients. The goal is to integrate whole genome sequencing based TB testing into India’s National Tuberculosis Elimination programme and incorporating it into standard diagnosis recommendations of the World Health Organization (WHO). Simultaneously, the accuracy of the diagnostic results of WGS will be validated vis-a-vis gold standard diagnostic testing method, namely Liquid culture Drug Susceptibility Testing (LCDST) and Line Probe Assay 1 & Line Probe Assay 2 (LPA 1 & LPA 2). Darshan GIVA Foundation (DGF) is at the forefront in this access intervention pilot with collaborative efforts partnering with government agencies, Mylan Pharmaceuticals and MedGenome. The project is aimed at supporting the Government of India’s 2025 TB elimination goals by making evidence-based recommendations for the use of WGS by clinicians, accelerating testing phase through accurate & quick determination of drug susceptibility in DRTB diagnosis, enabling customised & effective treatment for these DRTB patients.   ]]> https://biospectrumindia.com/news/92/24341/co-diagnostics-receives-cdsco-clearance-for-influenza-multiplex-pcr-test.html https://biospectrumindia.com/news/92/24341/co-diagnostics-receives-cdsco-clearance-for-influenza-multiplex-pcr-test.html Thu, 07 Mar 2024 00:00:00 +0530 US-based Co-Diagnostics, Inc. has announced that CoSara Diagnostics, its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its SARAPLEX Influenza Multiplex (IFM) Test Kit to clinical laboratories as an in vitro diagnostic (IVD) for the detection and differentiation of Influenza A and Influenza B. CoSara's new real-time multiplex PCR test is built on the company's patented Co-Primers technology and designed to simultaneously detect influenza A (H1N1, H3N2, H7N9, H1N2, H5N1, H2N2, H9N2, H10N8, H5N6, H7N7, H7N4, H7N2 and H2N1), influenza B (Yamagata and Victoria strains) and to differentiate between H1N1 and H3N2. Co-Primers utilise a unique design architecture to combat common issues with real-time PCR that can lead to inaccurate results, specifically primer dimer propagation, and which are magnified in multiplex reactions. CoSara Director Mohal Sarabhai commented, "This test marks the 15th of CoSara's clinical lab tests to receive IVD clearance by the CDSCO, and adds to our expanding menu of valuable diagnostic tools available to our growing distributor and laboratory customer base."  CoSara has previously received CDSCO clearance for RT-PCR tests for Mycobacterium tuberculosis, malaria, hepatitis B, hepatitis B viral load, hepatitis C, hepatitis C viral load, HPV types 16 and 18 and HPV-HR, two COVID-19 assays, chikungunya, dengue, a dengue/chikungunya duplex test, and a Flu A/Flu B/COVID-19 (ABC) multiplex test, all designed using the company's patented Co-Primers technology and cleared to be manufactured and sold to clinical laboratories in the Indian market as IVDs. ]]> https://biospectrumindia.com/news/92/24323/apollo-diagnostics-expands-presence-in-pune-with-launch-of-4-new-centres.html https://biospectrumindia.com/news/92/24323/apollo-diagnostics-expands-presence-in-pune-with-launch-of-4-new-centres.html Tue, 05 Mar 2024 00:00:00 +0530 Apollo Diagnostics, a division of Apollo Health and Lifestyle Limited (AHLL), has launched four new centres across Pune, Maharashtra in Kalyani Nagar, Baner, Ravet and Kothrud. With a total of 1700 centres operational across India & 150 centres now in operation Pune, Apollo Diagnostics is demonstrating its commitment in providing accessible and quality diagnostic services to a larger population in Pune. This expansion will likely enhance healthcare accessibility and contribute positively to the overall well-being of the community. A precise diagnosis is crucial for promptly identifying illnesses, allowing doctors to accurately diagnose health conditions and administer appropriate treatments for improved quality of life. The recently opened centre serves as a comprehensive hub across Kalyani Nagar, Baner, Ravet and Kothrud for various intricate pathology tests, ensuring reliable and high-quality reports, swift testing, and top-notch services for all individuals. Patients can conveniently opt for home sample collection through a simple 6-step procedure and easily access their reports whenever needed.  ]]> https://biospectrumindia.com/news/92/24304/icmr-inks-mou-with-cdsco-to-fortify-testing-validation-ecosystem-of-in-vitro-diagnostics.html https://biospectrumindia.com/news/92/24304/icmr-inks-mou-with-cdsco-to-fortify-testing-validation-ecosystem-of-in-vitro-diagnostics.html Sun, 03 Mar 2024 00:00:00 +0530 A groundbreaking partnership has been announced between the Indian Council of Medical Research (ICMR) and the Central Drugs Standard Control Organization (CDSCO), aimed at fortifying the Testing and Validation Ecosystem for In Vitro Diagnostics (IVDs).Both organisations have formalised their collaboration through a signed Memorandum of Understanding (MoU). This partnership heralds a new era of synergy, innovation, and excellence in the realm of healthcare diagnostics. The focus of this collaboration is to enhance the quality, efficacy, and safety of IVDs through robust testing and validation mechanisms. By leveraging the collective expertise and resources of ICMR and CDSCO, MedTech Mitra is poised to revolutionise the landscape of diagnostic technologies in India.MedTech Mitra was recently launched by the government as a strategic initiative to empower medtech innovators and advance healthcare solutions.   Image caption: L-R- Dr Rajeev Singh Raghuvanshi, Drugs Controller General of India, CDSCO; Dr VK Paul, Member (Health), NITI Aayog; Dr Rajiv Bahl, Director General, ICMR ]]> https://biospectrumindia.com/news/92/24251/ezerx-and-imgenex-india-join-hands-to-make-healthcare-affordable-and-accessible.html https://biospectrumindia.com/news/92/24251/ezerx-and-imgenex-india-join-hands-to-make-healthcare-affordable-and-accessible.html Mon, 26 Feb 2024 00:00:00 +0530 In a landmark development set to transform healthcare access across India, Bhubaneswar-based startup EzeRx has signed a strategic Memorandum of Understanding (MoU) with biotechnology company IMGENEX India. This collaboration brings together two healthcare innovators to advance a shared mission: making quality medical care affordable and accessible to all Indians. Leveraging EzeRx's expertise in artificial intelligence (AI)-powered medical devices and IMGENEX's leadership in cutting-edge biotechnology, the partners aim to develop cutting-edge screening and diagnostic solutions that are indigenous, low-cost, and effective. This first-of-its-kind partnership unites technical prowess with purpose, applying technology to bridge gaps in preventive care and early diagnosis. EzeRx has previously partnered with leading companies like TCS, Infosys Foundation, and Indian Oil Corporation. However, this strategic partnership with IMGENEX holds special significance for advancing indigenous manufacturing and R&D in healthcare. The MoU outlines joint initiatives to provide low-cost, effective, and privacy-protected screening solutions, particularly for diseases affecting women. This purpose-driven partnership aims to transform healthcare access across India and also explore global opportunities. Together, EzeRx and IMGENEX aim to develop India-centric solutions that set a benchmark in quality, cost-effectiveness, and scalability. ]]> https://biospectrumindia.com/news/92/24183/keralas-sabine-hospital-to-install-machine-which-detects-genetic-diseases-inside-womb.html https://biospectrumindia.com/news/92/24183/keralas-sabine-hospital-to-install-machine-which-detects-genetic-diseases-inside-womb.html Fri, 09 Feb 2024 00:00:00 +0530 Sabine Hospital, a Kerala-based in vitro fertilisation (IVF) hospital is all set to install a state-of-the-art machine which detects genetic diseases inside the womb. The machine, named Next Generation Sequencer (NGS) will be used to detect genetic diseases in foetuses. The NGS machine will be installed at the hospital as part of its mission to make advanced diagnosis and treatment affordable to the common people. Sabine Hospital, which holds the highest success rate in IVF treatment in the country, holds the record of having the largest number of babies born through IVF every year. Many diseases such as some cancers, sickle cell anemia, hemophilia, down syndrome and turner syndrome can be addressed in the foetal stage itself with the help of the Next Generation Sequencer. The DNA samples of children born with IVF treatment are tested using the NGS machine to identify the risk factors and genetic abnormalities.  The new NGS machine will be installed in the recently launched genetics department. Along with this, foetal medicine department, which ensures health of the expectant mothers and their unborn babies and upgraded NICU have also been launched. With a bed capacity of 50 and a NICU Level of 3, the state-of-the-art Neonatal Intensive Care Unit (NICU) ensures world class treatment for new born babies. ]]> https://biospectrumindia.com/news/92/24193/metropolis-healthcare-launches-advanced-diagnostic-testing-centre-in-ratlam-mp.html https://biospectrumindia.com/news/92/24193/metropolis-healthcare-launches-advanced-diagnostic-testing-centre-in-ratlam-mp.html Thu, 08 Feb 2024 00:00:00 +0530 Metropolis Healthcare, India’s leading diagnostic service provider, has launched a cutting-edge diagnostic testing centre in Ratlam, Madhya Pradesh (MP). This state-of-the-art world class diagnostic laboratory has the capacity to process up to 6000-8000 samples per month, encompassing routine pathology tests to advanced molecular diagnostics. The inauguration ceremony was graced by Prahlad Patel, Mayor, Ratlam Municipal Corporation, accompanied by Manisha Sharma, President, Ratlam Municipal Corporation, and Padmashree Dr Leela Joshi, a distinguished Physician, and Gynaecologist. Surendran Chemmenkottil, Chief Executive Officer, Metropolis Healthcare said, "The establishment of this lab in Ratlam aligns with our commitment to providing high-quality healthcare to Tier 2 and 3 towns, where our brand is already highly regarded. With multiple advanced labs in Madhya Pradesh, our new lab in Ratlam is poised to set new standards in accurate diagnosis and patient-centric care.”  Bhoopendra Singh Rajawat, Chief Business Officer (West, Central & North India), Metropolis Healthcare said, “Our new testing center in Ratlam is well-equipped for a variety of tests, from regular check-ups to advanced molecular diagnostics, all at reasonable costs."  Metropolis laboratories offers extensive tests and reports of the highest quality at affordable rates. It is known for numerous quality accreditations to its credit, both in India and abroad and with decades of experience under the hat, Metropolis has conscientiously developed the Indian Reference Range for an extensive test menu, which is now being used by thousands of laboratories across the country. ]]> https://biospectrumindia.com/news/92/24130/medtech-diagnostic-sectors-require-budget-2024-25-to-pay-attention-on-indigenous-production-skill-development.html https://biospectrumindia.com/news/92/24130/medtech-diagnostic-sectors-require-budget-2024-25-to-pay-attention-on-indigenous-production-skill-development.html Mon, 29 Jan 2024 00:00:00 +0530 Empowering the medtech and healthcare industry as a cornerstone of the Indian economy requires a dynamic shift towards Atmanirbhar Bharat and innovation. The diagnostic and medical devices industry players lay down their expectations from Union Budget 2024-25. “It is heartening to see that the government has placed affordability as one of its top priorities. However, the customs duties and taxes levied on medical devices in India are one of the highest in the world and highest among the neighbouring countries which directly impacts patient affordability; this is therefore contradictory to what the government is trying to achieve. As per government data, more than 80% of critical medical devices are imported into India to meet the rising demand for quality healthcare. We hope that as the preparation for the Union Budget 2024 gets underway, a correction on the tariff rates is urgently being considered”, said Pavan Choudary, Chairman, Medical Technology Association of India (MTaI). "In the upcoming budget, the government could further support the medtech sector by reducing import duties and lowering GST on locally procured raw materials, particularly for critical medical devices such as stents, heart valves, knee and hip implants. Incorporating advanced treatment methods like TAVI/TAVR into the Ayushman Bharat – Pradhan Mantri Jan Aarogya Yojana (AB-PMJAY) insurance scheme, and encouraging private health insurance companies to follow suit, can significantly enhance healthcare access for economically weaker sections",Vivek Shah, Chief Executive Officer, Meril voiced his opinion. Sharing his perspective, Mandeep Singh Kumar, Vice President and Country General Manager, Intuitive India said, “With the need for adoption of modern technology in various aspects of healthcare, accessibility to advanced surgical technologies like robotic-assisted surgery (RAS) must be a continued focus in this year’s union budget. Streamlined approval processes for high-tech devices across various ministries, coupled with a fair and predictable policy regime, would accelerate patient access to life-saving technologies and improve clinical outcomes. A reduction in the high customs duties for medical devices will enable the industry to expand its distribution in India and help the industry grow to its potential. Abolishing the 5% health cess ad valorem tax on imported medical devices is imperative to help the country gain better access to advanced technologies in healthcare.” “Through preferential treatment for homegrown companies in tender allocation and increased customs duties on readily available equipment, the nation can create the groundwork for a thriving ecosystem supporting the growth of local manufacturers. Furthermore, continued funding along with comprehensive technological and manpower-related assistance from the administration will establish a welcoming environment for Indian startups to flourish, leading to unprecedented technological advancements within the borders and beyond”, Chander Shekhar Sibal, Sr. Vice President & HOD, Healthcare Business, Fujifilm India further added. Giving an overview on behalf of the diagnostic industry, Chandra Ganjoo, Group Chief Executive Officer, Trivitron Healthcare said, “The industry advocates for a comprehensive strategy: incentivising R&D and indigenous production, streamlining regulatory processes for faster product approvals, and enhancing infrastructure and skills. Tax incentives for investment in advanced technology, streamlining bureaucratic procedures, and fostering industry-academia collaboration can stimulate domestic manufacturing. This approach should align with global standards and ensure a stable regulatory environment to attract investments.” Laying emphasis on the diagnosis of rare diseases,  Surajit Chakrabartty, Chief Financial Officer, MedGenome said, “We would urge the Government of India to lead awareness campaigns that can educate and build trust around the effectiveness and benefits of genetic testing in identifying and managing the genetic diseases. Making prenatal genetic testing accessible across all socioeconomic backgrounds coupled with nationwide awareness campaigns on rare diseases, will empower early interventions. For further progress and building a robust genomics infrastructure, increased investment in research is crucial along with establishing strict regulatory guidelines and ethical frameworks which address aspects like partnerships, data storage, usage protocols, consumer protection, de-identification methods, potential discoveries, and outcome distribution." "With the growing burden of non-communicable diseases (NCDs) and infectious diseases, we underscore the importance of comprehensive screening and diagnostics programmes, along with expanded skilling courses for healthcare professionals to attract and enhance talent in the advanced diagnostic field”, said Gaurav Srivastava, Co-Founder & Chief Operating Officer, HaystackAnalytics. Adding another perspective, Sandeep Gulati, General Manager, South Asia, ResMed said, “Considering the dynamic healthcare landscape, there is potential for medical equipment and home healthcare using telemonitoring to be covered under insurance. We also encourage the inclusion of sleep-related disorders such as Obstructive Sleep Apnea (OSA) to the classification of Noncommunicable illnesses (NCDs). Additionally, there is a need to incorporate sleep testing in the category of diagnostics under National Diagnostics Essential List.” Summing it up, Jatin Mahajan, Secretary, Association of Diagnostic Manufacturers of India (ADMI) said, "Even though the government has created a policy for purchase preference for Made in India products, unfortunately, this policy has not worked. In most government purchases, there is no preference for 'Made in India' as the state governments are not implementing this policy effectively. This policy is either ignored or side-lined." "The government must work with the industry to identify the specific need-gap for timely addressal of the issue. Industry-academia linkages should be strengthened, and more professional courses that fully cater to the industry's skill requirements and ensure higher employment for the trained personnel need to be introduced", Mahajan concluded.   ]]> https://biospectrumindia.com/news/92/24117/worlds-first-leg-health-test-utilising-neural-network-technology.html https://biospectrumindia.com/news/92/24117/worlds-first-leg-health-test-utilising-neural-network-technology.html Thu, 25 Jan 2024 00:00:00 +0530 Varco Leg Care, a New Delhi-based startup, has unveiled the world's first Artificial Intelligence (AI)-powered leg health test. This groundbreaking technology harnesses the power of AI, machine learning, and neural algorithms and provides users with personalisation in addressing conditions like spider veins, diabetic foot, restless leg syndrome and more.  Users start by answering ten carefully designed questions about lifestyle factors, health history, symptoms, and areas of concern. They then upload high-resolution images of their legs from multiple angles, which VarcoLeg Care's advanced neural network synthesises to compute the user's comprehensive leg health score, a single yet nuanced metric encapsulating their overall leg health standing.  The test further provides targeted product recommendations from Varco Leg Care products. These ultra-personalised recommendations include optimal products, solutions, dosages, durations, and applications to integrate into the user's daily health regimen.  Commenting on the launch, Anondeep Ganguly, CEO and Founder of Varco Leg Care said, “Our research shows that 30% of Indians face leg issues with no correct product or solution helping them relieve or cure the pain. More so, this part of the body is always ignored with people trudging their way with pain. Our first-of-its-kind Leg Health Test represents a significant leap forward in personalised leg healthcare, where we provide users with ultra-targeted recommendations to address their unique needs, empowering them to take charge of their health journey. By incorporating Neural Network Technology, we aim to empower individuals to proactively improve their leg health and maintain it.” ]]> https://biospectrumindia.com/news/92/24097/agappe-unveils-hx-series-haematology-equipment-and-ae-powered-immunology-clia-analyser.html https://biospectrumindia.com/news/92/24097/agappe-unveils-hx-series-haematology-equipment-and-ae-powered-immunology-clia-analyser.html Mon, 22 Jan 2024 00:00:00 +0530 In a landmark event for Indian healthcare technology, Kochi-based Agappe has unveiled its first indigenously manufactured  HX series haematology equipment and the AE-powered Immunology CLIA analyser, the Mispa i200, marking a new era in diagnostics and patient care. The HX series – HX50, HX58, HX80, and HX88 – represent the latest advancements in haematology analysers, utilising Nucleic Acid Fluorescence Staining technology. These machines, a first of their kind in India, promise to transform laboratory work by automating blood tests with unprecedented speed and accuracy. They are designed to provide comprehensive health information, aiding in the diagnosis of various conditions through blood counts, haemoglobin, platelet count, and other critical tests. The Mispa i200, an AE-powered CLIA (Chemiluminescence Immunoassay) analyser, is a unique innovation in detecting and quantifying biomarkers such as hormones, cancer markers, cardiac markers, infectious diseases, neuro-disorders, and autoimmune markers. Agappe's mission is to make top-tier healthcare technology accessible to all. The launch of these machines is a significant leap for Indian healthcare technology. By enhancing diagnostic capabilities and healthcare standards, these innovations are set to revolutionise patient care both in India and globally.   ]]> https://biospectrumindia.com/news/92/24080/qure-ai-and-project-data-sphere-partner-to-focus-on-advancing-cancer-research-using-ai.html https://biospectrumindia.com/news/92/24080/qure-ai-and-project-data-sphere-partner-to-focus-on-advancing-cancer-research-using-ai.html Wed, 17 Jan 2024 00:00:00 +0530 In a pivotal stride toward advancing cancer care, Mumbai-based startup Qure.ai, a leader in artificial intelligence (AI) solutions for medical imaging, and Project Data Sphere, a nonprofit initiative of the US-based CEO Roundtable on Cancer, have announced their partnership to augment tumour assessments using artificial intelligence (AI)-enabled solutions for clinical trials and cancer care. The collaboration aims to increase efficiency and consistency in evaluating the effectiveness of cancer treatments, ultimately improving the quality of care for patients. The focus of this collaboration is autoRECIST, a product of Project Data Sphere’s Images and Algorithms programme. The programme, initiated in consultation with the US Food and Drug Administration (FDA), includes stakeholders and experts from across the pharmaceutical industry and academia. In collaboration with Qure.ai, autoRECIST will address the critical need for automating and standardising tumour response assessments in medical imaging to enhance cancer treatment and research. Rooted in current imaging guidelines, this AI clinical tool will aid radiologists in the detection, selection, measuring and tracking of lesions using defined criteria. ]]> https://biospectrumindia.com/news/92/24069/sophia-genetics-and-karkinos-healthcare-partner-to-advance-cancer-research-in-india.html https://biospectrumindia.com/news/92/24069/sophia-genetics-and-karkinos-healthcare-partner-to-advance-cancer-research-in-india.html Mon, 15 Jan 2024 00:00:00 +0530 US-based cloud-native software company SOPHiA GENETICS has announced that Mumbai-based startup Karkinos Healthcare, will partner with SOPHiA GENETICS and adopt the SOPHiA DDM Platform to advance cancer testing and research for blood cancers and solid tumours to underserved areas in low and middle-income countries.   The SOPHiA DDM Platform is designed to compute a wide array of genomic variants and continually hone machine learning algorithms to detect rare and challenging cases. Karkinos Healthcare will use SOPHiA GENETICS' technology to expand its offerings, advance research and streamline workflow for a variety of blood cancers, including Myeloid cancer and Lymphoma. In addition, the company will analyse solid tumours for a variety of cancer types including ovarian, prostate, breast, pancreas, lung, colorectal, skin, and brain cancers. The SOPHiA DDM Platform offers tailored NGS-based workflows to streamline processes – from sample to report – to accelerate analysis. By using the SOPHiA DDM Platform, researchers from Karkinos Healthcare will quickly obtain high-quality and reproducible data that will ultimately accelerate clinical research studies and advance the use of precision medicine. ]]> https://biospectrumindia.com/news/92/24000/himedia-launches-covid-19-pcr-kit-to-detect-jn-1-variant.html https://biospectrumindia.com/news/92/24000/himedia-launches-covid-19-pcr-kit-to-detect-jn-1-variant.html Tue, 26 Dec 2023 00:00:00 +0530 HiMedia Laboratories has announced that its RT-PCR kits are capable of detecting the recently discovered JN.1, SARS-CoV-2 variant. The portfolio includes: MBPCR243 - Hi-PCR® Coronavirus (COVID-19) Multiplex Probe PCR Kit MBPCR255 - Hi-PCR® Triplex COVID-19 Detection Kit MBPCR262 - Hi-PCR® COVID FLU Multiplex Probe PCR Kit MBPCR270 - Hi-PCR® COVID FLU RSV Multiplex Probe PCR Kit JN.1 (BA.2.86.1.1) is a descendant of the BA.2.86 (Pirola). Pirola is the nickname of the BA.2.86 variant of Omicron, a variant of SARS-CoV-2. The number of cases caused by JN.1 and its close relative Pirola is on the rise all over the world. The first case of this variant was detected in Denmark in August and later in USA. Cases of JN.1 have been found in some European countries, in Singapore, in China, and recently in Kerala, Maharashtra and in other states across India. The company has tested the impact of the variant on its Multiplex PCR Kit. Mutations, especially in RNA viruses like SARS-CoV-2 were expected and strain JN.1 is an example of the same. Its immune-escape capabilities have made it a variant of concern. “Multiplexing has the substantial advantage of increased accuracy of data normalization, more data and higher throughput with limited samples in addition to sensitive and specific detection of multiple targets while eliminating the possibility of false positives, all in just one single run” says Dr Rajas V Warke – Director of HiGenoMB® and Virology, HiMedia Labs. To determine whether their RT-PCR kits can detect the JN.1 variant of the virus, the bioinformatics experts team at Hi-Gx360® analysed the latest genome sequencing data available from the Global Initiative on Sharing All Influenza Data (GSAID) in depth. DNA sequences are dynamic; the potential of the sequences to mutate due to errors in DNA replication caused by various genetic or acquired possibilities makes it imperative to keep learning and upgrading kits for attaining accuracy in diagnosis. In summary, based on the company's comprehensive bioinformatics analysis, all of above mentioned kits can detect the JN.1 variant.   ]]> https://biospectrumindia.com/news/92/23965/lupin-diagnostics-expands-presence-in-south-india-with-new-reference-lab-in-chennai.html https://biospectrumindia.com/news/92/23965/lupin-diagnostics-expands-presence-in-south-india-with-new-reference-lab-in-chennai.html Sat, 16 Dec 2023 00:00:00 +0530 Mumbai-based pharma major Lupin has announced the launch of its new state-of-the-art Regional Reference Laboratory in Chennai, Tamil Nadu. This expansion marks a pivotal moment in Lupin Diagnostics’ commitment to provide accessible, affordable, and quality diagnostic healthcare services in South India. The newly launched laboratory enhances Lupin Diagnostics’ extensive network which now comprises of 36 laboratories and over 600 collection centers across India. The Regional Reference Laboratory in Chennai is equipped with cutting-edge diagnostic technologies and a team of highly qualified clinical experts. Lupin Diagnostics offers an extensive range of reliable and high-quality diagnostic services, including molecular diagnostics, cytogenetics, flow cytometry, cytology, microbiology, serology, haematology, immunology, routine biochemistry, and more, apart from routine and specialized tests. Commenting on the launch, Ravindra Kumar, CEO, Lupin Diagnostics said, “The launch of our state-of-the-art Regional Reference Laboratory in Chennai signifies a significant step toward accessible and reliable healthcare. Our vision extends beyond lab tests; it encompasses a commitment to empowering doctors and patients through precise, evidence-based diagnostics. With cutting-edge technology and a team of dedicated experts, we aim to redefine healthcare experiences, fostering a society where accurate diagnosis is a cornerstone of well-being. This expansion reflects our relentless dedication towards patient-centricity and purpose of being a catalyst for healthier lives.” ]]> https://biospectrumindia.com/news/92/23966/himedia-ng-biotech-launch-amr-bacteria-detection-kits-in-india.html https://biospectrumindia.com/news/92/23966/himedia-ng-biotech-launch-amr-bacteria-detection-kits-in-india.html Sat, 16 Dec 2023 00:00:00 +0530 Mumbai-based HiMedia – HiGenoMB has received approval from the Central Drugs Standard Control Organization (CDSCO) for importing NG-Test CARBA 5 kit from NG Biotech, a France based company.   HiMedia – HiGenoMB in joint collaboration with NG Biotech are making this rapid kit available to Indian market. The kit is a rapid test for the qualitative detection and differentiation of five common carbapenemase enzymes (KPC (K), OXA-48-like (O), IMP (I), VIM (V), NDM (N)) in bacterial colonies. These carbapenemases producing bacteria are mainly detected in hospital settings and are responsible for most of the nosocomial infections, raising major global health problems since their presence can be difficult to detect. The kit is easy to use, portable, and requires minimal training to operate, making it especially useful in resource-constrained settings where diagnostic facilities are limited. Speaking on the occasion, Dr Rajas Warke, Director (Molecular Biology) of HiMedia Labs said, "It is a rapid test that aids in early detection of AMR bacteria, which is a global public health concern. This kit will play a crucial role in helping healthcare providers to diagnose and treat patients quickly & accurately, ultimately improving patient outcomes."  The NG-Test CARBA 5 kit is a result of HiMedia Labs expertise in the field of molecular diagnostics and commitment to providing the latest in diagnostic testing solutions. This approval from CDSCO is a testament to their strong reputation and credibility as a reliable provider of high-quality diagnostic products. ]]> https://biospectrumindia.com/news/92/23968/cytelabs-launches-dual-in-situ-hybridisation-testing-for-breast-cancer-patients.html https://biospectrumindia.com/news/92/23968/cytelabs-launches-dual-in-situ-hybridisation-testing-for-breast-cancer-patients.html Sat, 16 Dec 2023 00:00:00 +0530 Cytelabs, a first-of-its-kind, specialised oncopathology cancer diagnostic service powered by Cytecare Cancer Hospital in Bengaluru, has officially announced the launch of dual in situ hybridisation (DISH) testing for breast cancer patients. It is the first stand-alone private laboratory in India to make this cutting-edge diagnostic technique accessible for breast cancer patients in the country. This is increasingly getting popular as a preferred method of testing HER2 status in breast cancer. Approved by the United States Food and Drug Administration (US FDA), globally DISH is a gamechanger in accurate human epidermal growth factor receptor 2 (HER2) testing, which is crucial for precision therapy in breast cancer. It significantly reduces the waiting period (HER2 status report within 24-48 hours) and angst among patients and their families. Elaborating on the need to make this state-of-the-art technology easily accessible in India, Dr Aparna Gangoli, Director, Cytelabs, said, “DISH promises quality results and short turnaround time ensuring that the treatment for breast cancer can be planned and initiated without wasting undue time.The prognostic and predictive implications of HER2 status makes accurate and efficient HER2 testing of paramount importance in characterizing all invasive breast carcinomas.” Breast cancer cases are prognostically divided into HER2 positive and HER2 negative groups. HER2 positive patients can benefit from targeted therapy with Trastuzumab, a therapeutic agent which blocks the HER2 antigen sites on the HER2 expressing tumour cells and stops them from proliferating further. Accurate HER2 testing is critical for determining the most suitable treatment for patients.  Currently, Cytelabs provides easy access to high-quality cancer diagnostic services to oncologists and patients across 65 partner hospitals in Karnataka, Andhra Pradesh, and Telangana.  ]]> https://biospectrumindia.com/news/92/23958/molbio-diagnostics-partners-with-finlands-testi-technologies-to-commercialise-saliva-based-self-test-kits.html https://biospectrumindia.com/news/92/23958/molbio-diagnostics-partners-with-finlands-testi-technologies-to-commercialise-saliva-based-self-test-kits.html Fri, 15 Dec 2023 00:00:00 +0530 Goa-based Molbio Diagnostics has announced its partnership with Finnish innovation leader, Testi Technologies, to manufacture its flagship product PROMILLESS - a saliva-based diagnostics test to measure body alcohol content. According to the World Health Organization, alcohol consumption contributes to 3 million deaths each year globally as well as to the disabilities and poor health of millions of people. The harmful use of alcohol is responsible for 5.1% of the global burden of disease.  PROMILLESS, an easy to use, low cost, saliva based self-diagnostics test that has been developed together with VTT (Technical Research Centre of Finland), is a CE approved class 1 device that is patented worldwide.  The self-test alcohol strip recognises alcohol content from saliva and determines if the alcohol content is above or below the indicated threshold level. T  Broadening its scope, Testi Technologies is venturing into both human and pet healthcare markets with a forthcoming saliva-based glucose test.  Under the current agreement, Molbio will have the rights to commercialise, market and sell PROMILLESS under its own brand name globally. Sriram Natarajan, Chief Executive Officer of Molbio Diagnostics says, “The current test for alcohol, the upcoming test for glucose and many more human and veterinary tests in the pipeline will prove to be revolutionary.”   ]]> https://biospectrumindia.com/news/92/23941/astrazeneca-roche-diagnostics-to-improve-diagnostic-testing-for-breast-cancer-patients-in-india.html https://biospectrumindia.com/news/92/23941/astrazeneca-roche-diagnostics-to-improve-diagnostic-testing-for-breast-cancer-patients-in-india.html Tue, 12 Dec 2023 00:00:00 +0530 AstraZeneca Pharma India has signed a Memorandum of Understanding (MoU) with Roche Diagnostics India to improve diagnostics for breast cancer patients with a key focus to streamlining HER2 diagnostics with newer advancements in the field. Breast cancer, globally the most prevalent cancer among women, takes a critical turn when transitioning to metastatic stages, accounting for 30% of post-diagnosis cases and constituting a primary cause of breast cancer-related fatalities. Vital to patient care is the reassessment of biomarkers, specifically HER2, guiding crucial treatment decisions. The 15% to 20% of cases identified as HER2 positive present opportunities for targeted therapies, with advancements in HER2 testing continually optimizing its clinical application since the 1980s. In 2020, it was estimated that breast cancer claims nearly 700,000 lives worldwide each year and that there would be over 2.2 million new cases.  Approximately half of all patients with breast cancer (mBC) express low levels of HER2. These patients with HER2 low status may now be eligible for a targeted treatment, which could significantly improve their outcomes.      The new initiative is focused on advancements in HER2 testing standardisation and reporting. As per the partnership, comprehensive training initiatives for pathologists and medical oncologists will be imparted. Training modules designed for oncologists will cover advances in HER-2 testing and HER-2 low interpretations. The collaboration aims to address existing diagnostic challenges, reduce turnaround times, and elevate the overall patient experience, reinforcing the pivotal role of diagnostics in shaping effective treatment strategies for metastatic breast cancer patients in India. ]]> https://biospectrumindia.com/news/92/23940/progenesis-marks-indian-entry-with-state-of-the-art-genetic-lab-and-ai-centre.html https://biospectrumindia.com/news/92/23940/progenesis-marks-indian-entry-with-state-of-the-art-genetic-lab-and-ai-centre.html Mon, 11 Dec 2023 00:00:00 +0530 In a groundbreaking move, Progenesis, a renowned global genetic testing brand headquartered in the US, has officially entered the Indian market with the inauguration of its first Genetic Laboratory in New Delhi and an artificial intelligence (AI) & Bioinformatics Data Centre in Chennai.  Progenesis is globally acclaimed for its revolutionary genetic testing solutions, particularly in the realm of In Vitro Fertilisation (IVF) treatment. The brand's commitment to advancing reproductive genetics in India is evident through its introduction of cutting-edge technology, unmatched accuracy, and customer-centric services. Dr Nabil Arrach, Founder & CEO of Progenesis, expressed his enthusiasm at the launch, stating, "We are thrilled to bring Progenesis to India, a land of immense opportunity and possibilities. While our first laboratory is in Delhi, our goal is to establish a diverse market presence, reaching Tier 2 and 3 markets across the country." As a tech-strong lab testing brand, Progenesis aims to raise awareness about genetic diseases and disorders in India. Leveraging advanced technologies, including Artificial Intelligence, the brand promises non-invasive and precise genetic testing results. In a move towards digital innovation, Progenesis has introduced the first online medical portal for Preimplantation Genetic Testing, streamlining the testing process for convenience and accessibility.   ]]> https://biospectrumindia.com/news/92/23917/mylabs-multi-drug-resistance-tb-test-integration-into-national-tb-elimination-programme.html https://biospectrumindia.com/news/92/23917/mylabs-multi-drug-resistance-tb-test-integration-into-national-tb-elimination-programme.html Fri, 08 Dec 2023 00:00:00 +0530 In a significant stride towards eradicating tuberculosis (TB) from the nation, the National TB Elimination Programme has incorporated Pune-based startup Mylab’s PathoDetect MTB RIF & INH Resistance Detection Kit to further its effort to eliminate TB by 2025. Recognised as India's first multidrug-resistant TB test, it is now integrated into the Ni-kshay portal, amplifying the nation's capabilities in the fight against tuberculosis. The inclusion of the PathoDetect kit in the National TB Elimination Programme marks a pivotal moment in India's commitment to combating tuberculosis, a disease that continues to pose a significant public health challenge. This manual-intervention free test, designed for the rapid and accurate detection of multidrug-resistant TB, offers advanced capabilities for identifying TB and resistance to Rifampicin (RIF) and Isoniazid (INH), two critical first-line drugs in TB treatment. Hasmukh Rawal, MD & Co-founder, Mylab Discovery Solutions, said, "The availability of MTB on the Ni-kshay platform represents a milestone in India's fight against TB. As India takes a giant leap forward in its fight against TB, this diagnostic solution will make a substantial impact on the efficiency and effectiveness of TB control measures. It will prove beneficial for the State authorities to report the TB cases.” “We have dedicated our efforts to provide the most comprehensive portfolio of solutions that cater to the critical aspects of screening, detection, and prevention in the realm of TB. This includes the incorporation of our indigenous latent TB test, Cy-TB, into NTEP, as well as the integration of the MTB RIF & INH Resistance Detection Kit into NTEP, along with an AI-enabled portable X-Ray device for TB screening”, he added.     ]]> https://biospectrumindia.com/news/92/23929/neuberg-diagnostics-opens-national-reference-laboratory-in-chennai.html https://biospectrumindia.com/news/92/23929/neuberg-diagnostics-opens-national-reference-laboratory-in-chennai.html Wed, 06 Dec 2023 00:00:00 +0530 Neuberg Diagnostics, a leading diagnostic healthcare chain with a strong presence across India, South Africa, UAE, and the USA, has unveiled its state-of-the-art national reference laboratory which houses Genomics, Transplant Immunology, Molecular Diagnostics, Proteomics and Metabolomics testing along with integrated diagnostics in Chennai. This cutting-edge facility, hailed as “Chennai’s new Healthcare landmark,” represents India’s first state-of-the-art total lab automation solution utilising the Abbott GLP System, alongside the innovative WOW (Wellness on Wheels) concept. Neuberg Diagnostics launched its national reference laboratory operations with the inauguration of its Headquarters in Chennai, in the presence of Udhayanidhi Stalin, Minister of Youth Welfare and Sports Development of Tamil Nadu; T.R.B Rajaa, Minister of Industries of Tamil Nadu; Ma. Subramanian, Minister for Health and Family Welfare of Tamil Nadu; Dr GSK Velu, Chairman and Managing Director of Neuberg Diagnostics, and other dignitaries. The new high-end lab offers an extensive array of over 6000 routine and specialised tests and has a capacity to process a remarkable number of 10000 tests samples per day across pathology, microbiology, genomics, proteomics, metabolomics and molecular biology, specialisations, making it one of the largest clinical laboratory infrastructures in India ensuring efficiency and accuracy in diagnostic processes.  The modern wellness centre, focused on preventive wellness, is fully equipped with X-ray, ECG, Sonography, TMT, Echo, Mammography, Bone Densitometry, Eye Check, Audiometry, Spirometry etc.    Additionally, Jeenomics, a centre of excellence division within Neuberg Diagnostics, specialises in transplant immunology using Whole gene sequencing of HLA by Illumina Next-Gen Sequencing system (NGS) for clinical samples and adult stem cell registry samples. This division ensures high-resolution HLA matching critical for the success of Hematopoietic Stem Cell Transplantation.       ]]> https://biospectrumindia.com/news/92/23886/revvity-joins-indias-fight-against-tb-by-launching-t-spot-tb-for-latent-tb-screening-.html https://biospectrumindia.com/news/92/23886/revvity-joins-indias-fight-against-tb-by-launching-t-spot-tb-for-latent-tb-screening-.html Fri, 24 Nov 2023 00:00:00 +0530 Revvity, a global company that leverages innovation in diagnostics and life sciences, with a strong presence in India, has announced the country launch of its T-SPOT®.TB test for latent TB screening, at MICROCON in Lucknow, held from 23 to 26 November. Revvity’s T-SPOT®.TB is the only FDA-approved, commercially available IGRA (interferon gamma release assay) based on the ELISPOT technology. This technology includes the isolation, washing and counting of peripheral blood mononuclear cells (PBMCs) from whole blood to standardise the test and provide reproducible results for reliable detection, even in challenging-to-screen groups, such as the immunosuppressed. Based on the ELISPOT technology, the T-SPOT®.TB test is the only WHO recommended IGRA that uses a standardised sample, reducing the influence of factors in the blood which may affect performance and normalising for cell number variation. The WHO diagnostic guidelines acknowledge the benefits of the normalisation step prior to cell stimulation required in the T-SPOT®.TB test. Normalising the T-cell count before cell stimulation can help obtain accurate results in populations with weakened immune systems. In addition, the T-SPOT®.TB test does not cross-react with the BCG vaccine, which is commonly used in India. The T-SPOT®.TB test is one of the three IGRAs that are recommended by WHO as alternatives to the tuberculin skin test (TST) or the Mantoux test for the detection of TB infection. The T-SPOT®.TB test is available in over 50 countries including in Europe, China, Japan, and the US, and is in the list of in-vitro diagnostics (IVDs) recommended by WHO for use in countries to improve access to IVD testing and advance universal health coverage.  Automation of the T-SPOT®.TB test is possible using the T-Cell Select TM reagent kit, and automated platforms are available for low, medium, and high throughput settings. The use of the T-Cell SelectTM reagent kit in the automated workflow allows for the blood samples to be transported and stored at ambient temperature for up to 54 hours prior to processing, improving sample collection logistics.   ]]> https://biospectrumindia.com/news/92/23871/redcliffe-labs-expands-diagnostic-services-in-uttar-pradesh.html https://biospectrumindia.com/news/92/23871/redcliffe-labs-expands-diagnostic-services-in-uttar-pradesh.html Thu, 23 Nov 2023 00:00:00 +0530 Noida-based startup Redcliffe Labs has opened three new state-of-the-art diagnostic labs in Uttar Pradesh (UP). Strategically located in Prayagraj, Agra, and Jhansi, these facilities aim to bridge the significant gap between the demand and supply of quality diagnostic services in the region.  Uttar Pradesh is facing a 19% increase in the burden of Non-Communicable Diseases (NCDs). Recognising the urgent need to address this health challenge, Redcliffe Labs has expanded its presence in UP as part of its mission to implement a tier 2 and beyond strategy.  Beyond catering to the local community, individuals in surrounding areas can conveniently access state-of-the-art facilities by scheduling home sample collections for their health checkups.  The newly opened labs in Prayagraj, Agra, and Jhansi will offer a comprehensive range of diagnostic services, including Biochemistry, Hematology, Immunoassays, Clinical Pathology, Serology, and Hormones.  With 21+ labs and 500+ collection centers across Uttar Pradesh, Redcliffe Labs continues to lead in diagnostic healthcare services. MD Pathologist Dr Ravi Rani will head the Prayagraj facility in George Town. With a new lab at Shanti Madhuban Plaza, Agra will also benefit from Redcliffe Labs' presence. Consultant Pathologist Dr.Priya Jain will oversee this lab. In Jhansi, the state-of-the-art laboratory in Veerangna Nagar, JDA Colony, will be led by Consultant Pathologist Dr Tripti Aggarwal. ]]> https://biospectrumindia.com/news/92/23862/agilus-diagnostics-opens-advanced-laboratory-in-bongaigaon-assam.html https://biospectrumindia.com/news/92/23862/agilus-diagnostics-opens-advanced-laboratory-in-bongaigaon-assam.html Wed, 22 Nov 2023 00:00:00 +0530 Agilus Diagnostics, a subsidiary of Fortis Healthcare, has announced the launch of a new laboratory in Bongaigaon, Assam. The advanced laboratory has the capacity to process 25,000+ samples in a month ranging from simple routine tests to semi-specialised and specialised tests. Recognising the rising demand for quality diagnostic services, Agilus has expanded its capabilities by launching this laboratory in Bongaigaon. The citizens of Bongaigaon will now have access to Agilus’ extensive test menu comprising of 3,000+ tests and a range of well-curated preventive healthcare packages. This new Agilus lab in Bongaigaon along with its existing laboratory network in Assam will also cater to Dhuburi, Goalpara, Barpeta. Anand K, Managing Director & CEO, Agilus Diagnostics said, "Our new lab in Bongaigaon helps us improve the turnaround time on reports and also strengthen our position in the state of Assam. We have also enabled home collection services for the benefit of our customers and other valued added services like ordering tests through our website and intuitive mobile app, receiving diagnostic reports through WhatsApp etc." The advanced laboratory spread over 2000 sq ft has multiple laboratory divisions including Hematology, Biochemistry, Clinical Pathology, Serology and Microbiology. ]]> https://biospectrumindia.com/news/92/23867/major-milestone-in-ai-powered-fight-against-lung-cancer.html https://biospectrumindia.com/news/92/23867/major-milestone-in-ai-powered-fight-against-lung-cancer.html Wed, 22 Nov 2023 00:00:00 +0530 The quest to eliminate lung cancer as a global cause of death has taken a positive step forward with 1 million-milestone met of a 5-million lung health Artificial Intelligence (AI) commitment. This new proactive initiative casts a wider net to currently invisible and unprofiled global patient populations, innovating beyond traditional lung cancer screening profiles such as age and smoking history. The commitment was made at the 2022 World Economic Forum’s (WEF) Annual Meeting in Davos. It saw AstraZeneca, a global biopharmaceutical company, join the WEF EDISON Alliance, a partnership between commercial and non-profit sectors, to improve the lives of people through digital inclusion. The power of AI to screen for lung cancer risk was adopted as part of the AstraZeneca EDISON Alliance health goals via a partnership with Mumbai-based startup Qure.ai, a global leader of medical imaging AI. In addition, this novel approach is a fundamental component of AstraZeneca’s A.Catalyst Network, a network of solutioners to improve patient outcomes, and the Lung Ambition Alliance, a global coalition with the bold ambition to eliminate lung cancer as a cause of death. AI-powered chest X-ray analysis for the incidental detection of high-risk nodules that can be indicative of lung cancer has therefore been rolled-out across resource constrained regions of the UK, Asia, Latin America, Middle East and Africa. Highlights of one of the sites within this initiative were recently presented at the World Conference on Lung Cancer and at The Union World Conference on Lung Health 2023. In Vietnam, using Qure's AI enabled chest X-ray solution qXR, 31,000 chest X-rays were analysed identifying 212 individuals with lung nodules requiring further diagnostic analysis via CT scans. Of these, 19 individuals were then flagged as high risk and warranting further follow-up as per standard lung cancer detection guidelines. Prashant Warier, Co-Founder and CEO of Qure.ai, states, “Together with AstraZeneca, we are determined to make a significant difference in the early diagnosis of lung cancer in regions and to people that need it most."   ]]> https://biospectrumindia.com/news/92/23843/roche-launches-automated-serology-hepatitis-e-virus-tests.html https://biospectrumindia.com/news/92/23843/roche-launches-automated-serology-hepatitis-e-virus-tests.html Thu, 16 Nov 2023 00:00:00 +0530 Swiss firm Roche has announced the launch of the Elecsys®Anti-HEV IgM and Elecsys Anti-HEV IgG immunoassays for the detection of hepatitis E virus (HEV) infections in countries accepting the CE mark. Elecsys Anti-HEV IgM is an immunoassay for the in vitro qualitative detection of IgM antibodies to HEV in human serum and plasma, and is used as an aid to detect an acute or recently acquired HEV infection. Elecsys Anti-HEV IgG is an immunoassay for the in vitro quantitative determination of IgG antibodies to HEV in human serum and plasma, and is used as an aid to detect a recent or past HEV infection. The new assays are available for use on the cobas® e 411 analyser, cobas e 601/602 modules, and the cobas e 402 and cobas e 801 analytical modules.  By testing for HEV infection, clinicians can support their patients to identify the cause of their symptoms and determine appropriate treatment, monitor for progression to severe acute HEV and prevent severe disease progression with antiviral treatment. Recognising the value of diagnostics, the World Health Organization (WHO) has developed an “Essential Diagnostics List” which includes in-vitro diagnostics that should be available in all countries to increase timely and life-saving diagnoses. This year for the first time, tests for HEV are included to aid in the diagnosis and surveillance of HEV infection.   ]]> https://biospectrumindia.com/news/92/23820/hungary-based-firm-diatron-enters-into-indian-market.html https://biospectrumindia.com/news/92/23820/hungary-based-firm-diatron-enters-into-indian-market.html Wed, 08 Nov 2023 00:00:00 +0530 Diatron, a Hungary-headquartered player in the development, manufacturing, and marketing of haematology and clinical chemistry analysers and their associated reagents for medical and veterinary use, has taken a significant step by inaugurating a new office in New Delhi. This strategic move highlights Diatron's commitment to strengthening its presence in Asia, a region with a burgeoning diagnostics market, and to providing its services to both existing and new customers in the Asia-Pacific (APAC) region. Additionally, they plan to commence manufacturing their associated reagents for medical and veterinary use in India from 2024, a move that will create new job opportunities in India. Diatron's new office in India marks a pivotal development, bringing numerous advantages to customers and partners alike. The establishment of a sales presence in the APAC region ensures swift and timely support, expediting project progress and leading to more efficient outcomes. Enhanced communication capabilities and geographical proximity promise to eliminate language barriers, fostering a more productive collaboration. Peter Zsoka, CFO & Board of Director, Diatron MI Plc., Budapest, Hungary, said, "Our goal is to commence reagent manufacturing in India by 2024, reflecting our dedication to this region and the healthcare sector." Diatron's expert team in New Delhi is geared up to provide even swifter responses to the inquiries and requirements of both its existing and new customers in the APAC region. Over 50,000 Diatron clinical chemistry and haematology analysers are actively used in laboratories worldwide, and their continuous growth is attributed to strong customer relationships. ]]> https://biospectrumindia.com/news/92/23799/core-diagnostics-expands-footprint-in-south-india-with-new-specialised-lab-in-hyderabad.html https://biospectrumindia.com/news/92/23799/core-diagnostics-expands-footprint-in-south-india-with-new-specialised-lab-in-hyderabad.html Fri, 03 Nov 2023 00:00:00 +0530 Gurugram-based CORE Diagnostics, a leading provider of high end and specialised diagnostics services, has announced the opening of a new lab which is located in Secunderabad. This 4000 square feet new lab has all the latest tools for Histopathology, Immunohistochemistry, Nephropathology, Flow Cytometry, in addition to essential services including Biochemistry, Immunology, Hematology, Clinical Pathology and Serology. It is anticipated that this lab would strengthen CORE Diagnostics' capabilities and make it possible to offer a larger range of thorough diagnostic solutions to a larger customer in Telangana and Andhra Pradesh and other part of Southern India. This will ensure better and faster turn-around time (TAT) to patients. With this new specialised lab, CORE Diagnostics is poised to reinforce its presence in the southern region of India and anticipates a significant revenue boost of Rs 40 million. Also, this lab will allow to bring high quality diagnostic solutions closer to healthcare providers and patients, empowering them with timely and precise information for medical decisions.    ]]> https://biospectrumindia.com/news/92/23793/lordsmed-announces-launch-of-first-pathology-centre-in-maharashtra.html https://biospectrumindia.com/news/92/23793/lordsmed-announces-launch-of-first-pathology-centre-in-maharashtra.html Thu, 02 Nov 2023 00:00:00 +0530 LordsMed, the global healthcare division of Lords Mark Industries, has recently launched its first pathology centre in Kalyan, followed by another centre in Dombivli, and plans to open a total of 10 labs in and around Mumbai by December 2023.    The company is currently targeting to establish its presence across Maharashtra and will soon foray in other states such as Gujarat and Uttar Pradesh.   With an in-house Research and Development (R&D) team dedicated to researching reagents and chemicals used in range of diagnostics, LordsMed Pathology Lab offers Thyroid Profile, Lipid Profile, Liver Profile, Kidney Profile, S. Electrolytes, Diabetes Profile, Magnesium, Ferritin, Cystatin C, Alfa-1-Microglobulin, Arthritis, СВС, Vitamin, C Reactive Protein (hsCRP), Cardiac Risk Marker, Homocysteine, Pancreas Profile, ANC Profile, Triple H, Triple Marker, Infertility Profile, PCOD Profile among others.LordsMed Pathology Lab prioritises quality and efficiency, with significant capital investments directed towards state-of-the-art equipment and skilled staffing to ensure the seamless operation of their centres. They utilise cutting-edge auto and semi-auto machines for tests, assuring both efficiency and precision. ]]> https://biospectrumindia.com/news/92/23796/sterling-accuris-diagnostics-expands-reach-through-strategic-alliance-with-vpl-diagnostic.html https://biospectrumindia.com/news/92/23796/sterling-accuris-diagnostics-expands-reach-through-strategic-alliance-with-vpl-diagnostic.html Thu, 02 Nov 2023 00:00:00 +0530 Sterling Accuris Diagnostics has announced a strategic alliance with VPL diagnostic, a prominent provider of specialty allergy testing services located in Ahmedabad. This strategic alliance further solidifies Sterling Accuris' strong presence in the diagnostics industry. VPL diagnostic is a specialised ImmunoCAP & ELISA allergy testing laboratory. With 10+ years of experience in the field of allergy testing, it leverages cutting-edge technology in testing facilities to provide all kinds of allergy tests such as food, drugs, and inhalants. VPL diagnostic also offers a comprehensive pathology test menu. It is consistently expanding and upgrading its capabilities to maintain a competitive edge in the field of allergy testing. Rajiv Sharma, MD of Sterling Accuris Diagnostics, expressed that "Sterling Accuris has a comprehensive range of test menu, from basic haematology to high end genetics. VPL diagnostic is a highly specialised lab in the field of allergy testing and has more than 500 clients Pan India. This alliance will help us leverage this network of clients to also provide high-end testing services other than allergy testing to them.” According to Ankush Gupta, CEO of Sterling Accuris Diagnostics, "As per Data Bridge Model Research, the Indian Allergy market is expected to undergo a CAGR of 10.9% during the forecast period of 2022-2029. Through this strategic alliance with VPL diagnostic, both companies aim to leverage mutual synergies for strong growth.” Nirvi Shah, Head Business Operations of VPL Diagnostic stated, “Collectively both the companies will work towards introducing specific Microarray based allergy testing and food intolerance making VPL diagnostic one stop solution for allergy testing.” ]]> https://biospectrumindia.com/news/92/23777/redcliffe-labs-offers-prostate-health-index-test-for-patients-across-india.html https://biospectrumindia.com/news/92/23777/redcliffe-labs-offers-prostate-health-index-test-for-patients-across-india.html Wed, 01 Nov 2023 00:00:00 +0530 Redcliffe Labs has expanded its services with the addition of Prostate Health Index (PHI) test processing at its National Reference Laboratory located in Noida. The blood test may be included in the standard urologic armamentarium for biopsy decisions, risk stratification, and treatment selection for suspected prostate cancer. This pioneering advancement in diagnostic capabilities is set to revolutionise prostate cancer screening and diagnosis, benefiting patients across India. The incidence of prostate cancer has increased steadily in India over the years. According to data from the National Centre for Disease Informatics and Research (NCDIR), it is among the top 10 cancers in urban cancer registries of Bengaluru, Delhi, Bhopal, and Mumbai. Recognising the growing concern surrounding prostate cancer, Redcliffe Labs is introducing PHI testing as part of a multifaceted approach to screening.  The PHI test is a simple and cost-effective blood test that plays a crucial role in identifying patients who genuinely require a prostate biopsy, ultimately reducing the occurrence of negative biopsies. It combines serum total prostate-specific antigen (PSA), free PSA (fPSA), and p2PSA ([-2]proPSA) concentrations through a mathematical formula that enhances clinical sensitivity and specificity for prostate cancer risk assessment. This test will benefit men aged 50 and above with non-suspicious digital rectal examination (DRE) results and a total prostate-specific antigen (PSA) range of 4 to 10 ng/mL.   ]]> https://biospectrumindia.com/news/92/23785/molbio-diagnostics-forays-into-breast-cancer-screening-through-partnership-with-niramai-.html https://biospectrumindia.com/news/92/23785/molbio-diagnostics-forays-into-breast-cancer-screening-through-partnership-with-niramai-.html Wed, 01 Nov 2023 00:00:00 +0530 Goa-based Molbio Diagnostics has announced the launch of a strong collaboration with Niramai Health Analytix, a Bengaluru-based deep-tech startup. This partnership aims to accelerate the adoption of Niramai's innovative artificial intelligence (AI)-based non-invasive breast cancer screening solution in developing countries around the world.According to the World Health Organization (WHO), breast cancer is the most common cancer in the world and among top-5 deadliest of cancers globally. Although it affects people of all sexes, but it impacts women disproportionately – being among the leading causes of death in women and accounts for 24.5% of all new cancer cases in women worldwide. Late diagnosis of breast cancer is one of the challenges.Portable point of care (POC) breast cancer screening solutions that enable efficient screening of large populations, especially in low resource settings, is a critical healthcare need across many geographies today. Niramai's Thermalytix is able to bridge these crucial gaps through its unique features.Considering the high prevalence of breast cancer cases, it is important to screen populations at a large scale, which is possible only by deploying portable, non-invasive diagnostic devices like Thermalytix at point of care.Through this collaboration, Molbio will promote and distribute Thermalytix in both public and private healthcare markets globally. The partnership builds on the strengths of the two companies to bring cutting-edge technology which would make high-quality diagnostics accessible to everyone. ]]> https://biospectrumindia.com/news/92/23774/kriya-medical-receives-manufacturing-license-for-krivida-trivus-respi-panel-rt-qpcr-kit.html https://biospectrumindia.com/news/92/23774/kriya-medical-receives-manufacturing-license-for-krivida-trivus-respi-panel-rt-qpcr-kit.html Mon, 30 Oct 2023 00:00:00 +0530 Kriya Medical Technologies, a leading medical devices company headquartered in Chennai, has received its manufacturing license from the Central Drugs Standard Control Organization (CDSCO) for its product KRIVIDA Trivus Respi Panel RT-qPCR Kit, a first of its kind kit that has the unique capability to simultaneously identify Respiratory Syncytial Virus (RSV), Influenza viruses and SARS-CoV-2 in patients presenting with respiratory tract infections. KRIVIDA Trivus Respi Panel RT-qPCR kit has been validated by ICMR- National Institute of Virology, Pune, and the kit has shown 100% specificity and 99.11% sensitivity for the detection of all three viruses. A key feature of this kit is its ability to detect RSV, a virus that primarily causes viral pneumonia in children under the age of 5 and contributes significantly to hospitalizations. Additionally, RSV is a common cause of lower respiratory tract diseases (LRTD) in older adults, potentially leading to life-threatening pneumonia and bronchiolitis. Hence, early detection of RSV is imperative for both infants and the elderly. In India, influenza accounts for 35% of all respiratory tract infections. In severe cases, the progression from influenza-like illness (ILI) to acute lung injury and acute respiratory distress syndrome can be rapid, resulting in high mortality rates. The Krivida Trivus Respi Panel RT-qPCR Kit helps in early detection of influenza, thereby enabling the prompt initiation of specific antiviral medications. The kit can also detect co-infections, which are associated with increased disease severity, morbidity, and mortality due to a weakened immune system. The Krivida Trivus Respi Panel RT-qPCR Kit is a valuable tool for improving diagnostic and infection control capacity. ]]> https://biospectrumindia.com/news/92/23765/trustlab-diagnostics-expands-national-presence-by-opening-6-new-labs.html https://biospectrumindia.com/news/92/23765/trustlab-diagnostics-expands-national-presence-by-opening-6-new-labs.html Sun, 29 Oct 2023 00:00:00 +0530 TRUSTlab Diagnostics has announced a significant expansion initiative across India, representing a huge step towards its mission of delivering accessible, precise and top-quality diagnostic services nationwide. In a move that underscores its unwavering commitment to excellence, TRUSTlab Diagnostics takes pride in introducing the inauguration of five new state-of-the-art laboratories. These cutting-edge facilities are situated in Noida, Patna, Bengaluru and at Hanamkonda & Karimnagar in Telangana. Additionally, TRUSTlab has established a collaboration with Blossom Hospital in Rajahmundry for their lab services. In the current fiscal year of 2023, TRUSTlab has already opened 10 such labs, and they plan to open an additional 7 labs by March 2024. These newly established laboratories will offer a comprehensive range of departments, including Biochemistry, Hematology, Assay & Hormones, Clinical Pathology, and more. TRUSTlab Diagnostics plans to establish additional centres in the upcoming months, in an effort to ensure that the entire population of India has access to advanced and affordable diagnostic services.     ]]> https://biospectrumindia.com/news/92/23722/redcliffe-labs-teams-up-with-rgcb-to-bolster-single-cell-genomics-in-india-.html https://biospectrumindia.com/news/92/23722/redcliffe-labs-teams-up-with-rgcb-to-bolster-single-cell-genomics-in-india-.html Thu, 19 Oct 2023 00:00:00 +0530 Redcliffe Labs, a startup based in Noida, has collaborated with Rajiv Gandhi Centre for Biotechnology (RGCB) in Thiruvananthapuram to manage and operate a laboratory with Single Cell Genomics and High-Throughput Sequencing technologies – a rare combination in modern genomics. Both parties have signed a Memorandum of Understanding (MoU) aiming to revolutionise the field of modern genomics. The collaboration combines Redcliffe Labs' expertise in genomics research and its track record of delivering ambitious genomics studies and projects with RGCB's cutting-edge facilities and research prowess.  The partnership with RGCB will introduce advanced technologies like 10X Chromium, Illumina Novaseq, Nanopore Gridion, and various allied infrastructures to facilitate processing and expediting samples from the southern part of the country. By setting up a lab in Thiruvananthapuram, Redcliffe Labs is India's first company with two fully equipped genomics facilities. Ashish Dubey, Director of Research at Redcliffe Labs, said, “We aim to provide efficient, cost-effective, and high throughput NGS services to Kerala’s Research centres like IISR, RCC, CIFE, IISER, NISER, CPCRI, and various PSUs. This facility will be a great support system for many genomics startups in Kerala, which is turning out to be a new home for genomics startups after Karnataka and Telangana,” he added. The partnership between Redcliffe Labs and RGCB is set to advance genomics research in India and facilitate breakthroughs in healthcare, agriculture, and beyond. Prof. Chandrabhas Narayana, Director at RGCB, Thiruvananthapuram said, “Genomics-based technologies like NGS help researchers and breeders evaluate and predict genetic merit." ]]> https://biospectrumindia.com/interviews/92/23697/shaping-the-future-of-anaesthesia-and-critical-care-in-india-an-exclusive-interview-with-shalin-patel-managing-director-of-draeger-india-group.html https://biospectrumindia.com/interviews/92/23697/shaping-the-future-of-anaesthesia-and-critical-care-in-india-an-exclusive-interview-with-shalin-patel-managing-director-of-draeger-india-group.html Mon, 16 Oct 2023 00:00:00 +0530 In this exclusive interview, Mr. Patel shares invaluable insights into Draeger's journey in shaping the landscape of anaesthesia and critical care in India. From their rich history dating back to 1889 to their current endeavors in promoting patient-centric care, Draeger has been at the forefront of transformative healthcare. Join us in exploring the pivotal role of anaesthesia devices, the infusion of cutting-edge technology, and Draeger's vision for the future of anaesthesia in India. Draeger has a rich history in medical and safety technology. Can you share how Draeger's journey has evolved in the healthcare industry? Certainly. Draeger, with a legacy dating back to 1889, has grown into a global leader in medical and safety technology. Our commitment to protecting, supporting, and saving lives is reflected in our innovative solutions. In the healthcare sector, Draeger provides a comprehensive range of technology solutions and products, including Anaesthesia machines, Ventilators, Patient Monitoring & IT, Neonatal care products, Consumables & Accessories, and Workplace Infrastructure capabilities. Our products are developed to ensure accurate and dependable patient care, empowering medical practitioners for optimal therapeutic outcomes. At the forefront of innovation, Draeger is known for its advanced technology solutions designed to meet the demands of therapy and workplace infrastructure thereby promoting efficiency, reliability, and, most importantly, a higher standard of patient care. In what ways do anaesthesia devices become central in critical care, and how has Draeger positioned itself in India to meet evolving market needs? Anaesthesia devices are the cornerstone of critical care. They provide the foundation for administering precise and tailored care to patients undergoing surgeries and medical procedures. Generally, anaesthesia devices offer a wealth of information and data which are often not well contextualized and can thus be of limited use. At Draeger, our anaesthesia devices incorporate cutting-edge technologies, and intelligent algorithms to interpret the raw data and present it in a clinically relevant manner. These tools provide insights and alerts to clinicians, helping them make informed decisions during the procedure. Further, Draeger’s Atlan anaesthesia devices are scalable anesthetic workstations for all patient groups, and spatial requirements.  The comprehensive set of clinical features and proven ventilation quality make Atlan an ideal anesthesia workstation for challenging patients and surgical procedures.  Not only does this support error prevention in the OR, but Atlan workstations are also optimized for the delivery of low- and minimal-flow anesthesia. In critical care scenarios, every moment counts, and our anaesthesia devices are engineered to deliver consistent, reliable performance. As a company, we believe that advanced anaesthesia devices are not just tools; they are enablers of a patient-centric approach, ensuring that every breath matters. With patient-centric care gaining prominence, how is Draeger leveraging technology to align with this shift in healthcare? Technology remains at the heart of Draeger's approach. Our anaesthesia machines offer diverse technologies, smart software applications, helpful features, decision-support tools, and superior flexibility. Combined with our patient monitoring solutions, our anaesthesia devices bring patient-relevant data to the point of care and ICU-quality ventilation therapy to the OR, such as lung-protective ventilation and minimal- and low-flow anesthesia. Our Anaesthesia devices are equipped with advanced ventilation modes and controls, that allow anesthesiologists and clinicians to precisely tailor ventilation parameters, including tidal volume, respiratory rate, and positive end-expiratory pressure (PEEP). This minimizes ventilator-induced lung injury and improves outcomes. In addition, low-flow anesthesia approach, enables in minimizing the flow of fresh gas and efficiently recirculating gases, thereby reducing the overall exposure of the lungs to anesthetic agents while ensuring a more controlled breathing environment. These techniques are not only more resource-efficient but are also associated with benefits such as quicker recovery and reduced environmental impact. Overall, the goal is to empower healthcare providers with tools that enhance their capabilities and elevate the overall patient experience. What initiatives has Draeger undertaken in India to assist healthcare providers in adopting these advanced anaesthesia technologies? Draeger recognizes the crucial role of medical technologies in protecting patients and supporting treatment outcomes, especially in time-sensitive operating room scenarios.  Draeger, with a legacy in Anaesthesia dating back to the first Roth-Dräger anesthetic machine in 1902, brings not only practical insights garnered from countless operating rooms worldwide but also visionary concepts that shape the future of anesthetic workstations. In the vibrant landscape of Indian healthcare, Draeger's commitment extends beyond innovation; it focuses on weaving a seamless ecosystem. Acknowledging the diverse needs of healthcare providers, our local teams engage closely with hospitals, clinicians, and healthcare professionals. The goal is not just accessibility but the seamless integration of our technologies into their workflows. Through continuous, networked monitoring, we enable uninterrupted surveillance, offering a customized and well-organized view of critical parameters. The seamless transfer of data into the hospital information system (HIS) ensures a cohesive and comprehensive approach. Moreover, our training and support programs are meticulously crafted to empower healthcare providers, unlocking the full potential of our advanced anaesthesia solutions. As a company, we envision a future where every aspect of patient care is not just met but exceeded, and our efforts in India are a testament to that vision. Looking ahead, what does the future of anaesthesia in India look like, and how does Draeger envision contributing to this future? The future of anaesthesia in India is both exciting and challenging. With an evolving healthcare landscape, there's an increasing need for precision, efficiency, and patient-centric care. Draeger is committed to being at the forefront of this evolution. We foresee a future where anaesthesia is not merely a procedure but a holistic and personalized experience. Our global research and development initiatives are geared to introducing innovations that will redefine the standards of anaesthesia care in India. Any message you would like to share with the healthcare community on this World Anaesthesia Day? On this World Anaesthesia Day, I extend my heartfelt gratitude to the dedicated healthcare community, especially anaesthesiologist, who play a significant role in patient care. Draeger is more than a technology provider; we are partners in transforming healthcare. Together, I am confident that we will continue pushing boundaries, embracing technology, and redefining excellence in anaesthesia care, steering towards a healthier and more innovative future for healthcare in India.   ankit.kankar@mmactiv.com ]]> https://biospectrumindia.com/news/92/23700/core-diagnostics-and-cancertain-healthcare-join-forces-to-revolutionise-cancer-treatment.html https://biospectrumindia.com/news/92/23700/core-diagnostics-and-cancertain-healthcare-join-forces-to-revolutionise-cancer-treatment.html Mon, 16 Oct 2023 00:00:00 +0530 Gurugram-based CORE Diagnostics has announced a strategic collaboration with UK-based CanCertain Healthcare, a pioneering healthcare company dedicated to enhancing cancer treatment outcomes. This partnership marks a significant milestone in the field of oncology, aimed at revolutionising how cancer patients receive personalised treatment. Oncologists are tasked with the challenging responsibility of swiftly determining the most effective treatment plans for each patient. CanCertain Healthcare has set out to address this challenge with its groundbreaking CanCertain® test. By providing valuable insights into the sensitivity or resistance of a patient's tumour to specific cancer drugs, this innovative diagnostic tool empowers oncologists to make more informed treatment decisions. This not only saves precious time but also reduces the financial burden of ineffective treatments. This collaboration between CORE Diagnostics and CanCertain Healthcare is poised to reshape cancer care by bringing cutting-edge diagnostic capabilities to the forefront of oncology. The focus of this partnership is primarily on empowering healthcare providers and oncologists rather than direct patient interactions. Doctors will be equipped with the vital information needed to prescribe the most appropriate and effective treatments, optimizing the patient's journey toward recovery. By harnessing the power of advanced diagnostics, they aim to give cancer patients a fighting chance and make personalised cancer treatment a reality. ]]> https://biospectrumindia.com/news/92/23694/govt-of-karnataka-signs-mou-with-astrazeneca-to-accelerate-lung-cancer-testing.html https://biospectrumindia.com/news/92/23694/govt-of-karnataka-signs-mou-with-astrazeneca-to-accelerate-lung-cancer-testing.html Sat, 14 Oct 2023 00:00:00 +0530 National Health Mission, Health & Family Welfare Services, Govt of Karnataka has signed a Memorandum of Understanding (MoU) with AstraZeneca Pharma India to deploy Artificial Intelligence (AI) based lung cancer screening technology developed by Mumbai-based startup Qure.ai that will screen a patient for 29 lung diseases in one chest x-ray. This AI-powered chest X-ray system will help the government detect lung nodules, often precursors to lung cancer, in 19 district hospitals in Karnataka, overcoming a major early detection challenge. “Cancer can be treated with curative intent if detected early. We are bringing this technology in all our district hospitals across Karnataka, and we strongly believe that this will emerge as the most beneficial way of detecting lung cancer early and bringing down the financial and emotional burden of healthcare on patients especially who cannot afford even primary care”, said Dinesh Gundu Rao, Minister Health & Family Welfare Department. In Karnataka, the incidence of cancer is increasing by about 1% each year for both men and women. According to a study by the Indian Council for Medical Research (ICMR), cancer cases in Karnataka are expected to increase by 90,000 by 2025. In Bengaluru alone, the most common cancers in men are lung, stomach, esophagus, and prostate. In women, the most common cancers are breast, cervix, ovary, and corpus uteri.  The data collected through this advanced mechanism of disease detection will funnel into various critical healthcare programs of the government and will contribute in tracking and managing national healthcare challenges such as pulmonary tuberculosis as well in India. The real-world evidence will also set the foundation of multiple healthcare programmes and will sharpen strategies to overcome disease burden in the state. Hospitals where the technology will be deployed over the period of next 12 months are- District Hospitals at Bagalkote, Vijayapura, Dharwad, Gadag, Chkkaballapur, Chikkamagaluru, Chitradurga, Kalburgi, Ramanagaram, Tumkuru, Karwar, Udupi, Yadgiri, Haveri, Madikeri, Kolar, Koppal, Chigateri Hospital, Davanagere, Wenlock Hospital, Mangalore, K C General Hospital, Bangalore. ]]> https://biospectrumindia.com/news/92/23677/national-tuberculosis-elimination-programme-includes-serum-mylabs-latent-tb-test.html https://biospectrumindia.com/news/92/23677/national-tuberculosis-elimination-programme-includes-serum-mylabs-latent-tb-test.html Mon, 09 Oct 2023 00:00:00 +0530 The National Tuberculosis (TB) Elimination Programme (NTEP) has included Serum-Mylab's indigenously-developed latent TB test - Cy-TB - to further its effort to eliminate TB by 2025. This novel test can detect the presence of latent TB infection (LTBI) before it progresses to an active disease state. To achieve the TB elimination target by 2025, testing and treatment of LTBI is essential. The inclusion of Serum-Mylab's Cy-TB in the NTEP and its availability on the Ni-kshay platform marks a substantial leap forward in the country's TB control efforts. The Serum-Mylab Cy-TB Test, a fast and accurate diagnostic tool, represents a significant advancement in latent TB diagnosis. It combines the cost-effectiveness and simplicity of skin test with the accuracy of traditional high-cost lab-based test called interferon gamma release assay (IGRA). This test can be administered in field setting and does not require any lab infrastructure. The most important feature of this test is that it is unaffected by BCG vaccination status of an individual, addressing a significant concern among the Indian population where nearly everyone receives a BCG vaccination. Dr Umesh Shaligram, Executive Director - R&D, Serum Institute of India, said, "The availability of Cy-TB on the Ni-kshay platform represents a milestone in India's fight against TB. Cy-TB provides a rapid and reliable tool for latent TB diagnosis, ensuring swift and accurate identification of affected individuals who can then receive the necessary care without delay." Hasmukh Rawal, MD & Co-founder, Mylab Discovery Solutions, added, " The reservoir of latent TB infection (LTBI) poses a significant barrier to TB control and elimination. To achieve our TB elimination target, it is crucial to test and treat LTBI. The Cy-TB Test exemplifies our unwavering dedication to global TB eradication."   ]]> https://biospectrumindia.com/news/92/23630/mylab-transforms-new-born-screening-with-breakthrough-point-of-care-solution.html https://biospectrumindia.com/news/92/23630/mylab-transforms-new-born-screening-with-breakthrough-point-of-care-solution.html Thu, 28 Sep 2023 00:00:00 +0530 Pune-based startup Mylab Discovery Solutions has announced a ground-breaking advancement in new-born screening (NBS) with the introduction of its patent-pending Point-of-Care device named MyNeoShield for new-born screening. This device is set to transform the landscape of new-born healthcare by making screening faster, more accessible, and more affordable, ultimately saving lives and preventing lifelong illnesses. The device supports all the seven tests done for new-born screening globally- G-6-Phosphate Dehydrogenase Deficiency (G-6-PDD); Galactosemia; Phenylketonuria; Biotinidase Deficiency; 17-Hydroxyprogesterone; Immunoreactive Trypsinogen; and thyroid stimulating hormone (TSH). Traditionally, new-born screening has been a complex process, involving the collection of samples from new-borns, their transportation to centralised testing centres, and a wait time of up to a day or more for results. This time-consuming process posed significant logistical challenges, especially in remote or underserved areas because the doctors only have a window of 48 hours to take any action. Additionally, the high cost of specialised equipment made it difficult for smaller healthcare facilities, like nursing homes, to offer these critical tests. This innovative device brings the power of new-born screening directly to healthcare providers, allowing for quick and efficient testing at the point of care.  This Point-of-Care device for newborn screening is set to be available commercially from November. The company plans to take the device to global markets with its partners. ]]> https://biospectrumindia.com/news/92/23621/neodx-biotech-labs-launches-ivd-kit-for-detecting-autoimmune-disorders.html https://biospectrumindia.com/news/92/23621/neodx-biotech-labs-launches-ivd-kit-for-detecting-autoimmune-disorders.html Sat, 23 Sep 2023 00:00:00 +0530 NeoDx Biotech Labs, a Bengaluru-based startup has launched Real-time PCR-Technology-based in vitro diagnostic (IVD) kit for Ankylosing Spondylitis & empowers healthcare services to improve their testing capabilities.  The real-time PCR test kit, HLA-B27 RT-PCR detection kit for Exon 2/Exon 3, is used to find Human Leukocyte Antigen B27 in whole blood. The inflammatory disorders Ankylosing Spondylitis (AS), Psoriasis, Inflammatory Bowel Disease, and Reactive Arthritis are highly correlated with HLA-B27. Early identification and treatment of these illnesses can benefit from HLA-B27 testing. Around 0.25% population in India is estimated to be affected by these diseases. A recent study published in the Indian Journal of Rheumatology analysed different factors related to Axial Spondyloarthritis and revealed that close to 70% of AS patients are misdiagnosed for the initial 3 years or more, worsening their condition. The kit has undergone extensive testing and performance assessment, and it has been demonstrated to be extremely sensitive and specific as well as compatible with the majority of commercially available RT-PCR systems. The kit contains all the reagents and controls required to carry out the tests.   ]]> https://biospectrumindia.com/news/92/23613/redcliffe-labs-establishes-new-diagnostic-standards-for-pcos-in-indian-women.html https://biospectrumindia.com/news/92/23613/redcliffe-labs-establishes-new-diagnostic-standards-for-pcos-in-indian-women.html Wed, 20 Sep 2023 00:00:00 +0530   Noida-based startup Redcliffe Labs has announced groundbreaking achievement in women's health research led by Dr Sohini Sengupta, the Medical Laboratory Director. It is the first-ever study on Indian women for establishing age-specific reference intervals for Anti-Mullerian Hormone (AMH) and defining an AMH diagnostic cut-off for Polycystic Ovarian Syndrome (PCOS). The results will facilitate diagnosis accuracy and treatment of PCOS, a condition that affects approximately 11.34% of women in India. Dr Sohini Sengupta and her team of experts meticulously analysed nearly 2,000 samples obtained from Indian women. The study suggests the optimal cut-off point of AMH for PCOS diagnosis in the Indian female population is 7.51ng/ml. With an impressive sensitivity of 99.4% and specificity of 95.5%, this diagnostic cut-off provides a highly accurate tool for healthcare professionals to swiftly and accurately identify PCOS in their patients. This innovative approach holds the potential to expedite PCOS diagnoses and facilitate timely interventions and treatments. Healthcare providers in India have relied on AMH reference intervals and diagnostic thresholds derived from data collected from Caucasian women for years. Redcliffe Lab’s research is tailored specifically to the Indian female population and will provide healthcare professionals with a robust tool for better management and treatment of PCOS.  ]]> https://biospectrumindia.com/news/92/23615/neuberg-diagnostics-seals-merger-of-neuberg-supratech-and-neuberg-anand.html https://biospectrumindia.com/news/92/23615/neuberg-diagnostics-seals-merger-of-neuberg-supratech-and-neuberg-anand.html Wed, 20 Sep 2023 00:00:00 +0530 Chennai-based Neuberg Diagnostics has announced the successful merger of Neuberg Supratech Reference Laboratory, Ahmedabad, and Neuberg Anand Reference Laboratory, Bangalore, into Neuberg Diagnostics Private Limited. This merger has been facilitated through an NCLT court-based process, further solidifying Neuberg Diagnostics' position as a frontrunner in the diagnostic industry. With a strategic vision to streamline operations and enhance efficiency, this merger brings together two prominent entities under the canopy of Neuberg Diagnostics Private Limited. The amalgamation has resulted in consolidating more than 80% of the overall group revenues within a single entity, setting the stage for Neuberg Diagnostics to achieve remarkable milestones.   The merger is projected to contribute to Neuberg Diagnostics' ambitious target of achieving gross revenues exceeding Rs 1,000 crore as a group in the current fiscal year. With this united front, the company can leverage its enhanced capabilities to expand and offer an extensive range of cutting-edge diagnostic services to patients across India and beyond. Neuberg Diagnostics has also reshaped its senior management team as part of the merger. Dr Sandip Shah has been elevated to the role of Joint Managing Director at Neuberg Diagnostics; Dr Sujay Prasad is promoted to Chief Medical Director of Neuberg Diagnostics; A Ganesan, will continue with his role as Vice Chairman of Neuberg Diagnostics.   Neuberg Diagnostics has set its sights on the future with plans to launch an Initial Public Offering (IPO) in the latter part of 2024 or the early months of 2025. ]]> https://biospectrumindia.com/news/92/23589/qure-ai-teams-up-with-path-india-to-improve-covid-19-and-tb-screening.html https://biospectrumindia.com/news/92/23589/qure-ai-teams-up-with-path-india-to-improve-covid-19-and-tb-screening.html Thu, 14 Sep 2023 00:00:00 +0530 Artificial intelligence (AI) firm, Qure.ai, is supporting PATH India to initiate an innovative project to overhaul tuberculosis (TB) and COVID-19 screening in Maharashtra through Unitaid funding. This strategic collaboration is centered on deploying the AI-powered qXR software, which will enhance the ability to analyse chest X-rays and substantially improve COVID-19 and TB screening at chosen implementation sites. Hosted on a cloud-based platform, the software ensures unfettered connectivity between different locations.  Before the Unitaid grant, Mumbai-based startup Qure.ai's qXR was already operational in 7 Brihanmumbai Mahanagar Pallika Hospitals, where it was utilised to screen 90,000 plus patients for tuberculosis and other chest abnormalities. Remarkably, its implementation resulted in a 35% rise in TB notifications. This is attributed to the system's capability to identify patients who visited for reasons unrelated to TB, revealing incidental findings through the non-tuberculosis pathway. Under the Unitaid-funded project, within a 12-month period, qXR is scheduled for deployment at four key medical facilities across Maharashtra. These include Dr. Zakir Hussain Hospital in Kathada and Hindu Hriday Samrat Balasaheb Thackrey Rugnalaya under the purview of the Nashik Municipal Corporation, as well as K.B Bhabha Hospital in Bandra which falls under the jurisdiction of the Municipal Corporation of Greater Mumbai.  As a part of this project, patients will undergo AI-enabled chest X-ray screening for tuberculosis in the usual hospital workflow. Patients will commence their journey at the outpatient department (OPD), where an OPD doctor will perform initial screenings. Should it be deemed necessary, a chest X-ray will be carried out by an X-ray technician for patients suspected of having TB or chest infection. Patients will be directed to the TB counter for sputum collection when TB is suspected based on X-ray outcomes. This will be followed by CB-NAAT testing or AFB microscopy, ultimately leading to the commencement of treatment.  ]]> https://biospectrumindia.com/news/92/23590/anderson-diagnostics-expands-presence-with-cutting-edge-branch-in-chennai.html https://biospectrumindia.com/news/92/23590/anderson-diagnostics-expands-presence-with-cutting-edge-branch-in-chennai.html Thu, 14 Sep 2023 00:00:00 +0530 Anderson Diagnostics, a prominent name in the diagnostic services sector since its establishment in 2008, has announced the upcoming inauguration of its state-of-the-art facility in Nanganallur, Chennai. This new diagnostic centre in Chennai is a valuable addition to Anderson Diagnostics' extensive network of centres dedicated to delivering premium diagnostic services across South India.  The facility highlights include multifaceted laboratory departments encompassing haematology, biochemistry, and immunology; cutting-edge technology to uphold its tradition of utilising state-of-the-art technology to facilitate top-notch healthcare; concentration on cancer and chronic diseases; and packages include women's wellness and comprehensive body check-ups for holistic healthcare. Anderson Diagnostics offers PET-CT scans and 3D Biopsy Imaging revolutionising digital mammograms with 3D biopsy imaging for digital mammograms. This innovative approach enhances early breast cancer detection and improves patient prognosis. The new facility is equipped with a comprehensive array of clinical laboratory departments, ensuring its ability to cater to diverse diagnostic needs. ]]> https://biospectrumindia.com/news/92/23585/agilus-diagnostics-launches-advanced-laboratory-in-himachal-pradesh.html https://biospectrumindia.com/news/92/23585/agilus-diagnostics-launches-advanced-laboratory-in-himachal-pradesh.html Wed, 13 Sep 2023 00:00:00 +0530 Agilus Diagnostics, a subsidiary of Fortis Healthcare, has announced the launch of a new laboratory in Tanda, Himachal Pradesh. The advanced laboratory has the capacity to process 30,000+ samples in a month ranging from simple routine tests to semi-specialised and specialised tests. Recognising the rising demand for quality diagnostic services, Agilus has expanded its capabilities by launching this laboratory in Tanda. The citizens of Tanda will now have access to Agilus’ extensive test menu comprising of 3,000+ tests and a range of well-curated preventive healthcare packages. This new Agilus lab in Tanda along with its existing lab in Shimla will also cater to Kangra, Palampur and Dharmashala. Anand K, Managing Director & CEO, Agilus Diagnostics said "Agilus Diagnostics had been catering to the populace in Himachal Pradesh for over a decade through a private-public partnership (PPP) project with the state government. We have enabled home collection services for the benefit of our customers and other valued added services like ordering tests through our website and intuitive mobile app, receiving diagnostic reports through WhatsApp etc. In addition, we believe that our expansive test menu will help the local citizens and doctors to access a large number of tests.” The advanced laboratory spread over 3000 Sqft has multiple laboratory divisions including Hematology, Biochemistry, Clinical Pathology, Serology and Microbiology.   ]]> https://biospectrumindia.com/news/92/23570/national-diagnostics-chain-tenet-diagnostics-to-invest-rs-100-cr-for-karnataka-expansion.html https://biospectrumindia.com/news/92/23570/national-diagnostics-chain-tenet-diagnostics-to-invest-rs-100-cr-for-karnataka-expansion.html Fri, 08 Sep 2023 00:00:00 +0530 Tenet Medcorp with the brand name Tenet Diagnostics, a leading national integrated diagnostics chain with its presence in eight states and 25 locations across India, is all set to invest Rs 100 crore in Karnataka expansion. The move will boost access to the latest technology and infrastructure in diagnostics, laboratory services and preventive healthcare in the state.  With this investment, Tenet Diagnostics will double its presence in Karnataka from the current 5 to 15 by 2025. It’s five centres in Bengaluru are located in Jayanagar, Sadashivanagar, Indiranagar, Marathahalli and Whitefield. Two centres in Mysore and Mangalore will be operational by the end of 2023. Tenet Diagnostics will also add 1500+ skilled jobs to its current 150+ doctors and 800+ technicians employee base. This will take its total workforce tally to 2500+ dedicated staff serving the healthcare needs of the community.  Elaborating on the expansion plans, Devineni Sricharan, Executive Director of Tenet Diagnostics explains, “We started with one centre in Hyderabad in 2018 and have since expanded to Karnataka, AP, Telangana, Maharashtra, Bihar, Jharkhand, Orissa and UP. Tenet Diagnostics has registered a 100% turnover YOY and we plan to touch Rs 150+ crore this year. Karnataka is instrumental in our growth story. We plan to invest Rs 100 crore to start 15 centres providing advanced PET-CT, Gamma Camera, MRI, CT, Laboratory services, Ultrasound, X-ray, 2D echo, TMT, PFT, Mammography, ECG,EEG, ENMG, Audiometry, OPG, Corporate screening, Hospital lab management and preventive healthcare packages.” “We have also collaborated with the Ohio State University and signed groundbreaking master research agreements with industry leaders such as Siemens and United Imaging. We will continue to partner with various players to leverage technology, research and resources to set new benchmarks in the diagnostics and laboratory services,” he adds.  ]]> https://biospectrumindia.com/news/92/23491/himedia-announces-cdsco-approval-for-influenza-pcr-detection-kit.html https://biospectrumindia.com/news/92/23491/himedia-announces-cdsco-approval-for-influenza-pcr-detection-kit.html Wed, 23 Aug 2023 00:00:00 +0530 Mumbai-based HiGenoMB – HiMedia has announced that Central Drugs Standard Control Organisation (CDSCO) has granted approval for commercial production for its Influenza PCR detection kit (MBPCR263). HiMedia has developed a Multiplex Reverse Transcriptase Real‐Time PCR kit which enables the clinicians and public health laboratories to quickly diagnose influenza infection in a single tube. Hi‐PCR® Influenza Multiplex Probe PCR Kit is capable of simultaneous screening for multiple strains of the influenza virus in less than 90 mins. It includes primer‐probe sets specific to detect RNA from the three Influenza viruses: A, B & H1N1 pdm 09 and an internal control (IC). HiMedia has always offered open kits and instrument platform to ensure the industry always benefits from the progressive and innovative research in their laboratory and this kit is no different as it can be used to run on different Real time PCR machines in the market. The key factor distinguishing this CE-IVD and CDSCO approved kit from other kits is that it can detect an additional target Influenza B in the same tube as other targets. “The grave threat posed by these emerging and re‐emerging influenza viruses requires rapid laboratory detection. RT-PCR is considered as a gold standard method for influenza surveillance and diagnosis due to its high specificity, sensitivity and rapid detection and our Hi‐PCR® Influenza Multiplex Probe PCR Kit delivers just that’’ says, Dr. Rajas V Warke – Director of HiGenoMB® and Virology, HiMedia Labs.   ]]> https://biospectrumindia.com/news/92/23485/south-korean-firm-ngenbio-in-a-strategic-alliance-with-mgi-a-global-ngs-equipment-company.html https://biospectrumindia.com/news/92/23485/south-korean-firm-ngenbio-in-a-strategic-alliance-with-mgi-a-global-ngs-equipment-company.html Tue, 22 Aug 2023 23:55:00 +0530 South Korean firm Ngenbio, a company specializing in next-generation sequencing-based precision diagnosis platform signed a business agreement with MGI , China's largest NGS company and global NGS equipment manufacturer.   Through this business agreement, the two sides will apply NgenBio's NGS cancer precision diagnosis product to MGI 's NGS platform, DNBSEQ-G99 sequencer ,  Asian region ( Singapore , Thailand , Malaysia , Taiwan , Philippines , Indonesia , Vietnam , China , etc. ) They plan to strengthen their competitiveness in the precision medicine field by promoting joint business development , such as promotion of local joint commercialization , joint marketing and global distribution cooperation , and production of equipment and NGS diagnostic product packages . With the recent development of molecular diagnostic technology , the demand for precise diagnosis based on NGS technology is increasing in the global diagnostic market . NGS diagnostic technology is one of the most important diagnostic technologies in precision medicine , and is used in a wide variety of fields, such as personalized treatment for cancer patients , early disease diagnosis , prognosis diagnosis , and accompanying diagnosis. In particular , it is necessary to converge diagnostic reagents for disease diagnosis, base sequence analysis equipment , and genome data analysis technology to obtain rapid and accurate diagnosis results, which are the core of the precision medicine market. The reason why the industry is paying attention to this strategic MOU is that a large equipment company and a company with diagnostic reagents and genome analysis technology collaborated to challenge the precision medical market .  Through cooperation with MGI, which has an extensive distribution network, NGNBio expects to expand its overseas market in earnest by packaging NGNBio's diagnostic reagents and analysis SW in NGS sequencing equipment for more global customers.  Meanwhile , according to Frost&Sullivan market data , the total sales of the global in vitro diagnostics market are expected to grow to $ 99.22 billion in 2021 , increasing by 6.9% on average per year , to $ 138.3 billion in 2026 . North American countries are expected to continue to grow, leading the market with a growth rate of 13.1% for in vitro diagnostics in 2021. As global players that make the ecosystem in the Asia Pacific region competitive, China and Japan are domestic manufacturers ) is growing based on . ]]> https://biospectrumindia.com/news/92/23489/mylab-unveils-two-state-of-the-art-dengue-tests.html https://biospectrumindia.com/news/92/23489/mylab-unveils-two-state-of-the-art-dengue-tests.html Tue, 22 Aug 2023 00:00:00 +0530 Dengue fever, a viral disease transmitted by mosquitoes, poses a significant public health challenge in India. To meet the testing requirements for this virus, Pune-based startup Mylab Discovery Solutions has introduced two state-of-the-art tests for the detection of dengue infections: the dengue rapid gold test and the dengue high accuracy dry luminescence assay test. These rapid point-of-care tests have been developed to meet the critical testing needs for dengue infections in our country. The tests effectively differentiate between IgM and IgG antibodies, providing valuable insights into the stage and progression of the dengue infection. Both tests offer rapid point-of-care capabilities, ensuring quick and on-the-spot diagnosis within 15-20 minutes without the need for laboratory setup or complex procedures. Speaking about the launch of the Tests, Hasmukh Rawal, Co-founder & Managing Director of Mylab said, “The introduction of these tests reinforces our commitment to combating the rise of dengue cases in India. These rapid point-of-care tests provide healthcare professionals with accurate and efficient tools for timely diagnosis, ultimately aiding in effective disease management”. Positive IgM and IgG tests for dengue antibodies indicate recent infection with the dengue virus. In the case of primary dengue infection, detectable levels of IgM antibodies emerge as early as the 3rd day after infection and generally persist for 2-6 months. Following IgM, dengue IgG antibodies appear around day 7 of the fever during the primary infection and remain present for an extended period, potentially lasting for years.  ]]> https://biospectrumindia.com/news/92/23478/agilus-diagnostics-strengthens-presence-in-hyderabad-with-advanced-lab-in-panjagutta.html https://biospectrumindia.com/news/92/23478/agilus-diagnostics-strengthens-presence-in-hyderabad-with-advanced-lab-in-panjagutta.html Mon, 21 Aug 2023 00:00:00 +0530 Agilus Diagnostics, a subsidiary of Fortis Healthcare, has announced the launch of a new laboratory in Panjagutta. The advanced laboratory has the capacity to process 60,000+ samples in a month ranging from simple routine tests to semi-specialised and specialised tests. Recognising the rising demand for quality diagnostic services, Agilus has expanded its capabilities by launching this laboratory in Hyderabad. The citizens of Hyderabad will now have access to Agilus’ extensive test menu comprising of 3,000+ tests and a range of well-curated preventive healthcare packages. The lab will cater to Hyderabad and nearby districts namely Warangal, Karimnagar, Nizambad, Rangareddy etc.  The advanced laboratory spread over 5000 sq ft has multiple laboratory divisions including hematology, biochemistry, clinical pathology, serology and microbiology.  This new laboratory will complement the network of over 30 collection centres in the state of Telengana. ]]> https://biospectrumindia.com/news/92/23458/centre-for-advanced-molecular-diagnostics-and-research-for-cancer-to-open-in-lucknow.html https://biospectrumindia.com/news/92/23458/centre-for-advanced-molecular-diagnostics-and-research-for-cancer-to-open-in-lucknow.html Wed, 16 Aug 2023 00:00:00 +0530 Kalyan Singh Super Specialty Cancer Institute (KSSSCI), a prominent institution under the aegis of the Government of Uttar Pradesh, has joined hands with Karkinos Healthcare and the Indian Institute of Technology Kanpur (IIT-K). This transformative tripartite partnership marks the inception of the 'Centre for Advanced Molecular Diagnostics and Research for Cancer (CAMDRC)', set to be established in Lucknow. The formalisation of this collaboration was marked by a Memorandum of Understanding (MoU) signed in the presence of Brajesh Pathak, Deputy Chief minister and Minister of Medical Education, Government of Uttar Pradesh.  Uttar Pradesh is facing a concerning rise in cancer cases, evident from the Indian Council of Medical Research's 2020 report, which documents 2,01,319 cases prompting a strong push to elevate healthcare standards in the region. Te Uttar Pradesh Cabinet’s approval on the project and the Government’s vision to develop the cancer-care infrastructure in the state for the common people has led to the creation of the Centre for Advanced Molecular Diagnostics and Research for Cancer (CAMDRC), marking a step towards affordable precision medicine. This initiative aligns with the shift towards molecular diagnostics in cancer care, offering personalised treatments based on genetic insights and improving patient outcomes. The CAMDRC Lab, located within the KSSSCI premises, will feature cutting-edge next-generation sequencing (NGS) machines for high throughput testing in its 25,000 square feet space. ]]> https://biospectrumindia.com/news/92/23459/american-institute-of-pathology-laboratory-sciences-launches-second-reference-lab-in-india-.html https://biospectrumindia.com/news/92/23459/american-institute-of-pathology-laboratory-sciences-launches-second-reference-lab-in-india-.html Wed, 16 Aug 2023 00:00:00 +0530 American Institute of Pathology & Laboratory Sciences (Ampath) has opened its first reference laboratory in Gurugram as part of its expansion plans in North India. This marks the company's second reference lab in India.  The 7000 sq. ft. laboratory is equipped with latest technology platforms capable of delivering quality reports with a quick Turn-Around-Time (TAT). The reference lab will become an independent ecosystem for Delhi and the neighbouring states in North India.  The newly launched spacious pathology centre serves a comprehensive menu of more than 2,500 tests, performed under the supervision of highly experienced pathologists. The lab offers diagnostic tests in Clinical Biochemistry, Hematology, Flow cytometry, Clinical Pathology, Serology, Immunology, Microbiology, Cytology, Histopathology, Immunohistochemistry, Molecular diagnosis, NGS, & Cytogenetics amongst others. These services help in diagnosis and detection of various diseases affecting different organs and parts of the body that can be extremely vital for the clinician to decide on the treatment protocol. Ampath has a Central Reference Laboratory in Hyderabad, with 14 satellite labs in different locations. It is NABL accredited (National Accreditation Board for Testing and Calibration Laboratories) and has collaborated with the University of Pittsburgh Medical Center (UPMC), one of the top ranked hospitals in the United States, which allows technical team at Ampath to work with the world’s leading clinicians to help them deliver on comprehensive lab services.  ]]> https://biospectrumindia.com/news/92/23463/crisprbits-partners-with-molbio-diagnostics-to-launch-crispr-based-point-of-care-tests.html https://biospectrumindia.com/news/92/23463/crisprbits-partners-with-molbio-diagnostics-to-launch-crispr-based-point-of-care-tests.html Wed, 16 Aug 2023 00:00:00 +0530 CrisprBits, a Bengaluru-based biotech startup specialising in CRISPR gene-editing technology, has announced a strategic collaboration with Goa-based Molbio Diagnostics, to revolutionise point of care diagnostics by the introduction of CRISPR in Point-of-Care tests (POCTs). The strategic partnership between CrisprBits and Molbio Diagnostics represents a significant milestone in the advancement of accessible, cost effective and accurate diagnostic testing in the frontline. The collaboration is set to identify and capitalise on market opportunities, bringing together their respective strengths and expertise. By harnessing the unprecedented sensitivity and specificity of RNA guide-based target identification of nucleic acid, and the presence of both cis and trans-cleavage property of certain Cas enzymes, CrisprBits has developed a platform to build rapid, precise, and affordable POCTs for a wide range of disease and health conditions. CrisprBits will spearhead the development of its platform, PathCrisp, for Point-of-Care testing. Simultaneously, Molbio Diagnostics will leverage its large-scale manufacturing capability and well-established sales and marketing network to promote and distribute the developed POCTs worldwide. The collaboration will focus on building POCTs for swift and accurate detection of various pathogens and genetic markers at the site. The tests will be made available in diverse settings, including clinics, hospitals, and resource-limited areas, where access to reliable diagnostic tools is crucial.   ]]> https://biospectrumindia.com/news/92/23359/lordsmed-expands-global-footprint-with-new-export-division-for-diagnostic-supplies.html https://biospectrumindia.com/news/92/23359/lordsmed-expands-global-footprint-with-new-export-division-for-diagnostic-supplies.html Wed, 19 Jul 2023 00:00:00 +0530 Mumbai-based LordsMed, the global healthcare division of Lord's Mark Industries, has announced the commencement of export venture of diagnostic supplies to Nepal. The company aims to establish itself as a leading global player in In-Vitro Diagnostics (IVD) manufacturing and export. With a strong commitment to delivering quality IVD solutions at a reduced cost, LordsMed has successfully built a vast network of over 300 distributor channels across India. The manufacturing facilities located in the outskirts of Mumbai, currently has the capacity to facilitate an impressive 1.7 crore diagnostic tests per month, covering a wide range of specialties including biochemistry, haematology, serology, rapid tests, and urine strip tests. Commenting on the launch, Manav Teli, Executive Director, Lord’s Mark Industries said “Our goal has always been to emerge as a global leader in IVD manufacturing and export, providing top-quality solutions at an affordable cost. With our advanced manufacturing facilities and extensive distributor network, we are now expanding our reach to neighbouring countries." As Lord’s Mark Industries continues to strengthen its presence in the Indian market, the company is now strategically focusing on supplying neighbouring countries with its high-quality IVD products. The conglomerate currently has five companies: LordsMed, Lord’s Mark Biotech, Lord’s Mark Microbiotech, Brahamastra Defense Techno Products Limited, Lord’s Mark Insurance Broking Limited, and Lords Automative Private Limited, with other verticals in renewable energy products and paper.   ]]> https://biospectrumindia.com/news/92/23352/mylab-launches-mybox-device-with-proprietary-dry-luminescence-immunoassay-technology.html https://biospectrumindia.com/news/92/23352/mylab-launches-mybox-device-with-proprietary-dry-luminescence-immunoassay-technology.html Tue, 18 Jul 2023 00:00:00 +0530 Pune-based biotech startup Mylab Discovery Solutions has launched Mybox+ diagnostic device with a range of important tests including Thyroid panel (T-3, T-4, TSH), Cardiac marker (Troponin), and biomarker (CRP, D-Dimer). The introduction of MyBox+ and its Dry Luminescence technology represents a transformative step forward in the field of diagnostics. It empowers small labs and clinics, enabling them to offer a broader range of tests and improve patient care. This technology marks a departure from traditional liquid reagent-based testing methods, offering a game-changing solution for small labs and clinics that previously faced limitations in performing certain tests. Until now, many small labs had to rely on outsourcing these tests to larger facilities, which often resulted in delayed results and increased costs associated with sample transportation. MyBox+ is a portable device powered by optical artificial intelligence (AI) engines, to deliver highly accurate, rapid quantitative and qualitative results in clinical samples. The device can be used to conduct tests for 30+ diseases and can invaluable diagnostic tool that can be easily set up in small labs and centres. Dry Luminescence Assay testing is a diagnostic technique that utilises luminescent reactions to detect and quantify specific substances or biomarkers in biological samples. It is a groundbreaking technology in clinical diagnostics, research laboratories and point-of-care testing.   ]]> https://biospectrumindia.com/news/92/23341/cre-diagnostics-collaborates-with-predomix-to-launch-multi-cancer-detection-test-for-women.html https://biospectrumindia.com/news/92/23341/cre-diagnostics-collaborates-with-predomix-to-launch-multi-cancer-detection-test-for-women.html Fri, 14 Jul 2023 00:00:00 +0530 Gurugram-based CŌRE Diagnostics, a leading player in the health and diagnostics industry, has announced its collaboration with PredOmix Technologies, a startup based in Gurugram, to launch OncoVeryx-F, a ground-breaking multi-cancer detection test specifically designed for high-risk and asymptomatic women.  Early-stage cancer detection is critical in improving treatment outcomes and saving lives, and OncoVeryx-F is set to revolutionise early-stage cancer detection and improve treatment outcomes. OncoVeryx-F's ability to identify cancer at Stages 1 and 2 increases the likelihood of successful treatment, providing patients a better chance of recovery. With an impressive accuracy rate of 98%, OncoVeryx-F can detect the presence or absence of cancer and accurately identify the Tissue of Origin (TOO) in a single test. This breakthrough technology offers a comprehensive screening solution for four cancers, including breast, endometrial, cervical, and ovarian cancer. By offering a highly accurate and non-invasive screening tool, OncoVeryx-F aims to empower women and their healthcare providers to take proactive steps towards early intervention and personalised treatment plans.     ]]> https://biospectrumindia.com/news/92/23345/metropolis-healthcare-launches-advanced-diagnostic-lab-in-kunnamkulam-kerala.html https://biospectrumindia.com/news/92/23345/metropolis-healthcare-launches-advanced-diagnostic-lab-in-kunnamkulam-kerala.html Fri, 14 Jul 2023 00:00:00 +0530 Metropolis Healthcare has announced the launch of an advanced diagnostic testing centre in Kunnamkulam, a prominent business town in Kerala’s Thrissur district. This new cutting-edge diagnostic testing laboratory can process up to 200 samples per day, ranging from basic day-to-day pathology tests to complex molecular diagnostic tests. Surendran Chemmenkottil, Chief Executive Officer, Metropolis Healthcare Limited said, “The opening of this lab in Kunnamkulam is in line with Metropolis’ mission to expand our reach in Tier 2 and Tier 3 towns in core geographic locations where the company has strong brand recognition. Metropolis has grown its presence in Kerala over the years, with over 25 processing laboratories and more than 70 patient collection centres serving a network of hospitals and doctors throughout the state. With the opening of the new processing lab, we hope to provide high-quality diagnostic testing services and reliable reports to clinicians and patients in Kunnamkulam and nearby areas in a timely manner.” Metropolis Laboratories have earned numerous quality accreditations, both in India and internationally. The company has developed the Indian Reference Range for an extensive test menu, which is now being used by thousands of laboratories across the country.  ]]> https://biospectrumindia.com/news/92/23339/cytelabs-expanding-diagnostic-services-to-hospitals-and-patients-across-south-india.html https://biospectrumindia.com/news/92/23339/cytelabs-expanding-diagnostic-services-to-hospitals-and-patients-across-south-india.html Thu, 13 Jul 2023 00:00:00 +0530 Cytelabs, a first-of-its-kind independent and specialised oncopathology cancer diagnostic services, is looking at expanding its services to hospitals and patients across South India. Launched in 2020 by Bengaluru-based Cytecare Cancer Hospital, Cytelabs provides easy access to high-quality cancer diagnostic services to surgeons and patients across 65 partnered hospitals in Karnataka, Andhra Pradesh, and Telangana. Given the overwhelming response, the plan is to expand the diagnostic services to other States in near future. Recognizing the limited access to super-specialised oncopathology in India, Cytelabs was conceived with the idea to extend the exceptional oncopathological expertise available within Cytecare to oncologists, oncosurgeons and patients beyond the Bengaluru hospital. Oncopathology is an integral part of cancer diagnosis and treatment. It is a branch of medicine which essentially deals with establishing the tissue diagnosis of cancer and forms the basis of cancer treatment.  Cytelabs, the brainchild of Dr Aparna Gangoli, plans to digitise pathology services in the near future in its attempt to provide access to the remote places, thus, ensuring everyone has access to the advanced services for proper diagnosis and treatment.     ]]> https://biospectrumindia.com/news/92/23319/oncquest-collaborates-with-nashik-specialty-laboratory-for-stronger-foothold-in-maharashtra.html https://biospectrumindia.com/news/92/23319/oncquest-collaborates-with-nashik-specialty-laboratory-for-stronger-foothold-in-maharashtra.html Mon, 10 Jul 2023 00:00:00 +0530 Oncquest Laboratories, a leading super-specialised laboratory network in India, has teamed up with Nasik Specialty Laboratory to enhance its operations in Maharashtra. The strategic collaboration aims to address the advanced testing needs of clinicians and hospitals in Northwest Maharashtra, solidifying Oncquest's position as a prominent player in the field of cancer diagnostics and specialised testing.  Nashik Specialty Laboratory will offer a comprehensive range of tests, including routine tests, specialised and super-specialised categories of tests, and highly advanced genome testing.  With this collaboration, Oncquest Laboratories aims to continue its mission of providing accurate and reliable diagnostics to healthcare providers and patients, ensuring timely and effective treatments.  Oncquest, promoted by the Burman family (Promoters of Dabur India), started as a Dabur Research Foundation research entity in 2001 and has been a forerunner in molecular diagnostics services across India and neighbouring countries.It conducts over 4,000 different tests - from the routine to the most complex, spanning over 200 technologies.   ]]> https://biospectrumindia.com/news/92/23323/medgenome-acquires-illuminas-novaseq-x-plus-launches-new-genome-sequencing-test.html https://biospectrumindia.com/news/92/23323/medgenome-acquires-illuminas-novaseq-x-plus-launches-new-genome-sequencing-test.html Mon, 10 Jul 2023 00:00:00 +0530 Bengaluru-based MedGenome becomes the first to offer advanced genomics services using Illumina’s NovaSeq X Plus in South Asia. With this, the company anticipates bringing down the reagent cost of Human Whole Genome sequencing to $200 in the near future. The NovaSeq X Series is Illumina's most powerful sequencing system. With the ability to generate more than 20,000 whole genomes per year – 2.5 times the throughput of prior sequencers at shorter turnaround time, this latest sequencer is aimed at making genomics more sustainable and accessible to more people globally. MedGenome has had a long-standing partnership with Illumina over the last decade expanding its portfolio of sequencing equipment with the latest offerings and becoming leaders in adopting the most up to date sequencing technology. NovaSeq X Plus promises to accelerate a deeper understanding of genetic disorders and can perform a broad range of data-intensive applications, bringing more breakthroughs genetic disease diagnosis and treatment. In conjunction with this acquisition, MedGenome has launched KaryoSeq (or Karyotype Sequencing), an innovative Whole Genome Sequencing to diagnose prenatal and newborn conditions. KaryoSeq is a faster and accurate solution which allows for the detection of small chromosomal abnormalities, such as microdeletions or microduplications, that may not be easily identified through microscopic examination alone. ]]> https://biospectrumindia.com/news/92/23295/empe-diagnostics-launches-path-breaking-mdr-tb-test-kit.html https://biospectrumindia.com/news/92/23295/empe-diagnostics-launches-path-breaking-mdr-tb-test-kit.html Thu, 06 Jul 2023 13:20:00 +0530 In a bid to reduce the life-threatening complications and consequences associated with tuberculosis (TB), Swedish startup EMPE Diagnostics has launched its one-of-its-kind test kit — mfloDx™ MDR-TB — at Telangana Lifesciences office, in Hyderabad. The path-breaking kit was unveiled by Kalvakuntla Taraka Rama Rao, Minister for IT, Industries and Municipal Administration, Government of Telangana and Raghavendra Goud Vaggu, Global CEO, EMPE Diagnostics, in the presence of Jayesh Ranjan, Principal Secretary, Industries and Commerce and Information Technology; Satish Reddy, Chairman - Dr Reddy Labs; and Shakti Nagappan, Director, Lifesciences, Govt of Telangana. The mfloDx™ multi drug resistant (MDR)-TB is a rapid, accurate, and affordable kit that provides reliable answers about the bacterium and its resistance profile. The multiplex molecular test indicates the presence of Mycobacterium tuberculosis and its genotypic resistance profile by developing a visual signal. Clinicians can get confirmatory results in a qualitative ‘YES’ or ‘NO’ format, within 3 hours. The kit has been recognised by the World Health Organisation (WHO), and is currently undergoing clinical evaluation in multiple countries and has patents in 19 countries. According to CEO Raghavendra Goud, the mfloDx™ MDR-TB test kit has been designed to detect TB and its antibiotic resistance. It includes controls and MDR-TB Rifampicin and Isoniazid and has been approved by Central Drugs Standard Control Organisation (CDSCO). The company has established a global production and R&D facility at Genome Valley and has invested about Rs 25 crore. “We’re the first ever company to receive grants from the European Innovation Council and Bill & Melinda Gates Foundation. We currently have a capacity to make 25 million kits and will be expanding to 100 million kits soon,” Goud added.   ]]> https://biospectrumindia.com/news/92/23264/genworks-health-launches-ivd-tests-for-dengue-malaria.html https://biospectrumindia.com/news/92/23264/genworks-health-launches-ivd-tests-for-dengue-malaria.html Wed, 28 Jun 2023 00:00:00 +0530 To improve the offering in the in vitro diagnostics (IVD) field, Bengaluru-based startup GenWorks has announced the launch of its IVD tests including rapid card test kits for dengue and malaria. The use of IVD products for dengue and malaria are aimed at preventing, diagnosing, curing, and treating seasonal epidemics and mitigating their impact. iScreen Malaria Card Antigen (Pf/Pv) by GenWorks is a visual lateral flow immunoassay designed for the qualitative and differential detection of P. falciparum specific histidine-rich protein-2 (Pf. HRP-2) and P. Vivax specific lactate dehydrogenase (pLDH) in human whole blood with 98.5% sensitivity & 95% specificity. A blood specimen collected from the patient is applied to the sample pad on the test card along with buffer reagent. After 15 minutes, the presence of specific bands in the test card window indicates whether the patient is infected with Plasmodium falciparum or Plasmodium vivax of human malaria. On the other hand, iScreen Dengue NS1 by GenWorks offers an immunochromatographic one-step rapid card solution for qualitative early acute dengue detection with NS1 antigen and differential detection of dengue IgG & IgM antibodies in human serum.     ]]> https://biospectrumindia.com/news/92/23239/mumbai-based-invex-health-develops-oral-fluid-based-hiv-self-test.html https://biospectrumindia.com/news/92/23239/mumbai-based-invex-health-develops-oral-fluid-based-hiv-self-test.html Tue, 20 Jun 2023 00:00:00 +0530 Mumbai-based startup Invex Health has developed an Oral Fluid-Based HIV Self-Test, a ground-breaking product currently undergoing validation in India. Developing this test is considerably more challenging than traditional blood-based tests, with only one company worldwide having achieved commercialisation with WHO pre-qualification.  In a significant stride towards expanding its therapeutic offerings, Invex Health has recently acquired the global licensing rights for a patented product addressing Psoriasis. By manufacturing this product in India and gradually making it available in various markets at an affordable price, it can been revolutionising the treatment landscape for individuals affected by Psoriasis. This strategic move underscores the company's commitment to innovation in patient care. Invex Health is also expanding its market by offering natural OTC antidepressant and mood boosters, which can be used by many people searching for better and safer options to deal with multiple mood disorders. The startup is further establishing itself and creating the largest platform for cancer therapy in India. Through strategic collaborations with renowned oncologists, hospitals, and cancer treatment centres, the company ensures timely access to advanced cancer treatments. .   ]]> https://biospectrumindia.com/news/92/23213/mylab-introduces-indigenous-point-of-care-sickle-cell-anaemia-test.html https://biospectrumindia.com/news/92/23213/mylab-introduces-indigenous-point-of-care-sickle-cell-anaemia-test.html Wed, 14 Jun 2023 00:00:00 +0530 Continuing with its effort to introduce quality diagnostic tests for diseases of public health importance, Pune-based startup Mylab Discovery Solutions has launched a strip-based, rapid point of care test, PathoCatch Sickle Cell Rapid Test for Sickle Cell Anaemia (SCA). Approved by Central Drugs Standard Control Organisation (CDSCO), this test aims to transform the way healthcare professionals diagnose and manage SCA, offering rapid and accurate results at the patient's site. This will be instrumental in supporting the government’s mission to eliminate SCA by 2047 from India. Traditionally, diagnosing sickle cell anaemia has been a laborious and time-consuming process, involving blood sample collection, transportation to a laboratory, and subsequent analysis by skilled technicians. This lengthy process often results in delayed diagnosis and treatment, leading to increased morbidity and mortality rates. By utilising cutting-edge technology, PathoCatch Sickle Cell Rapid Test can detect the presence of abnormal haemoglobin in a small blood sample within a few minutes. It can be used easily by healthcare professionals without the use of laboratory equipment. The test is made up of three indicators, which detect the presence of haemoglobin A, S and C, allowing the user to rapidly distinguish between normal, carrier and sickle cell samples. It has a both combined sensitivity and specificity of 100%, making it one of the fastest and most accurate tests in India. ]]> https://biospectrumindia.com/news/92/23209/american-institute-of-pathology-laboratory-sciences-expands-footprint-in-andhra-pradesh-.html https://biospectrumindia.com/news/92/23209/american-institute-of-pathology-laboratory-sciences-expands-footprint-in-andhra-pradesh-.html Tue, 13 Jun 2023 00:00:00 +0530 Expanding its footprint in Andhra Pradesh, American Institute of Pathology & Laboratory Sciences (Ampath) has recently launched a lab at Punnaiah and Vajramma Complex, Ramachandra Nagar, Vijayawada. The 2700 sq. ft. laboratory is equipped with latest technology platforms capable of delivering quality reports with a quick Turn-Around-Time (TAT). The newly launched spacious pathology centre serves a comprehensive menu of more than 2500 tests, performed under the supervision of highly experienced pathologists. The lab offers diagnostic tests in Clinical Biochemistry, Hematology, Flow cytometry, Clinical Pathology, Serology, Immunology, Microbiology, Cytology, Histopathology, Immunohistochemistry, Molecular diagnosis, NGS, Cytogenetics amongst others. These services help in diagnosis and detection of various diseases affecting different organs and parts of the body that can be extremely vital for the clinician to decide on the treatment protocol.   Residents of these cities and nearby towns like Guntur, Narsarapeta, Tenali, Gudiwada, Machilipatnam, Eluru, Narsipatnam, Anakapalle, Rajamundry, Vizianagram, and Srikakulam will get benefit from the world-class diagnostic services provided by the well-equipped lab facility. Ampath has a Central Reference Laboratory in Hyderabad, with 14 satellite labs in different locations.   ]]> https://biospectrumindia.com/news/92/23198/aarthi-scans-introduces-innovative-ai-screening-to-assess-risk-of-heart-attacks.html https://biospectrumindia.com/news/92/23198/aarthi-scans-introduces-innovative-ai-screening-to-assess-risk-of-heart-attacks.html Fri, 09 Jun 2023 00:00:00 +0530 Chennai-headquartered Aarthi Scans & Labs, a pan-India integrated diagnostic chain, has announced a strategic partnership with Siemens Healthineers for a cause. The aim of this collaboration is to offer artificial intelligence (AI)-based calcium scoring of heart by CT scanning, which measures the amount of calcium deposition in the arteries supplying the heart. Previously, CT calcium scoring of the heart was possible only in high-end CT scanners equipped with dedicated acquisition techniques, making it unaffordable for the general public and unviable for mass screening. But by using AI technology by Siemens Healthineers, Aarthi Scans has rolled out CT calcium scoring of the heart in all its 45 branches across 10 states. This AI technology from Siemens Healthineers is FDA-approved and analyses images from low-dose Chest CT exams which apart from calcium scoring of the heart, may support detection of additional abnormalities like dilated aortic diameter, abnormal height and density of the thoracic vertebral bodies, lung nodules and high pulmonary density values, that are imaging markers for other life-threatening diseases. ]]> https://biospectrumindia.com/news/92/23159/srl-diagnostics-rebrands-as-agilus-diagnostics.html https://biospectrumindia.com/news/92/23159/srl-diagnostics-rebrands-as-agilus-diagnostics.html Sat, 27 May 2023 00:00:00 +0530 SRL Diagnostics, instituted in 1995, one of India’s leading network of diagnostic centres, has announced that as a result of its work over the past few years towards  rebranding, it would be adopting a new identity - ‘Agilus Diagnostics’. Agilus is inspired by the Latin term, agilis which stands for ‘agility’.   The company has built an extensive laboratory network comprising 410+labs, 3700+ customer touchpoints, and 12000+ direct clients. Agilus Diagnostics is India’s largest chain in terms of network with presence in 1000+ cities, 34 states, and union territories. Agilus also operates one of the largest accredited network of laboratories in the country; 43 of their labs are accredited by NABL and 3 are recognised under the NABL M(EL)T programme. It also has two CAP accredited laboratories in Mumbai, India and Dubai. In FY23, the business served a total of over 16.6 million patients and completed 39.1 million tests. The company also has 3 Centres of Excellence (CoEs) focused on Histopathology, Transplantation Immunology and Molecular Pathology.  Agilus Diagnostics (Formerly SRL Diagnostics) has a long list of firsts to its credit, including being one of the first NABL and CAP Accredited Medical Laboratory in the nation, the first ABDM Integrated Laboratory and the only Indian lab to ever partner with the Indian Olympic Association for the Olympics 2020 and 2024, and many more. Through strategic expansion, the development of capabilities in genomics and next-generation diagnostics, superior client experiences, and digitally enabled services, the company aims to continue its legacy of delivering exceptional diagnostic care. ]]> https://biospectrumindia.com/news/92/23151/lupin-diagnostics-launches-satellite-laboratory-in-vijayawada.html https://biospectrumindia.com/news/92/23151/lupin-diagnostics-launches-satellite-laboratory-in-vijayawada.html Thu, 25 May 2023 00:00:00 +0530 Global pharma major Lupin has announced the launch of its Satellite Laboratory in Vijayawada, Andhra Pradesh. The move is part of Lupin Diagnostics’ ongoing expansion aimed at enhancing access to high-quality testing services and increasing the diagnostics network across the country. The newly launched laboratory complements Lupin Diagnostics extensive network of 27 laboratories and over 410 collection centres across India.  Lupin’s new laboratory at Vijayawada is equipped with state-of-the-art diagnostic technology and staffed by a team of highly qualified clinical experts. This advanced infrastructure empowers Lupin Diagnostics to offer reliable and high-quality diagnostic services to the local community. The integration of cutting-edge technology and expertise ensures accurate and efficient testing, enabling timely diagnosis and improved patient care. In addition to routine and specialised tests, the newly launched laboratory in Vijayawada offers an extensive range of diagnostics services. These include clinical pathology, microbiology, hematology, biochemistry, serology, and immunology. With a strong home collection service team and network, Lupin Diagnostics ensures patient convenience and enables tracking assigned phlebotomists, at the click of a button. The company has also enhanced its value-added services through inclusion of dynamic smart reports for patients along with tips for monitoring their health, and historical trend graphs.   ]]> https://biospectrumindia.com/news/92/23146/molbio-diagnostics-shanmukha-to-offer-rapid-low-cost-portable-devices-for-detection-of-blood-disorders.html https://biospectrumindia.com/news/92/23146/molbio-diagnostics-shanmukha-to-offer-rapid-low-cost-portable-devices-for-detection-of-blood-disorders.html Wed, 24 May 2023 00:00:00 +0530 Molbio Diagnostics is collaborating with Bengaluru-based startup ShanMukha Innovations to design develop, and commercialise affordable point-of-care diagnostic devices to diagnose haemoglobinopathy-related diseases.Shanmukha Innovations has developed SickleCert, India’s first indigenous point-of-care confirmatory test for quantitative detection and differentiation of sickle-cell disease/trait, approved by Central Drugs Standard Control Organisation. The technology based on High-Performance Optical Spectroscopy (HPOS) demonstrated high accuracy in clinical evaluations and has been approved by ICMR and recommended by the Department of Health Research. This platform will soon also be able to test for Anemia and Thalassemia.Goa-based firm Molbio will help Shanmukha with the development, manufacturing and commercialisation of the platform, in line with its vision of enabling the availability of futuristic health technologies to the world.Sickle cell anemia is a genetic disorder that is characterised by an altered haemoglobin structure, which causes flexible red blood cells to become stiff sickle-shaped cells, leading to debilitating effects like obstruction of blood flow, oxygen deficiency and an increasing risk of organ damage.  With a tiny amount of blood from a finger prick, the test provides highly accurate results in 15 minutes. In batch mode, over 40 samples can be tested in an hour enabling a large volume of screenings to be completed in a much shorter time span. ]]> https://biospectrumindia.com/news/92/23124/core-diagnostics-launches-satellite-lab-to-expand-diagnostic-services.html https://biospectrumindia.com/news/92/23124/core-diagnostics-launches-satellite-lab-to-expand-diagnostic-services.html Mon, 22 May 2023 00:00:00 +0530 Core Diagnostics, a high-end diagnostic solutions provider headquartered in Gurugram, has announced its new satellite lab launch in East Delhi, Hargobind Enclave. This strategic expansion aims to broaden the company's testing capacities, ensuring enhanced accessibility to high-quality diagnostic services for healthcare providers and patients. The satellite lab is an integral part of Core Diagnostics' strategic expansion plan, aimed at extending its testing capabilities and meeting the growing demand for efficient and accurate diagnostic services. This expansion allows them to bring high-quality diagnostic solutions closer to healthcare providers and patients, empowering them with timely and precise information for informed medical decisions. It is equipped with cutting-edge technology and staffed by a team of highly skilled professionals who share Core Diagnostics' passion for excellence in diagnostics. With advanced diagnostic equipment, automation systems, and quality control measures, the laboratory aims to maintain the highest standards of testing excellence.  This expansion will allow quicker and more convenient access to critical diagnostic tests, reducing turnaround time and enabling prompt treatment decisions.     ]]> https://biospectrumindia.com/news/92/23105/find-and-via-global-health-partner-to-expand-access-to-quality-diagnostics-in-lmics.html https://biospectrumindia.com/news/92/23105/find-and-via-global-health-partner-to-expand-access-to-quality-diagnostics-in-lmics.html Thu, 18 May 2023 00:00:00 +0530 Global health non-profit based in Geneva, Switzerland, FIND has announced that a new partnership with VIA Global Health will provide new routes to market for regional and global manufacturers of high-quality diagnostic tests, to expand access to testing in low- and middle-income countries (LMICs). A collaborative agreement brings together VIA Global Health, a leading online marketplace that delivers medical products to over 80 countries, and the DxConnect Marketplace, conceived by FIND to directly connect buyers with approved test suppliers to serve market segments that cannot access quality products through other procurement mechanisms. The DxConnect Marketplace initiative is aligned with FIND’s Global Access Policy, which aims to provide affordable, available, and accessible diagnostics in LMICs. Specifically, the DxConnect Marketplace addresses challenges including insufficient product knowledge, fragmented supply chains, opaque pricing information, and high logistics costs that continue to impede diagnostic access. The partnership with VIA Global Health complements FIND’s efforts to expand the reach of the DxConnect Marketplace so that more people can access quality, affordable diagnostic tests. Rapid diagnostic tests from Premier Medical Corporation (PMC) in India were already available to purchase via the DxConnect Marketplace by buyers for LMIC markets. This partnership means that availability of these PMC products will now be extended to the VIA Global Health platform. FIND and VIA Global Health are already working together to include additional diagnostic products and expand the partnership to enable more regional and global manufacturers to reach a wider audience. ]]> https://biospectrumindia.com/news/92/23095/ground-breaking-research-on-prenatal-screening-for-chromosomal-anomalies.html https://biospectrumindia.com/news/92/23095/ground-breaking-research-on-prenatal-screening-for-chromosomal-anomalies.html Wed, 17 May 2023 00:00:00 +0530 Redcliffe Labs, a Noida-based startup, has come out with an comprehensive research study on prenatal screening for chromosomal anomalies. Led by Dr Sohini Sengupta, Medical Laboratory Director, Redcliffe Labs and a team of esteemed doctors, this collaborative effort took a period of four months and was aimed at addressing the lack of scientific data on antenatal risk assessment among Indian women. The study was performed on a sample of 362 pregnant women for prenatal screening. Nine (2.48%) women out of 362 were screen positive for chromosomopathy. The study focused on the significance of Maternal Dual Marker screening during the first trimester to predict the probability of a foetus being born with chromosomal abnormalities such as Down Syndrome, Edward Syndrome, and Patau Syndrome. One of the key findings of this study is the importance of a detailed risk assessment using a combination of factors rather than relying solely on maternal age as a risk indicator. While it is widely believed that women above the age of 35 have an increased risk of giving birth to children with chromosomal abnormalities, the research conducted by Redcliffe reveals that age alone may not accurately reflect the true risk.  Dr Sohini Sengupta said, "By collaborating with Roche Diagnostics India to utilise their advanced diagnostic instrument the cobas 8000,  and Elecsys PAPP-A & Elecsys free βhCG, we were able to obtain accurate data and generate valuable insights. We believe that this research will contribute to improved medical decision-making and patient outcomes across all genres."  ]]> https://biospectrumindia.com/news/92/23065/mylab-receives-cdsco-approval-for-herpes-virus-rt-pcr-detection-kit.html https://biospectrumindia.com/news/92/23065/mylab-receives-cdsco-approval-for-herpes-virus-rt-pcr-detection-kit.html Tue, 09 May 2023 00:00:00 +0530 Pune-based startup Mylab Discovery Solutions has launched PathoDetect HSV Type 1& 2 Detection kit, a multiplex real-time PCR test detect and differentiate herpes simplex virus type I (HSV-l) and type 2 (HSV-2) in single tube. Herpes infection is caused by the highly contagious herpes simplex virus. The Herpes Simplex Virus -1, also called, HSV-1 virus infects every two out of three people under the age of 50 and HSV-2 infection occurs in one out of ten people aged 15, as per WHO 2022 report. Sensitivity of testing decreases as the disease progresses, as lesions heal, and in recurrences. PCR test can detect the presence of HSV from later stages of lesions. Approved by Central Drugs Standard Control Organisation (CDSCO), ‘PathoDetect HSV Type 1 & 2 Detection Test’ delivers high sensitivity and specificity in the detection of HSV-1 and HSV-2 DNA in clinical specimens, provides sample-to-test results in 2 hours. These tests are compatible with Mylab Compact Series to allow completely automated and high throughput results.  Speaking about the launch of ‘PathoDetect HSV Type 1 & 2 Detection Test’, Hasmukh Rawal, Co-founder & Managing Director of Mylab said, “HSV is a highly contagious virus that can affect a person's physical, emotional, and psychological health. Symptoms of herpes can be misinterpreted or confused among other diseases. For this reason, the introduction of a fast and accurate molecular test that distinguishes between HSV 1 and HSV 2 will be an important diagnostic tool."      ]]> https://biospectrumindia.com/news/92/23016/vanguard-diagnostics-announces-launch-of-indias-first-typhoid-rt-pcr-test-based-on-patented-technology.html https://biospectrumindia.com/news/92/23016/vanguard-diagnostics-announces-launch-of-indias-first-typhoid-rt-pcr-test-based-on-patented-technology.html Thu, 27 Apr 2023 00:00:00 +0530 New Delhi-based Vanguard Diagnostics announced the launch of VANSCAN Typhoid RT PCR Test, at the 28th edition of Medical Fair India, taking place from 27th to 29th April 2023 at Pragati Maidan. The test has been developed in technical collaboration with Dehradun-based Graphic Era University. The patented technology is a one-of-a-kind in India and exhibits a strong example of industry and academia collaboration. VANSCAN Typhoid RT PCR Test is the new gold standard, reliable, rapid and compatible with all open RT PCR systems. "Treatment of this disease is often delayed using the Widal test which is obsolete and unstandardised. Likewise, there are rapid card tests for typhoid detection which are unreliable due to false positive or negative tests. Even the conventional blood culture is cumbersome", pointed out Veena Kohli, Chief Executive Officer, Vanguard Diagnostics. Typhoid fever is common in developing countries. India is an endemic country for typhoid with a burden of approximately 4.8 million cases per year, according to health experts. In the given set of the diagnostic challenges, VANSCAN Typhoid RT PCR test has been found to be highly sensitive and specific. ]]> https://biospectrumindia.com/news/92/22998/diagnostics-industry-wants-centre-to-promote-innovations-in-digital-health-and-personalised-medicine.html https://biospectrumindia.com/news/92/22998/diagnostics-industry-wants-centre-to-promote-innovations-in-digital-health-and-personalised-medicine.html Mon, 24 Apr 2023 00:00:00 +0530 With molecular diagnostics, Point-of-care testing (POCT), telemedicine, Artificial Intelligence (AI) and Machine Learning (ML) gaining prominence in the diagnostics sector, the industry has sought Centre’s intervention to further enhance transparency and competitiveness to rationalise costs and improve the quality of care. Industry leaders have asked to implement certain measures to improve healthcare professionals’ training and education, and incentivise healthcare professionals working in rural areas. According to Manav Teli, Director, LordsMed, “Furthermore, we also propose to promote innovation in the healthcare industry, particularly in areas such as digital health and personalised medicine. This could include measures such as supporting R&D, providing tax incentives for innovation and developing regulatory frameworks that encourage innovation while guaranteeing patient safety. The economic situation in the healthcare industry is complex and heavily regulated. It is, therefore, essential for authorities and policymakers to create an environment that fosters innovation, encourages investment, promotes transparency and guarantees that patients receive high-quality care.” Thane-based LordsMed recently collaborated with Hindustan Antibiotics Limited to distribute affordable rapid antigen kits across the country. The company manufactures an extensive range of rapid test kits for detecting malaria, cardiovascular disease, hepatitis C virus (HCV), HIV, syphilis, hepatitis B surface antigen (HBsAg), dengue, typhoid, COVID, chikungunya, ovulation and pregnancy. The company has also recently launched its 20,000 square feet in-vitro diagnostics (IVD) manufacturing facility at Vasai near Mumbai. The facility manufactures IVD and point-of-care diagnostic solutions such as analysers, reagents for clinical biochemistry, haematology, serology, immunology, Indian Council of Medical Research (ICMR) approved antigen kits, and lab consumables. LordsMed, the pharma division of Lord’s Mark Industries, has collaborated with Singapore's Sensing Self to launch a 99 per cent accuracy rate saliva-based rapid antigen test kit to support large scale mass screening for COVID-19 at various passenger transit points like airports, apart from offices and manufacturing units. The market for diagnostic labs in India was valued at  $14.796 billion in 2022, and by 2028, it is expected to grow at a CAGR of 11.53 per cent. This could be attributed to the country's growing population, which is susceptible to various diseases. The global in vitro diagnostics market in terms of revenue was estimated to be worth $115.8 billion in 2022 and is poised to reach $144.7 billion by 2027, growing at a CAGR of 4.6 per cent from 2022 to 2027. The diagnostics sector is constantly evolving, and several trends are gaining prominence in the industry like molecular diagnostics, Point-of-care testing (POCT), telemedicine,  AI and ML.   Molecular diagnostics, which involve the analysis of DNA, RNA, and other genetic markers, are gaining prominence in the diagnostics sector. Molecular tests are highly accurate and can provide rapid results, making them useful for diagnosing infectious diseases, genetic disorders, and certain types of cancer. POCT is also gaining prominence in the diagnostics sector due to its ability to improve access to diagnostics, particularly in remote or resource-limited settings. Its potential for early detection and management of diseases such as infectious diseases, diabetes, and cardiovascular conditions. Digital health technologies, including electronic health records (EHRs), telemedicine, and telehealth, are becoming increasingly important in the diagnostics sector. There are various advanced technological equipment that allow for seamless sharing of patient data and test results among healthcare providers, improving communication and coordination.   Bhagwati Prasad   ]]> https://biospectrumindia.com/news/92/22986/neuberg-diagnostics-expands-presence-in-east-india-through-jv-with-pulse-diagnostics.html https://biospectrumindia.com/news/92/22986/neuberg-diagnostics-expands-presence-in-east-india-through-jv-with-pulse-diagnostics.html Fri, 21 Apr 2023 00:00:00 +0530 Chennai-headquartered Neuberg Diagnostics has announced a joint venture (JV) with Pulse Diagnostics in Kolkata, to expand integrated diagnostics centres combining advanced pathology and advanced radiology modalities across Eastern & North Eastern States. The new company will be called Neuberg Pulse Diagnostics and will integrate the ten labs of Neuberg located across East India with the nine integrated diagnostic centres of Pulse Diagnostics in Kolkata. This will result in close to 20 integrated diagnostic centres, 20 labs, and over 200 collection centres covering the entire length and breadth of Eastern India within this financial year. Sunaina Bihani will be the MD & CEO of the Joint Venture, and will be ably supported by the Neuberg’s leadership team. 7i Capital Advisors, Indian partner of Clairfield, acted as the exclusive sell side advisor to Pulse Diagnostics and its shareholders in this transaction. The partnership between Neuberg Diagnostics and Pulse Diagnostics is expected to improve access and affordability for high end integrated diagnostic services across Eastern India. With this merger, Neuberg group becomes one of the largest diagnostics providers in East India with annual revenues to reach more than Rs 100 crore in this financial year with an aim to triple this revenue in the coming three years.   ]]> https://biospectrumindia.com/news/92/22963/redcliffe-labs-extends-reach-in-up-with-new-cutting-edge-facility-in-muzaffarnagar.html https://biospectrumindia.com/news/92/22963/redcliffe-labs-extends-reach-in-up-with-new-cutting-edge-facility-in-muzaffarnagar.html Tue, 18 Apr 2023 00:00:00 +0530 Redcliffe Labs, Noida-based diagnostics service provider, has recently launched its state-of-the-art diagnostic lab in Muzaffarnagar, to provide world-class diagnostics services to the doorsteps of the people of Uttar Pradesh (UP). With the launch of Muzaffarnagar Lab, the startup now has a network of 15+ diagnostic centres in Uttar Pradesh. The lab has a setup of all clinical laboratory departments, including Biochemistry, Hematology, Immunoassays, Clinical Pathology, Hormones, and more.  Redcliffe Labs has made healthcare services accessible for the residents of Muzaffarnagar and nearby areas like  Khatauli, Purquazi, Shamli, Jansath, Bhopa, and Bhadana. Redcliffe already has an impressive footprint in Himachal Pradesh, Punjab, Haryana, Uttar Pradesh, Jammu Kashmir, and Uttarakhand. Just like the entire network of Redcliffe labs, the lab in Muzaffarnagar is equipped with state-of-the-art, fully automatic instruments, ensuring the optimum levels of accurate reporting as per NABL & ISO guidelines.        ]]> https://biospectrumindia.com/news/92/22945/molbio-diagnostics-sigtuple-to-build-next-gen-ai-enabled-portable-devices.html https://biospectrumindia.com/news/92/22945/molbio-diagnostics-sigtuple-to-build-next-gen-ai-enabled-portable-devices.html Thu, 13 Apr 2023 12:15:00 +0530 Goa-based Molbio Diagnostics has collaborated with SigTuple, a Bengaluru-based medtech startup in the field of artificial intelligence (AI) for diagnostics, to build next-generation AI-enabled portable devices for many routines but critical diagnostic tests. These devices will enable testing to be performed at the point of care – a doctor’s chamber, a public health centre, or an emergency room of a hospital – without having to send samples to central laboratories. The aim is to reduce turnaround time for testing, reduce errors, and help in early diagnosis and initiation of correct treatment.  Molbio and SigTuple are joining hands to collaborate on the development of AI-powered, battery-operated, portable devices for many diagnostic tests in the fields of haematology, biochemistry, electrochemistry and others. The testing process will be extremely simplified and will not require a trained laboratory technician to perform the tests. Accurate, laboratory-quality test results will be available to the patient within a few minutes.  The collaboration builds on the strengths of the two organizations to drive cutting-edge technology which can make high-quality diagnostics accessible to everyone.  Image caption- Tathagato Rai Dastidar, Founder & CEO, SigTuple (L) and Dr Chandrasekhar Nair, Co-founder & Chief Technology Officer of Molbio Diagnostics ]]> https://biospectrumindia.com/news/92/22943/lupin-diagnostics-unveils-regional-reference-lab-in-bengaluru.html https://biospectrumindia.com/news/92/22943/lupin-diagnostics-unveils-regional-reference-lab-in-bengaluru.html Thu, 13 Apr 2023 10:25:00 +0530 Global pharma major Lupin has announced the launch of its new state-of-the-art Regional Reference Laboratory in Bengaluru, Karnataka, as part of the expansion of its diagnostics network. The new laboratory marks a significant step forward in Lupin Diagnostics' mission to provide accessible and affordable diagnostics and preventive healthcare services across India. The Regional Reference Laboratory complements the company's existing network of 25 laboratories and 410+ collection centres across India. The new laboratory in Bengaluru is equipped with cutting-edge technologies and staffed by highly qualified clinical experts, enabling Lupin Diagnostics to deliver high-quality and reliable diagnostic services to patients and consumers across Bengaluru and neighboring cities. In addition to routine and specialised tests, the laboratory offers a comprehensive range of diagnostics services, including molecular diagnostics, cytogenetics, flow cytometry, cytology, microbiology, serology, haematology, histopathology, immunology, routine biochemistry, among others. Lupin Diagnostics leverages state-of-the-art automation and streamlined processes to deliver highly accurate test results, empowering patients to make informed decisions about their health.   Image caption- Ravindra Kumar, Chief Executive Officer, Lupin Diagnostics and Shweta Munjal, Vice President & Global Head - Corporate Communications & Sustainability at Lupin ]]> https://biospectrumindia.com/news/92/22890/molbio-diagnostics-adds-truenat-h3n2-h1n1-test-to-respiratory-disease-portfolio-.html https://biospectrumindia.com/news/92/22890/molbio-diagnostics-adds-truenat-h3n2-h1n1-test-to-respiratory-disease-portfolio-.html Mon, 03 Apr 2023 00:00:00 +0530 Goa-based Molbio Diagnostics has launched the Truenat H3N2/H1N1 for differential diagnosis of the H3N2 and H1N1 virus. The test is approved by the Central Drugs Standard Control Organization (CDSCO) and can provide sample-to-result in an hour’s time. Truenat H3N2/H1N1 is the first point-of-care Real-Time PCR test that aids in the confirmatory diagnosis of Influenza infections. The test will work on the existing Truenat machines that are deployed across over 3500 primary and community healthcare centres and over 1200 private labs and hospitals across India, making it possible for patients to obtain a quick diagnosis at all levels of the healthcare chain.   India is currently seeing a surge in influenza viral infections due to H3N2 and H1N1. The viruses that spread through the air, have the ability for sustained human-to-human transmission, which can potentially cause an influenza pandemic.  Commenting on the launch, Sriram Natarajan, CEO, Founder, and Director of Molbio Diagnostics, said, “The launch of Truenat H3N2/H1N1 further strengthens Molbio’s product portfolio by providing complete testing solutions for respiratory illnesses. The multi-disease testing capability of the Truenat platform keeps healthcare facilities prepared to combat all kinds of pandemics and disease outbreaks at early stage. Going forward, Molbio will continue to bring innovative solutions for better patient management and appropriate treatment of the disease.”   ]]> https://biospectrumindia.com/news/92/22886/redcliffe-labs-buys-rajasthans-integrated-diagnostics-chain-medicentre-sonography-clinical-lab.html https://biospectrumindia.com/news/92/22886/redcliffe-labs-buys-rajasthans-integrated-diagnostics-chain-medicentre-sonography-clinical-lab.html Sat, 01 Apr 2023 00:00:00 +0530 Noida-based startup Redcliffe Labs, one of the fastest growing pan-India omnichannel diagnostics chain, has acquired Medicentre Sonography & Clinical Lab. Medicentre Sonography and Clinical Lab, led by Dr Manish and Dr Mayanka in Udaipur, is one of the largest independent diagnostic labs in Rajasthan, having 10 labs and an extensive network of 40 collection centers across the southern Rajasthan region. Medicentre marks Redcliffe’s first significant acquisition as it expands its presence across India. The valuation details of the transaction were not disclosed; however, the payout structure was a mix of cash and equity.  Redcliffe plans to retain and leverage the premium brand positioning and brand-recall of Medicentre in the region and expand its operations to become the largest integrated lab chain in Rajasthan. Commenting on the acquisition, Dheeraj Jain, Founder of Redcliffe said “Medicentre sits perfectly with our vision and strategy of building a sustainable business offering a one-stop diagnostic services with a very wide selection of tests (pathology and radiology) and delivering care closer to the customer, especially for patients living in tier-2 to 4 cities of India. In addition to accelerating our growth trajectory, this acquisition also benefits us with onboarding the right set of partners in the form of Dr Manish Seth and Dr Mayanka Seth, who with over 25 years of experience has built an amazing diagnostic business in the last 15 years, making Medicentre one of the largest labs and brands in southern Rajasthan.”.   ]]> https://biospectrumindia.com/news/92/22848/illumina-and-genoscreen-unveil-ngs-innovation-to-eliminate-tuberculosis-in-india.html https://biospectrumindia.com/news/92/22848/illumina-and-genoscreen-unveil-ngs-innovation-to-eliminate-tuberculosis-in-india.html Fri, 24 Mar 2023 00:00:00 +0530 US-based Illumina Inc., a global leader in DNA sequencing and array-based technologies, and French firm GenoScreen, have launched a package combining Illumina products and the GenoScreen Deeplex Myc-TB assay, a targeted next-generation sequencing (NGS) based test for the rapid and extensive detection of anti-TB drug resistance. This will help advance the World Health Organization’s (WHO) strategy to end the global TB epidemic by 2035. This latest in NGS innovation, is part of a partnership between Illumina and Genoscreen announced last year to accelerate progress to end TB worldwide. The partnership is expanding capabilities for countries most impacted by tuberculosis, including India, to more effectively detect and combat multidrug-resistant TB (MDR-TB). Standard culture-based testing methods currently incur turnaround times of up to two months, and conventional molecular assays are limited in identifying drug resistance. The combined use of the GenoScreen Deeplex Myc-TB assay and the Illumina NGS platforms allows much more rapid determination of extensive drug resistance profiles and TB strain types. Implementing NGS testing will also benefit national TB programmes around the world by providing critical surveillance data about resistance to different anti-TB drugs—important information for high-burden countries to guide TB control strategies. ]]> https://biospectrumindia.com/news/92/22850/first-of-its-kind-ai-based-app-to-detect-active-tb-cases-within-seconds.html https://biospectrumindia.com/news/92/22850/first-of-its-kind-ai-based-app-to-detect-active-tb-cases-within-seconds.html Fri, 24 Mar 2023 00:00:00 +0530 India Health Fund, a Tata Trusts initiative, is collaborating with ACT, a non-profit venture philanthropy platform, to support Hyderabad-based startup Salcit Technologies in piloting Swaasa - an artificial intelligence (AI)-led solution that can revolutionise the detection and early treatment of tuberculosis in India. India Health Fund and ACT For Health will co-fund the development of Swaasa - an AI platform by Salcit Technologies that record cough sounds from suspected TB patients using a phone’s microphone and analyses them to decode unique cough signatures to detect the possible presence of pulmonary tuberculosis using a proprietary AI algorithm and give a report in just a few seconds.  The grant by IHF and ACT For Health will aid Salcit Technologies in the technical validation of the Swaasa’s AI algorithm - the six-month-long project will include the collection of cough sounds from about 5700 subjects (TB and Non-TB), the technical validation of the platform across 6 public health centres and the enhancement of the platform to reach an accuracy of 90% for detecting the likely presence of TB. Unlike other cough screening algorithms coming to the market, Swaasa is a multi-focus platform that can be used for screening of various lung ailments including Covid-19, for which it is currently undergoing clinical trials. Swaasa is also registered with Central Drugs Standard Control Organisation (CDSCO), is HIPAA and ISO27001 certified and has two granted patents and three publications backing its technology and use. Salcit’s proprietary combination of audiometric analysis and AI technology will undergo two more development phases post the review of the first phase by an external panel of technical experts representing Central TB Division, ICMR and WHO-India, among others. ]]> https://biospectrumindia.com/news/92/22836/redcliffe-labs-introduces-bd-max-mdr-tb-test-in-india.html https://biospectrumindia.com/news/92/22836/redcliffe-labs-introduces-bd-max-mdr-tb-test-in-india.html Thu, 23 Mar 2023 00:00:00 +0530 Noida-based startup Redcliffe Labs, a leading pan-India omnichannel diagnostic company in India, has announced the launch of the BD MAX MDR TB test, which can detect multidrug-resistant tuberculosis (MDR-TB) in a single test, enabling clinicians to quickly test for TB and multidrug resistance as a first-line test. The test, conducted at Redcliffe Labs in Noida, is the first of its kind in India and will significantly enhance the information available to direct the optimal treatment for patients. Launching the BD MAX MDR TB test marks a significant milestone in the fight against TB in India. According to the India TB Report 2022, the country reported a sharp 19% rise in tuberculosis cases in 2021, with 19 lakh incident TB patients notified. With proper detection and treatment, TB is curable, and Redcliffe Labs' latest offering promises to help clinicians make informed clinical decisions and improve patient treatment outcomes. With the new BD MAX MDR TB test, clinicians can simultaneously detect bacteria that cause TB and determine if the bacteria contain mutations associated with resistance to two important first-line drugs - Isoniazid (INH) and Rifampicin (RIF), respectively. This makes TB detection quick and easy and eliminates the need for separate tests for drug resistance against Rifampicin and Isoniazid.  "This new launch is a game-changer for TB detection in India," said Prof. Ashok Rattan, Chairman of Medical Committee & Quality, Redcliffe Labs. "Antimicrobial resistance has made TB identification more complex, and the BD MAX MDR-TB panel provides a comprehensive solution that is quick, efficient, and accurate."       ]]> https://biospectrumindia.com/news/92/22827/niramai-set-to-launch-full-body-scan-technology-in-global-markets.html https://biospectrumindia.com/news/92/22827/niramai-set-to-launch-full-body-scan-technology-in-global-markets.html Tue, 21 Mar 2023 00:00:00 +0530 Bengaluru-based startup Niramai is all set to launch a new technology in the global market which is focused on diagnosing basic abnormailities within the human body. "We plan to launch this technology for doing whole body scanning and finding out if there are abnormalities. It is not centered around cancer detection in particular, as such diagnosis requires further clinical validation. We will launch globally first, and then introduce the technology in India", said Dr Geetha Manjunath, Founder and CEO, Niramai. Over the years, the company has bagged a global recognition after its innovative artificial intelligence (AI)-based, radiation-free breast cancer screening test received the prestigious CE mark approval in 2021. As a result, Niramai‘s Thermalytix solution can now be applied to all countries of Europe, as well as applicable to many Asian, African and Middle-East countries. Later in 2022, Niramai emerged as the first Indian company to get a US FDA clearance for a medical device (SMILE-100 System) used for women's health. The SMILE-100 System is a breast thermography device that helps healthcare personnel to review, measure and analyse thermally significant indications in the breast region.  "The entire journey uptil now has been challenging, especially when you build a team, and reach a certain level. Gradually, a few members move out and then one has to re-build the team. Funding is another challenge. We are now in the process of closing another round of funding very soon", concluded Dr Geetha, during an exclusive chat with BioSpectrum. ]]> https://biospectrumindia.com/news/92/22815/kriya-medical-receives-icmr-approval-for-new-kit-to-detect-influenza.html https://biospectrumindia.com/news/92/22815/kriya-medical-receives-icmr-approval-for-new-kit-to-detect-influenza.html Fri, 17 Mar 2023 00:00:00 +0530 KRIVIDA TRIVUS, developed by Chennai-based KRIYA Medical Technologies, has received approval from the Indian Council of Medical Research (ICMR). The RT-qPCR kit can detect the presence or absence of three pathogens - Influenza (H1N1, H3N2,Yamagata and Victoria sublineages), SARS CoV2, and Respiratory Syncytial Virus (RSV). The three pathogens have similar initial symptoms but differ in how the illness progresses, how easily they spread, and how they are treated. The kit helps identify which pathogen is causing the respiratory illness, aiding clinicians and patients to opt for the right course of treatment. The kit can help healthcare providers stay informed about the current burden of respiratory infections and be prepared for any new ones that may emerge. The kit has the shortest cycle time of 27 minutes. The time taken for result to be read can vary between 50-60 minute. It’s an open kit that can be used in all the available RT PCR equipment. The kit is evaluated by ICMR at National Institute of Virology, Pune, using 225 known positive samples and 85 negative samples. The overall sensitivity of KRIVIDA TRIVUS is 99.11% and specificity is 100%. The kit will be produced at KRIYA’s state-of-the-art manufacturing facility in Oragadam in Chennai. The test is priced competitively, and it will soon be commercially available across the country.  ]]> https://biospectrumindia.com/news/92/22798/molbio-diagnostics-to-expand-access-to-rapid-molecular-tests-for-tb-globally.html https://biospectrumindia.com/news/92/22798/molbio-diagnostics-to-expand-access-to-rapid-molecular-tests-for-tb-globally.html Tue, 14 Mar 2023 00:00:00 +0530 Global Fund, United States Agency for International Development (USAID) and Stop TB Partnership have entered into a collaboration with Goa-based Molbio Diagnostics, inventor of the globally renowned Truenat platform. The collaboration will enable countries to procure the WHO endorsed Truenat platform at internationally negotiated prices, making the technology more accessible and affordable across the world. The collaborative partnership is a crucial move in the global fight to end tuberculosis (TB) by 2030. The move enables high-quality rapid TB testing - one of the largest shortfalls in the global TB response - in all nations supported by the Global Fund, USAID, and the Stop TB Partnership.   The National Tuberculosis Elimination Programme has already deployed Truenat in over 3500 primary/community health centres (PHCs/CHCs) across all states in India. The international collaboration will now provide an opportunity for other countries to adopt this Indian technology under their respective national TB programmes, for global impact. ]]> https://biospectrumindia.com/news/92/22788/mylab-partners-with-uk-based-dnanudge-for-point-of-decision-diagnostic-solutions.html https://biospectrumindia.com/news/92/22788/mylab-partners-with-uk-based-dnanudge-for-point-of-decision-diagnostic-solutions.html Mon, 13 Mar 2023 00:00:00 +0530 Pune-based startup Mylab Discovery Solutions, and DnaNudge, a UK-based pioneer of consumer genetics testing and medical diagnostics, have announced a strategic partnership to develop next-generation molecular diagnostic solutions for diabetic foot ulcer detection and other key health conditions. The Memorandum of Understanding (MoU) was signed between the two companies in the presence of Dr Thaksin Shinawatra, Former Prime Minister of Thailand, Yingluck Shinawatra, Former Prime Minister of Thailand, Regius Professor Chris Toumazou, Co-founder of DnaNudge and Founder of the Institute of Biomedical Engineering at Imperial College London and Hasmukh Rawal, MD of Mylab. The novel diabetic foot ulcer detection kit will be the first of the many testing kits to be co-developed by the companies. Together, DnaNudge and Mylab will introduce transformative point-of-decision testing kits for health conditions which are of major public health concern in India. The collaboration between Mylab and DnaNudge aims to save lives and limbs from amputation, in the 80 million diabetic population of India. The diabetic foot ulcer detection kit is one of the world’s first point-of-decision molecular technology solutions, delivering early identification of the spectrum of microbial flora in the ulcer and supporting clinicians to plan appropriate antimicrobial therapy regimes. The test can identify the bacteria involved in the infection and provide molecular antimicrobial resistance (AMR) results in just over an hour – helping clinicians to determine which antibiotics will be optimally effective against these bacteria, enabling more personalised treatment and reducing the risk of AMR. The new kits will provide a key tool for the early initiation of therapy, which can play a pivotal role in the management of diabetic foot infections and delivering successful treatment outcomes. The diagnostic solution for diabetes will be introduced in the markets in the next quarter of this year.     ]]> https://biospectrumindia.com/news/92/22761/neuberg-centre-for-genomic-medicine-revolutionises-prenatal-diagnosis-outcomes.html https://biospectrumindia.com/news/92/22761/neuberg-centre-for-genomic-medicine-revolutionises-prenatal-diagnosis-outcomes.html Wed, 08 Mar 2023 00:00:00 +0530 Neuberg Centre for Genomic Medicine (NCGM) has announced the launch of the most cutting edge and fastest prenatal diagnostic test called the Prenatal Aneuploidy NCG test (PAN Test) and an upgraded version of Chromosomal Microarray Analysis test with launch of Cyto-ONE test for the first time in India. Neuberg's PAN test and Cyto-ONE test are innovative prenatal diagnostic tests that are designed to provide better coverage of disorders in the foetus without compromising on turnaround time or cost. These tests are developed by Neuberg Centre for Genomic Medicine, and they represent significant upgrades to existing technologies for diagnosing foetal abnormalities. The PAN test is capable of detecting abnormalities on all chromosomes and sub-chromosomal regions, providing comprehensive answers for doctors and expecting mothers who wish to get most robust and exhaustive diagnostic results in the shortest time without the need for getting multiple tests done. The Cyto-One test is a high resolution microarray based test that will transform the realm of definitive diagnosis. This test is a major upgrade to the currently available microarray tests with its over 1 million probes, higher detection rates and lower failure rates. It will help doctors get better quality diagnostic results in both- prenatal and postnatal settings. The advantage is that the new PAN test has better sensitivity and detection capabilities than the current QF-PCR test. It can detect more disorders and covers 22 chromosomal instead of just 5, which expands its scope and coverage. The test has a quick turnaround time of 48-72 hours and at no additional cost, making it more accessible to doctors and patients.   ]]> https://biospectrumindia.com/news/92/22752/caped-and-roche-diagnostics-india-unveil-cervical-cancer-screening-programme-on-international-womens-day-.html https://biospectrumindia.com/news/92/22752/caped-and-roche-diagnostics-india-unveil-cervical-cancer-screening-programme-on-international-womens-day-.html Tue, 07 Mar 2023 00:00:00 +0530 Roche Diagnostics India has announced the signing of a Memorandum of Understanding (MoU) with the Cancer Awareness Prevention and Early Detection Trust (CAPED), a non-profit organisation dedicated to promoting cancer awareness, prevention, and early detection. The MoU outlines a collaboration between the two organisations to combat cervical cancer in India - the second most common cancer among Indian women. As part of the partnership, CAPED will reach out to companies in Mumbai, Delhi, Chennai, Hyderabad and Bengaluru to conduct around 100 awareness workshops to encourage women employees to take charge of their health, help them understand the benefits of HPV DNA screening, recommend screening frequency, and educate them about the need to take a clinically validated test to ensure optimal test efficiency. "Cervical cancer is preventable in up to 93% of cases and yet, India contributes to 21% of the world’s total cases of cervical cancer. There is an urgent need to develop innovative strategies that go beyond the traditional healthcare response. HPV DNA self-sampling kits can be one such innovation which provides women with ease and comfort during screening ,” said Mridu Gupta, CEO, CAPED. Narendra Varde, Managing Director, India and Neighbouring Markets, Roche Diagnostics, added ,"Our Be Your Own Shero campaign is aimed at encouraging women to take charge of their lives so that every woman has the chance to fulfil her potential. Last year, we took a small step by offering free HPV DNA screening for all our women employees and the women family members of male employees; around 82% of the eligible employees opted for screening. We are expanding our efforts this year by joining forces with equally passionate organisations to further the cause."      ]]> https://biospectrumindia.com/news/92/22724/neuberg-diagnostics-joins-hands-with-mdc-scans-and-lab-to-mark-presence-in-trivandrum.html https://biospectrumindia.com/news/92/22724/neuberg-diagnostics-joins-hands-with-mdc-scans-and-lab-to-mark-presence-in-trivandrum.html Wed, 01 Mar 2023 00:00:00 +0530 Neuberg Diagnostics, with more than 150 labs and 2000+ collection centres and having a presence in India, South Africa, UAE, and the US, and MDC Scans and Lab, one of the oldest and leading medical diagnostics network in Kerala, have joined hands to launch Neuberg MDC Scans and Labs. The lab was inaugurated by Adv. Antony Raju, Minister for Transport, Government of Kerala, Dr GSK Velu, Chairman and Managing Director, Neuberg Diagnostics, and MN Shibhu, Managing Director, MDC Scans & Labs. Neuberg MDC Scans and Lab brings with it Neuberg Diagnostic's extensive network and clinical expertise, enabling the center to offer high-end testing and genomics to the people and clinicians of Trivandrum. The state-of-the-art centre has the latest technology and equipment to ensure accurate and timely results. Moreover, the centre will provide a complete routine to high-end diagnostic services under one roof, covering both pathology and radiology as an integrated model. Maintaining the highest quality standards by having the best doctors onboard and ensuring regular quality checks, the lab will conduct over 1000 pathological investigations in 4 integrated high diagnostic centres and 6 pathology processing lab with basic radiology diagnostics such as MRI, CT, Ultrasound, X-Ray, ECG, 2D ECHO, TMT and Mammography along with wellness centre. Neuberg MDC Scans has 14 collection centres with total touch points of 20 in the district of Trivandrum. Additionally, with this joint venture, Neuberg MDC Scans & Lab will have access to the entire lab medicine test menu of over 6000 investigations covering routine investigations, & advanced investigations including genomics, proteomics, metabolomics, proteomics, oncopathology, transplant immunology, newborn screening, etc benefiting the population of Trivandrum & adjoining districts.     ]]> https://biospectrumindia.com/news/92/22725/lupin-diagnostics-expands-presence-in-south-india-with-new-lab-in-hyderabad.html https://biospectrumindia.com/news/92/22725/lupin-diagnostics-expands-presence-in-south-india-with-new-lab-in-hyderabad.html Wed, 01 Mar 2023 00:00:00 +0530 Lupin has announced the launch of its new Regional Reference Laboratory in Hyderabad. This expansion of Lupin Diagnostics’ network is part of the company’s strategy to build and strengthen its presence in South India. This regional reference laboratory adds to Lupin Diagnostics’ existing network of 380+ LupiMitra collection centres and 23 laboratories across India. In addition to routine and specialised tests, Lupin Diagnostics offers molecular diagnostics, cytogenetics, flow cytometry, cytology, microbiology, serology, haematology, immunology, routine biochemistry and many more. The team of qualified clinical experts at Lupin Diagnostics leverage state-of-the-art automation and streamlined processes to deliver highly accurate test results.   Lupin Diagnostics provides a comprehensive range of diagnostic services to doctors, patients, and consumers. The company offers several consumer-centric features, such as live home collection booking and tracking, GPS-enabled temperature-controlled sample movement, free home collection, NABL accreditation of each laboratory, smart reports, and trend report analysis. The company started its journey by establishing a state-of-the-art 45,000 sq. ft. National Reference Laboratory in Navi Mumbai with world-class equipment, experienced doctors assisted by trained technologists and stringent quality control protocols. ]]> https://biospectrumindia.com/news/92/22728/redcliffe-labs-expands-coverage-in-andhra-pradesh.html https://biospectrumindia.com/news/92/22728/redcliffe-labs-expands-coverage-in-andhra-pradesh.html Wed, 01 Mar 2023 00:00:00 +0530 Noida-based startup Redcliffe Labs has launched two advanced labs at MVV Neeladri Apartments, Maharanipeta, Vizag and A S Rama Rao Street, Kasturibaipet, Vijayawada. This move is in line with the company’s strategic expansion plans in Andhra Pradesh and Southern states of India. These labs are staffed with highly skilled and qualified team of technicians and scientific officers, supervised with MD Pathologist Dr Lakshmi Kasula at Vijayawada and Dr Polamarasetty Meghana at Vizag. These labs house all clinical laboratory departments, including Biochemistry, Hematology, Immunoassays, Clinical Pathology, Hormones, etc. Residents of these cities and nearby towns like Guntur, Tenali, Narsaraopera, Gudiwada, Machilipatnam, Eluru, Vizianagram, Narsipatnam, Anakapalle, Srikakulam & Rajamundry will get benefit from the world-class diagnostic services provided by the well-equipped lab facility. Redcliffe has opened 250+ collection centres in the southern geography. The startup already has impressive footprint in Andhra Pradesh, Telangana, Tamil Nadu and Karnataka. These labs are equipped with state-of-the-art fully automatic instruments, ensuring highest level of accurate reporting. All diagnostic test reports are delivered by the labs within 24 hrs of receiving the sample.   ]]> https://biospectrumindia.com/news/92/22715/medgenome-labs-unveils-fshd1-genetic-screening-test-for-rare-disease-diagnosis.html https://biospectrumindia.com/news/92/22715/medgenome-labs-unveils-fshd1-genetic-screening-test-for-rare-disease-diagnosis.html Tue, 28 Feb 2023 00:00:00 +0530 Bengaluru-based MedGenome Labs has announced the launch of a ground-breaking first-ever Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1) test in India. MedGenome Labs is the first commercial lab to offer this new genetic test that will help individuals with FSHD1 to get an early and accurate diagnosis, leading to improved disease management options.  The FSHD1 Optical Genome Mapping Test (OGM) is a highly advanced diagnostic tool that uses cutting-edge technology to provide a comprehensive and accurate assessment of genetic changes in patients with FSHD1. The test can detect large-scale insertions and duplications, as well as more subtle changes in DNA that can cause FSHD1. Facioscapulohumeral Muscular Dystrophy (FSHD) is a common form of muscular dystrophy with an extremely complex genotype. It is progressive myopathy which accounts for 2 to 3% of the muscular dystrophy cases in India. FSHD1 is a rare genetic disorder that affects the muscles of the face, shoulder blades, and upper arms. The disease is caused by the deletion of genetic material from the D4Z4 repeat region on chromosome 4, leading to the loss of muscle tissue and weakness in affected areas. FSHD1 affects approximately 1 in 20,000 individuals worldwide, with symptoms typically starting in early adulthood. FSHD1 can have a significant impact on quality of life, as it can result in difficulty with daily activities such as lifting objects or raising arms. The disease is also progressive and can lead to severe disability in some cases. In the present day, there is no known cure for FSHD1, and treatment options are limited. However, many clinical trials are being conducted at an accelerated rate. ]]> https://biospectrumindia.com/news/92/22705/iisc-incubated-shanmukha-innovations-develops-indias-first-diagnostic-kit-for-sickle-cell-anaemia.html https://biospectrumindia.com/news/92/22705/iisc-incubated-shanmukha-innovations-develops-indias-first-diagnostic-kit-for-sickle-cell-anaemia.html Mon, 27 Feb 2023 00:00:00 +0530 Shanmukha Innovations, a health-tech startup incubated by the Society for Innovation and Development (SID) at the Indian Institute of Science (IISc) in Bengaluru, has developed SickleCert, India’s first indigenous diagnostic kit for Sickle-Cell Anaemia. A screening test kit called SickleFind has also been developed. Sickle-Cell Anaemia is caused by a defective gene, Haemoglobin S, which causes flexible red blood cells to become stiff sickle-shaped cells, obstructing blood flow and increasing the risk of organ damage. The technology called High Performance Optical Spectroscopy (HPOS) consisting of test kits (SickleCert), portable analyser (HaemoCube) was developed by researchers at IISc. The technology has been licensed to a spin-off from IISc, ShanMukha Innovations for commercialisation. A companion smartphone application enables digital data recording, analysis and integration with various registries, Ayushman Bharat Health Account (ABHA) and other cloud-based patient health record systems. The Government of India has announced an ambitious National Sickle Cell Elimination Mission to eradicate the disease from the country by 2047 in the recent Budget. The Mission plans to screen 7 crore people over the next 3 years as a first step. “With a tiny amount of blood from a finger prick, the test provides highly accurate results in 15 minutes. In batch mode over 40 samples can be tested in an hour enabling a large volume of screenings to be completed in a much shorter time span” says Prof. Sai Siva Gorthi, Principal Investigator, lead inventor of the technology and Associate Professor at the Instrumentation and Applied Physics Department, IISc. The Central Drugs Standard Control Organisation (CDSCO) had approved the manufacturing license for SickleCert kits for ShanMukha Innovations as a Class C in-vitro diagnostic medical device in November 2022. In February this year, multi-centric field studies were successfully carried out as prescribed by the Indian Council of Medical Research (ICMR) across tribal districts in Madhya Pradesh and Maharashtra. The tests yielded an accuracy measure of 97.6%, with a sensitivity of 96.9% and a specificity of 98.6%. ]]> https://biospectrumindia.com/news/92/22687/mylab-launches-range-of-rapid-tests-for-sexually-transmitted-diseases.html https://biospectrumindia.com/news/92/22687/mylab-launches-range-of-rapid-tests-for-sexually-transmitted-diseases.html Thu, 23 Feb 2023 00:00:00 +0530 Pune-based startup Mylab Discovery Solutions has expanded its portfolio of rapid tests for sexually transmitted diseases (STIs), namely HIV, HCV and Syphilis. Among these tests, HIV 1/2 Ab and HCV Ab are rapid tests for the detection of antibodies specific to HIV-1 and HIV-2 and HCV respectively, while Syphilis Antibody test detects antibodies (IgG, IgA, IgM) to Treponema Pallidum (TP) to aid in the diagnosis of Syphilis. Speaking about the launch of these tests, Hasmukh Rawal, MD & Co-founder, Mylab said, " Sexually transmitted infections (STIs) are a major health challenge. WHO estimates daily caseload of STIs to reach 1 million per day globally. Early and fast detection are the core pillars to prevent transmission of these diseases and to aid that, we are launching three new rapid kits - HIV, HCV & Syphilis - for detection at point of care. We will continue to strengthen this portfolio.” These tests are easy to use, capable of being stored at room temperature and can be deployed at point of care in resource-limited settings. Additionally, these tests can be used at blood banks for effective detection of transfusion-transmissible infections (TTIs) among blood donors and reducing their transmission. The test kits will be available at hospitals and labs by end of this month. The PathoCatch HIV 1/2 Ab test measures the presence of antibodies in response to the presence of HIV, providing accurate and reliable results in less than 20 minutes, while the PathoCatch HCV Ab test detects antibodies generated as a response to hepatitis C virus (HCV) infection. This test is particularly beneficial for high-risk populations such as HIV patients, blood transfusion patients, and pregnant women.  PathoCatch Syphilis Ab test is a rapid immunoassay, detects IgG, IgM and IgA antibodies, providing accurate results during all stages of the disease, within 20 minutes.     ]]> https://biospectrumindia.com/news/92/22676/thyrocare-technologies-automates-manual-microscopy-process-with-sigtuples-ai100.html https://biospectrumindia.com/news/92/22676/thyrocare-technologies-automates-manual-microscopy-process-with-sigtuples-ai100.html Wed, 22 Feb 2023 00:00:00 +0530 Thyrocare Technologies are again at the forefront of technology adoption for pathology, using artificial intelligence (AI)-powered technology (SigTuple's AI100) to automate the manual microscopy process across its network.   This is expected to significantly reduce the turnaround time, standardise reporting quality and increase efficiency multi-fold. Rahul Guha, Managing Director - Thyrocare Technologies, said, “Digitalising microscopy has the potential to transform the face of diagnostics throughout India, and AI-integration in diagnostics is a game-changer. It has brought remarkable precision to our diagnostic capabilities. With the flagship product SigTuple AI100, we can now provide more accurate results, increased productivity, reduced TAT, and all this at lower costs.”    Thyrocare is in the process of expanding its presence across tier-2/3 cities and towns. Digital microscopy with artificial intelligence will be an enabler in a big way to do peer review on abnormal samples reporting and diagnosing several critical disorders like malarial infections, cancers, etc.   SigTuple AI100 is the premier solution for AI-assisted digital pathology. It is also the only digital pathology solution available, which is economical and robust enough for wide scale adoption in emerging markets. Dr Tathagato Rai Dastidar, Founder & CEO, SigTuple commented on the association, “SigTuple started in 2015 with a singular goal – to make quality healthcare more accessible, more accurate and more affordable. AI100 was built to solve the problem of digital pathology with that aim in mind."   Thyrocare is in the process of deploying SigTuple AI100 across its laboratories. As a pilot, installations have been done in the Thyrocare labs at Lucknow, Nagpur and Ranchi where a panel of doctors are already using the technology to serve patients in reduced turnaround time.   ]]> https://biospectrumindia.com/news/92/22674/redcliffe-labs-first-to-launch-single-test-for-tb-detection-multi-drug-resistance-in-india.html https://biospectrumindia.com/news/92/22674/redcliffe-labs-first-to-launch-single-test-for-tb-detection-multi-drug-resistance-in-india.html Tue, 21 Feb 2023 00:00:00 +0530 To enable clinicians to rapidly test for tuberculosis (TB) and multidrug resistance as a first-line test, Noida-based  startup Redcliffe Labs becomes the first diagnostics company in India to launch the BD MAX MDR TB test which is performed on BD MAX molecular diagnostic system. Presently there are two different tests to be conducted: one to detect TB and the other to check drug resistance – against only one drug (Rifampicin). With this new test, drug resistance against both Rifampicin and Isoniazid can be detected in a single test. Clinicians can use the test to simultaneously detect bacteria that cause tuberculosis (TB) and determine if the bacteria contain mutations associated with resistance to two important first line drugs - Isoniazid (INH) and Rifampicin (RIF) respectively.  This enhances the information available to direct the optimal treatment for patients and rules out the need for separate test for isoniazid (INH) detection.   "This new test is a big step forward for clinical practice as antimicrobial resistance has made this identification more complex with the BD MAX MDR-TB panel including MTB, RIF & INH together in less than 4 hours”, said Prof. Ashok Rattan, Chairman Medical Committee & Quality, Redcliffe Labs.   ]]> https://biospectrumindia.com/news/92/22660/molbio-diagnostics-acquires-majority-stake-in-prognosys-medical-systems.html https://biospectrumindia.com/news/92/22660/molbio-diagnostics-acquires-majority-stake-in-prognosys-medical-systems.html Mon, 20 Feb 2023 00:00:00 +0530 Goa-based medtech firm Molbio Diagnostics has acquired a 70% stake in Bengaluru-based Prognosys Medical Systems, a renowned manufacturer of the Prorad range of Digital X-Ray units and C-arms and developer of a comprehensive digital health platform. Prognosys builds radiology and fluoroscopy solutions under the brand name PRORAD at its facility based out of Bengaluru that complies with national and international regulatory requirements. The recent introduction of the unique PRORAD Portable and Ultra-Portable digital x-ray units manufactured, for the first time in India, by Prognosys, can deliver high-quality chest images combined with Artificial Intelligence (AI) driven algorithms for automated interpreting and reporting at the point of care. The combination of PRORAD and Truenat system offers a game-changing solution for screening and confirming large populations for highly contagious and devastating diseases such as tuberculosis (TB), COVID-19 and other chest anomalies. This technology will be offered alongside Molbio’s patented Truenat technology, a point-of-care, portable, battery-operated Real-Time PCR platform that can screen over 40 diseases with a sample-to-result time of 60 minutes. Hailed globally as a high-impact breakthrough innovation, Truenat is the world’s first point-of-care molecular diagnostic platform endorsed by the World Health Organisation (WHO) and approved by the Indian Council of Medical Research (ICMR) for TB detection and COVID-19 testing. Molbio and Prognosys are already working together on mobile solutions for end-to-end screening and diagnosis of MTB and E-Clinics for delivering comprehensive healthcare to the last mile.     ]]> https://biospectrumindia.com/news/92/22642/thermo-fisher-launches-real-time-pcr-kits-for-detection-of-infectious-diseases-in-india.html https://biospectrumindia.com/news/92/22642/thermo-fisher-launches-real-time-pcr-kits-for-detection-of-infectious-diseases-in-india.html Wed, 15 Feb 2023 00:00:00 +0530 Designed to deliver confidence and reliability for diagnostic development and testing, the Applied Biosystems TaqPath PCR kits for infectious diseases such as Multi-Drug Resistant Tuberculosis (MTB MDR), M. Tuberculosis complex (MTB), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and for genetic analysis (HLA B27), have received licensing rights by the Central Drugs Standard Control Organisation (CDSCO) and will be manufactured in India in association with Pune-based Mylab Discovery Solutions. The Applied Biosystems TaqPath PCR kits by Thermo Fisher have been analytically- and clinically-validated for use in patient care for disease screening and diagnosis, monitoring of therapeutic response and disease progression, and identification of genetic risk factors. “Over the years, India has made significant progress in addressing infectious diseases such as Hepatitis B and C, HIV, and Tuberculosis. The country has implemented large-scale vaccination and treatment programs, as well as invested in research to better understand the epidemiology of these diseases and develop new diagnostic tools. However, India still faces challenges in controlling the spread of these diseases", said Jagjit Singh Anthak, Director, Genetic Sciences Group and Specialty Diagnostics Group, Thermo Fisher Scientific. Hasmukh Rawal, Managing Director at Mylab Discovery Solutions said, “Laboratories in India and globally rely on the innovative products from Thermo Fisher, will now also benefit with a much wider range of quality diagnostic tests. Also, we would be assisting in tools for analysis of data to help labs make accurate results to their customers. This is a milestone moment in Indian diagnostics.” ]]> https://biospectrumindia.com/news/92/22635/jammu-to-bring-down-lung-cancer-burden-and-enhance-efforts-towards-early-detection.html https://biospectrumindia.com/news/92/22635/jammu-to-bring-down-lung-cancer-burden-and-enhance-efforts-towards-early-detection.html Tue, 14 Feb 2023 00:00:00 +0530 Enhancing its efforts toward early detection of lung diseases, India-Sweden healthcare Innovation Centre and its knowledge partner AstraZeneca India have collaborated with the Directorate of Health Services (DHS) Jammu to integrate Qure.ai’s smart artificial intelligent technology to detect lung cancer early on. Under the aegis of Indo Sweden Healthcare Innovation Centre (ISHIC), Mumbai-based startup Qure.ai is scaling-up the integration of its artificial intelligent (AI)-powered chest x-ray interpretation tool that can benefit early and easy detection of lung diseases including lung cancer. The collaboration with DHS Jammu is a significant example of how technology can be leveraged and simply integrated in the primary healthcare settings.  The AI powered chest X-ray is designed to distinguish lung nodules in under a minute and minimise the chances of lung cancers going undetected. Importantly, this tool is being accessed in primary care setting where x-rays are utilised most commonly.   In 2020, there were an estimated 18.1 million cancer cases worldwide with lung cancer being the second most common form of the disease. The constant increase in the incidence of lung cancer highlighted the need for healthcare organisation around the world to come together, collaborate and innovate the way lung cancer was addressed.  ]]> https://biospectrumindia.com/news/92/22628/neuberg-diagnostics-unveils-upgraded-facility-for-genomic-medicine-in-ahmedabad.html https://biospectrumindia.com/news/92/22628/neuberg-diagnostics-unveils-upgraded-facility-for-genomic-medicine-in-ahmedabad.html Mon, 13 Feb 2023 00:00:00 +0530 Neuberg Diagnostics has launched Asia’s largest upgraded genomic facility of Neuberg Centre for Genomic Medicine (NCGM) in Ahmedabad. The facility was inaugurated by ricketer M.S Dhoni in the presence of Dr GSK Velu, Chairman, and Managing Director, Neuberg Diagnostics, Dr Sandip Shah, Executive Director, Neuberg Diagnostics. The Centre has a sprawling 30,000 sqft standalone premises with state-of-the-art testing devices and provides research-based genomic service, including comprehensive range of genetic testing solutions and dedicated genetic counseling services. NCGM is one of the top Genomics testing providers in Asia with comprehensive Genomics labs located in Ahmedabad, Chennai and North Carolina (USA). With the latest advanced technology and a skilled bioinformatics team, NCGM is a global entity that works with the largest team of genomic sub specialists housed under one roof and researchers across the world to provide solutions to the genomic conundrum. The centre offers a wide range of services, including Inherited Genetics, Reproductive Genetics, Solid Oncology Genomics, Hemato-Oncology Genomics, Transplant Immunology, Cytogenetics and other tests. NCGM is also equipped with state-of-the-art research infrastructure, high end -throughput sequencers, fragment analysers, and high-end HPC clusters for population-scale bioinformatics analysis.  “With its focus on delivering the best-in-class genetic services, NCGM is poised to make a significant impact in the field of genomic medicine. NCGM is India’s largest Exclusive Genomic Testing Facility with 30,000 Sqft infrastructure combined with a team of highly skilled professionals, make NCGM a one-stop solution for genomic testing and research.” said Dr Sandip Shah, Executive Director , Neuberg Diagnostics . ]]> https://biospectrumindia.com/news/92/22615/mylab-introduces-conventional-diagnostic-solutions-to-create-decentralised-ecosystem.html https://biospectrumindia.com/news/92/22615/mylab-introduces-conventional-diagnostic-solutions-to-create-decentralised-ecosystem.html Thu, 09 Feb 2023 00:00:00 +0530 Pune-based startup Mylab Discovery Solutions is all set to roll out new in vitro diagnostic (IVD) medical devices and kits range to empower small labs across the country. These devices and reagents are specially designed to enable small to medium size laboratories and physicians’ clinics to perform diagnoses at their facilities, without having to send samples to central labs or other cities, which increases the risk of spoiled samples and delayed reporting.  Mylab is introducing conventional diagnostic solutions to create a decentralized diagnostic ecosystem where the lab near you will be able to offer quality diagnostics at faster turn-around. Labs in semi-urban and rural areas in India can now offer specialised tests to patients. This will help patients from remote areas to access specialised tests easily at their home locations and avail timely treatment. The company is doing this by offering devices which have smaller reagent packs, smaller sample volume requirements, better sensitivity, linearity and are point of care and high throughput. Another interesting technology is that now consumers will be able to a detect accurate levels of natural vitamins levels (Biotin) even if an individual is consuming vitamin supplements. The company plans to roll out pan India through its network of distributors, and a highly trained and experienced sales force of more than 150 people.   ]]> https://biospectrumindia.com/news/92/22578/centre-for-cellular-and-molecular-platforms-c-camp-unveils-national-diagnostics-catapult.html https://biospectrumindia.com/news/92/22578/centre-for-cellular-and-molecular-platforms-c-camp-unveils-national-diagnostics-catapult.html Thu, 02 Feb 2023 00:00:00 +0530 Bengaluru-based Centre for Cellular and Molecular Platforms (C-CAMP) has launched the National Diagnostics Catapult (C-CAMP InDx 2.0). The programme is anchored by C-CAMP with support from the Bangalore Life Sciences Cluster (BLiSc) and funding from The Rockefeller Foundation, Bill & Melinda Gates Foundation and FIND, a global alliance for diagnostics. The Catapult, C-CAMP InDx 2.0 aims to boost India’s preparedness for current and future pandemics and scale up India’s diagnostics space for infectious diseases including but not limited to COVID-19. Further, the Catapult is envisioned to set a global model for capacity building in the diagnostics domain in lower- and middle-income countries (LMICs) to meet the twin goals of affordability and accessibility in the United Nations vision for Universal Health Coverage.  C-CAMP InDx 2.0, builds on the hugely successful, India-wide COVID-19 diagnostics platform, Indigenization of Diagnostics (CCAMP-InDx) initiative launched in July 2020. In one year since its launch the programme had achieved its target of 1 million indigenous RT-PCR test kits for SARS CoV2 per day, building capacity of more than 200 indigenous MSMEs and academic labs in the diagnostics ecosystem, the largest such cohort in the country. CCAMP-InDx has enabled development of 40+ regulatory approved RT PCR Kits and 12 RAPID tests, all in the market currently. The CCAMP-InDx programme through it’s already established and future Centres of Excellence (CoEs) across India's leading academic institutes, hospitals/medical research centres  and industry  partners will play a significant role in supporting exploratory research, development, analytical/clinical validations, and commercialization pathways. The focus of the CoEs in CCAMP InDx 2.0 will be on enabling development of high-quality, affordable testing tools for human disease diagnostics as well as human and environmental surveillance ]]> https://biospectrumindia.com/news/92/22557/neuberg-diagnostics-unveils-state-of-the-art-regional-reference-laboratory-in-nagercoil-tn.html https://biospectrumindia.com/news/92/22557/neuberg-diagnostics-unveils-state-of-the-art-regional-reference-laboratory-in-nagercoil-tn.html Tue, 31 Jan 2023 00:00:00 +0530 Neuberg Diagnostics has launched a state-of-the-art regional reference lab in Southern Tamil Nadu in Nagercoil. The lab was inaugurated by Thiru T Mano Thangaraj, Minister for Information Technology & Digital services, Tamil Nadu, India, and Dr GSK Velu, Chairman and Managing Director, Neuberg Diagnostics. The lab is equipped with the latest technology which can conduct and process 1000 samples in a day and deliver results within the given turnaround time while maintaining the best-in-class quality. People can avail services such as preventive health checks, home collection, and specialty blood tests. The lab will be accessible through 6 collection centres to be launched in the region over the next three months, with plans to expand to 10 centres in total. Neuberg as a group is equipped to conduct futuristic tests such as genomics, proteomics, metabolomics, molecular biology, and digital pathology.  Dr GSK Velu, Chairman and Managing Director, Neuberg Diagnostics, said “Neuberg is starting with three facilities in Nagercoil, Thakkalai and Marthandam and has plans to be present in every town of Kanyakumari district.”   ]]> https://biospectrumindia.com/news/92/22530/lordsmed-hindustan-antibiotics-to-distribute-affordable-rapid-antigen-kits-for-multiple-diseases.html https://biospectrumindia.com/news/92/22530/lordsmed-hindustan-antibiotics-to-distribute-affordable-rapid-antigen-kits-for-multiple-diseases.html Thu, 26 Jan 2023 00:00:00 +0530 LordsMed, the global healthcare division of Lord’s Mark Industries, has entered into a distribution partnership with Hindustan Antibiotics Limited (HAL), a leading public sector drug manufacturer. The healthcare company will manufacture high-quality rapid antigen test kits at its ICMR approved facility at Vasai, near Mumbai, and distribute those kits in government healthcare centres across India at an affordable rate- 10 percent less than the average market rates. The broadening of the distribution network is part of LordsMed's goal of facilitating early-stage healthcare intervention and generating Rs 75 crore in revenue in six months.  LordsMed has deployed top-notch German technologies to manufacture an extensive range of rapid test kits for detecting malaria, cardiovascular disease, hepatitis C virus (HCV), HIV, syphilis, hepatitis B surface antigen (HBsAg), dengue, typhoid, COVID-19, chikungunya, ovulation, and pregnancy. The company has developed a robust R&D team comprised of experienced microbiologists and doctors and has emerged as the only in vitro diagnostic (IVD) kit manufacturing company in India, working to roll out saliva-based diagnostic solutions for a range of diseases. The company has successfully carried out trials of its saliva-based diagnostics kits for diabetes and liver diseases. Commenting on the partnership with HAL, Sachidanand Upadhyay, MD & CEO, Lord’s Mark Industries, said, “The distribution partnership with HAL will help us reach out to all parts of the country cities including metros, Tier -1, 2 and 3 cities and rural areas with our affordable and advanced rapid antigen test kits. Our goal is to gain first-mover advantage by launching advanced saliva-based diagnostics solutions. The larger goal is to play our role in making India atmanirbhar (self-reliant) in diagnostics kit manufacturing”. LordsMed has plans to set up a manufacturing unit in Gujarat by 2023 and another facility in Lucknow by 2024 to further boost its manufacturing capabilities and serve the growing market demand. The company also has plans to expand its exports to all countries in Africa and Europe.   ]]> https://biospectrumindia.com/news/92/22526/crisprbits-develops-indias-first-crispr-based-sars-cov-2-test-with-omicron-detection.html https://biospectrumindia.com/news/92/22526/crisprbits-develops-indias-first-crispr-based-sars-cov-2-test-with-omicron-detection.html Tue, 24 Jan 2023 00:00:00 +0530 CrisprBits, one of the first Indian companies using CRISPR, a breakthrough gene-editing technology, has developed OmiCrisp, a CRISPR- based test to detect SARS-CoV-2 and to determine whether it is an Omicron or non-omicron variant. The test has been developed with support and collaboration from Bengaluru-based C-CAMP-InDx (Indigenisation of Diagnostics Programme), an initiative supported by the Department of Biotechnology, Govt of India. The test has been validated with significant contribution and expertise of DBT- inStem biorepository and the COVID-19 testing laboratory (The Institute for Stem Cell Science and Regenerative Medicine or inStem, an autonomous institute funded by the Dept. of Biotechnology, Govt Of India), and Strand Life Sciences, a genomics-based research and diagnostics company. The patent pending OmiCrisp test uses the Cas12a enzyme and separate guides to target variant-specific sequences found in Omicron and non-Omicron variants of SARS-CoV-2. This is different from many other tests in the market that use RT-PCR signal drop-out to identify Omicron variants. The test was tested on over 80 clinical samples and was 100% accurate in identifying whether a sample was Omicron or non-Omicron when compared to sequencing results. Dr Vijay Chandru, Co-Founder of CrisprBits, said, "CRISPR as a detection system for nucleic signal offers great promise to meet the need for pervasive and distributed diagnostic platforms. The accuracy of these tests on both clinical and environmental samples gives us great hope, as well as the ease of rapidly redesigning assays as new emerging variants of pathogens and resistance markers need to be detected." The OmiCrisp test is now being used in a study to detect the presence of Omicron variants in sewage samples in an ongoing collaborative study with the support of a grant from GiveIndia & CryptoRelief, a community-run fund delivering relief during the recent SARS-CoV2 pandemic. ]]> https://biospectrumindia.com/news/92/22520/neodx-biotech-labs-launches-detection-kit-for-chronic-myelogenous-leukaemia.html https://biospectrumindia.com/news/92/22520/neodx-biotech-labs-launches-detection-kit-for-chronic-myelogenous-leukaemia.html Mon, 23 Jan 2023 00:00:00 +0530 Bengaluru-based startup NeoDx Biotech Labs has expanded its portfolio with the BCR-ABL range of  Real-Time PCR detection kit, an in-vitro diagnostic test for aiding in the diagnosis of chronic myelogenous leukaemia (CML).   BCR-ABL1 translocation is detected in 90-95% of CML cases. Detection of the BCR-ABL translocation not only aids the initial diagnosis of CML but is also useful for monitoring tyrosine kinase inhibitor response status and monitoring minimal residual disease (MRD).NeoDx’s BCR-ABL Qualitative and Quantitative is a one-step (no additional cDNA conversion of RNA is required), multiplex (Major, Minor,  and Micro transcripts) format along with ABL amplification in a single tube.Quantitative kits were standardised using World Health Organisation (WHO) reference standards, where the deep molecular response up to 4.5 log reduction can be analysed. The assay run time for both qualitative and quantitative is under 90 minutes.While developing the kit was a challenge, NeoDx’s team of scientists wanted to design a product that would help healthcare professionals better understand their patient’s prognosis; thereby supporting the overall treatment outcomes for the patients.BCR ABL Quantitative kit identifies over 14 BCR-ABL major transcripts making it one of the most unique indigenously developed kits. ]]> https://biospectrumindia.com/news/92/22503/cipla-launches-point-of-care-testing-device-for-multiple-health-conditions.html https://biospectrumindia.com/news/92/22503/cipla-launches-point-of-care-testing-device-for-multiple-health-conditions.html Wed, 18 Jan 2023 00:00:00 +0530 Mumbai-based pharma firm Cipla has announced the launch of Cippoint, a point-of-care testing device. This state-of-the-art device offers a wide range of testing parameters including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers. The device is CE IVD approved – indicating the device is approved by the European In-Vitro Diagnostic Device Directive, thus ensuring reliable testing solutions. With entry in these new segments, Cipla has expanded its product offerings for diagnostics laboratories and aims to bridge the current gap in the diagnostic ecosystem in India by providing reliable and accurate tests at affordable prices. Cippoint, an immunofluorescence based quantitative analyser, will allow healthcare professionals to get test results in 3 to 15 minutes, thus enabling a faster clinical decision-making process. Cippoint has an automated system and user-friendly interface which can be used even in rural areas, mobile vans, and remote areas with limited infrastructure. It aims to enable smaller healthcare establishments provide an accurate point-of-care testing experience, ultimately improving patient health outcomes.   ]]> https://biospectrumindia.com/news/92/22475/molbio-diagnostics-launches-truenat-mtb-inh-test-to-expand-mdr-tb-portfolio.html https://biospectrumindia.com/news/92/22475/molbio-diagnostics-launches-truenat-mtb-inh-test-to-expand-mdr-tb-portfolio.html Thu, 12 Jan 2023 00:00:00 +0530 Goa-based Molbio Diagnostics has launched Truenat MTB-INH for testing the presence of isoniazid (INH) resistance in Mycobacterium tuberculosis (MTB) infection. The test is validated by the Indian Council of Medical Research (ICMR) and approved by the Central Drugs Standard Control Organisation (CDSCO) and can provide sample-to-test results in an hour's time. Multi-drug resistant Mycobacterium tuberculosis (MDR-TB) is a serious public health issue. So far, resistance to Rifampicin was assumed as resistance to Isoniazid also for deciding the case as susceptible or MDR-TB. However, the growing occurrence of Isoniazid mono-resistance is posing a major challenge to the treatment of Rifampicin Susceptible Isoniazid resistant (Hr-TB) patients who often end up with treatment failure, relapse and develop further drug resistance. The new treatment recommendations issued by the World Health Organisation (WHO) for treating Hr-TB patients necessitate the diagnosis of INH resistance in Rifampicin susceptible patients. Thus, the detection of INH resistance is crucial for the treatment and control of MDR-TB. Truenat MTB-INH will immediately be available to the existing 3300 primary/community health centres using Truenat under the National TB Elimination Programme (NTEP) as per the programme needs. Truenat MTB-INH is also expected to play a major role internationally,  in high TB-burden countries as well as countries that already have a policy in place for INH testing on all TB-positive samples.   ]]> https://biospectrumindia.com/news/92/22468/apollo-hospitals-launches-genomics-institutes-in-navi-mumbai.html https://biospectrumindia.com/news/92/22468/apollo-hospitals-launches-genomics-institutes-in-navi-mumbai.html Wed, 11 Jan 2023 00:00:00 +0530 Apollo Hospitals Navi Mumbai, an advanced quartenary care hospital, has launched the Apollo Genomics Institutes to provide comprehensive care to patients and families with genetic disorders. Genomic medicine is a new medical discipline that deals with genetic disorders and helps in the diagnosis and treatment of rare and inherited diseases. It also provides information on the risk of an individual developing a disease and their response to a particular treatment and enables precision and personalised medicine. In addition to rare disorder diagnosis, genomic medicine is also being used in cancer pharmacogenomics and for tracking outbreaks of infectious diseases.   The Apollo Genomics Institutes will help individuals, couples and families understand the medical, psychological, familial and reproductive implications of genetic disorders. Large population groups with genetic disorders, abnormal genetic tests, children with developmental delays, congenital anomalies, and family members with genetic indispositions will be significantly benefitted from the Apollo Genomics Institutes. The Genomic Centre would ensure early assessment and identification of genetic conditions with relevant interventions, long-term treatment and care.   Prof. (Dr) Anupam Sibal, Group Medical Director, Apollo Hospitals said, “The sequencing and analysis of the human genome has revolutionised medicine enabling the era of personalised care. Genomic medicine focuses on treating and preventing disease through an assessment of an individual’s genetic structure. The Apollo Genomics Institutes will translate advancements in genetic medicine into real benefits for patients with dedicated and experienced genetic consultants and certified genetic counsellors." ]]> https://biospectrumindia.com/news/92/22461/fujifilm-india-expands-endoscopy-solutions-for-therapeutic-gastrointestinal-applications.html https://biospectrumindia.com/news/92/22461/fujifilm-india-expands-endoscopy-solutions-for-therapeutic-gastrointestinal-applications.html Tue, 10 Jan 2023 12:50:00 +0530 Fujifilm India has announced the expansion of its endoscopy solutions portfolio by launching the ClutchCutter and FushKnife. The products were unveiled at the 63rd Annual Conference of Indian Society of Gastroenterology-ISGCON, Jaipur, held from 5th to 8th January 2023.    The three-in-one device, ClutchCutter is a rotatable forceps that supports clinicians in making incisions, dissections and coagulation. Built for the most rigorous procedures, ClutchCutter features jagged, serrated jaws for enhanced clutching ability and an insulated outer edge for maximum durability. Where else the FlushKnife is a diathermic slitter that allows clinicians to carry out multiple applications including marking, flushing, incision, dissection and coagulation. Product features include a ball tip option with excellent traction, enabling dissection of the target tissue and effective coagulation.    The products were launched in the presence of Kohei Aiba, Senior Manager, Bio CDMO Div, FUJIFILM Asia, Dheeraj Chaudhri, Head of Endoscopy Division, Endoscopy Systems Division , FUJIFILM India and Tomosuke Okada, Japanese Advisor, Endoscopy Systems Division, FUJIFILM India. ]]> https://biospectrumindia.com/news/92/22454/suburban-diagnostics-unveils-state-of-the-art-reference-lab-in-mumbai.html https://biospectrumindia.com/news/92/22454/suburban-diagnostics-unveils-state-of-the-art-reference-lab-in-mumbai.html Mon, 09 Jan 2023 00:00:00 +0530 Suburban Diagnostics has opened a 13000 sq ft reference laboratory in Vidya Vihar, Mumbai. The ultra-modern laboratory offers an extensive test menu with the use of the latest technology in testing and process automation for precise and timely diagnostics.   The lab is also the first private lab in West India to have built its mycobacteriology, mycology, and molecular biology departments within a separate Bio Safety Level -3 (BSL3) bio-containment lab thereby reducing any potential exposure to both the lab personnel and to those outside the lab by the accidental release of any bio-risk material into the environment. The lab has a test menu of 2800.   Brig Dr Arvind Lal, Chairman, Dr Lal PathLabs said, “The new reference lab provides a wide array of super-specialised, specialised and routine tests for meeting all their diagnostic needs.”    Dr Om Manchanda, MD, Lal PathLabs said, “We will be able to provide high-quality services to a large set of practising doctors and patients. The new reference lab will provide a great impetus to our growth in Mumbai, Maharashtra, and Western Region.”   Dr Sanjay Arora, Chairman, Suburban Diagnostics & Group Medical Director, Dr Lal Pathlabs, said, “With the launch of the Reference Laboratory, we are fulfilling our promise to provide access to high-end super-specialized tests to the medical fraternity of Mumbai, Maharashtra and Western India. The reference laboratory leverages the power of technology at every level. It uses automation in accession, sample integrity check, quality control, sample tracking, reporting, and report delivery. AI-empowered algorithms and digital microscopy are used to aid pathologists.”    ]]> https://biospectrumindia.com/news/92/22450/pathkind-labs-roche-diagnostics-to-offer-comprehensive-diabetes-and-cardiac-care.html https://biospectrumindia.com/news/92/22450/pathkind-labs-roche-diagnostics-to-offer-comprehensive-diabetes-and-cardiac-care.html Sat, 07 Jan 2023 00:00:00 +0530 Gurugram-based Pathkind Diagnostics is all set to transform diabetes care in India with Roche Diagnostics’ cardiac biomarker- NTProBNP that is used in the management of Type 2 Diabetes (T2DM). NTProBNP is the gold-standard biomarker for detecting heart failure in patients and Roche Diagnostics is the only company to have received a claim extension allowing it to be used for identification of the risk of heart failure and other cardiovascular disease (CVD) risks in people living with T2DM. With the incorporation of NTProBNP in diabetes management, Pathkind will be a leader in providing comprehensive and holistic diabetes and cardiac care. Speaking on the occasion, Sanjeev Vashishta, MD & CEO Pathkind Labs said, “The co-existence of diabetes mellitus and heart failure has significant clinical and economic implications in terms of clinical visits, hospital admissions, quality of life, morbidity, and mortality. The addition of this high-sensitivity NTProBNP test will assist healthcare professionals and patients in making important medical decisions." Narendra Varde, Managing Director, Roche Diagnostics India & Neighboring Markets, said, "Incorporating NTProBNP, a simple blood test, to help detect and monitor heart failure as part of diabetes treatment and management is critical and essential. In order to lower mortality and CVD events, it is crucial to screen people with T2DM for CVD risk, therefore our partnership with Pathkind will be a turning point in diabetes management.”   ]]> https://biospectrumindia.com/news/92/22442/molbio-diagnostics-unveils-truenat-hsv-1-2-test-for-herpes-simplex-virus.html https://biospectrumindia.com/news/92/22442/molbio-diagnostics-unveils-truenat-hsv-1-2-test-for-herpes-simplex-virus.html Wed, 04 Jan 2023 00:00:00 +0530 Molbio Diagnostics has launched the Truenat® HSV 1/2 for testing the Herpes Simplex Virus (HSV). The test is approved by the Central Drugs Standard Control Organisation (CDSCO) and can provide sample-to-test results in an hour's time. The Real Time PCR test works on the existing Truelab infrastructure and doesn't require any additional setup and equipment to run the test, making it possible to test at resource-limited settings.  Infection with HSV, known as herpes, is common globally. HSV infections are classified into two types: HSV-1 and HSV-2. They can be spread when an infected person begins shedding the virus. HSV-1 is mainly transmitted by oral-to-oral contact to cause oral herpes which can include symptoms known as “cold sores”, but can also cause genital herpes. HSV-2 is a sexually transmitted infection that causes genital herpes. According to WHO’s 2022 report, an estimated 3.7 billion people under age 50 (67%) have HSV-1 infection and an estimated 491 million people aged 15–49 (13%) have HSV-2 infection worldwide. People with HSV - 1 are not at risk of reinfection but they are at risk of acquiring HSV-2 infection which increases the risk of HIV in patients by two or threefold.  Also commenting on the launch, Dr Chandrasekhar Nair, Chief Technology Officer, and Director, of Molbio Diagnostics, said, “HSV is rarely addressed, and currently there is no cure. So, as the first step in preventing the disease's spread, we need an effective method of testing at the point of care that is both cost-effective and provides accurate test results." ]]> https://biospectrumindia.com/news/92/22428/indian-oil-corporation-signs-mou-with-central-tb-division.html https://biospectrumindia.com/news/92/22428/indian-oil-corporation-signs-mou-with-central-tb-division.html Wed, 28 Dec 2022 00:00:00 +0530 Indian Oil Corporation has signed a Memorandum of Understanding (MoU), as part of its Corporate Social Responsibility (CSR) with the Central TB Division (CTD) under the Ministry of Health and Family Welfare, Government of India and the states of Uttar Pradesh and Chhattisgarh to undertake intensified tuberculosis (TB) elimination project. The MoU was signed in presence of Union Minister of Health and Family Welfare Dr Mansukh Mandaviya and Union Minister of Petroleum & Natural Gas and Housing & Urban Affairs, Hardeep Singh Puri. Uttar Pradesh and Chhatisgarh share the highest burden of TB cases among large states in India. With a multi-pronged approach that addresses all aspects of TB at its different stages, this ambitious anti-TB campaign aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep. The drive also aims to offer sustainable and equitable access to free high-quality TB treatment, care, and support services to the people of Uttar Pradesh and Chhatisgarh. With this pathbreaking foray, IndianOil has emerged as the first corporate to supplement state efforts in Active Case Finding campaign (ACF) by investing close to Rs 64 crore in all 75 districts of UP, covering approximately 10% of its population once a year for three years. IndianOil will also introduce 18 Mobile Medical Vans equipped with cutting-edge diagnostic technology in Uttar Pradesh. This would aid diagnosis of TB in rural areas and hard-to-reach communities leading to improved early case detection and thereby ensuring early treatment. IndianOil will provide a cost-effective, novel molecular diagnostic machine, which will improve access, availability, and utilization of TB diagnostic services in aspirational districts of UP and remote tribal areas of Chhattisgarh. ]]> https://biospectrumindia.com/news/92/22419/trivitron-healthcare-ensures-effective-detection-of-new-omicron-variants-bf-7-and-xbb.html https://biospectrumindia.com/news/92/22419/trivitron-healthcare-ensures-effective-detection-of-new-omicron-variants-bf-7-and-xbb.html Tue, 27 Dec 2022 00:00:00 +0530 Medical devices company Trivitron Healthcare has developed and commercialised a wide range of diagnostic products for effective diagnosis of new variants of SARS-CoV-2. Trivitron’s R&D conducted an in-silico analysis of mutations of the SARS-CoV-2 virus, ensuring Trivitron’s COVID-19 testing kits can effectively detect the mutated strain variants, Omicron BF.7 and XBB. “The new strain of Omicron contains mutations in its Spike (S) protein. The in-silico analysis suggests that none of the mutations associated with these variants impact Trivitron COVID-19 test kits against the detection. They do not rely on the spike gene-based detection,” said Dr Suresh Thakur, President – Scientific Affairs, Trivitron Healthcare. Trivitron’s COVIDSure, COVIDSure PRO and COVIDsure Direct RT-PCR Kits detect the conserved region of SARS-CoV-2 and ORF1ab, Envelope E-gene, and Nucleocapsid N-gene. Mutation in the S gene associated with Omicron and other variants remains unaffected by this multiplex RT-PCR test. These kits can detect SARS-COV-2 variants, including Omicron BF.7 and XBB variants. Trivitron BIOCARD Pro COVID-19 Rapid Antigen Kit is an immunochromatography-based test that offers qualitative detection of specific antigens to COVID-19 present in the human nasopharyngeal swab. This antigen test kit detects the conserved region of the N gene of SARS-CoV-2 that remains unaffected by the mutation in the S gene, hence can detect the Omicron variants BF.7 and XBB of COVID-19.   ]]> https://biospectrumindia.com/news/92/22404/predomix-launches-blood-test-for-early-cancer-detection-in-women.html https://biospectrumindia.com/news/92/22404/predomix-launches-blood-test-for-early-cancer-detection-in-women.html Fri, 23 Dec 2022 00:00:00 +0530 Gurugram-based startup PredOmix has unveiled one-of-its-kind innovative cancer detection blood test, OncoVeryx-F, capable of detecting early-stage cancers in women with a 98% accuracy. Backed by advanced metabolomics technology coupled with artificial intelligence (AI), the new-age innovation will enable the screening for early-stage cancers. Designed for women, the screening tool accurately diagnoses cancer before tumor development begins. According to the Lancet study on the disease, India is first in terms of the number of cervical cancer cases after India. The research revealed that out of 40% of the total deaths from cervical cancer, 23% occurred in India. During the last decade, a research effort has been directed toward improving outcomes for ovarian cancer by screening for preclinical, early-stage disease using both imaging techniques and serum markers. OncoVeryx-F is a patented technology that combines metabolomics and artificial intelligence to detect early cancers. It is a blood-based screening approach that accurately identifies four major female-specific malignancies in a single blood test: breast, endometrium, cervix, and ovary. This is one of the first of its kind Multi Cancer Early Detection (MCED) blood test developed by PredOmix that is now available in India and will aid in determining the presence or absence of cancer as well as the tissue of origin or cancer type. "Our company has plans to expand its testing capabilities by 2023 for detecting 17 types of cancers in both men and women. As an introductory offer, we are offering the women-specific multi-cancer test at a 50% discount. The test is nominally priced at Rs 12,000”, said Dr Kanury V S Rao, Co-Founder & Chief Scientific Officer (CSO), PredOmix.     ]]> https://biospectrumindia.com/news/92/22398/sciverse-solutions-signs-mou-with-iit-goa-to-build-lab-on-a-chip-ivd-microfluidics-platforms.html https://biospectrumindia.com/news/92/22398/sciverse-solutions-signs-mou-with-iit-goa-to-build-lab-on-a-chip-ivd-microfluidics-platforms.html Thu, 22 Dec 2022 00:00:00 +0530 Pune-based startup Sciverse Solutions has signed a Memorandum of Understanding (MoU) with the Indian Institute of Technology (IIT) Goa to design, develop, and fabricate lab-on-a-chip (LOC) and in vitro diagnostic (IVD) microfluidics technologies to provide rapid, high throughput and lower cost per test point of care service to the patients. Along with IIT Goa, the company also aims to conduct comprehensive research to promote excellence in healthcare, clinical and biomedical applications. Funded by Mylab, Sciverse is working along with Mylab to develop advanced and cost-effective artificial intelligence-based microfluidic platforms and invitro-diagnostic laboratory devices. Rapid diagnosis by robust LOC devices have become significant for the diagnosis of different diseases, particularly in resource-limited areas. These devices are paving the way for critically improved diagnostics at POC settings. They can provide healthcare professionals and patients with vital information on health-related issues, even in remote settings and in real-time. Prof. Bidhan Pramanick, Principle Investigator (Joint research programme under MoU), Assistant Professor, School of Electrical Sciences will lead the collaboration from IIT Goa's side. Sciverse will provide fellowship support to IIT Goa students for development of novel point-of-care medical diagnostics and solutions.   ]]> https://biospectrumindia.com/news/92/22392/fujifilm-spreads-awareness-about-early-detection-of-breast-cancer-in-bhubaneshwar.html https://biospectrumindia.com/news/92/22392/fujifilm-spreads-awareness-about-early-detection-of-breast-cancer-in-bhubaneshwar.html Wed, 21 Dec 2022 00:00:00 +0530 Fujifilm India hosted an event to raise awareness about the early detection of breast cancer in Bhubaneshwar, Odisha. As part of the event, Fujifilm addressed key problems and potential solutions in digital mammography breast imaging while also highlighting the clinical relevance of the technology. Fujifilm has installed its cutting-edge AMULET Innovality, a highly advanced breast cancer diagnostic tool with contrast enhanced digital mammography (CEDM) technology at NIDAN Diagnostic which enables women to diagnose breast cancer at an early stage. Breast cancer is one of the most prevalent and fatal forms of cancer. Government data shows that, on average, nearly four out of ten women diagnosed with breast cancer succumbed to the disease in India in 2020. As per the 2020 National Cancer Registry Program Report, the number is expected to rise to more than 2.3 lakh cases in 2025. Despite the advancements in treatment, the risks associated with breast cancer continue to rise. The primary reason for this is lack of awareness amongst patients and only reaching the doctor during their last stages of the disease. Understanding this problem, Fujifilm strives to educate people and take the early detection technology across India to save lives.     ]]> https://biospectrumindia.com/news/92/22382/indira-ivf-integrates-diagnostics-services-with-special-focus-on-women-child-care.html https://biospectrumindia.com/news/92/22382/indira-ivf-integrates-diagnostics-services-with-special-focus-on-women-child-care.html Tue, 20 Dec 2022 00:00:00 +0530 Indira IVF has announced its entry into diagnostics by offering pathology tests uniquely catering to the needs of women and child. The organisation has inaugurated its state-of-the-art laboratories in Lucknow, New Delhi, Patna and Mumbai, and aims to launch a total of 30+ pathology laboratories in strategic geographies by FY24 and two super speciality labs in Mumbai and Delhi. Indira PathLabs will leverage Indira IVF’s already established network of 114 centres in the country. In the Phase 1 of expansion in FY23, it will gradually expand services to all major geographies where it has a robust presence including Lucknow, Patna, New Delhi, Mumbai, Pune, Udaipur, Jaipur, Varanasi, Kolkata, Ranchi, Bhubaneswar, and Bengaluru to name a few. The company aspires to launch its pathology offerings by way of fully-equipped, independent laboratories and harnessing the benefits of automation. Backed by an array of trusted clinical offerings, Indira PathLabs will provide accessible, high-quality diagnostics services and hopes to bridge the existing gaps in the market specifically related to conception and the needs of women and their child. The organisation aspires to incorporate more than 1000 tests to fully encompass the gamut of diagnostic investigations required on the journey of conception and leading to a healthy child’s birth. Dr Nitiz Murdia – Managing Director & Co-Founder of Indira IVF said, “Genetic testing is an essential tool to ascertain the future child’s health and check for the presence of any genetic anomalies. In this regard, in addition to our pathology services, we also seek to introduce two genetic testing laboratories in the country that can perform highly specialised tests required for the prediction of such genetic anomalies in the child conceived." ]]> https://biospectrumindia.com/news/92/22373/srl-diagnostics-opens-state-of-the-art-laboratory-in-panchkula.html https://biospectrumindia.com/news/92/22373/srl-diagnostics-opens-state-of-the-art-laboratory-in-panchkula.html Fri, 16 Dec 2022 00:00:00 +0530 SRL Diagnostics has announced the launch of a new laboratory in Panchkula, Haryana. The state-of-the-art laboratory has the capacity to conduct 20,000+ tests in a month ranging from simple routine tests to semi-specialised and specialised tests. Recognising the rising demand for quality diagnostic services, SRL has expanded its capabilities by launching the additional laboratory in Haryana. The citizens of Panchkula will now have access to SRL’s extensive test menu comprising of 3500+ tests and a range of well-curated preventive healthcare packages. The lab will cater to the population in Panchkula as well as sub districts Barwala, Pinjore, Kalka, and Raipur Rani. The advanced laboratory spread over 2200 Sqft has multiple laboratory divisions including Hematology, Biochemistry, Clinical pathology, Serology and Microbiology. With the addition of this new laboratory, SRL now has a network of 4 labs and 70 collection centres across Haryana.  ]]> https://biospectrumindia.com/news/92/22335/fujifilm-india-launches-next-phase-of-tb-diagnosis-campaigns-in-assam-gujarat-and-kerala.html https://biospectrumindia.com/news/92/22335/fujifilm-india-launches-next-phase-of-tb-diagnosis-campaigns-in-assam-gujarat-and-kerala.html Wed, 07 Dec 2022 00:00:00 +0530 Fujifilm India has launched the second phase of its campaign on TB “NEVER STOP: SCREENING TO REDUCE DIAGNOSTIC DELAYS” in selected districts of Assam, Gujarat and Kerala.  The second phase of this campaign aims to increase awareness of tuberculosis (TB) as a curable disease and promote screening and early diagnosis among tea sector workers, difficult to reach population in rural and urban areas including the tribal population. Apart from symptomatic screening, Fujifilm would be providing nutrition support to identified TB patients in Sivasagar district of Assam. In association with International Union Against TB and Lung Disease (The Union), the project aims to demonstrate a model for promoting early diagnosis of TB by utilising newer solutions in community settings. Through the campaign, Fujifilm will be offering door-to-door awareness on TB and provide mobile digital X-ray services along with Qure.ai’s computed aided radiology software application designed with deep-learning for the intervention. Fujifilm screening initiative aims to reach more than 5 million people and conduct X-ray for around 30,000 of identified people using handheld X-ray machines. The project will also facilitate TB testing of identified presumptive cases.   ]]> https://biospectrumindia.com/news/92/22336/lifecell-unveils-drug-resistance-tb-test-in-partnership-with-haystackanalytics.html https://biospectrumindia.com/news/92/22336/lifecell-unveils-drug-resistance-tb-test-in-partnership-with-haystackanalytics.html Wed, 07 Dec 2022 00:00:00 +0530 LifeCell has announced the launch of a revolutionary genetic test – Omega TB, in partnership with HaystackAnalytics, a genomics based health-tech startup. The collaboration marks LifeCell’s foray into the genetic testing industry for TB patients.  The whole genome sequencing (WGS) test, designed by Haystack Analytics, aims to tackle the looming challenge of drug resistance. Apart from this, the test also helps in treating and preventing the spread of tuberculosis (TB) by providing timely, affordable and accurate diagnosis. The current culture and molecular tests providing limited information can take up to weeks for results. Omega TB is a single test that identifies all diagnostic information on TB infections. The test screens resistance of 18 listed antibiotics and shares results in just 10-12 days.  LifeCell’s whole genome sequencing (WGS) in collaboration with HaystackAnalytics can identify low-frequency resistance mutations and heterogeneous resistance with greater sensitivity. Moreover, WGS is also well-known in predicting resistant phenotypes against anti-TB drugs, designing optimum personalised treatment regimen, thereby enhancing favorable treatment outcomes in TB endemic settings.  With the launch of this affordable genome sequence analysis test, clinicians and patients will have access to one of the most powerful assessment tools to get vital insights and directions. This will help in early prevention and screening of a critical disease like TB.  Affordable rates are available for these tests.    ]]> https://biospectrumindia.com/news/92/22328/tata-1mg-commences-drone-services-for-diagnostic-samples-in-dehradun.html https://biospectrumindia.com/news/92/22328/tata-1mg-commences-drone-services-for-diagnostic-samples-in-dehradun.html Tue, 06 Dec 2022 00:00:00 +0530 Tata 1mg has established its presence in Uttarakhand by launching three integrated pharmacy and diagnostics stores and a diagnostic lab in Dehradun. In a unique initiative, the company has also commenced drone service pilot for diagnostic samples and medicines in the city to ensure faster collection and delivery, avoiding delays due to road traffic. The drones will be used to collect medical samples from various parts of the city and transport them to the Tata 1mg lab for processing. They will also be used to deliver medicines to distant areas. A single drone will be able to carry a payload of up to 150 samples. All components of the sample transportation supply chain, including drones, will be temperature-controlled, and equipped with technology to continuously monitor temperature during the flight to the lab. Tata 1mg has partnered with TSAW drones, a leading drone logistics service provider, to transport diagnostic samples throughout the city. The samples will be carried by a drone, which can carry a payload of up to 6 kg and cover an aerial distance of 100 km.   ]]> https://biospectrumindia.com/news/92/22322/4th-gen-rapid-tests-to-aid-in-hiv-detection.html https://biospectrumindia.com/news/92/22322/4th-gen-rapid-tests-to-aid-in-hiv-detection.html Fri, 02 Dec 2022 10:15:00 +0530 Bridging India’s testing gap is essential to strengthen the nation’s infection response and help meet the UNAIDS’ first goal – to diagnose 95 per cent of all HIV-positive patients, which can lead to effective treatment for those diagnosed, prompting viral suppression and an end to new HIV infections by 2030.   Early and accurate detection of HIV-positive patients is important to simplify the patient journey to access the needed care as quickly as possible. More so, it prevents future HIV transmissions, with individuals who are unaware of their infection 3.5 times more likely to transmit the virus to someone else. It also reduces the risk of patient morbidity and mortality.    Dr Ishwar Gilada, Consultant in HIV in Infectious Diseases, Unison Medicare and Research Centre Mumbai and President of AIDs Society of India, said, “Across India, the HIV burden is significant. Yet, only 79.4 per cent of the total estimated people living with HIV nationwide have been diagnosed positive. There remains a clear need to bridge the availability of diagnostic solutions so more people can have access to testing services. By using simple and scalable HIV testing offerings like rapid point-of-care tests under robust regulatory processes, we can plug such gaps in testing. Early testing and detection of infection, especially in acute cases where individuals have a higher risk of transmission owing to high viral load, is critical. This facilitates timely treatment which can support better patient outcomes, while also curbing the spread of infection.”   Sunil Mehra, GM, Abbott’s Rapid Diagnostics business in India, commented, "We believe that the 4th generation of point-of-care testing reflects a new standard of testing, which supports earlier detection of HIV-positive cases, even when viral load is lesser, making way for new possibilities in patient care. In India, we are supporting private and government hospitals and diagnostic centres with these next-generation tools to help address the country’s HIV burden.”     4th generation testing, equipped with high sensitivity and specificity, detects more acute infections, which account for 5 to 20 per cent of all HIV infections among people seeking testing, compared to the previous generation of tests. This helps close the window period of detection earlier, within as early as 12 days of living with the HIV infection, as compared to a typical 20 days or later period of detection seen by third-generation tests.           ]]> https://biospectrumindia.com/news/92/22321/mylab-unveils-indigenous-tb-and-multi-drug-resistance-detection-kit.html https://biospectrumindia.com/news/92/22321/mylab-unveils-indigenous-tb-and-multi-drug-resistance-detection-kit.html Wed, 30 Nov 2022 00:00:00 +0530 Pune-based startup Mylab has received CDSCO, TB Expert Committee and ICMR approval for first Made in India tuberculosis (TB) detection kit which simultaneously detects multiple drug resistance to Rifampicin (RIF) and Isoniazid (INH) in single test. The kit named PathoDetect MTB RIF and INH drug resistance kit is a RT-PCR based kit for accurate detection and will be used with Mylab Compact device systems , which will allow completely automated testing of multiple samples within 2 hours.   Explaining how this kit gives better testing option for TB, Hasmukh Rawal, MD of Mylab said, “We are addressing several problems simultaneously here. First being able to speed up testing by automated systems that can do multiple tests at one time. Secondly, there is scarce trained  manpower for RT-PCR testing, which India can now overcome with fully automated system which does not need highly technical person to handle samples and reagents.” Multicentre centre evaluation study and field feasibility testing studies were carried out for the “PathoDetect MTB RIF and INH drug resistance kits” & Compact device systems. The centres of trials included the most reputed TB research centres of India. The test kits have been designed to work in ambient temperatures compared to existing PCR options which need 2-8 degree cold storage. Mylab Compact device systems do not require special infrastructure for operations and feasibility studies done on mobile van in rural areas indicate them to be very robust.      ]]> https://biospectrumindia.com/news/92/22302/srl-diagnostics-launches-state-of-the-art-laboratory-in-sambalpur-odisha.html https://biospectrumindia.com/news/92/22302/srl-diagnostics-launches-state-of-the-art-laboratory-in-sambalpur-odisha.html Tue, 29 Nov 2022 00:00:00 +0530 SRL Diagnostics has announced the launch of a new laboratory in Sambalpur, Odisha. The state-of-the-art laboratory has the capacity to conduct 20,000+ tests in a month ranging from simple routine tests to semi-specialised and specialised tests.   Recognising the rising demand for quality diagnostic services, SRL has expanded its capabilities by launching the additional laboratory in Odisha. The citizens of Sambalpur will now have access to SRL’s extensive test menu comprising of 3500+ tests and a range of well-curated preventive healthcare packages. The lab will cater to the populace in Sambalpur as well as nearby districts like Burla, Baragarh, Jharsuguda, Barpali, Bolangir, Brajarajnagar and Rourkela.   The advanced laboratory spread over 1200 Sqft has multiple laboratory divisions including Hematology, Biochemistry, Clinical pathology, Serology and Microbiology.   With the addition of this new laboratory, SRL now has a network of 2 labs and 50 collection centres across Odisha. ]]> https://biospectrumindia.com/news/92/22305/mission-radiology-launches-in-india-to-provide-diagnostic-imaging-services-at-subsidised-prices.html https://biospectrumindia.com/news/92/22305/mission-radiology-launches-in-india-to-provide-diagnostic-imaging-services-at-subsidised-prices.html Tue, 29 Nov 2022 00:00:00 +0530 Minister of State for Road Transport & Highways and Civil Aviation, Government of India, General (Dr) V. K. Singh (Retd), launched Mission Radiology India (MRI) with a customised “My Stamp” of Mission Radiology India. Ashok Kumar, Post Master General (Operations), Delhi Circle, presented the first album for release. MRI is a social initiative by Sundeep Sharma Foundation. The Mission Radiology India (MRI) project aims to provide state-of-the-art diagnostic imaging services at highly subsidised prices. To set up the diagnostic centre, the Sundeep Sharma Foundation will bear 50% of the costs. The MRI centralised command centre will be set up in Delhi, and the ancillary unit in Patna. MRI will establish a network of diagnostic centres across the nation that would adhere to the code of conduct laid down and will be comprehensively supervised by the stakeholders. The established diagnostic centres will offer state-of-the-art services, including Magnetic Resonance Imaging 1.5 T, Computed Tomography, Digital X-Ray, Tele Consultation, and Pathology Services among others. While unveiling “My Stamp”, General (Dr) Vijay Kumar Singh, MoS - Road Transport & Highways and Civil Aviation said, ''Mission Radiology India will carve a new paradigm in the Indian healthcare sector by bridging the contrast between urban and rural healthcare services and will also complement the ambitious healthcare programmes of the Government of India,including the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB PM-JAY) and Ayushman Bharat Digital Mission." Over 60 per cent of hospitals, 70 per cent of dispensaries, and 80 per cent of well-trained and qualified doctors operate only in urban areas. Mission Radiology India aims to change the scenario by ensuring last mile, quality health services. ]]> https://biospectrumindia.com/news/92/22287/lumiradx-launches-poc-test-to-help-combat-antimicrobial-resistance-in-india.html https://biospectrumindia.com/news/92/22287/lumiradx-launches-poc-test-to-help-combat-antimicrobial-resistance-in-india.html Thu, 24 Nov 2022 00:00:00 +0530 UK-based LumiraDx Healthcare has launched its highly sensitive C-Reactive Protein (CRP) point of care (POC) antigen test across India. The point of care CRP test can be used in multiple clinical settings to help reduce unnecessary antibiotic prescribing that leads to antimicrobial resistance (AMR). From a tiny sample of finger-prick blood, the CRP test gives results within four minutes on the portable LumiraDx platform which weighs just over a kilogram.  Studies show that point of care CRP testing reduces antibiotic prescribing by 23-36% for respiratory tract infections (RTI), and 22% for chronic obstructive pulmonary disease (COPD). In India, CRP tests are available in intensive care units (ICUs), paediatric departments, outpatient departments (OPDs), and other clinical care settings. The Government of India considers AMR a priority health issue and has undertaken a nationwide initiative by launching an AMR stewardship programme. ]]> https://biospectrumindia.com/news/92/22276/neuberg-launches-first-high-end-integrated-diagnostics-centre-in-raipur.html https://biospectrumindia.com/news/92/22276/neuberg-launches-first-high-end-integrated-diagnostics-centre-in-raipur.html Mon, 21 Nov 2022 00:00:00 +0530 Neuberg Diagnostics has announced the launch of its first high-end integrated diagnostic centre in Raipur. The centre was inaugurated by T.S. Singh Deo, Minister of Health, Family Welfare, and Medical Education, Government of Chhattisgarh in the presence of Dr GSK Velu, Chairman and Managing Director, Neuberg Diagnostics, Dr Sandip Shah, Executive Director, Neuberg Diagnostics, Dr Ashwani Bansal, Sr Vice President, Neuberg Diagnostics , and Vishal Dutta, Centre Director (Raipur), Neuberg Diagnostics. The Neuberg Diagnostics centre in Raipur offers complete routine to high-end diagnostic services under one roof, covering both pathology and radiology as an integrated model. The centre offers a length of services across modalities from routine to super-specialty testing. Maintaining the highest quality standards by having the best doctors onboard and ensuring regular quality checks, the lab will conduct over 5000 pathological investigations, along with radiological & cardiology diagnostics such as MRI, CT, X-ray, sonography, mammography, echo-cardiography and ECG at this centre. Apart from the tests and investigation, the centre also offers various in-house services such as home collection services across Raipur, ambulance services, counseling for various advanced investigations, and soon will start emergency scans which will be available 24x7.     ]]> https://biospectrumindia.com/news/92/22268/strand-life-sciences-unveils-new-line-of-genomic-based-tests-for-preventive-wellness.html https://biospectrumindia.com/news/92/22268/strand-life-sciences-unveils-new-line-of-genomic-based-tests-for-preventive-wellness.html Fri, 18 Nov 2022 00:00:00 +0530 Strand Life Sciences, a genomics-based research and diagnostics company, has launched ‘Strand Genomic Wellness’, a new line of genomic-based tests for preventive wellness. Launched at Bengaluru Tech Summit- held from 16th to 18th November, this new offering from Strand can help individuals understand and manage their disease better. As the first offering of the programme, Strand has introduced the ‘Genomic Health Insight’ report to help individuals understand how their personal genomic variations might influence their risk for a broad range of diseases with 30-100% heritability. This knowledge can help individuals work with their doctors to manage their risk with proactive wellness measures. Strand’s new Genomic Health Insight screening offers benefits such as understanding the risk of developing certain inherited diseases that manifest later in life; help identify risks to progeny; help individuals work with their clinicians to make lifestyle changes and adopt necessary preventive measures to lower their risk and that of their progeny; and provides a catalogue of genomic variants in ~20,000 genes for life and access to new research findings on these variations, as and when they arise. As a part of the new launch, and in order for families to understand their risks more comprehensively, Strand will also be offering a limited number of free Genomic Health Insight reports for parents of any adult choosing to get one for themselves. ]]> https://biospectrumindia.com/news/92/22256/oncostem-grants-zydus-lifesciences-exclusive-marketing-rights-for-breast-cancer-test.html https://biospectrumindia.com/news/92/22256/oncostem-grants-zydus-lifesciences-exclusive-marketing-rights-for-breast-cancer-test.html Thu, 17 Nov 2022 00:00:00 +0530 Ahmedabad-based Zydus Lifesciences has announced that it will be exclusively marketing CanAssist Breast, an innovative and a highly advanced prognostic test for breast cancer patients in the early stages to help clinicians decide whether the patient needs chemotherapy or not. Out of 2.1 lac breast cancer cases in India, almost 50 percent are hormone positive. In the absence of such prognostic tests, many patients undergo chemotherapy which may not help them. However, with the aid of CanAssist Breast and its precise findings, clinicians can avoid chemotherapy for their patients based on scientific evidence. Bengaluru-based startup OncoStem has developed this test after five years of research and has generated a lot of data on patients suffering from breast cancer in India and across the world. CanAssist Breast is a test to optimise treatment selection in early stage (I & II) hormone receptor positive, HER2 receptor negative type of breast cancer. It determines the patient’s risk of breast cancer recurrence and classifies patient as ‘low risk’ or ‘high risk’ using proprietary Artificial Intelligence/ Machine Learning methods. CanAssist Breast spares patients of physiological toxicity and is also patient-centric in terms of affordability as it is being made available at 80 percent lesser than the cost of global tests.   ]]> https://biospectrumindia.com/news/92/22253/roche-diagnostics-launches-indias-first-automated-csf-based-test-for-alzheimers.html https://biospectrumindia.com/news/92/22253/roche-diagnostics-launches-indias-first-automated-csf-based-test-for-alzheimers.html Tue, 15 Nov 2022 00:00:00 +0530 Roche Diagnostics India has announced the launch of the Elecsys ß-Amyloid (1-42) cerebrospinal fluid (CSF),  Elecsys Phospho-Tau (181P) CSF assays, and Elecsys Total -Tau CSF. Elecsys Alzheimer’s disease (AD) CSF assays are intended to be used in adult patients with cognitive impairment to support the early diagnosis of AD and in patients with mild cognitive impairment (MCI) as an aid to identify a higher risk of cognitive decline.  A diagnosis of AD based on cognitive measures alone is only correct in 70 – 80 percent of cases. Identifying the disease and its progression with CSF immunoassays, associated with AD pathology, increases the certainty of a diagnosis of AD and can help clinicians to evaluate the progression of the disease. Narendra Varde, Managing Director, Roche Diagnostic India and Neighboring Markets shares, “India currently faces a dual problem in terms of lack of effective diagnostic mechanisms and access to treatment for Dementia and Alzheimer's disease. According to a 2020 report by the Alzheimer’s and Related Disorders Society of India (ARDSI), an estimated 5.3 million people above the age of 60 have dementia in the country and the burden of Alzheimers is expected to increase in the coming years. The need of the hour is to ensure timely diagnosis and intervention." The assays are now available at top neurological institutes across India. In the coming months, Roche Diagnostics is committed to expanding access to these assays to a broader network of hospitals and labs across the country. ]]> https://biospectrumindia.com/news/92/22239/mylab-sets-up-advanced-genetic-lab-and-cancer-research-centre-for-muhs-in-pune.html https://biospectrumindia.com/news/92/22239/mylab-sets-up-advanced-genetic-lab-and-cancer-research-centre-for-muhs-in-pune.html Fri, 11 Nov 2022 00:00:00 +0530 The Maharashtra University of Health Sciences (MUHS) has launched a state-of-the-art genetic laboratory and cancer research centre, designed by Mylab Discovery Solutions, in Pune. The facility was inaugurated by Bhagat Singh Koshyari, Governor of Maharashtra. The cutting-edge laboratory will offer a wide portfolio of tests to analyse DNA, RNA, chromosomes, proteins through biochemical, cytogenetic, molecular methods to evaluate and diagnose congenital disorders, prenatal disorders, hematologic and oncologic disorders. Pune-based startup Mylab has been transforming the diagnostics landscape through its market-leading, innovative solutions. The company is committed to apply deep knowledge in science and technologies to create solutions that help resolve challenges in healthcare. ]]> https://biospectrumindia.com/news/92/22225/astrazeneca-4basecare-enhance-access-to-genomic-testing-for-cancer-patients-in-india.html https://biospectrumindia.com/news/92/22225/astrazeneca-4basecare-enhance-access-to-genomic-testing-for-cancer-patients-in-india.html Wed, 09 Nov 2022 00:00:00 +0530 Bengaluru-based precision oncology startup 4baseCare has announced a collaboration with AstraZeneca for advancing cancer care in India.  Under this collaboration, the two organisations will support advanced-stage cancer patients with targeted therapy options using affordable genomic solutions. AstraZeneca and 4baseCare will work with the oncologist community to support a large number of patients by providing services locally and also at a low cost ultimately increasing the chances of identifying optimal treatment options thereby improving clinical outcomes. According to a report by the Indian Council of Medical Research (ICMR) on the ‘Burden of cancers in India’, seven cancers accounted for more than 40% of the total disease burden; lung and breast cancer being the highest. The number of Indians suffering from cancer is projected to increase to 29.8 million in 2025 from 26.7 million in 2021. Given the advancement of technology in current times, patients have an opportunity to benefit significantly from various new age strategies including ‘Precision Oncology'.   After doing massive research in collaboration with top hospitals and oncologists from India, 4baseCare recently launched a gene panel called TARGT IndieGene. It is India’s largest and first population-specific tumour gene panel derived from Whole Exome and Whole Transcriptome data from over 1,500 cancer patients across 28 different cancer types. ]]> https://biospectrumindia.com/news/92/22208/fujifilm-launches-next-phase-of-early-tb-diagnosis-campaign-in-kerala.html https://biospectrumindia.com/news/92/22208/fujifilm-launches-next-phase-of-early-tb-diagnosis-campaign-in-kerala.html Fri, 04 Nov 2022 00:00:00 +0530 Fujifilm India has launched the second phase of its campaign on tuberculosis- TB “NEVER STOP: SCREENING TO REDUCE DIAGNOSTIC DELAYS” in Waynad, Kerala. The second phase of this campaign aims to increase awareness of TB as a curable disease and promote screening and early diagnosis among tea sector workers, difficult to reach the population in rural and urban areas including the tribal population. Under the campaign, Fujifilm India will support three mobile handheld X-ray machines and implementation of the project in community settings. Apart from symptomatic screening, Fujifilm would be providing nutrition support to identified TB patients in Waynad district. Fujifilm aims to reach more than 5 million people and screen around 30,000 of them by using handheld X-ray machines. The project will also facilitate TB testing of identified presumptive cases. In association with International Union Against TB and Lung Disease (The Union), the project aims to demonstrate a model for promoting early diagnosis of TB by utilising newer solutions in community settings. Through the campaign, Fujifilm will be offering door-to-door awareness on TB and provide mobile digital X-ray services along with Qure.ai’s computed aided radiology software application designed with deep-learning for the intervention.   ]]> https://biospectrumindia.com/news/92/22201/srl-diagnostics-opens-upgraded-state-of-the-art-laboratory-at-gurugram.html https://biospectrumindia.com/news/92/22201/srl-diagnostics-opens-upgraded-state-of-the-art-laboratory-at-gurugram.html Wed, 02 Nov 2022 00:00:00 +0530 SRL Diagnostics has launched its newest upgraded state-of-the-art laboratory at Gurugram. The new reference laboratory sprawled over 25,000 sqft will serve as the nodal laboratory for all its reference labs in North India and East India. The facility was inaugurated in the presence of luminary doctors; Prof. Dr Ashok Seth (Padmashri, Padmanbhushan Awardee), Dr Narottam Puri and Dr Ashutosh Raghuvanshi.    The laboratory is equipped to perform high-volume diagnostic testing services offering increased productivity, superior diagnostic quality, and enhanced capacity to meet current and future regional demands.   The SRL lab at Gurugram is also the Centre of Excellence for human leukocyte antigen (HLA) testing & transplant immunology. Apart from highly specialised compatibility testing and evaluation needed for successful transplants, the centre of excellence will also focus on research, academics, knowledge sharing and skill building.    The lab also houses all clinical laboratory departments including clinical chemistry, haematology, histopathology, biochemistry, flow cytometry, microbiology etc. The laboratory has the capacity to conduct over 10,000 tests per day with a team of experienced and qualified pathologists.      ]]> https://biospectrumindia.com/news/92/22165/veera-health-tata-1mg-launch-indias-first-comprehensive-test-for-diagnosing-pcos-.html https://biospectrumindia.com/news/92/22165/veera-health-tata-1mg-launch-indias-first-comprehensive-test-for-diagnosing-pcos-.html Tue, 25 Oct 2022 04:00:00 +0530 Mumbai-based startup Veera Health, one of the largest digital therapeutics platforms for managing Polycystic Ovary Syndrome (PCOS), has recently launched a comprehensive test for diagnosing PCOS, in partnership with Tata 1mg. The diagnosis package is the company’s second major offering for PCOS care while its core product helps navigate PCOS, through a multi-disciplinary approach of medical care, nutrition therapy, lifestyle coaching and doctor support. Polycystic ovary syndrome (PCOS) is one of the most common lifelong hormonal conditions in women, affecting 1 in 5 Indian women. Lack of awareness and differing sets of criteria for PCOS evaluation makes it difficult to get an accurate diagnosis. Veera Health and 1 mg’s single comprehensive lab test simplifies diagnosis that eliminates the need for PCOS women to consult different specialists to get a conclusive answer. Designed as an at-home lab test with Tata 1mg, the samples are collected from home and the results are made available in just 48 hours. The reports are available online and also include a 30-minute video consultation with a qualified gynaecologist. Veera offers a similar comprehensive test package for PCOS patients looking to conceive. The test packages start at Rs 2900. The diagnostic packages are currently available in 24 Indian cities including Agra, Allahabad, Bangalore, Bhubaneswar, Chandigarh, Chennai, Faridabad, Ghaziabad, Gurgaon, Howrah WB, Hyderabad, Jaipur, Kanpur, Kolkata, Lucknow, Meerut, Mumbai, New Delhi, Noida, Patna, Pune, Ranchi, Surat, Varanasi.   ]]> https://biospectrumindia.com/news/92/22120/us-based-plexision-opens-personalised-transplant-diagnostic-testing-lab-in-hyderabad.html https://biospectrumindia.com/news/92/22120/us-based-plexision-opens-personalised-transplant-diagnostic-testing-lab-in-hyderabad.html Fri, 14 Oct 2022 00:00:00 +0530 Plexision, a US-based biotechnology company, has initiated overseas operations with the establishment of a reference laboratory in Hyderabad, India. This laboratory will offer a comprehensive range of tests for transplant patients. These tests include the company’s exclusive personalised transplant diagnostic tests to predict rejection and viral infections, as well as drug level monitoring, pharmacogenomics, and genetic testing. The company’s products were showcased at the Annual meeting of the Indian Society for Organ Transplantation in Nagpur, India, this week, and will become available later this year. “The success of anti-rejection medications depends on the unique metabolic, immunological and genetic makeup of each individual”, said Ravi Mohanka, MD, President of the Indian Society of Transplantation, and Director of Liver Transplantation at the Sir H.N Reliance Foundation Hospital and Research Center in Mumbai, India. “Plexision’s test systems can define this complex makeup to personalise care and improve outcomes in the rapidly growing transplant recipient population in India” said Rajeev Sindhi, CEO of Plexision. ]]> https://biospectrumindia.com/news/92/22089/c-camp-swissnex-announce-indo-swiss-bilateral-innovation-collaboration-in-amr-space.html https://biospectrumindia.com/news/92/22089/c-camp-swissnex-announce-indo-swiss-bilateral-innovation-collaboration-in-amr-space.html Tue, 11 Oct 2022 00:00:00 +0530 Bengaluru-based Centre for Cellular and Molecular Platforms (C-CAMP) is joined by Swissnex in India to launch an IndoSwiss bilateral innovation collaboration in Antimicrobial Resistance (AMR) space. The partnership will seek to create avenues for deeper Indo-Swiss cooperation in reducing India’s and the world’s AMR burden by urgently enabling exchanges in AMR science and innovation. The agreement was signed on 7th Oct, 2022 at C-CAMP premises by its CEO-Director Dr Taslimarif Saiyed and Jonas Brunschwig CEO, Consul General, Swissnex in India The agreement underlines C-CAMP’s growing prominence as a global destination for cutting-edge AMR innovation. Dr Saiyed welcomed the signing saying that, “C-CAMP is eagerly looking forward to operationalizing this new Indo-Swiss bilateral partnership in the crucial domain of AMR. It will be underpinned by C-CAMP’s strong portfolio of AMR technologies ranging from AMR therapeutics/drug discovery, preventatives and diagnostics, together addressing the multi-layered problem of AMR from a holistic viewpoint." Jonas Brunschwig mentioned Switzerland’s strong interest in strengthening ties with Indian research and innovation ecosystem and said “Both India and Switzerland share a concern for antimicrobial resistance (AMR), which is why Swissnex in India is working to bring the two countries together on the issue."  ]]> https://biospectrumindia.com/news/92/22066/lordsmed-opens-advanced-multidisciplinary-ivd-manufacturing-facility-at-vasai-.html https://biospectrumindia.com/news/92/22066/lordsmed-opens-advanced-multidisciplinary-ivd-manufacturing-facility-at-vasai-.html Thu, 06 Oct 2022 02:10:00 +0530 LordsMed, the global healthcare division of Lord’s Mark Industries, has launched its in-vitro diagnostics (IVD) manufacturing facility at Vasai near Mumbai. Spread over 20,000 sq ft area, the IVD manufacturing facility is equipped with state-of-the-art technologies and infrastructure of global standards and will manufacture a diversified range of IVD and point of care diagnostic solutions such as analysers, reagents for clinical biochemistry, haematology, serology, immunology, rapid testing kits (ICMR approved antigen kit) and lab consumables. The manufacturing facility has the capability to facilitate 1.7 crore diagnostic tests a month including bio chemistry, haematology, serology, rapid test and urine strip tests. LordsMed has plans to further scale up the capacity by investing Rs33 crore more in future. With this advanced IVD manufacturing facility, LordsMed plans to facilitate backward integration, reduce import dependence and build self-reliance in procurement as well as foray into the OEM (original equipment manufacturer) market.  LordsMed is in talks with pharmaceutical companies for OEM opportunities and plans to explore more opportunities both in the domestic and international markets. The company aims to go for R&D collaborations for developing rapid test kits as well. LordsMed has recently partnered with a Singapore-based diagnostics kit manufacturer Sensing Self to manufacture its diagnostics solutions. The full-fledged manufacturing for Sensing Self will begin soon after the completion of the due diligence process. LordsMed is also in discussion with a few prominent distributors in Africa to export IVD solutions to the key markets of that region.     ]]> https://biospectrumindia.com/news/92/22026/srl-diagnostics-unveils-heart-assure-test-to-predict-risk-of-cardiac-event.html https://biospectrumindia.com/news/92/22026/srl-diagnostics-unveils-heart-assure-test-to-predict-risk-of-cardiac-event.html Wed, 28 Sep 2022 10:00:00 +0530 SRL Diagnostics has announced the launch of 'Heart Assure’, a specialized test that can predict the risk of a cardiac event in an individual. High sensitivity Troponin I (hsTnI) is a simple blood test that can precisely predict a cardiac event/injury by providing a heart health risk score. This cardiac-specific test measures even small amounts (picogram/ml) of Troponin I in the blood to calculate the risk of developing a cardiac event in the future. Based on the value attained in the test, the risk is reported as Low, Moderate or Elevated. Patients with moderate or elevated risk in the test should immediately consult a cardiologist for further diagnosis and workup. Cardiac events like heart attacks are rising, even in the most productive age group. India has one of the highest burdens of cardiovascular disease (CVD) worldwide. The annual number of deaths from CVD in India was projected to rise from 2.26 (1990) million to 4.77 (2020) million. Heart disease prevalence rates in India have been estimated over the past several decades and have ranged from 1.6% to 7.4% in rural populations and from 1% to 13.2% in urban populations. Troponin I is the only troponin isotope in the myocardium and is not expressed during any developmental stage in skeletal muscle. Troponin I is released into the bloodstream soon after the onset of symptoms of myocardial infarction or ischemic damage. It rises rapidly within 3 to 6 hours following the onset of chest pain, with peak concentrations at 16 to 24 hours, and remains elevated for days. In asymptomatic and healthy individuals, the troponin 1 test can be used to stratify risk and predict future cardiovascular risks.   ]]> https://biospectrumindia.com/news/92/22022/j-mitra-launches-4th-gen-elisa-based-hcv-test.html https://biospectrumindia.com/news/92/22022/j-mitra-launches-4th-gen-elisa-based-hcv-test.html Wed, 28 Sep 2022 00:00:00 +0530 J Mitra has announced the launch of their 4th Generation Elisa-based HCV Test – the HCV Gen 4 Ag  & Ab Microlisa. The 4th Generation HCV Microlisa is an in-vitro qualitative enzyme-linked immunosorbent assay for detecting HCV core antigen and antibodies against HCV (anti-HCVs) in human serum or plasma. The kit is intended to screen blood donations to identify and eliminate the infected units of blood and for clinical diagnostic testing of Hepatitis C. Hepatitis C is a type of viral infection that sometimes leads to severe liver damage and causes liver inflammation. Hepatitis C virus (HCV) spreads through contaminated blood. The 4th Generation test is even more advanced than the existing 3rd generation kit. It detects HCV Core Antigen and Antibody to HCV Core, NS3, NS4, NS5 in human serum or plasma. It can detect all 11 HCV Genotypes; is user friendly with total test time being 150 mins; long shelf life of 24 months at 2-8° C exhibiting 100 % Sensitivity & 100 % Specificity. The HCV Microlisa Test Kit has been evaluated by the National Institute of Biologicals (NIB), Government of India.    ]]> https://biospectrumindia.com/news/92/22009/fujifilm-spreads-awareness-about-early-detection-of-breast-cancer-in-imphal.html https://biospectrumindia.com/news/92/22009/fujifilm-spreads-awareness-about-early-detection-of-breast-cancer-in-imphal.html Sat, 24 Sep 2022 01:05:00 +0530 Fujifilm India, a pioneer in diagnostic imaging and information systems for healthcare facilities, hosted an event to raise awareness about the early detection of breast cancer in Imphal, Manipur. As part of the event, Fujifilm will be addressing key problems and potential solutions in digital mammography breast imaging while also highlighting the clinical relevance of the technology. Fujifilm has installed its cutting-edge Amulet Innovality, a highly advanced breast cancer diagnostic tool at Babina Healthcare and hospitality Industries and Shija Hospital Research Institute which enables women to diagnose breast cancer at an early stage. One in 22 women get breast cancer at some point in their lifetime. Despite the innovations in treatment, the risks associated with breast cancer continue to rise. The biggest reason for this is lack of awareness amongst patients, and only reaching the doctor during their last stages of the disease. Understanding this problem, Fujifilm strives to educate people and take the early detection technology across India to save lives. Commenting on the occasion Shunsuke Honda, Japanese Advisor, Medical Division, Fujifilm India said, “Breast cancer is a leading cause of concern amongst women health issues. Early diagnosis, effective treatment, and high-quality palliative care can lessen symptoms and prevent the disease from progressing."  ]]> https://biospectrumindia.com/news/92/21996/krsnaa-diagnostics-to-set-up-tele-pathology-reporting-centre-in-pune.html https://biospectrumindia.com/news/92/21996/krsnaa-diagnostics-to-set-up-tele-pathology-reporting-centre-in-pune.html Thu, 22 Sep 2022 16:30:00 +0530 Krsnaa Diagnostics will set up a tele-pathology reporting centre in Pune, to use AI100 to digitise its entire network of pathology labs. For this, Krsnaa Diagnostics has tied up with SigTuple to use artificial intelligence (AI)-powered technology to automate the manual microscopy process across its entire pathology network.  The tie-up is expected to significantly reduce the turnaround time, standardise reporting quality and increase efficiency. SigTuple AI100 is the premier solution for AI-assisted digital pathology. It is also the only digital pathology solution available, which is economical and robust enough for wide-scale adoption in emerging markets.  Dr Ravinder Sethi, COO, Krsnaa Diagnostics said, “The SigTuple’s AI100 will be deployed across our laboratories. To begin with, we have commenced deployment in Punjab, Himachal Pradesh and Maharashtra.” COO of Pathology Services at Krsnaa Diagnostics, Dr Manish Dattatreya Karekar, said, “One of the major challenges that any diagnostics provider faces in setting up quality diagnostic centres outside of the large urban areas, is the availability of pathologists. In the absence of a pathologist at site in laboratories outside urban areas, these samples need to be shipped to central reference laboratories for review. This tie-up will help the pathologists work efficiently and bring standardization in reporting processes."  ]]> https://biospectrumindia.com/news/92/21985/maharashtra-govt-deploys-150-truenat-devices-to-facilitate-tuberculosis-testing.html https://biospectrumindia.com/news/92/21985/maharashtra-govt-deploys-150-truenat-devices-to-facilitate-tuberculosis-testing.html Wed, 21 Sep 2022 00:00:00 +0530 With the aim of eradicating Tuberculosis (TB) by 2025 as per the National TB Elimination Programme (NTEP), the Government of Maharashtra has deployed 150 Truenat devices at peripheral labs in all the districts to speed up TB testing. This enhances the state’s testing capability by providing the test results in less than one hour.  Endorsed by WHO in 2020 as the world’s first point-of-care rapid molecular diagnostic platform for the diagnosis of TB as a replacement for microscopy, the Truenat technology has the ability to operate in resource-limited settings with minimal dependence on infrastructure and skilled manpower.  Under the guidance of Dr N D Deshmukh, CMO STDC (State Training Demonstration Centre) Pune, IRL Pune, Maharashtra state conducted Truenat training programme in association with Molbio Diagnostics, the manufacturer and innovator of the Truenat platform and Foundation for Innovative New Diagnostics (FIND), India to increase the TB testing skills.  The training programme was held at the State Training Demonstration Center (STDC) IRL Pune, Maharashtra and was attended by 160 trainees. The STLS (Senior tuberculosis laboratory supervisor) and  LTs (laboratory technicians) were trained on proper sputum sample collection, packaging, transportation, processing for TB diagnosis, and hands-on training for each individual on Truenat devices. They were also trained on the result interpretation and reporting techniques and action points to be taken at Truenat centres.        ]]> https://biospectrumindia.com/news/92/21983/niramai-expands-presence-by-launching-breast-cancer-screening-facility-in-kerala.html https://biospectrumindia.com/news/92/21983/niramai-expands-presence-by-launching-breast-cancer-screening-facility-in-kerala.html Tue, 20 Sep 2022 08:40:00 +0530 The first installation of Bengaluru-based startup Niramai’s Artificial Intelligence-based Thermalytix solution for early detection of breast cancer was launched in Kerala recently.  The founder & CEO of NIRAMAI Health Analytix, Dr Geetha Manjunath who developed this innovative technology inaugurated the 1st Centre in Kerala at Keyhole Clinic, Edapally, Kochi along with leading doctors from Kerala, Dr R Padmakumar, Dr Madhukar Pai, Dr Arun Warrier, Dr Maria Varghese and Dr Mabel V Periera. Niramai’s innovative solution called ‘Thermalytix’ is an automated breast health screening and diagnostic tool, which combines thermal imaging with artificial intelligence. NIRAMAI Thermalytix test can be done for women of 18 years and above. It is privacy-sensitive, non-invasive, radiation-free, and has high accuracy which can detect the minutest of lumps or other abnormalities.  Dr Geetha Manjunath, Founder & CEO, Niramai Health Analytix, said, “We are conducting many free programmes to raise awareness amongst women about early detection of breast cancer and educating the masses on the importance of frequent checks.”   ]]> https://biospectrumindia.com/news/92/21957/neuberg-diagnostics-unveils-advanced-oncopathology-reference-lab-in-mumbai.html https://biospectrumindia.com/news/92/21957/neuberg-diagnostics-unveils-advanced-oncopathology-reference-lab-in-mumbai.html Thu, 15 Sep 2022 01:00:00 +0530 Neuberg Diagnostics has launched Neuberg Oncopathology Reference Laboratory, a state-of-the-art second opinion Oncopathology laboratory in Mumbai. The lab was inaugurated by Dr GSK Velu, Chairman and Managing Director, Dr Sandip Shah, Executive Director, Neuberg Diagnostics, and Dr Jay Mehta, President & Head, Neuberg Oncopath. The centre will pave way for advanced cancer care diagnosis, with experienced Oncopathologists, and geneticists, and will house all modern technologies & technical infrastructure, to deliver better diagnostic insights to Oncologists across the country and improve the quality of life for cancer patients. The newly established Neuberg Oncopathology lab, which is located at Vidyavihar, Mumbai, Maharashtra will be headed by Dr Jay Mehta, President & Head, of Neuberg Oncopath. Speaking on the occasion, Dr GSK Velu, Chairman, and Managing Director, Neuberg Diagnostics said, “This centre will leverage the capabilities of the Neuberg Centre for Genomic Medicine and spearhead cancer care delivery with a robust belief in the Whole Genome Sequencing (WGS) method to enable understanding of the Indian genomic cancer map. Further, these practices will bring in a generational shift in the way cancer care is delivered in India.” “Oncopathologists play an essential role by testing tumour samples with various techniques to diagnose cancer and its pathological stage. This would further impact the modality and outcome of treatment and the quality of the patient’s life, post-treatment,” added Dr Velu.   ]]> https://biospectrumindia.com/news/92/21918/avesthagen-introduces-innovative-platform-for-precision-diagnostics.html https://biospectrumindia.com/news/92/21918/avesthagen-introduces-innovative-platform-for-precision-diagnostics.html Tue, 06 Sep 2022 00:00:00 +0530 Bengaluru-based Avesthagen Limited has launched AVGEN Diagnostics, the first fully integrated end-to-end personalized genetic testing service. The innovative platform employs the latest in next-generation sequencing (NGS) technology and artificial intelligence (AI) driven precision analytics that drive diagnostic testing services at B2C, B2B levels forging partnerships with hospitals, private clinics and health insurers. AVGEN Diagnostics address the $15 billion global genetic diagnostic testing market through AvestaScan, its portfolio of NGS-driven tests that cover Whole Genome Sequencing, Whole Exome Sequencing and CALiBRx (Directed Panel Sequencing) for early diagnosis and risk management of heritable conditions. The portfolio addresses Cancers, Cardiac Care Diagnostics, Neurodegenerative conditions, Autoimmune conditions, Rare diseases, pharmacogenomics, ancestry analysis and a unique set of tests for women’s health – reproductive genomics and fertility testing, Carrier Screening, and Pre-Natal Diagnostics with precision analytics powered by Congenica, UK a digital health company, that enables precision medicine through its AI-powered diagnostic decision support platform for genomic data. AVGEN Diagnostics will be uniquely supported by the R&D outcomes of its flagship, The Avestagenome Project, which will provide accelerated and continuous innovation to create a pipeline of novel diagnostic tests, enabling best-in-class patient care.  The Avestagenome Project uses Congenica’s variant prioritization platform for its projects that include screening of the Zoroastrian Parsi Female Reference Genome and the Male Reference Genome for Clinically actionable variants, Clinical study of Pancreatitis, Type 1 Diabetes and Ulcerative Colitis among Zoroastrian Parsi family cohorts from The Avestagenome Project. ]]> https://biospectrumindia.com/news/92/21859/sonde-health-inks-multi-year-partnership-with-koye-pharma-for-copd-detection-in-india.html https://biospectrumindia.com/news/92/21859/sonde-health-inks-multi-year-partnership-with-koye-pharma-for-copd-detection-in-india.html Thu, 25 Aug 2022 00:00:00 +0530 US-based Sonde Health has signed a multi-year agreement with Koye Pharmaceuticals, a Mumbai-based specialty pharma organization focused on the Indian Pharmaceutical market, to develop a new vocal biomarker detection and monitoring capability for chronic obstructive pulmonary disease (COPD) in India. This deal represents Sonde’s first partnership with a pharmaceutical company. As part of this arrangement, Koye will leverage Sonde’s vocal biomarker development (VBD) platform, expanding upon its already existing respiratory responsive vocal biomarker, to create an entirely novel vocal biomarker for COPD in India. This will allow Koye to develop solutions that help track and treat respiratory health in COPD patients using their voice. Sonde Health has previously developed and commercialized vocal biomarker technology to detect and monitor respiratory impairment. In early 2022, the company partnered with GN Group, a leading global manufacturer of hearing instruments and audiological diagnostics equipment and headsets, to create vocal biomarker technology to detect Mild Cognitive Impairment. Preetish Toraskar, Founder and Director at Koye Pharmaceuticals said, “Not only is Sonde at the forefront of vocal biomarker technology, but their extensive experience in respiratory health will prove invaluable as we work to get this debilitating condition under control in India.” ]]> https://biospectrumindia.com/news/92/21743/lordsmed-brings-covid-19-saliva-based-rapid-antigen-test-kit-to-india.html https://biospectrumindia.com/news/92/21743/lordsmed-brings-covid-19-saliva-based-rapid-antigen-test-kit-to-india.html Tue, 02 Aug 2022 00:00:00 +0530 LordsMed, the pharma division of Mumbai-based Lord's Mark Industries, has entered into an exclusive partnership with Singapore-based diagnostics kit manufacturer Sensing Self to bring world’s first COVID-19 saliva-based rapid antigen test kit to India. With a reduced turn-around time, the first-of-its-kind non-invasive rapid antigen test kit will make COVID-19 mass screening scalable, a 99% accuracy rate i.e., gold standard, affordable and accessible to facilitate prevention of pandemic spread whenever there is a spike in the infection rate. The innovative technology collaboration marks LordsMed foray into the fast-growing rapid antigen diagnostic kit segment. It has plans to venture into the OEM manufacturing space in the diagnostics sector with its advanced manufacturing facility at Vasai near Mumbai which will be operational soon. As a part of the agreement with Sensing Self, Lord’s Mark Industries will collaborate with various government agencies and authorities to offer the saliva-based rapid antigen kits to support large-scale mass screening for COVID-19 at various passenger transit-points like airports apart from offices and manufacturing units.  The company will also tie up with primary health centres (PHCs) in various rural areas to strengthen the COVID-19 mass-screening facility in the hinterland of the country. ]]> https://biospectrumindia.com/news/92/21580/hemex-health-mylab-launch-new-covid-19-test-to-detect-all-variants-in-20-seconds.html https://biospectrumindia.com/news/92/21580/hemex-health-mylab-launch-new-covid-19-test-to-detect-all-variants-in-20-seconds.html Wed, 06 Jul 2022 17:50:00 +0530 Pune-based startup Mylab Discovery Solutions and US-based Hemex Health, a medical diagnostic device company focussed on creating diagnostics to transform frontline healthcare, have announced the official launch of the Gazelle PathoCatch COVID-19 FIA test, their collaborative diagnostic solution for point-of-care (POC) testing in India.   This portable, lightweight test detects all COVID-19 variants in 20 seconds with 99.4 per cent accuracy compared to the gold standard, PCR. The diagnostic is currently under review with US FDA for Emergency Use Authorization and will launch in Africa and the Middle East later this summer.   The Gazelle PathoCatch test includes a fluorescent lateral flow immunoassay (FIA) and a reader that utilises image-recognition software for the detection of nucleocapsid protein from SARS-CoV-2. The reader uses AI imaging and signal-to-noise enhancement techniques to achieve near-PCR accuracy. Specimens are collected using a nasal swab.     ]]>